id sid tid token lemma pos fnp-2993 1 1 neuropathology neuropathology NOUN fnp-2993 1 2 of of ADP fnp-2993 1 3 covid-19 covid-19 PROPN fnp-2993 1 4 ( ( PUNCT fnp-2993 1 5 neuro neuro NOUN fnp-2993 1 6 - - PUNCT fnp-2993 1 7 covid covid PROPN fnp-2993 1 8 ): ): PUNCT fnp-2993 1 9 clinicopathological clinicopathological ADJ fnp-2993 1 10 update update NOUN fnp-2993 1 11 feel feel VERB fnp-2993 1 12 free free ADJ fnp-2993 1 13 to to PART fnp-2993 1 14 add add VERB fnp-2993 1 15 comments comment NOUN fnp-2993 1 16 by by ADP fnp-2993 1 17 clicking click VERB fnp-2993 1 18 these these DET fnp-2993 1 19 icons icon NOUN fnp-2993 1 20 on on ADP fnp-2993 1 21 the the DET fnp-2993 1 22 sidebar sidebar NOUN fnp-2993 1 23 free free ADJ fnp-2993 1 24 neuropathology neuropathology NOUN fnp-2993 1 25 2:2 2:2 NUM fnp-2993 1 26 ( ( PUNCT fnp-2993 1 27 2021 2021 NUM fnp-2993 1 28 ) ) PUNCT fnp-2993 1 29 review review VERB fnp-2993 1 30 neuropathology neuropathology NOUN fnp-2993 1 31 of of ADP fnp-2993 1 32 covid-19 covid-19 PROPN fnp-2993 1 33 ( ( PUNCT fnp-2993 1 34 neuro neuro NOUN fnp-2993 1 35 - - PUNCT fnp-2993 1 36 covid covid PROPN fnp-2993 1 37 ): ): PUNCT fnp-2993 1 38 clinicopathological clinicopathological ADJ fnp-2993 1 39 update update NOUN fnp-2993 1 40 jerry jerry PROPN fnp-2993 1 41 j. j. PROPN fnp-2993 1 42 lou1,2 lou1,2 PROPN fnp-2993 1 43 * * PROPN fnp-2993 1 44 , , PUNCT fnp-2993 1 45 mehrnaz mehrnaz ADJ fnp-2993 1 46 movassaghi1 movassaghi1 NOUN fnp-2993 1 47 * * PROPN fnp-2993 1 48 , , PUNCT fnp-2993 1 49 dominique dominique PROPN fnp-2993 1 50 gordy1 gordy1 PROPN fnp-2993 1 51 , , PUNCT fnp-2993 1 52 madeline madeline PROPN fnp-2993 1 53 g. g. PROPN fnp-2993 1 54 olson1 olson1 PROPN fnp-2993 1 55 , , PUNCT fnp-2993 1 56 ting ting PROPN fnp-2993 1 57 zhang1 zhang1 PROPN fnp-2993 1 58 , , PUNCT fnp-2993 1 59 maya maya PROPN fnp-2993 1 60 s. s. PROPN fnp-2993 1 61 khurana2 khurana2 PROPN fnp-2993 1 62 , , PUNCT fnp-2993 1 63 zesheng zesheng PROPN fnp-2993 1 64 chen1 chen1 PROPN fnp-2993 1 65 , , PUNCT fnp-2993 1 66 mari mari PROPN fnp-2993 1 67 perez perez PROPN fnp-2993 1 68 - - PUNCT fnp-2993 1 69 rosendahl2 rosendahl2 ADJ fnp-2993 1 70 , , PUNCT fnp-2993 1 71 samasuk samasuk NOUN fnp-2993 1 72 thammachantha3 thammachantha3 PROPN fnp-2993 1 73 , , PUNCT fnp-2993 1 74 elyse elyse PROPN fnp-2993 1 75 j. j. PROPN fnp-2993 1 76 singer4 singer4 PROPN fnp-2993 1 77 , , PUNCT fnp-2993 1 78 shino shino PROPN fnp-2993 1 79 d. d. PROPN fnp-2993 1 80 magaki1 magaki1 PROPN fnp-2993 1 81 , , PUNCT fnp-2993 1 82 harry harry PROPN fnp-2993 1 83 v. v. ADP fnp-2993 1 84 vinters1,4 vinters1,4 PROPN fnp-2993 1 85 , , PUNCT fnp-2993 2 1 william william PROPN fnp-2993 2 2 h. h. PROPN fnp-2993 2 3 yong1,2 yong1,2 PROPN fnp-2993 2 4 1 1 NUM fnp-2993 2 5 department department NOUN fnp-2993 2 6 of of ADP fnp-2993 2 7 pathology pathology NOUN fnp-2993 2 8 and and CCONJ fnp-2993 2 9 laboratory laboratory NOUN fnp-2993 2 10 medicine medicine NOUN fnp-2993 2 11 , , PUNCT fnp-2993 2 12 david david PROPN fnp-2993 2 13 geffen geffen PROPN fnp-2993 2 14 school school PROPN fnp-2993 2 15 of of ADP fnp-2993 2 16 medicine medicine NOUN fnp-2993 2 17 at at ADP fnp-2993 2 18 ucla ucla PROPN fnp-2993 2 19 , , PUNCT fnp-2993 2 20 usa usa PROPN fnp-2993 2 21 2 2 NUM fnp-2993 2 22 department department NOUN fnp-2993 2 23 of of ADP fnp-2993 2 24 pathology pathology NOUN fnp-2993 2 25 and and CCONJ fnp-2993 2 26 laboratory laboratory NOUN fnp-2993 2 27 medicine medicine NOUN fnp-2993 2 28 , , PUNCT fnp-2993 2 29 university university PROPN fnp-2993 2 30 of of ADP fnp-2993 2 31 california california PROPN fnp-2993 2 32 irvine irvine PROPN fnp-2993 2 33 school school PROPN fnp-2993 2 34 of of ADP fnp-2993 2 35 medicine medicine NOUN fnp-2993 2 36 , , PUNCT fnp-2993 2 37 usa usa PROPN fnp-2993 2 38 3 3 NUM fnp-2993 2 39 department department PROPN fnp-2993 2 40 of of ADP fnp-2993 2 41 pathology pathology PROPN fnp-2993 2 42 , , PUNCT fnp-2993 2 43 prasat prasat ADJ fnp-2993 2 44 neurological neurological ADJ fnp-2993 2 45 institute institute NOUN fnp-2993 2 46 , , PUNCT fnp-2993 2 47 thailand thailand PROPN fnp-2993 2 48 4 4 NUM fnp-2993 2 49 department department PROPN fnp-2993 2 50 of of ADP fnp-2993 2 51 neurology neurology NOUN fnp-2993 2 52 , , PUNCT fnp-2993 2 53 david david PROPN fnp-2993 2 54 geffen geffen PROPN fnp-2993 2 55 school school PROPN fnp-2993 2 56 of of ADP fnp-2993 2 57 medicine medicine NOUN fnp-2993 2 58 at at ADP fnp-2993 2 59 ucla ucla PROPN fnp-2993 2 60 , , PUNCT fnp-2993 2 61 usa usa PROPN fnp-2993 2 62     SPACE fnp-2993 2 63 * * PUNCT fnp-2993 2 64 authors author NOUN fnp-2993 2 65 contributed contribute VERB fnp-2993 2 66 equally equally ADV fnp-2993 2 67 and and CCONJ fnp-2993 2 68 are be AUX fnp-2993 2 69 listed list VERB fnp-2993 2 70 in in ADP fnp-2993 2 71 alphabetical alphabetical ADJ fnp-2993 2 72 order order NOUN fnp-2993 2 73 corresponding correspond VERB fnp-2993 2 74 author author NOUN fnp-2993 2 75 : : PUNCT fnp-2993 2 76 william william PROPN fnp-2993 2 77 h. h. PROPN fnp-2993 2 78 yong yong PROPN fnp-2993 2 79 md md PROPN fnp-2993 2 80 · · PUNCT fnp-2993 2 81 department department PROPN fnp-2993 2 82 of of ADP fnp-2993 2 83 pathology pathology NOUN fnp-2993 2 84 and and CCONJ fnp-2993 2 85 laboratory laboratory NOUN fnp-2993 2 86 medicine medicine NOUN fnp-2993 2 87 · · PUNCT fnp-2993 2 88 university university PROPN fnp-2993 2 89 of of ADP fnp-2993 2 90 california california PROPN fnp-2993 2 91 irvine irvine PROPN fnp-2993 2 92 school school PROPN fnp-2993 2 93 of of ADP fnp-2993 2 94 medicine medicine PROPN fnp-2993 2 95 · · PUNCT fnp-2993 2 96 usa usa PROPN fnp-2993 2 97 and and CCONJ fnp-2993 2 98 department department PROPN fnp-2993 2 99 of of ADP fnp-2993 2 100 pathology pathology NOUN fnp-2993 2 101 and and CCONJ fnp-2993 2 102 laboratory laboratory NOUN fnp-2993 2 103 medicine medicine NOUN fnp-2993 2 104 , , PUNCT fnp-2993 2 105 david david PROPN fnp-2993 2 106 geffen geffen PROPN fnp-2993 2 107 school school PROPN fnp-2993 2 108 of of ADP fnp-2993 2 109 medicine medicine NOUN fnp-2993 2 110 at at ADP fnp-2993 2 111 ucla ucla PROPN fnp-2993 2 112 · · PUNCT fnp-2993 2 113 usa usa PROPN fnp-2993 2 114 yongwh@hs.uci.edu yongwh@hs.uci.edu PROPN fnp-2993 2 115 submitted submit VERB fnp-2993 2 116 : : PUNCT fnp-2993 2 117 03 03 NUM fnp-2993 2 118 september september PROPN fnp-2993 2 119 2020 2020 NUM fnp-2993 2 120 accepted accept VERB fnp-2993 2 121 : : PUNCT fnp-2993 2 122 14 14 NUM fnp-2993 2 123 january january PROPN fnp-2993 2 124 2021 2021 NUM fnp-2993 2 125 copyedited copyedit VERB fnp-2993 2 126 by by ADP fnp-2993 2 127 : : PUNCT fnp-2993 2 128 calixto calixto NOUN fnp-2993 2 129 - - PUNCT fnp-2993 2 130 hope hope PROPN fnp-2993 2 131 g g PROPN fnp-2993 2 132 lucas lucas PROPN fnp-2993 2 133 , , PUNCT fnp-2993 2 134 jr jr PROPN fnp-2993 2 135 . . PROPN fnp-2993 3 1 published publish VERB fnp-2993 3 2 : : PUNCT fnp-2993 3 3 18 18 NUM fnp-2993 3 4 january january NOUN fnp-2993 3 5 2021 2021 NUM fnp-2993 3 6 https://doi.org/10.17879/freeneuropathology-2021-2993 https://doi.org/10.17879/freeneuropathology-2021-2993 NOUN fnp-2993 3 7 additional additional ADJ fnp-2993 3 8 resources resource NOUN fnp-2993 3 9 and and CCONJ fnp-2993 3 10 electronic electronic ADJ fnp-2993 3 11 supplementary supplementary ADJ fnp-2993 3 12 material material NOUN fnp-2993 3 13 : : PUNCT fnp-2993 3 14 supplementary supplementary ADJ fnp-2993 3 15 material material NOUN fnp-2993 3 16 keywords keyword NOUN fnp-2993 3 17 : : PUNCT fnp-2993 3 18 cns cns PROPN fnp-2993 3 19 , , PUNCT fnp-2993 3 20 covid-19 covid-19 PROPN fnp-2993 3 21 , , PUNCT fnp-2993 3 22 sars sar NOUN fnp-2993 3 23 - - PUNCT fnp-2993 3 24 cov-2 cov-2 NOUN fnp-2993 3 25 , , PUNCT fnp-2993 3 26 brain brain NOUN fnp-2993 3 27 , , PUNCT fnp-2993 3 28 pituitary pituitary ADJ fnp-2993 3 29 abstract abstract ADJ fnp-2993 3 30 coronavirus coronavirus NOUN fnp-2993 3 31 disease disease NOUN fnp-2993 3 32 2019 2019 NUM fnp-2993 3 33 ( ( PUNCT fnp-2993 3 34 covid-19 covid-19 PROPN fnp-2993 3 35 ) ) PUNCT fnp-2993 3 36 is be AUX fnp-2993 3 37 emerging emerge VERB fnp-2993 3 38 as as ADP fnp-2993 3 39 the the DET fnp-2993 3 40 greatest great ADJ fnp-2993 3 41 public public ADJ fnp-2993 3 42 health health NOUN fnp-2993 3 43 crisis crisis NOUN fnp-2993 3 44 in in ADP fnp-2993 3 45 the the DET fnp-2993 3 46 early early ADJ fnp-2993 3 47 21st 21st ADJ fnp-2993 3 48 century century NOUN fnp-2993 3 49 . . PUNCT fnp-2993 4 1 its its PRON fnp-2993 4 2 causative causative ADJ fnp-2993 4 3 agent agent NOUN fnp-2993 4 4 , , PUNCT fnp-2993 4 5 severe severe ADJ fnp-2993 4 6 acute acute ADJ fnp-2993 4 7 respiratory respiratory ADJ fnp-2993 4 8 syndrome syndrome NOUN fnp-2993 4 9 coronavirus coronavirus NOUN fnp-2993 4 10 2 2 NUM fnp-2993 4 11 ( ( PUNCT fnp-2993 4 12 sars sar NOUN fnp-2993 4 13 - - PUNCT fnp-2993 4 14 cov-2 cov-2 NOUN fnp-2993 4 15 ) ) PUNCT fnp-2993 4 16 , , PUNCT fnp-2993 4 17 is be AUX fnp-2993 4 18 an an DET fnp-2993 4 19 enveloped envelop VERB fnp-2993 4 20 single single ADJ fnp-2993 4 21 - - PUNCT fnp-2993 4 22 stranded strand VERB fnp-2993 4 23 positive positive ADJ fnp-2993 4 24 - - PUNCT fnp-2993 4 25 sense sense NOUN fnp-2993 4 26 ribonucleic ribonucleic ADJ fnp-2993 4 27 acid acid NOUN fnp-2993 4 28 virus virus NOUN fnp-2993 4 29 that that PRON fnp-2993 4 30 enters enter VERB fnp-2993 4 31 cells cell NOUN fnp-2993 4 32 via via ADP fnp-2993 4 33 the the DET fnp-2993 4 34 angiotensin angiotensin NOUN fnp-2993 4 35 converting convert VERB fnp-2993 4 36 enzyme enzyme NOUN fnp-2993 4 37 2 2 NUM fnp-2993 4 38 receptor receptor NOUN fnp-2993 4 39 or or CCONJ fnp-2993 4 40 several several ADJ fnp-2993 4 41 other other ADJ fnp-2993 4 42 receptors receptor NOUN fnp-2993 4 43 . . PUNCT fnp-2993 5 1 while while SCONJ fnp-2993 5 2 covid-19 covid-19 PROPN fnp-2993 5 3 primarily primarily ADV fnp-2993 5 4 affects affect VERB fnp-2993 5 5 the the DET fnp-2993 5 6 respiratory respiratory ADJ fnp-2993 5 7 system system NOUN fnp-2993 5 8 , , PUNCT fnp-2993 5 9 other other ADJ fnp-2993 5 10 organs organ NOUN fnp-2993 5 11 including include VERB fnp-2993 5 12 the the DET fnp-2993 5 13 brain brain NOUN fnp-2993 5 14 can can AUX fnp-2993 5 15 be be AUX fnp-2993 5 16 involved involve VERB fnp-2993 5 17 . . PUNCT fnp-2993 6 1 in in ADP fnp-2993 6 2 western western ADJ fnp-2993 6 3 clinical clinical ADJ fnp-2993 6 4 studies study NOUN fnp-2993 6 5 , , PUNCT fnp-2993 6 6 relatively relatively ADV fnp-2993 6 7 mild mild ADJ fnp-2993 6 8 neurological neurological ADJ fnp-2993 6 9 dysfunction dysfunction NOUN fnp-2993 6 10 such such ADJ fnp-2993 6 11 as as ADP fnp-2993 6 12 anosmia anosmia NOUN fnp-2993 6 13 and and CCONJ fnp-2993 6 14 dysgeusia dysgeusia NOUN fnp-2993 6 15 is be AUX fnp-2993 6 16 frequent frequent ADJ fnp-2993 6 17 ( ( PUNCT fnp-2993 6 18 ~70 ~70 ADJ fnp-2993 6 19 - - SYM fnp-2993 6 20 84 84 NUM fnp-2993 6 21 % % NOUN fnp-2993 6 22 ) ) PUNCT fnp-2993 6 23 while while SCONJ fnp-2993 6 24 severe severe ADJ fnp-2993 6 25 neurologic neurologic ADJ fnp-2993 6 26 disorders disorder NOUN fnp-2993 6 27 such such ADJ fnp-2993 6 28 as as ADP fnp-2993 6 29 stroke stroke NOUN fnp-2993 6 30 ( ( PUNCT fnp-2993 6 31 ~1 ~1 ADV fnp-2993 6 32 - - SYM fnp-2993 6 33 6 6 NUM fnp-2993 6 34 % % NOUN fnp-2993 6 35 ) ) PUNCT fnp-2993 6 36 and and CCONJ fnp-2993 6 37 meningoencephalitis meningoencephalitis NOUN fnp-2993 6 38 are be AUX fnp-2993 6 39 less less ADV fnp-2993 6 40 common common ADJ fnp-2993 6 41 . . PUNCT fnp-2993 7 1 it it PRON fnp-2993 7 2 is be AUX fnp-2993 7 3 unclear unclear ADJ fnp-2993 7 4 how how SCONJ fnp-2993 7 5 much much ADJ fnp-2993 7 6 sars sar NOUN fnp-2993 7 7 - - PUNCT fnp-2993 7 8 cov-2 cov-2 PART fnp-2993 7 9 infection infection NOUN fnp-2993 7 10 contributes contribute VERB fnp-2993 7 11 to to ADP fnp-2993 7 12 the the DET fnp-2993 7 13 incidence incidence NOUN fnp-2993 7 14 of of ADP fnp-2993 7 15 stroke stroke NOUN fnp-2993 7 16 given give VERB fnp-2993 7 17 co co NOUN fnp-2993 7 18 - - NOUN fnp-2993 7 19 morbidities morbidity NOUN fnp-2993 7 20 in in ADP fnp-2993 7 21 the the DET fnp-2993 7 22 affected affected ADJ fnp-2993 7 23 patient patient ADJ fnp-2993 7 24 population population NOUN fnp-2993 7 25 . . PUNCT fnp-2993 8 1 rarely rarely ADV fnp-2993 8 2 , , PUNCT fnp-2993 8 3 clinically clinically ADV fnp-2993 8 4 - - PUNCT fnp-2993 8 5 defined define VERB fnp-2993 8 6 cases case NOUN fnp-2993 8 7 of of ADP fnp-2993 8 8 acute acute NOUN fnp-2993 8 9 disseminated disseminate VERB fnp-2993 8 10 encephalomyelitis encephalomyelitis NOUN fnp-2993 8 11 , , PUNCT fnp-2993 8 12 guillain guillain NOUN fnp-2993 8 13 - - PUNCT fnp-2993 8 14 barré barré PROPN fnp-2993 8 15 syndrome syndrome PROPN fnp-2993 8 16 and and CCONJ fnp-2993 8 17 acute acute ADJ fnp-2993 8 18 necrotizing necrotizing NOUN fnp-2993 8 19 encephalopathy encephalopathy NOUN fnp-2993 8 20 have have AUX fnp-2993 8 21 been be AUX fnp-2993 8 22 reported report VERB fnp-2993 8 23 in in ADP fnp-2993 8 24 covid-19 covid-19 PROPN fnp-2993 8 25 patients patient NOUN fnp-2993 8 26 . . PUNCT fnp-2993 9 1 common common ADJ fnp-2993 9 2 neuropathological neuropathological ADJ fnp-2993 9 3 findings finding NOUN fnp-2993 9 4 in in ADP fnp-2993 9 5 the the DET fnp-2993 9 6 184 184 NUM fnp-2993 9 7 patients patient NOUN fnp-2993 9 8 reviewed review VERB fnp-2993 9 9 include include VERB fnp-2993 9 10 microglial microglial ADJ fnp-2993 9 11 activation activation NOUN fnp-2993 9 12 ( ( PUNCT fnp-2993 9 13 42.9 42.9 NUM fnp-2993 9 14 % % NOUN fnp-2993 9 15 ) ) PUNCT fnp-2993 9 16 with with ADP fnp-2993 9 17 microglial microglial ADJ fnp-2993 9 18 nodules nodule NOUN fnp-2993 9 19 in in ADP fnp-2993 9 20 a a DET fnp-2993 9 21 subset subset NOUN fnp-2993 9 22 ( ( PUNCT fnp-2993 9 23 33.3 33.3 NUM fnp-2993 9 24 % % NOUN fnp-2993 9 25 ) ) PUNCT fnp-2993 9 26 , , PUNCT fnp-2993 9 27 lymphoid lymphoid ADJ fnp-2993 9 28 inflammation inflammation NOUN fnp-2993 9 29 ( ( PUNCT fnp-2993 9 30 37.5 37.5 NUM fnp-2993 9 31 % % NOUN fnp-2993 9 32 ) ) PUNCT fnp-2993 9 33 , , PUNCT fnp-2993 9 34 acute acute ADJ fnp-2993 9 35 hypoxic hypoxic ADV fnp-2993 9 36 - - PUNCT fnp-2993 9 37 ischemic ischemic ADJ fnp-2993 9 38 changes change NOUN fnp-2993 9 39 ( ( PUNCT fnp-2993 9 40 29.9 29.9 NUM fnp-2993 9 41 % % NOUN fnp-2993 9 42 ) ) PUNCT fnp-2993 9 43 , , PUNCT fnp-2993 9 44 astrogliosis astrogliosis NOUN fnp-2993 9 45 ( ( PUNCT fnp-2993 9 46 27.7 27.7 NUM fnp-2993 9 47 % % NOUN fnp-2993 9 48 ) ) PUNCT fnp-2993 9 49 , , PUNCT fnp-2993 9 50 acute acute ADJ fnp-2993 9 51 / / SYM fnp-2993 9 52 subacute subacute NOUN fnp-2993 9 53 brain brain NOUN fnp-2993 9 54 infarcts infarct NOUN fnp-2993 9 55 ( ( PUNCT fnp-2993 9 56 21.2 21.2 NUM fnp-2993 9 57 % % NOUN fnp-2993 9 58 ) ) PUNCT fnp-2993 9 59 , , PUNCT fnp-2993 9 60 spontaneous spontaneous ADJ fnp-2993 9 61 hemorrhage hemorrhage NOUN fnp-2993 9 62 ( ( PUNCT fnp-2993 9 63 15.8 15.8 NUM fnp-2993 9 64 % % NOUN fnp-2993 9 65 ) ) PUNCT fnp-2993 9 66 , , PUNCT fnp-2993 9 67 and and CCONJ fnp-2993 9 68 microthrombi microthrombi NOUN fnp-2993 9 69 ( ( PUNCT fnp-2993 9 70 15.2 15.2 NUM fnp-2993 9 71 % % NOUN fnp-2993 9 72 ) ) PUNCT fnp-2993 9 73 . . PUNCT fnp-2993 10 1 in in ADP fnp-2993 10 2 our our PRON fnp-2993 10 3 institutional institutional ADJ fnp-2993 10 4 cases case NOUN fnp-2993 10 5 , , PUNCT fnp-2993 10 6 we we PRON fnp-2993 10 7 also also ADV fnp-2993 10 8 note note VERB fnp-2993 10 9 occasional occasional ADJ fnp-2993 10 10 anterior anterior ADJ fnp-2993 10 11 pituitary pituitary ADJ fnp-2993 10 12 infarcts infarct NOUN fnp-2993 10 13 . . PUNCT fnp-2993 11 1 covid-19 covid-19 PROPN fnp-2993 11 2 coagulopathy coagulopathy ADJ fnp-2993 11 3 , , PUNCT fnp-2993 11 4 sepsis sepsis NOUN fnp-2993 11 5 , , PUNCT fnp-2993 11 6 and and CCONJ fnp-2993 11 7 acute acute ADJ fnp-2993 11 8 respiratory respiratory ADJ fnp-2993 11 9 distress distress NOUN fnp-2993 11 10 likely likely ADV fnp-2993 11 11 contribute contribute VERB fnp-2993 11 12 to to ADP fnp-2993 11 13 a a DET fnp-2993 11 14 number number NOUN fnp-2993 11 15 of of ADP fnp-2993 11 16 these these DET fnp-2993 11 17 findings finding NOUN fnp-2993 11 18 . . PUNCT fnp-2993 12 1 when when SCONJ fnp-2993 12 2 present present ADJ fnp-2993 12 3 , , PUNCT fnp-2993 12 4 central central ADJ fnp-2993 12 5 nervous nervous ADJ fnp-2993 12 6 system system NOUN fnp-2993 12 7 lymphoid lymphoid ADJ fnp-2993 12 8 inflammation inflammation NOUN fnp-2993 12 9 is be AUX fnp-2993 12 10 often often ADV fnp-2993 12 11 minimal minimal ADJ fnp-2993 12 12 to to ADP fnp-2993 12 13 mild mild ADJ fnp-2993 12 14 , , PUNCT fnp-2993 12 15 is be AUX fnp-2993 12 16 detected detect VERB fnp-2993 12 17 best good ADJ fnp-2993 12 18 by by ADP fnp-2993 12 19 immunohistochemistry immunohistochemistry NOUN fnp-2993 12 20 and and CCONJ fnp-2993 12 21 , , PUNCT fnp-2993 12 22 in in ADP fnp-2993 12 23 one one NUM fnp-2993 12 24 study study NOUN fnp-2993 12 25 , , PUNCT fnp-2993 12 26 indistinguishable indistinguishable ADJ fnp-2993 12 27 from from ADP fnp-2993 12 28 control control NOUN fnp-2993 12 29 sepsis sepsis NOUN fnp-2993 12 30 cases case NOUN fnp-2993 12 31 . . PUNCT fnp-2993 13 1 some some DET fnp-2993 13 2 cases case NOUN fnp-2993 13 3 evince evince VERB fnp-2993 13 4 microglial microglial ADJ fnp-2993 13 5 nodules nodule NOUN fnp-2993 13 6 or or CCONJ fnp-2993 13 7 neuronophagy neuronophagy VERB fnp-2993 13 8 , , PUNCT fnp-2993 13 9 strongly strongly ADV fnp-2993 13 10 supporting support VERB fnp-2993 13 11 viral viral ADJ fnp-2993 13 12 meningoencephalitis meningoencephalitis NOUN fnp-2993 13 13 , , PUNCT fnp-2993 13 14 with with ADP fnp-2993 13 15 a a DET fnp-2993 13 16 proclivity proclivity NOUN fnp-2993 13 17 for for ADP fnp-2993 13 18 involvement involvement NOUN fnp-2993 13 19 of of ADP fnp-2993 13 20 the the DET fnp-2993 13 21 medulla medulla NOUN fnp-2993 13 22 oblongata oblongata NOUN fnp-2993 13 23 . . PUNCT fnp-2993 14 1 the the DET fnp-2993 14 2 virus virus NOUN fnp-2993 14 3 is be AUX fnp-2993 14 4 detectable detectable ADJ fnp-2993 14 5 by by ADP fnp-2993 14 6 reverse reverse ADJ fnp-2993 14 7 transcriptase transcriptase NOUN fnp-2993 14 8 polymerase polymerase NOUN fnp-2993 14 9 chain chain NOUN fnp-2993 14 10 reaction reaction NOUN fnp-2993 14 11 , , PUNCT fnp-2993 14 12 immunohistochemistry immunohistochemistry NOUN fnp-2993 14 13 , , PUNCT fnp-2993 14 14 or or CCONJ fnp-2993 14 15 electron electron NOUN fnp-2993 14 16 microscopy microscopy NOUN fnp-2993 14 17 in in ADP fnp-2993 14 18 human human ADJ fnp-2993 14 19 cerebrum cerebrum PROPN fnp-2993 14 20 , , PUNCT fnp-2993 14 21 cerebellum cerebellum NOUN fnp-2993 14 22 , , PUNCT fnp-2993 14 23 cranial cranial ADJ fnp-2993 14 24 nerves nerve NOUN fnp-2993 14 25 , , PUNCT fnp-2993 14 26 olfactory olfactory NOUN fnp-2993 14 27 bulb bulb NOUN fnp-2993 14 28 , , PUNCT fnp-2993 14 29 as as ADV fnp-2993 14 30 well well ADV fnp-2993 14 31 as as ADP fnp-2993 14 32 in in ADP fnp-2993 14 33 the the DET fnp-2993 14 34 olfactory olfactory NOUN fnp-2993 14 35 epithelium epithelium NOUN fnp-2993 14 36 ; ; PUNCT fnp-2993 14 37 neurons neuron NOUN fnp-2993 14 38 and and CCONJ fnp-2993 14 39 endothelium endothelium NOUN fnp-2993 14 40 can can AUX fnp-2993 14 41 also also ADV fnp-2993 14 42 be be AUX fnp-2993 14 43 infected infect VERB fnp-2993 14 44 . . PUNCT fnp-2993 15 1 review review NOUN fnp-2993 15 2 of of ADP fnp-2993 15 3 the the DET fnp-2993 15 4 extant extant ADJ fnp-2993 15 5 cases case NOUN fnp-2993 15 6 has have VERB fnp-2993 15 7 limitations limitation NOUN fnp-2993 15 8 including include VERB fnp-2993 15 9 selection selection NOUN fnp-2993 15 10 bias bias NOUN fnp-2993 15 11 and and CCONJ fnp-2993 15 12 limited limited ADJ fnp-2993 15 13 clinical clinical ADJ fnp-2993 15 14 information information NOUN fnp-2993 15 15 in in ADP fnp-2993 15 16 some some DET fnp-2993 15 17 cases case NOUN fnp-2993 15 18 . . PUNCT fnp-2993 16 1 much much ADJ fnp-2993 16 2 remains remain VERB fnp-2993 16 3 to to PART fnp-2993 16 4 be be AUX fnp-2993 16 5 learned learn VERB fnp-2993 16 6 about about ADP fnp-2993 16 7 the the DET fnp-2993 16 8 effects effect NOUN fnp-2993 16 9 of of ADP fnp-2993 16 10 direct direct ADJ fnp-2993 16 11 viral viral ADJ fnp-2993 16 12 infection infection NOUN fnp-2993 16 13 of of ADP fnp-2993 16 14 brain brain NOUN fnp-2993 16 15 cells cell NOUN fnp-2993 16 16 and and CCONJ fnp-2993 16 17 whether whether SCONJ fnp-2993 16 18 sars sar NOUN fnp-2993 16 19 - - PUNCT fnp-2993 16 20 cov-2 cov-2 NOUN fnp-2993 16 21 persists persist VERB fnp-2993 16 22 long long ADJ fnp-2993 16 23 - - PUNCT fnp-2993 16 24 term term NOUN fnp-2993 16 25 contributing contribute VERB fnp-2993 16 26 to to ADP fnp-2993 16 27 chronic chronic ADJ fnp-2993 16 28 symptomatology symptomatology NOUN fnp-2993 16 29 . . PUNCT fnp-2993 17 1 1 1 X fnp-2993 17 2 . . X fnp-2993 17 3 introduction introduction NOUN fnp-2993 17 4 in in ADP fnp-2993 17 5 late late ADJ fnp-2993 17 6 2019 2019 NUM fnp-2993 17 7 , , PUNCT fnp-2993 17 8 a a DET fnp-2993 17 9 novel novel ADJ fnp-2993 17 10 infectious infectious ADJ fnp-2993 17 11 disease disease NOUN fnp-2993 17 12 associated associate VERB fnp-2993 17 13 with with ADP fnp-2993 17 14 pneumonia pneumonia NOUN fnp-2993 17 15 and and CCONJ fnp-2993 17 16 acute acute ADJ fnp-2993 17 17 respiratory respiratory ADJ fnp-2993 17 18 distress distress NOUN fnp-2993 17 19 emerged emerge VERB fnp-2993 17 20 in in ADP fnp-2993 17 21 wuhan wuhan PROPN fnp-2993 17 22 , , PUNCT fnp-2993 17 23 china china PROPN fnp-2993 17 24 . . PUNCT fnp-2993 18 1 the the DET fnp-2993 18 2 implicated implicated ADJ fnp-2993 18 3 human human ADJ fnp-2993 18 4 coronavirus coronavirus NOUN fnp-2993 18 5 was be AUX fnp-2993 18 6 genetically genetically ADV fnp-2993 18 7 related relate VERB fnp-2993 18 8 to to ADP fnp-2993 18 9 but but CCONJ fnp-2993 18 10 distinct distinct ADJ fnp-2993 18 11 from from ADP fnp-2993 18 12 the the DET fnp-2993 18 13 underlying underlie VERB fnp-2993 18 14 viral viral ADJ fnp-2993 18 15 agent agent NOUN fnp-2993 18 16 behind behind ADP fnp-2993 18 17 the the DET fnp-2993 18 18 2003 2003 NUM fnp-2993 18 19 severe severe ADJ fnp-2993 18 20 acute acute ADJ fnp-2993 18 21 respiratory respiratory ADJ fnp-2993 18 22 syndrome syndrome NOUN fnp-2993 18 23 ( ( PUNCT fnp-2993 18 24 sars sars PROPN fnp-2993 18 25 ) ) PUNCT fnp-2993 18 26 outbreak outbreak PROPN fnp-2993 18 27 , , PUNCT fnp-2993 18 28 sars sars PROPN fnp-2993 18 29 coronavirus coronavirus PROPN fnp-2993 18 30 ( ( PUNCT fnp-2993 18 31 sars sars PROPN fnp-2993 18 32 - - PUNCT fnp-2993 18 33 cov cov NOUN fnp-2993 18 34 ) ) PUNCT fnp-2993 18 35 . . PUNCT fnp-2993 19 1 the the DET fnp-2993 19 2 international international PROPN fnp-2993 19 3 committee committee NOUN fnp-2993 19 4 of of ADP fnp-2993 19 5 taxonomy taxonomy NOUN fnp-2993 19 6 of of ADP fnp-2993 19 7 viruses virus NOUN fnp-2993 19 8 designated designate VERB fnp-2993 19 9 this this DET fnp-2993 19 10 novel novel ADJ fnp-2993 19 11 coronavirus coronavirus NOUN fnp-2993 19 12 as as ADP fnp-2993 19 13 severe severe ADJ fnp-2993 19 14 acute acute ADJ fnp-2993 19 15 respiratory respiratory ADJ fnp-2993 19 16 syndrome syndrome NOUN fnp-2993 19 17 coronavirus coronavirus NOUN fnp-2993 19 18 2 2 NUM fnp-2993 19 19 ( ( PUNCT fnp-2993 19 20 sars sar NOUN fnp-2993 19 21 - - PUNCT fnp-2993 19 22 cov-2)1 cov-2)1 NOUN fnp-2993 19 23 and and CCONJ fnp-2993 19 24 the the DET fnp-2993 19 25 world world PROPN fnp-2993 19 26 health health PROPN fnp-2993 19 27 organization organization NOUN fnp-2993 19 28 termed term VERB fnp-2993 19 29 the the DET fnp-2993 19 30 associated associated ADJ fnp-2993 19 31 disease disease NOUN fnp-2993 19 32 as as ADP fnp-2993 19 33 coronavirus coronavirus NOUN fnp-2993 19 34 disease disease NOUN fnp-2993 19 35 2019 2019 NUM fnp-2993 19 36 ( ( PUNCT fnp-2993 19 37 covid-19).1 covid-19).1 NOUN fnp-2993 19 38 as as SCONJ fnp-2993 19 39 unsuspecting unsuspecting ADJ fnp-2993 19 40 asymptomatic asymptomatic ADJ fnp-2993 19 41 patients patient NOUN fnp-2993 19 42 readily readily ADV fnp-2993 19 43 spread spread VERB fnp-2993 19 44 the the DET fnp-2993 19 45 disease disease NOUN fnp-2993 19 46 , , PUNCT fnp-2993 19 47 the the DET fnp-2993 19 48 covid-19 covid-19 PROPN fnp-2993 19 49 pandemic pandemic NOUN fnp-2993 19 50 has have AUX fnp-2993 19 51 swept sweep VERB fnp-2993 19 52 rapidly rapidly ADV fnp-2993 19 53 across across ADP fnp-2993 19 54 the the DET fnp-2993 19 55 world world NOUN fnp-2993 19 56 resulting result VERB fnp-2993 19 57 , , PUNCT fnp-2993 19 58 by by ADP fnp-2993 19 59 the the DET fnp-2993 19 60 end end NOUN fnp-2993 19 61 of of ADP fnp-2993 19 62 december december PROPN fnp-2993 19 63 2020 2020 NUM fnp-2993 19 64 , , PUNCT fnp-2993 19 65 in in ADP fnp-2993 19 66 over over ADP fnp-2993 19 67 79 79 NUM fnp-2993 19 68 million million NUM fnp-2993 19 69 confirmed confirm VERB fnp-2993 19 70 human human ADJ fnp-2993 19 71 infections infection NOUN fnp-2993 19 72 and and CCONJ fnp-2993 19 73 over over ADP fnp-2993 19 74 1.7 1.7 NUM fnp-2993 19 75 million million NUM fnp-2993 19 76 deaths.2 deaths.2 PROPN fnp-2993 19 77 these these DET fnp-2993 19 78 numbers number NOUN fnp-2993 20 1 are be AUX fnp-2993 20 2 believed believe VERB fnp-2993 20 3 to to PART fnp-2993 20 4 be be AUX fnp-2993 20 5 substantial substantial ADJ fnp-2993 20 6 underestimates underestimate NOUN fnp-2993 20 7 of of ADP fnp-2993 20 8 the the DET fnp-2993 20 9 true true ADJ fnp-2993 20 10 toll toll NOUN fnp-2993 20 11 . . PUNCT fnp-2993 21 1 covid-19 covid-19 PROPN fnp-2993 21 2 is be AUX fnp-2993 21 3 best well ADV fnp-2993 21 4 known know VERB fnp-2993 21 5 for for ADP fnp-2993 21 6 its its PRON fnp-2993 21 7 pulmonary pulmonary ADJ fnp-2993 21 8 involvement involvement NOUN fnp-2993 21 9 , , PUNCT fnp-2993 21 10 but but CCONJ fnp-2993 21 11 other other ADJ fnp-2993 21 12 organs organ NOUN fnp-2993 21 13 are be AUX fnp-2993 21 14 often often ADV fnp-2993 21 15 affected affect VERB fnp-2993 21 16 including include VERB fnp-2993 21 17 heart heart NOUN fnp-2993 21 18 , , PUNCT fnp-2993 21 19 kidney kidney NOUN fnp-2993 21 20 and and CCONJ fnp-2993 21 21 nervous nervous ADJ fnp-2993 21 22 system system NOUN fnp-2993 21 23 . . PUNCT fnp-2993 22 1 this this DET fnp-2993 22 2 review review NOUN fnp-2993 22 3 will will AUX fnp-2993 22 4 provide provide VERB fnp-2993 22 5 an an DET fnp-2993 22 6 overview overview NOUN fnp-2993 22 7 of of ADP fnp-2993 22 8 tissue tissue NOUN fnp-2993 22 9 - - PUNCT fnp-2993 22 10 based base VERB fnp-2993 22 11 covid-19 covid-19 PROPN fnp-2993 22 12 neuropathological neuropathological ADJ fnp-2993 22 13 analyses analysis NOUN fnp-2993 22 14 , , PUNCT fnp-2993 22 15 almost almost ADV fnp-2993 22 16 entirely entirely ADV fnp-2993 22 17 autopsy autopsy ADJ fnp-2993 22 18 derived derive VERB fnp-2993 22 19 , , PUNCT fnp-2993 22 20 as as ADV fnp-2993 22 21 well well ADV fnp-2993 22 22 as as ADP fnp-2993 22 23 a a DET fnp-2993 22 24 brief brief ADJ fnp-2993 22 25 discussion discussion NOUN fnp-2993 22 26 of of ADP fnp-2993 22 27 sars sar NOUN fnp-2993 22 28 - - PUNCT fnp-2993 22 29 cov-2 cov-2 NOUN fnp-2993 22 30 virology virology NOUN fnp-2993 22 31 to to PART fnp-2993 22 32 provide provide VERB fnp-2993 22 33 context context NOUN fnp-2993 22 34 for for ADP fnp-2993 22 35 understanding understand VERB fnp-2993 22 36 its its PRON fnp-2993 22 37 pathogenesis pathogenesis NOUN fnp-2993 22 38 , , PUNCT fnp-2993 22 39 and and CCONJ fnp-2993 22 40 of of ADP fnp-2993 22 41 diagnostic diagnostic ADJ fnp-2993 22 42 testing testing NOUN fnp-2993 22 43 limitations limitation NOUN fnp-2993 22 44 that that PRON fnp-2993 22 45 may may AUX fnp-2993 22 46 bias bias VERB fnp-2993 22 47 the the DET fnp-2993 22 48 examined examine VERB fnp-2993 22 49 cases case NOUN fnp-2993 22 50 . . PUNCT fnp-2993 23 1 the the DET fnp-2993 23 2 nervous nervous ADJ fnp-2993 23 3 system system NOUN fnp-2993 23 4 is be AUX fnp-2993 23 5 affected affect VERB fnp-2993 23 6 both both CCONJ fnp-2993 23 7 secondarily secondarily ADV fnp-2993 23 8 from from ADP fnp-2993 23 9 systemic systemic ADJ fnp-2993 23 10 complications complication NOUN fnp-2993 23 11 such such ADJ fnp-2993 23 12 as as ADP fnp-2993 23 13 hypoxia hypoxia NOUN fnp-2993 23 14 and and CCONJ fnp-2993 23 15 coagulopathy coagulopathy ADJ fnp-2993 23 16 , , PUNCT fnp-2993 23 17 and and CCONJ fnp-2993 23 18 also also ADV fnp-2993 23 19 likely likely ADJ fnp-2993 23 20 from from ADP fnp-2993 23 21 primary primary ADJ fnp-2993 23 22 infection infection NOUN fnp-2993 23 23 though though SCONJ fnp-2993 23 24 much much ADJ fnp-2993 23 25 remains remain VERB fnp-2993 23 26 to to PART fnp-2993 23 27 be be AUX fnp-2993 23 28 elucidated elucidate VERB fnp-2993 23 29 regarding regard VERB fnp-2993 23 30 viral viral ADJ fnp-2993 23 31 invasion invasion NOUN fnp-2993 23 32 of of ADP fnp-2993 23 33 the the DET fnp-2993 23 34 brain brain NOUN fnp-2993 23 35 , , PUNCT fnp-2993 23 36 spinal spinal ADJ fnp-2993 23 37 cord cord NOUN fnp-2993 23 38 and and CCONJ fnp-2993 23 39 other other ADJ fnp-2993 23 40 components component NOUN fnp-2993 23 41 of of ADP fnp-2993 23 42 the the DET fnp-2993 23 43 nervous nervous ADJ fnp-2993 23 44 system system NOUN fnp-2993 23 45 . . PUNCT fnp-2993 24 1 2 2 X fnp-2993 24 2 . . X fnp-2993 24 3 sars sar NOUN fnp-2993 24 4 - - PUNCT fnp-2993 24 5 cov-2 cov-2 NOUN fnp-2993 24 6 virology virology NOUN fnp-2993 24 7 sars sar NOUN fnp-2993 24 8 - - PUNCT fnp-2993 24 9 cov-2 cov-2 PART fnp-2993 24 10 is be AUX fnp-2993 24 11 the the DET fnp-2993 24 12 latest late ADJ fnp-2993 24 13 coronavirus coronavirus NOUN fnp-2993 24 14 to to PART fnp-2993 24 15 emerge emerge VERB fnp-2993 24 16 as as ADP fnp-2993 24 17 a a DET fnp-2993 24 18 human human ADJ fnp-2993 24 19 pathogen pathogen NOUN fnp-2993 24 20 . . PUNCT fnp-2993 25 1 coronaviruses coronaviruse NOUN fnp-2993 25 2 are be AUX fnp-2993 25 3 single single ADV fnp-2993 25 4 - - PUNCT fnp-2993 25 5 stranded strand VERB fnp-2993 25 6 , , PUNCT fnp-2993 25 7 positive positive ADJ fnp-2993 25 8 - - PUNCT fnp-2993 25 9 sensed sense VERB fnp-2993 25 10 ribonucleic ribonucleic ADJ fnp-2993 25 11 acid acid NOUN fnp-2993 25 12 ( ( PUNCT fnp-2993 25 13 rna rna PROPN fnp-2993 25 14 ) ) PUNCT fnp-2993 25 15 viruses virus NOUN fnp-2993 25 16 subdivided subdivide VERB fnp-2993 25 17 into into ADP fnp-2993 25 18 four four NUM fnp-2993 25 19 genera genera NOUN fnp-2993 25 20 : : PUNCT fnp-2993 25 21 alpha alpha NOUN fnp-2993 25 22 - - PUNCT fnp-2993 25 23 coronavirus coronavirus NOUN fnp-2993 25 24 ( ( PUNCT fnp-2993 25 25 α α NOUN fnp-2993 25 26 - - PUNCT fnp-2993 25 27 cov cov NOUN fnp-2993 25 28 ) ) PUNCT fnp-2993 25 29 , , PUNCT fnp-2993 25 30 beta beta NOUN fnp-2993 25 31 - - PUNCT fnp-2993 25 32 coronavirus coronavirus NOUN fnp-2993 25 33 ( ( PUNCT fnp-2993 25 34 β β NOUN fnp-2993 25 35 - - NOUN fnp-2993 25 36 cov cov NOUN fnp-2993 25 37 ) ) PUNCT fnp-2993 25 38 , , PUNCT fnp-2993 25 39 gamma gamma NOUN fnp-2993 25 40 - - PUNCT fnp-2993 25 41 coronavirus coronavirus NOUN fnp-2993 25 42 ( ( PUNCT fnp-2993 25 43 γ γ NOUN fnp-2993 25 44 - - PUNCT fnp-2993 25 45 cov cov NOUN fnp-2993 25 46 ) ) PUNCT fnp-2993 25 47 , , PUNCT fnp-2993 25 48 and and CCONJ fnp-2993 25 49 delta delta NOUN fnp-2993 25 50 - - PUNCT fnp-2993 25 51 coronavirus coronavirus NOUN fnp-2993 25 52 ( ( PUNCT fnp-2993 25 53 δ δ NOUN fnp-2993 25 54 - - PUNCT fnp-2993 25 55 cov).3 cov).3 PUNCT fnp-2993 25 56 sars sar NOUN fnp-2993 25 57 - - PUNCT fnp-2993 25 58 cov-2 cov-2 NUM fnp-2993 25 59 is be AUX fnp-2993 25 60 a a DET fnp-2993 25 61 beta beta NOUN fnp-2993 25 62 - - PUNCT fnp-2993 25 63 coronavirus coronavirus NOUN fnp-2993 25 64 , , PUNCT fnp-2993 25 65 typically typically ADV fnp-2993 25 66 60 60 NUM fnp-2993 25 67 to to PART fnp-2993 25 68 140 140 NUM fnp-2993 25 69 nm4–6 nm4–6 PROPN fnp-2993 25 70 in in ADP fnp-2993 25 71 size size NOUN fnp-2993 25 72 , , PUNCT fnp-2993 25 73 that that PRON fnp-2993 25 74 shares share VERB fnp-2993 25 75 genetic genetic ADJ fnp-2993 25 76 similarities similarity NOUN fnp-2993 25 77 to to ADP fnp-2993 25 78 sars sar NOUN fnp-2993 25 79 - - PUNCT fnp-2993 25 80 cov cov NOUN fnp-2993 25 81 ( ( PUNCT fnp-2993 25 82 ~79 ~79 ADP fnp-2993 25 83 % % NOUN fnp-2993 25 84 homology homology NOUN fnp-2993 25 85 ) ) PUNCT fnp-2993 25 86 and and CCONJ fnp-2993 25 87 middle middle PROPN fnp-2993 25 88 east east PROPN fnp-2993 25 89 respiratory respiratory ADJ fnp-2993 25 90 syndrome syndrome NOUN fnp-2993 25 91 coronavirus coronavirus NOUN fnp-2993 25 92 ( ( PUNCT fnp-2993 25 93 mers mers NOUN fnp-2993 25 94 - - PUNCT fnp-2993 25 95 cov cov NOUN fnp-2993 25 96 ) ) PUNCT fnp-2993 25 97 ( ( PUNCT fnp-2993 26 1 ~50 ~50 NUM fnp-2993 26 2 % % NOUN fnp-2993 26 3 homology).7 homology).7 PROPN fnp-2993 26 4 the the DET fnp-2993 26 5 sars sar NOUN fnp-2993 26 6 - - PUNCT fnp-2993 26 7 cov-2 cov-2 NOUN fnp-2993 26 8 genome genome NOUN fnp-2993 26 9 encodes encode NOUN fnp-2993 26 10 16 16 NUM fnp-2993 26 11 non non ADJ fnp-2993 26 12 - - ADJ fnp-2993 26 13 structural structural ADJ fnp-2993 26 14 proteins protein NOUN fnp-2993 26 15 involved involve VERB fnp-2993 26 16 in in ADP fnp-2993 26 17 viral viral ADJ fnp-2993 26 18 replication replication NOUN fnp-2993 26 19 and and CCONJ fnp-2993 26 20 four four NUM fnp-2993 26 21 structural structural ADJ fnp-2993 26 22 proteins protein NOUN fnp-2993 26 23 consisting consist VERB fnp-2993 26 24 of of ADP fnp-2993 26 25 the the DET fnp-2993 26 26 envelope envelope NOUN fnp-2993 26 27 , , PUNCT fnp-2993 26 28 membrane membrane NOUN fnp-2993 26 29 , , PUNCT fnp-2993 26 30 nucleocapsid nucleocapsid NOUN fnp-2993 26 31 , , PUNCT fnp-2993 26 32 and and CCONJ fnp-2993 26 33 spike spike ADJ fnp-2993 26 34 glycoprotein glycoprotein NOUN fnp-2993 26 35 ( ( PUNCT fnp-2993 26 36 figure figure NOUN fnp-2993 26 37 1).3,8,9 1).3,8,9 NUM fnp-2993 26 38 the the DET fnp-2993 26 39 virus virus NOUN fnp-2993 26 40 is be AUX fnp-2993 26 41 constantly constantly ADV fnp-2993 26 42 evolving evolve VERB fnp-2993 26 43 with with ADP fnp-2993 26 44 numerous numerous ADJ fnp-2993 26 45 strains strain NOUN fnp-2993 26 46 of of ADP fnp-2993 26 47 sars sar NOUN fnp-2993 26 48 - - PUNCT fnp-2993 26 49 cov-2 cov-2 NOUN fnp-2993 26 50 identified identify VERB fnp-2993 26 51 , , PUNCT fnp-2993 26 52 some some PRON fnp-2993 26 53 preferentially preferentially ADV fnp-2993 26 54 localized localize VERB fnp-2993 26 55 ( ( PUNCT fnp-2993 26 56 at at ADP fnp-2993 26 57 least least ADJ fnp-2993 26 58 temporarily temporarily ADV fnp-2993 26 59 ) ) PUNCT fnp-2993 26 60 to to ADP fnp-2993 26 61 geographic geographic ADJ fnp-2993 26 62 regions region NOUN fnp-2993 26 63 such such ADJ fnp-2993 26 64 as as ADP fnp-2993 26 65 europe europe PROPN fnp-2993 26 66 or or CCONJ fnp-2993 26 67 north north NOUN fnp-2993 26 68 america.10 america.10 VERB fnp-2993 26 69 the the DET fnp-2993 26 70 mutation mutation NOUN fnp-2993 26 71 rate rate NOUN fnp-2993 26 72 of of ADP fnp-2993 26 73 sars sar NOUN fnp-2993 26 74 - - PUNCT fnp-2993 26 75 cov-2 cov-2 NUM fnp-2993 26 76 is be AUX fnp-2993 26 77 estimated estimate VERB fnp-2993 26 78 to to PART fnp-2993 26 79 be be AUX fnp-2993 26 80 0.84 0.84 NUM fnp-2993 26 81 - - SYM fnp-2993 26 82 1.12 1.12 NUM fnp-2993 26 83 x x SYM fnp-2993 26 84 10 10 NUM fnp-2993 26 85 - - SYM fnp-2993 26 86 3 3 NUM fnp-2993 26 87 substitutions substitution NOUN fnp-2993 26 88 per per ADP fnp-2993 26 89 site site NOUN fnp-2993 26 90 per per ADP fnp-2993 26 91 year,7,11 year,7,11 NOUN fnp-2993 26 92 which which PRON fnp-2993 26 93 is be AUX fnp-2993 26 94 lower low ADJ fnp-2993 26 95 than than ADP fnp-2993 26 96 that that PRON fnp-2993 26 97 of of ADP fnp-2993 26 98 human human ADJ fnp-2993 26 99 immunodeficiency immunodeficiency NOUN fnp-2993 26 100 virus virus NOUN fnp-2993 26 101 ( ( PUNCT fnp-2993 26 102 hiv)12 hiv)12 PROPN fnp-2993 26 103 or or CCONJ fnp-2993 26 104 influenza influenza NOUN fnp-2993 26 105 a.13 a.13 PUNCT fnp-2993 26 106 the the DET fnp-2993 26 107 genetic genetic ADJ fnp-2993 26 108 spectrum spectrum NOUN fnp-2993 26 109 of of ADP fnp-2993 26 110 disparate disparate ADJ fnp-2993 26 111 sars sar NOUN fnp-2993 26 112 - - PUNCT fnp-2993 26 113 cov-2 cov-2 NOUN fnp-2993 26 114 strains strain NOUN fnp-2993 26 115 undergoing undergo VERB fnp-2993 26 116 continued continued ADJ fnp-2993 26 117 mutation mutation NOUN fnp-2993 26 118 could could AUX fnp-2993 26 119 contribute contribute VERB fnp-2993 26 120 to to ADP fnp-2993 26 121 the the DET fnp-2993 26 122 variability variability NOUN fnp-2993 26 123 of of ADP fnp-2993 26 124 neuropathological neuropathological ADJ fnp-2993 26 125 findings finding NOUN fnp-2993 26 126 discussed discuss VERB fnp-2993 26 127 later later ADV fnp-2993 26 128 . . PUNCT fnp-2993 27 1 antibodies antibodie VERB fnp-2993 27 2 against against ADP fnp-2993 27 3 nucleocapsid nucleocapsid ADJ fnp-2993 27 4 and and CCONJ fnp-2993 27 5 spike spike ADJ fnp-2993 27 6 proteins protein NOUN fnp-2993 27 7 have have AUX fnp-2993 27 8 been be AUX fnp-2993 27 9 used use VERB fnp-2993 27 10 for for ADP fnp-2993 27 11 immunohistochemical immunohistochemical ADJ fnp-2993 27 12 studies study NOUN fnp-2993 27 13 . . PUNCT fnp-2993 28 1 figure figure VERB fnp-2993 28 2 1 1 NUM fnp-2993 28 3 : : PUNCT fnp-2993 28 4 severe severe ADJ fnp-2993 28 5 acute acute ADJ fnp-2993 28 6 respiratory respiratory ADJ fnp-2993 28 7 coronavirus coronavirus NOUN fnp-2993 28 8 2 2 NUM fnp-2993 28 9 ( ( PUNCT fnp-2993 28 10 sars sar NOUN fnp-2993 28 11 - - PUNCT fnp-2993 28 12 cov-2 cov-2 NOUN fnp-2993 28 13 ) ) PUNCT fnp-2993 28 14 structure structure NOUN fnp-2993 28 15 . . PUNCT fnp-2993 29 1 there there PRON fnp-2993 29 2 are be VERB fnp-2993 29 3 four four NUM fnp-2993 29 4 structural structural ADJ fnp-2993 29 5 proteins protein NOUN fnp-2993 29 6 : : PUNCT fnp-2993 29 7 spike spike X fnp-2993 29 8 ( ( PUNCT fnp-2993 29 9 s s NOUN fnp-2993 29 10 ) ) PUNCT fnp-2993 29 11 protein protein NOUN fnp-2993 29 12 ( ( PUNCT fnp-2993 29 13 red red ADJ fnp-2993 29 14 ) ) PUNCT fnp-2993 29 15 , , PUNCT fnp-2993 29 16 envelope envelope NOUN fnp-2993 29 17 ( ( PUNCT fnp-2993 29 18 e e NOUN fnp-2993 29 19 ) ) PUNCT fnp-2993 29 20 protein protein NOUN fnp-2993 29 21 ( ( PUNCT fnp-2993 29 22 violet violet NOUN fnp-2993 29 23 ) ) PUNCT fnp-2993 29 24 , , PUNCT fnp-2993 29 25 membrane membrane NOUN fnp-2993 29 26 ( ( PUNCT fnp-2993 29 27 m m NOUN fnp-2993 29 28 ) ) PUNCT fnp-2993 29 29 protein protein NOUN fnp-2993 29 30 ( ( PUNCT fnp-2993 29 31 blue blue ADJ fnp-2993 29 32 ) ) PUNCT fnp-2993 29 33 , , PUNCT fnp-2993 29 34 and and CCONJ fnp-2993 29 35 nucleocapsid nucleocapsid ADJ fnp-2993 29 36 ( ( PUNCT fnp-2993 29 37 n n CCONJ fnp-2993 29 38 ) ) PUNCT fnp-2993 29 39 protein protein NOUN fnp-2993 29 40 ( ( PUNCT fnp-2993 29 41 orange orange ADJ fnp-2993 29 42 ) ) PUNCT fnp-2993 29 43 . . PUNCT fnp-2993 30 1 3 3 X fnp-2993 30 2 . . X fnp-2993 30 3 ace2 ace2 PROPN fnp-2993 30 4 and and CCONJ fnp-2993 30 5 other other ADJ fnp-2993 30 6 receptors receptor NOUN fnp-2993 30 7 mediate mediate VERB fnp-2993 30 8 sars sar NOUN fnp-2993 30 9 - - PUNCT fnp-2993 30 10 cov-2 cov-2 PART fnp-2993 30 11 entry entry NOUN fnp-2993 30 12 the the DET fnp-2993 30 13 entry entry NOUN fnp-2993 30 14 of of ADP fnp-2993 30 15 sars sar NOUN fnp-2993 30 16 - - PUNCT fnp-2993 30 17 cov-2 cov-2 NOUN fnp-2993 30 18 into into ADP fnp-2993 30 19 human human ADJ fnp-2993 30 20 cells cell NOUN fnp-2993 30 21 is be AUX fnp-2993 30 22 commonly commonly ADV fnp-2993 30 23 thought think VERB fnp-2993 30 24 to to PART fnp-2993 30 25 be be AUX fnp-2993 30 26 mediated mediate VERB fnp-2993 30 27 by by ADP fnp-2993 30 28 the the DET fnp-2993 30 29 interaction interaction NOUN fnp-2993 30 30 of of ADP fnp-2993 30 31 the the DET fnp-2993 30 32 spike spike ADJ fnp-2993 30 33 protein protein NOUN fnp-2993 30 34 with with ADP fnp-2993 30 35 the the DET fnp-2993 30 36 angiotensin angiotensin NOUN fnp-2993 30 37 converting convert VERB fnp-2993 30 38 enzyme enzyme NOUN fnp-2993 30 39 2 2 NUM fnp-2993 30 40 ( ( PUNCT fnp-2993 30 41 ace2 ace2 NOUN fnp-2993 30 42 ) ) PUNCT fnp-2993 30 43 receptor receptor NOUN fnp-2993 30 44 , , PUNCT fnp-2993 30 45 an an DET fnp-2993 30 46 important important ADJ fnp-2993 30 47 regulator regulator NOUN fnp-2993 30 48 of of ADP fnp-2993 30 49 the the DET fnp-2993 30 50 renin renin ADJ fnp-2993 30 51 - - PUNCT fnp-2993 30 52 angiotensin angiotensin NOUN fnp-2993 30 53 system system NOUN fnp-2993 30 54 ( ( PUNCT fnp-2993 30 55 ras).14 ras).14 NOUN fnp-2993 30 56 gender gender NOUN fnp-2993 30 57 , , PUNCT fnp-2993 30 58 age age NOUN fnp-2993 30 59 , , PUNCT fnp-2993 30 60 lifestyle lifestyle NOUN fnp-2993 30 61 , , PUNCT fnp-2993 30 62 smoking smoking NOUN fnp-2993 30 63 , , PUNCT fnp-2993 30 64 and and CCONJ fnp-2993 30 65 other other ADJ fnp-2993 30 66 patient patient ADJ fnp-2993 30 67 co co NOUN fnp-2993 30 68 - - NOUN fnp-2993 30 69 morbidities morbidity NOUN fnp-2993 30 70 are be AUX fnp-2993 30 71 implicated implicate VERB fnp-2993 30 72 in in ADP fnp-2993 30 73 the the DET fnp-2993 30 74 modulation modulation NOUN fnp-2993 30 75 of of ADP fnp-2993 30 76 ace2 ace2 NOUN fnp-2993 30 77 receptor receptor NOUN fnp-2993 30 78 expression expression NOUN fnp-2993 30 79 in in ADP fnp-2993 30 80 various various ADJ fnp-2993 30 81 tissues.15–21 tissues.15–21 ADP fnp-2993 30 82 ace2 ace2 NOUN fnp-2993 30 83 receptor receptor NOUN fnp-2993 30 84 expression expression NOUN fnp-2993 30 85 has have AUX fnp-2993 30 86 been be AUX fnp-2993 30 87 reported report VERB fnp-2993 30 88 in in ADP fnp-2993 30 89 the the DET fnp-2993 30 90 cerebrum cerebrum NOUN fnp-2993 30 91 , , PUNCT fnp-2993 30 92 cerebellum cerebellum NOUN fnp-2993 30 93 , , PUNCT fnp-2993 30 94 brainstem brainstem NOUN fnp-2993 30 95 , , PUNCT fnp-2993 30 96 retina retina NOUN fnp-2993 30 97 , , PUNCT fnp-2993 30 98 and and CCONJ fnp-2993 30 99 olfactory olfactory ADJ fnp-2993 30 100 mucosa.22–24 mucosa.22–24 PROPN fnp-2993 30 101 neurons neuron NOUN fnp-2993 30 102 , , PUNCT fnp-2993 30 103 vascular vascular ADJ fnp-2993 30 104 pericytes pericyte NOUN fnp-2993 30 105 and and CCONJ fnp-2993 30 106 smooth smooth ADJ fnp-2993 30 107 muscle muscle NOUN fnp-2993 30 108 , , PUNCT fnp-2993 30 109 and and CCONJ fnp-2993 30 110 glia glia NOUN fnp-2993 30 111 express express VERB fnp-2993 30 112 the the DET fnp-2993 30 113 ace2 ace2 NOUN fnp-2993 30 114 receptor.22,23,25 receptor.22,23,25 ADP fnp-2993 30 115 in in ADP fnp-2993 30 116 addition addition NOUN fnp-2993 30 117 to to ADP fnp-2993 30 118 the the DET fnp-2993 30 119 ace2 ace2 NOUN fnp-2993 30 120 receptor receptor NOUN fnp-2993 30 121 , , PUNCT fnp-2993 30 122 in in ADP fnp-2993 30 123 vitro vitro X fnp-2993 30 124 studies study NOUN fnp-2993 30 125 show show VERB fnp-2993 30 126 that that SCONJ fnp-2993 30 127 sars sar NOUN fnp-2993 30 128 - - PUNCT fnp-2993 30 129 cov-2 cov-2 PART fnp-2993 30 130 may may AUX fnp-2993 30 131 gain gain VERB fnp-2993 30 132 entry entry NOUN fnp-2993 30 133 using use VERB fnp-2993 30 134 other other ADJ fnp-2993 30 135 cell cell NOUN fnp-2993 30 136 receptors receptor NOUN fnp-2993 30 137 , , PUNCT fnp-2993 30 138 such such ADJ fnp-2993 30 139 as as ADP fnp-2993 30 140 basigin basigin NOUN fnp-2993 30 141 ( ( PUNCT fnp-2993 30 142 bsg bsg PROPN fnp-2993 30 143 ; ; PUNCT fnp-2993 30 144 cd147),26 cd147),26 PROPN fnp-2993 30 145 neuropilin-1 neuropilin-1 NUM fnp-2993 30 146 ( ( PUNCT fnp-2993 30 147 nrp1),27 nrp1),27 NOUN fnp-2993 30 148 transmembrane transmembrane ADJ fnp-2993 30 149 serine serine NOUN fnp-2993 30 150 protease protease NOUN fnp-2993 30 151 2 2 NUM fnp-2993 30 152 and and CCONJ fnp-2993 30 153 4 4 NUM fnp-2993 30 154 ( ( PUNCT fnp-2993 30 155 tmprss2/4),28,29 tmprss2/4),28,29 PROPN fnp-2993 30 156 and and CCONJ fnp-2993 30 157 cathepsin cathepsin PROPN fnp-2993 30 158 l l PROPN fnp-2993 30 159 ( ( PUNCT fnp-2993 30 160 ctsl).9 ctsl).9 PROPN fnp-2993 30 161 expression expression NOUN fnp-2993 30 162 of of ADP fnp-2993 30 163 ace2 ace2 PROPN fnp-2993 30 164 receptor receptor NOUN fnp-2993 30 165 is be AUX fnp-2993 30 166 highest high ADJ fnp-2993 30 167 in in ADP fnp-2993 30 168 oligodendrocytes oligodendrocyte NOUN fnp-2993 30 169 , , PUNCT fnp-2993 30 170 tmprss2/4 tmprss2/4 NOUN fnp-2993 30 171 in in ADP fnp-2993 30 172 neurons neuron NOUN fnp-2993 30 173 , , PUNCT fnp-2993 30 174 ctsl ctsl NOUN fnp-2993 30 175 in in ADP fnp-2993 30 176 microglia microglia NOUN fnp-2993 30 177 , , PUNCT fnp-2993 30 178 and and CCONJ fnp-2993 30 179 nrp1 nrp1 PROPN fnp-2993 30 180 in in ADP fnp-2993 30 181 endothelial endothelial ADJ fnp-2993 30 182 cells.25 cells.25 NOUN fnp-2993 30 183 in in ADP fnp-2993 30 184 principle principle NOUN fnp-2993 30 185 therefore therefore ADV fnp-2993 30 186 , , PUNCT fnp-2993 30 187 a a DET fnp-2993 30 188 broad broad ADJ fnp-2993 30 189 range range NOUN fnp-2993 30 190 of of ADP fnp-2993 30 191 cells cell NOUN fnp-2993 30 192 in in ADP fnp-2993 30 193 the the DET fnp-2993 30 194 central central ADJ fnp-2993 30 195 nervous nervous ADJ fnp-2993 30 196 system system NOUN fnp-2993 30 197 ( ( PUNCT fnp-2993 30 198 cns cns NOUN fnp-2993 30 199 ) ) PUNCT fnp-2993 30 200 have have VERB fnp-2993 30 201 a a DET fnp-2993 30 202 variety variety NOUN fnp-2993 30 203 of of ADP fnp-2993 30 204 receptors receptor NOUN fnp-2993 30 205 that that PRON fnp-2993 30 206 may may AUX fnp-2993 30 207 facilitate facilitate VERB fnp-2993 30 208 infection infection NOUN fnp-2993 30 209 . . PUNCT fnp-2993 31 1 4 4 X fnp-2993 31 2 . . X fnp-2993 31 3 laboratory laboratory NOUN fnp-2993 31 4 testing testing NOUN fnp-2993 31 5 for for ADP fnp-2993 31 6 covid-19 covid-19 PROPN fnp-2993 31 7 has have VERB fnp-2993 31 8 significant significant ADJ fnp-2993 31 9 limitations limitation NOUN fnp-2993 31 10 in in ADP fnp-2993 31 11 part part NOUN fnp-2993 31 12 due due ADP fnp-2993 31 13 to to ADP fnp-2993 31 14 the the DET fnp-2993 31 15 natural natural ADJ fnp-2993 31 16 course course NOUN fnp-2993 31 17 of of ADP fnp-2993 31 18 disease disease NOUN fnp-2993 31 19 wherein wherein SCONJ fnp-2993 31 20 viral viral ADJ fnp-2993 31 21 titers titer NOUN fnp-2993 31 22 rise rise VERB fnp-2993 31 23 over over ADP fnp-2993 31 24 time time NOUN fnp-2993 31 25 , , PUNCT fnp-2993 31 26 laboratory laboratory NOUN fnp-2993 31 27 testing testing NOUN fnp-2993 31 28 for for ADP fnp-2993 31 29 sars sar NOUN fnp-2993 31 30 - - PUNCT fnp-2993 31 31 cov-2 cov-2 NOUN fnp-2993 31 32 does do AUX fnp-2993 31 33 not not PART fnp-2993 31 34 completely completely ADV fnp-2993 31 35 exclude exclude VERB fnp-2993 31 36 patient patient ADJ fnp-2993 31 37 infection infection NOUN fnp-2993 31 38 , , PUNCT fnp-2993 31 39 complicating complicate VERB fnp-2993 31 40 the the DET fnp-2993 31 41 neuropathologist neuropathologist NOUN fnp-2993 31 42 ’s ’s PART fnp-2993 31 43 management management NOUN fnp-2993 31 44 of of ADP fnp-2993 31 45 surgical surgical ADJ fnp-2993 31 46 or or CCONJ fnp-2993 31 47 autopsy autopsy ADJ fnp-2993 31 48 cases case NOUN fnp-2993 31 49 . . PUNCT fnp-2993 32 1 there there PRON fnp-2993 32 2 may may AUX fnp-2993 32 3 also also ADV fnp-2993 32 4 be be AUX fnp-2993 32 5 a a DET fnp-2993 32 6 bias bias NOUN fnp-2993 32 7 towards towards ADP fnp-2993 32 8 evaluating evaluate VERB fnp-2993 32 9 autopsies autopsy NOUN fnp-2993 32 10 of of ADP fnp-2993 32 11 covid-19 covid-19 PROPN fnp-2993 32 12 patients patient NOUN fnp-2993 32 13 with with ADP fnp-2993 32 14 severe severe ADJ fnp-2993 32 15 disease disease NOUN fnp-2993 32 16 and and CCONJ fnp-2993 32 17 high high ADJ fnp-2993 32 18 viral viral ADJ fnp-2993 32 19 loads load NOUN fnp-2993 32 20 . . PUNCT fnp-2993 33 1 the the DET fnp-2993 33 2 analytical analytical ADJ fnp-2993 33 3 sensitivity sensitivity NOUN fnp-2993 33 4 of of ADP fnp-2993 33 5 the the DET fnp-2993 33 6 commonly commonly ADV fnp-2993 33 7 used use VERB fnp-2993 33 8 covid-19 covid-19 PROPN fnp-2993 33 9 reverse reverse ADJ fnp-2993 33 10 transcriptase transcriptase NOUN fnp-2993 33 11 polymerase polymerase NOUN fnp-2993 33 12 chain chain NOUN fnp-2993 33 13 reaction reaction NOUN fnp-2993 33 14 ( ( PUNCT fnp-2993 33 15 rt rt NOUN fnp-2993 33 16 - - PUNCT fnp-2993 33 17 pcr pcr NOUN fnp-2993 33 18 ) ) PUNCT fnp-2993 33 19 assay assay NOUN fnp-2993 33 20 is be AUX fnp-2993 33 21 excellent excellent ADJ fnp-2993 33 22 with with ADP fnp-2993 33 23 a a DET fnp-2993 33 24 limit limit NOUN fnp-2993 33 25 of of ADP fnp-2993 33 26 detection detection NOUN fnp-2993 33 27 as as ADV fnp-2993 33 28 low low ADJ fnp-2993 33 29 as as ADP fnp-2993 33 30 6.25 6.25 NUM fnp-2993 33 31 copies/µl copies/µl NOUN fnp-2993 33 32 in in ADP fnp-2993 33 33 a a DET fnp-2993 33 34 nasopharyngeal nasopharyngeal ADJ fnp-2993 33 35 sample.30 sample.30 NOUN fnp-2993 33 36 in in ADP fnp-2993 33 37 a a DET fnp-2993 33 38 clinical clinical ADJ fnp-2993 33 39 setting setting NOUN fnp-2993 33 40 , , PUNCT fnp-2993 33 41 the the DET fnp-2993 33 42 sensitivity sensitivity NOUN fnp-2993 33 43 of of ADP fnp-2993 33 44 rt rt PROPN fnp-2993 33 45 - - PUNCT fnp-2993 33 46 pcr pcr PROPN fnp-2993 33 47 may may AUX fnp-2993 33 48 be be AUX fnp-2993 33 49 83.3 83.3 NUM fnp-2993 33 50 % % NOUN fnp-2993 33 51 or or CCONJ fnp-2993 33 52 significantly significantly ADV fnp-2993 33 53 less less ADV fnp-2993 33 54 , , PUNCT fnp-2993 33 55 and and CCONJ fnp-2993 33 56 may may AUX fnp-2993 33 57 be be AUX fnp-2993 33 58 affected affect VERB fnp-2993 33 59 by by ADP fnp-2993 33 60 infection infection NOUN fnp-2993 33 61 phase phase NOUN fnp-2993 33 62 , , PUNCT fnp-2993 33 63 sample sample NOUN fnp-2993 33 64 type type NOUN fnp-2993 33 65 , , PUNCT fnp-2993 33 66 collection collection NOUN fnp-2993 33 67 procedures procedure NOUN fnp-2993 33 68 , , PUNCT fnp-2993 33 69 and and CCONJ fnp-2993 33 70 testing testing NOUN fnp-2993 33 71 platforms.31,32 platforms.31,32 NOUN fnp-2993 33 72 covid-19 covid-19 PROPN fnp-2993 33 73 rt rt PROPN fnp-2993 33 74 - - PUNCT fnp-2993 33 75 pcr pcr NOUN fnp-2993 33 76 testing testing NOUN fnp-2993 33 77 may may AUX fnp-2993 33 78 produce produce VERB fnp-2993 33 79 false false ADJ fnp-2993 33 80 - - PUNCT fnp-2993 33 81 negative negative ADJ fnp-2993 33 82 results result NOUN fnp-2993 33 83 in in ADP fnp-2993 33 84 the the DET fnp-2993 33 85 initial initial ADJ fnp-2993 33 86 phase phase NOUN fnp-2993 33 87 of of ADP fnp-2993 33 88 infection infection NOUN fnp-2993 33 89 . . PUNCT fnp-2993 34 1 in in ADP fnp-2993 34 2 sequential sequential ADJ fnp-2993 34 3 testing testing NOUN fnp-2993 34 4 of of ADP fnp-2993 34 5 patients patient NOUN fnp-2993 34 6 who who PRON fnp-2993 34 7 have have VERB fnp-2993 34 8 symptoms symptom NOUN fnp-2993 34 9 , , PUNCT fnp-2993 34 10 suspicious suspicious ADJ fnp-2993 34 11 chest chest NOUN fnp-2993 34 12 computed compute VERB fnp-2993 34 13 tomography tomography NOUN fnp-2993 34 14 ( ( PUNCT fnp-2993 34 15 ct ct NOUN fnp-2993 34 16 ) ) PUNCT fnp-2993 34 17 findings finding NOUN fnp-2993 34 18 and and CCONJ fnp-2993 34 19 an an DET fnp-2993 34 20 initial initial ADJ fnp-2993 34 21 negative negative ADJ fnp-2993 34 22 rt rt ADJ fnp-2993 34 23 - - PUNCT fnp-2993 34 24 pcr pcr ADJ fnp-2993 34 25 test test NOUN fnp-2993 34 26 , , PUNCT fnp-2993 34 27 covid-19 covid-19 PROPN fnp-2993 34 28 rt rt PROPN fnp-2993 34 29 - - PUNCT fnp-2993 34 30 pcr pcr PROPN fnp-2993 34 31 positivity positivity NOUN fnp-2993 34 32 occurs occur VERB fnp-2993 34 33 at at ADP fnp-2993 34 34 a a DET fnp-2993 34 35 mean mean NOUN fnp-2993 34 36 of of ADP fnp-2993 34 37 5.1 5.1 NUM fnp-2993 34 38 ± ± NUM fnp-2993 34 39 1.5 1.5 NUM fnp-2993 34 40 days day NOUN fnp-2993 34 41 after after SCONJ fnp-2993 34 42 the the DET fnp-2993 34 43 initial initial ADJ fnp-2993 34 44 test.32 test.32 VERB fnp-2993 34 45 a a DET fnp-2993 34 46 patient patient NOUN fnp-2993 34 47 with with ADP fnp-2993 34 48 a a DET fnp-2993 34 49 negative negative ADJ fnp-2993 34 50 rt rt ADJ fnp-2993 34 51 - - PUNCT fnp-2993 34 52 pcr pcr ADJ fnp-2993 34 53 test test NOUN fnp-2993 34 54 result result NOUN fnp-2993 34 55 in in ADP fnp-2993 34 56 a a DET fnp-2993 34 57 nasopharyngeal nasopharyngeal ADJ fnp-2993 34 58 swab swab NOUN fnp-2993 34 59 but but CCONJ fnp-2993 34 60 with with ADP fnp-2993 34 61 a a DET fnp-2993 34 62 positive positive ADJ fnp-2993 34 63 sars sar NOUN fnp-2993 34 64 - - PUNCT fnp-2993 34 65 cov-2 cov-2 NOUN fnp-2993 34 66 cerebrospinal cerebrospinal ADJ fnp-2993 34 67 fluid fluid NOUN fnp-2993 34 68 ( ( PUNCT fnp-2993 34 69 csf csf NOUN fnp-2993 34 70 ) ) PUNCT fnp-2993 34 71 test test NOUN fnp-2993 34 72 has have AUX fnp-2993 34 73 been be AUX fnp-2993 34 74 reported.33 reported.33 NOUN fnp-2993 34 75 while while SCONJ fnp-2993 34 76 rt rt ADJ fnp-2993 34 77 - - PUNCT fnp-2993 34 78 pcr pcr ADJ fnp-2993 34 79 detection detection NOUN fnp-2993 34 80 of of ADP fnp-2993 34 81 genomic genomic ADJ fnp-2993 34 82 rna rna NOUN fnp-2993 34 83 is be AUX fnp-2993 34 84 not not PART fnp-2993 34 85 specific specific ADJ fnp-2993 34 86 for for ADP fnp-2993 34 87 viable viable ADJ fnp-2993 34 88 virus virus NOUN fnp-2993 34 89 , , PUNCT fnp-2993 34 90 identification identification NOUN fnp-2993 34 91 of of ADP fnp-2993 34 92 sub sub ADJ fnp-2993 34 93 - - ADJ fnp-2993 34 94 genomic genomic ADJ fnp-2993 34 95 rnas rna NOUN fnp-2993 34 96 transcribed transcribe VERB fnp-2993 34 97 in in ADP fnp-2993 34 98 infected infected ADJ fnp-2993 34 99 cells cell NOUN fnp-2993 34 100 have have AUX fnp-2993 34 101 been be AUX fnp-2993 34 102 used use VERB fnp-2993 34 103 in in ADP fnp-2993 34 104 clinical clinical ADJ fnp-2993 34 105 testing testing NOUN fnp-2993 34 106 to to PART fnp-2993 34 107 document document VERB fnp-2993 34 108 the the DET fnp-2993 34 109 presence presence NOUN fnp-2993 34 110 of of ADP fnp-2993 34 111 actively actively ADV fnp-2993 34 112 replicating replicate VERB fnp-2993 34 113 virus virus NOUN fnp-2993 34 114 in in ADP fnp-2993 34 115 lieu lieu NOUN fnp-2993 34 116 of of ADP fnp-2993 34 117 viral viral ADJ fnp-2993 34 118 cultures.34 cultures.34 NOUN fnp-2993 34 119 although although SCONJ fnp-2993 34 120 chest chest NOUN fnp-2993 34 121 ct ct PROPN fnp-2993 34 122 scans scan NOUN fnp-2993 34 123 may may AUX fnp-2993 34 124 detect detect VERB fnp-2993 34 125 signs sign NOUN fnp-2993 34 126 of of ADP fnp-2993 34 127 covid-19 covid-19 PROPN fnp-2993 34 128 days day NOUN fnp-2993 34 129 before before ADP fnp-2993 34 130 rt rt PROPN fnp-2993 34 131 - - PUNCT fnp-2993 34 132 pcr pcr PROPN fnp-2993 34 133 positivity positivity NOUN fnp-2993 34 134 , , PUNCT fnp-2993 34 135 ct ct PROPN fnp-2993 34 136 findings finding NOUN fnp-2993 34 137 overlap overlap VERB fnp-2993 34 138 with with ADP fnp-2993 34 139 other other ADJ fnp-2993 34 140 viral viral ADJ fnp-2993 34 141 pneumonias.35 pneumonias.35 NOUN fnp-2993 34 142 serologic serologic NOUN fnp-2993 34 143 testing testing NOUN fnp-2993 34 144 has have AUX fnp-2993 34 145 uses use NOUN fnp-2993 34 146 for for ADP fnp-2993 34 147 contact contact NOUN fnp-2993 34 148 tracing tracing NOUN fnp-2993 34 149 , , PUNCT fnp-2993 34 150 epidemiology epidemiology NOUN fnp-2993 34 151 , , PUNCT fnp-2993 34 152 and and CCONJ fnp-2993 34 153 vaccine vaccine NOUN fnp-2993 34 154 studies study NOUN fnp-2993 34 155 but but CCONJ fnp-2993 34 156 is be AUX fnp-2993 34 157 more more ADV fnp-2993 34 158 challenging challenging ADJ fnp-2993 34 159 to to PART fnp-2993 34 160 use use VERB fnp-2993 34 161 for for ADP fnp-2993 34 162 primary primary ADJ fnp-2993 34 163 diagnosis diagnosis NOUN fnp-2993 34 164 given give VERB fnp-2993 34 165 the the DET fnp-2993 34 166 latency latency NOUN fnp-2993 34 167 for for ADP fnp-2993 34 168 development development NOUN fnp-2993 34 169 of of ADP fnp-2993 34 170 antibodies.36–40 antibodies.36–40 PUNCT fnp-2993 34 171 the the DET fnp-2993 34 172 most most ADV fnp-2993 34 173 common common ADJ fnp-2993 34 174 serological serological ADJ fnp-2993 34 175 assays assay NOUN fnp-2993 34 176 are be AUX fnp-2993 34 177 the the DET fnp-2993 34 178 rapid rapid ADJ fnp-2993 34 179 lateral lateral ADJ fnp-2993 34 180 flow flow NOUN fnp-2993 34 181 assay assay NOUN fnp-2993 34 182 , , PUNCT fnp-2993 34 183 enzyme enzyme NOUN fnp-2993 34 184 linked link VERB fnp-2993 34 185 immunosorbent immunosorbent ADJ fnp-2993 34 186 assay assay PROPN fnp-2993 34 187 ( ( PUNCT fnp-2993 34 188 elisa elisa NOUN fnp-2993 34 189 ) ) PUNCT fnp-2993 34 190 , , PUNCT fnp-2993 34 191 and and CCONJ fnp-2993 34 192 virus virus NOUN fnp-2993 34 193 neutralization neutralization NOUN fnp-2993 34 194 assay assay VERB fnp-2993 34 195 . . PUNCT fnp-2993 35 1 two two NUM fnp-2993 35 2 - - PUNCT fnp-2993 35 3 step step NOUN fnp-2993 35 4 elisa elisa NOUN fnp-2993 35 5 assays assay NOUN fnp-2993 35 6 are be AUX fnp-2993 35 7 quantitative quantitative ADJ fnp-2993 35 8 and and CCONJ fnp-2993 35 9 more more ADV fnp-2993 35 10 reliable reliable ADJ fnp-2993 35 11 than than ADP fnp-2993 35 12 flow flow NOUN fnp-2993 35 13 assays assay NOUN fnp-2993 35 14 that that PRON fnp-2993 35 15 are be AUX fnp-2993 35 16 easily easily ADV fnp-2993 35 17 scalable scalable ADJ fnp-2993 35 18 but but CCONJ fnp-2993 35 19 are be AUX fnp-2993 35 20 qualitative.40 qualitative.40 PROPN fnp-2993 35 21 the the DET fnp-2993 35 22 virus virus NOUN fnp-2993 35 23 neutralization neutralization NOUN fnp-2993 35 24 assay assay VERB fnp-2993 35 25 detects detect NOUN fnp-2993 35 26 and and CCONJ fnp-2993 35 27 quantifies quantifie NOUN fnp-2993 35 28 antibodies antibodie VERB fnp-2993 35 29 that that PRON fnp-2993 35 30 inhibit inhibit VERB fnp-2993 35 31 viral viral ADJ fnp-2993 35 32 replication replication NOUN fnp-2993 35 33 but but CCONJ fnp-2993 35 34 is be AUX fnp-2993 35 35 technically technically ADV fnp-2993 35 36 complex.37 complex.37 PROPN fnp-2993 35 37 5 5 NUM fnp-2993 35 38 . . PUNCT fnp-2993 36 1 systemic systemic ADJ fnp-2993 36 2 pathophysiology pathophysiology NOUN fnp-2993 36 3 of of ADP fnp-2993 36 4 covid-19 covid-19 PROPN fnp-2993 36 5 in in ADP fnp-2993 36 6 the the DET fnp-2993 36 7 first first ADJ fnp-2993 36 8 stage stage NOUN fnp-2993 36 9 of of ADP fnp-2993 36 10 infection infection NOUN fnp-2993 37 1 , , PUNCT fnp-2993 37 2 sars sar NOUN fnp-2993 37 3 - - PUNCT fnp-2993 37 4 cov-2 cov-2 NOUN fnp-2993 37 5 targets target NOUN fnp-2993 37 6 nasal nasal NOUN fnp-2993 37 7 and and CCONJ fnp-2993 37 8 bronchial bronchial ADJ fnp-2993 37 9 epithelial epithelial ADJ fnp-2993 37 10 cells cell NOUN fnp-2993 37 11 as as ADV fnp-2993 37 12 well well ADV fnp-2993 37 13 as as ADP fnp-2993 37 14 pneumocytes.28 pneumocytes.28 NOUN fnp-2993 37 15 as as ADP fnp-2993 37 16 infection infection NOUN fnp-2993 37 17 progresses progress NOUN fnp-2993 37 18 , , PUNCT fnp-2993 37 19 sars sar NOUN fnp-2993 37 20 - - PUNCT fnp-2993 37 21 cov-2 cov-2 NOUN fnp-2993 37 22 infects infect VERB fnp-2993 37 23 pulmonary pulmonary ADJ fnp-2993 37 24 endothelial endothelial ADJ fnp-2993 37 25 cells cell NOUN fnp-2993 37 26 , , PUNCT fnp-2993 37 27 abrogating abrogate VERB fnp-2993 37 28 the the DET fnp-2993 37 29 epithelial epithelial ADJ fnp-2993 37 30 - - PUNCT fnp-2993 37 31 endothelial endothelial NOUN fnp-2993 37 32 barrier.41 barrier.41 NOUN fnp-2993 37 33 a a DET fnp-2993 37 34 subsequent subsequent ADJ fnp-2993 37 35 ingress ingress NOUN fnp-2993 37 36 of of ADP fnp-2993 37 37 neutrophils neutrophil NOUN fnp-2993 37 38 and and CCONJ fnp-2993 37 39 monocytes monocyte NOUN fnp-2993 37 40 is be AUX fnp-2993 37 41 followed follow VERB fnp-2993 37 42 by by ADP fnp-2993 37 43 pulmonary pulmonary ADJ fnp-2993 37 44 edema edema NOUN fnp-2993 37 45 and and CCONJ fnp-2993 37 46 hyaline hyaline ADJ fnp-2993 37 47 membrane membrane NOUN fnp-2993 37 48 formation formation NOUN fnp-2993 37 49 , , PUNCT fnp-2993 37 50 a a DET fnp-2993 37 51 component component NOUN fnp-2993 37 52 of of ADP fnp-2993 37 53 early early ADJ fnp-2993 37 54 acute acute ADJ fnp-2993 37 55 respiratory respiratory ADJ fnp-2993 37 56 distress distress NOUN fnp-2993 37 57 syndrome syndrome NOUN fnp-2993 37 58 ( ( PUNCT fnp-2993 37 59 ards).41,42 ards).41,42 ADP fnp-2993 37 60 in in ADP fnp-2993 37 61 severe severe ADJ fnp-2993 37 62 covid-19 covid-19 PROPN fnp-2993 37 63 , , PUNCT fnp-2993 37 64 coagulopathy coagulopathy ADJ fnp-2993 37 65 can can AUX fnp-2993 37 66 occur occur VERB fnp-2993 37 67 , , PUNCT fnp-2993 37 68 reflecting reflect VERB fnp-2993 37 69 microthrombi microthrombi NOUN fnp-2993 37 70 formation formation NOUN fnp-2993 37 71 secondary secondary ADJ fnp-2993 37 72 to to ADP fnp-2993 37 73 endothelial endothelial ADJ fnp-2993 37 74 cell cell NOUN fnp-2993 37 75 inflammation inflammation NOUN fnp-2993 37 76 and and CCONJ fnp-2993 37 77 cytokine cytokine VERB fnp-2993 37 78 storms.41,43 storms.41,43 ADJ fnp-2993 37 79 covid-19 covid-19 PROPN fnp-2993 37 80 associated associate VERB fnp-2993 37 81 hypercoagulability hypercoagulability NOUN fnp-2993 37 82 induces induce VERB fnp-2993 37 83 venous venous ADJ fnp-2993 37 84 thromboembolism thromboembolism NOUN fnp-2993 37 85 and and CCONJ fnp-2993 37 86 arterial arterial NOUN fnp-2993 37 87 occlusion.41 occlusion.41 NOUN fnp-2993 37 88 the the DET fnp-2993 37 89 interplay interplay NOUN fnp-2993 37 90 of of ADP fnp-2993 37 91 these these DET fnp-2993 37 92 systemic systemic ADJ fnp-2993 37 93 derangements derangement NOUN fnp-2993 37 94 likely likely ADV fnp-2993 37 95 contributes contribute VERB fnp-2993 37 96 to to ADP fnp-2993 37 97 the the DET fnp-2993 37 98 pathologic pathologic ADJ fnp-2993 37 99 changes change NOUN fnp-2993 37 100 seen see VERB fnp-2993 37 101 in in ADP fnp-2993 37 102 the the DET fnp-2993 37 103 cns cns NOUN fnp-2993 37 104 ( ( PUNCT fnp-2993 37 105 figure figure NOUN fnp-2993 37 106 2 2 NUM fnp-2993 37 107 ) ) PUNCT fnp-2993 37 108 . . PUNCT fnp-2993 38 1 figure figure NOUN fnp-2993 38 2 2 2 NUM fnp-2993 38 3 : : PUNCT fnp-2993 38 4 flow flow VERB fnp-2993 38 5 chart chart NOUN fnp-2993 38 6 modeling model VERB fnp-2993 38 7 covid-19 covid-19 PROPN fnp-2993 38 8 pathogenesis pathogenesis NOUN fnp-2993 38 9 and and CCONJ fnp-2993 38 10 neurological neurological ADJ fnp-2993 38 11 dysfunction dysfunction NOUN fnp-2993 38 12 . . PUNCT fnp-2993 39 1 adem= adem= NOUN fnp-2993 39 2 acute acute NOUN fnp-2993 39 3 disseminated disseminate VERB fnp-2993 39 4 encephalomyelitis encephalomyelitis NOUN fnp-2993 39 5 ; ; PUNCT fnp-2993 39 6 ane= ane= PROPN fnp-2993 39 7 acute acute NOUN fnp-2993 39 8 necrotizing necrotizing NOUN fnp-2993 39 9 encephalopathy encephalopathy NOUN fnp-2993 39 10 ; ; PUNCT fnp-2993 39 11 gbs= gbs= PROPN fnp-2993 39 12 guillain guillain NOUN fnp-2993 39 13 - - PUNCT fnp-2993 39 14 barré barré NOUN fnp-2993 39 15 syndrome syndrome NOUN fnp-2993 39 16 . . PUNCT fnp-2993 40 1 6 6 X fnp-2993 40 2 . . X fnp-2993 40 3 covid-19 covid-19 PROPN fnp-2993 40 4 neurological neurological ADJ fnp-2993 40 5 manifestations manifestation NOUN fnp-2993 40 6 covid-19 covid-19 PROPN fnp-2993 40 7 associated associate VERB fnp-2993 40 8 neurological neurological ADJ fnp-2993 40 9 manifestations manifestation NOUN fnp-2993 40 10 range range VERB fnp-2993 40 11 from from ADP fnp-2993 40 12 mild mild ADJ fnp-2993 40 13 symptoms symptom NOUN fnp-2993 40 14 such such ADJ fnp-2993 40 15 as as ADP fnp-2993 40 16 dizziness dizziness NOUN fnp-2993 40 17 , , PUNCT fnp-2993 40 18 headache headache NOUN fnp-2993 40 19 , , PUNCT fnp-2993 40 20 dysgeusia dysgeusia NOUN fnp-2993 40 21 , , PUNCT fnp-2993 40 22 or or CCONJ fnp-2993 40 23 anosmia anosmia NOUN fnp-2993 40 24 to to ADP fnp-2993 40 25 severe severe ADJ fnp-2993 40 26 disorders disorder NOUN fnp-2993 40 27 such such ADJ fnp-2993 40 28 as as ADP fnp-2993 40 29 stroke stroke NOUN fnp-2993 40 30 , , PUNCT fnp-2993 40 31 guillain guillain NOUN fnp-2993 40 32 - - PUNCT fnp-2993 40 33 barré barré PROPN fnp-2993 40 34 syndrome syndrome PROPN fnp-2993 40 35 ( ( PUNCT fnp-2993 40 36 gbs gbs PROPN fnp-2993 40 37 ) ) PUNCT fnp-2993 40 38 , , PUNCT fnp-2993 40 39 acute acute ADJ fnp-2993 40 40 hemorrhagic hemorrhagic NOUN fnp-2993 40 41 necrotizing necrotizing NOUN fnp-2993 40 42 encephalopathy encephalopathy NOUN fnp-2993 40 43 , , PUNCT fnp-2993 40 44 meningoencephalitis meningoencephalitis NOUN fnp-2993 40 45 , , PUNCT fnp-2993 40 46 and and CCONJ fnp-2993 40 47 cerebral cerebral ADJ fnp-2993 40 48 venous venous ADJ fnp-2993 40 49 thrombosis thrombosis NOUN fnp-2993 40 50 . . PUNCT fnp-2993 41 1 the the DET fnp-2993 41 2 frequency frequency NOUN fnp-2993 41 3 of of ADP fnp-2993 41 4 reported report VERB fnp-2993 41 5 neurological neurological ADJ fnp-2993 41 6 signs sign NOUN fnp-2993 41 7 and and CCONJ fnp-2993 41 8 symptoms symptom NOUN fnp-2993 41 9 is be AUX fnp-2993 41 10 variable variable ADJ fnp-2993 41 11 but but CCONJ fnp-2993 41 12 substantial substantial ADJ fnp-2993 41 13 regardless regardless ADV fnp-2993 41 14 . . PUNCT fnp-2993 42 1 in in ADP fnp-2993 42 2 an an DET fnp-2993 42 3 early early ADJ fnp-2993 42 4 chinese chinese ADJ fnp-2993 42 5 retrospective retrospective ADJ fnp-2993 42 6 study study NOUN fnp-2993 42 7 , , PUNCT fnp-2993 42 8 36.4 36.4 NUM fnp-2993 42 9 % % NOUN fnp-2993 42 10 of of ADP fnp-2993 42 11 214 214 NUM fnp-2993 42 12 covid-19 covid-19 PROPN fnp-2993 42 13 patients patient NOUN fnp-2993 42 14 had have VERB fnp-2993 42 15 neurological neurological ADJ fnp-2993 42 16 symptoms symptom NOUN fnp-2993 42 17 which which PRON fnp-2993 42 18 included include VERB fnp-2993 42 19 dizziness dizziness NOUN fnp-2993 42 20 ( ( PUNCT fnp-2993 42 21 16.8 16.8 NUM fnp-2993 42 22 % % NOUN fnp-2993 42 23 ) ) PUNCT fnp-2993 42 24 , , PUNCT fnp-2993 42 25 headache headache NOUN fnp-2993 42 26 ( ( PUNCT fnp-2993 42 27 13.1 13.1 NUM fnp-2993 42 28 % % NOUN fnp-2993 42 29 ) ) PUNCT fnp-2993 42 30 , , PUNCT fnp-2993 42 31 impaired impaired ADJ fnp-2993 42 32 consciousness consciousness NOUN fnp-2993 42 33 ( ( PUNCT fnp-2993 42 34 7.5 7.5 NUM fnp-2993 42 35 % % NOUN fnp-2993 42 36 ) ) PUNCT fnp-2993 42 37 , , PUNCT fnp-2993 42 38 dysgeusia dysgeusia PROPN fnp-2993 42 39 ( ( PUNCT fnp-2993 42 40 5.6 5.6 NUM fnp-2993 42 41 % % NOUN fnp-2993 42 42 ) ) PUNCT fnp-2993 42 43 , , PUNCT fnp-2993 42 44 and and CCONJ fnp-2993 42 45 anosmia anosmia NOUN fnp-2993 42 46 ( ( PUNCT fnp-2993 42 47 5.1%).44 5.1%).44 NUM fnp-2993 42 48 in in ADP fnp-2993 42 49 western western ADJ fnp-2993 42 50 studies study NOUN fnp-2993 42 51 , , PUNCT fnp-2993 42 52 dysgeusia dysgeusia PROPN fnp-2993 42 53 and and CCONJ fnp-2993 42 54 anosmia anosmia NOUN fnp-2993 42 55 are be AUX fnp-2993 42 56 reported report VERB fnp-2993 42 57 in in ADP fnp-2993 42 58 the the DET fnp-2993 42 59 majority majority NOUN fnp-2993 42 60 of of ADP fnp-2993 42 61 patients.45,46 patients.45,46 PROPN fnp-2993 42 62 a a DET fnp-2993 42 63 french french ADJ fnp-2993 42 64 study study NOUN fnp-2993 42 65 reports report VERB fnp-2993 42 66 that that SCONJ fnp-2993 42 67 49 49 NUM fnp-2993 42 68 out out ADP fnp-2993 42 69 of of ADP fnp-2993 42 70 58 58 NUM fnp-2993 42 71 ( ( PUNCT fnp-2993 42 72 84 84 NUM fnp-2993 42 73 % % NOUN fnp-2993 42 74 ) ) PUNCT fnp-2993 43 1 covid-19 covid-19 PROPN fnp-2993 43 2 intensive intensive ADJ fnp-2993 43 3 care care NOUN fnp-2993 43 4 unit unit NOUN fnp-2993 43 5 ( ( PUNCT fnp-2993 43 6 icu icu PROPN fnp-2993 43 7 ) ) PUNCT fnp-2993 43 8 patients patient NOUN fnp-2993 43 9 had have VERB fnp-2993 43 10 neurological neurological ADJ fnp-2993 43 11 signs sign NOUN fnp-2993 43 12 which which PRON fnp-2993 43 13 included include VERB fnp-2993 43 14 agitation agitation NOUN fnp-2993 43 15 ( ( PUNCT fnp-2993 43 16 69 69 NUM fnp-2993 43 17 % % NOUN fnp-2993 43 18 ) ) PUNCT fnp-2993 43 19 , , PUNCT fnp-2993 43 20 confusion confusion NOUN fnp-2993 43 21 ( ( PUNCT fnp-2993 43 22 65 65 NUM fnp-2993 43 23 % % NOUN fnp-2993 43 24 ) ) PUNCT fnp-2993 43 25 , , PUNCT fnp-2993 43 26 corticospinal corticospinal ADJ fnp-2993 43 27 tract tract NOUN fnp-2993 43 28 signs sign NOUN fnp-2993 43 29 ( ( PUNCT fnp-2993 43 30 67 67 NUM fnp-2993 43 31 % % NOUN fnp-2993 43 32 ) ) PUNCT fnp-2993 43 33 , , PUNCT fnp-2993 43 34 and and CCONJ fnp-2993 43 35 dysexecutive dysexecutive ADJ fnp-2993 43 36 syndrome syndrome NOUN fnp-2993 43 37 ( ( PUNCT fnp-2993 43 38 33%).47 33%).47 NUM fnp-2993 43 39 a a DET fnp-2993 43 40 study study NOUN fnp-2993 43 41 from from ADP fnp-2993 43 42 a a DET fnp-2993 43 43 british british ADJ fnp-2993 43 44 referral referral ADJ fnp-2993 43 45 center center NOUN fnp-2993 43 46 also also ADV fnp-2993 43 47 describes describe VERB fnp-2993 43 48 cases case NOUN fnp-2993 43 49 of of ADP fnp-2993 43 50 septic septic ADJ fnp-2993 43 51 or or CCONJ fnp-2993 43 52 para para NOUN fnp-2993 43 53 - - PUNCT fnp-2993 43 54 infectious infectious ADJ fnp-2993 43 55 encephalopathy encephalopathy NOUN fnp-2993 43 56 , , PUNCT fnp-2993 43 57 autoimmune autoimmune ADJ fnp-2993 43 58 encephalitis encephalitis NOUN fnp-2993 43 59 including include VERB fnp-2993 43 60 acute acute NOUN fnp-2993 43 61 disseminated disseminate VERB fnp-2993 43 62 encephalomyelitis encephalomyelitis NOUN fnp-2993 43 63 ( ( PUNCT fnp-2993 43 64 adem adem PROPN fnp-2993 43 65 ) ) PUNCT fnp-2993 43 66 , , PUNCT fnp-2993 43 67 and and CCONJ fnp-2993 43 68 gbs.48 gbs.48 X fnp-2993 43 69 7 7 NUM fnp-2993 43 70 . . PUNCT fnp-2993 43 71 specific specific ADJ fnp-2993 43 72 neurological neurological ADJ fnp-2993 43 73 disorders disorder NOUN fnp-2993 43 74 associated associate VERB fnp-2993 43 75 with with ADP fnp-2993 43 76 covid-19 covid-19 PROPN fnp-2993 43 77 olfactory olfactory NOUN fnp-2993 43 78 and and CCONJ fnp-2993 43 79 gustatory gustatory ADJ fnp-2993 43 80 dysfunction dysfunction NOUN fnp-2993 43 81 in in ADP fnp-2993 43 82 the the DET fnp-2993 43 83 aforementioned aforementioned ADJ fnp-2993 43 84 study study NOUN fnp-2993 43 85 from from ADP fnp-2993 43 86 china china PROPN fnp-2993 43 87 , , PUNCT fnp-2993 43 88 covid-19 covid-19 PROPN fnp-2993 43 89 patients patient NOUN fnp-2993 43 90 had have VERB fnp-2993 43 91 gustatory gustatory ADJ fnp-2993 43 92 dysfunction dysfunction NOUN fnp-2993 43 93 and and CCONJ fnp-2993 43 94 olfactory olfactory ADJ fnp-2993 43 95 dysfunction dysfunction NOUN fnp-2993 43 96 at at ADP fnp-2993 43 97 frequencies frequency NOUN fnp-2993 43 98 of of ADP fnp-2993 43 99 less less ADJ fnp-2993 43 100 than than ADP fnp-2993 43 101 6 6 NUM fnp-2993 43 102 % % NOUN fnp-2993 43 103 each.44 each.44 NOUN fnp-2993 43 104 in in ADP fnp-2993 43 105 a a DET fnp-2993 43 106 prospective prospective ADJ fnp-2993 43 107 european european ADJ fnp-2993 43 108 study study NOUN fnp-2993 43 109 , , PUNCT fnp-2993 43 110 88.8 88.8 NUM fnp-2993 43 111 % % NOUN fnp-2993 43 112 of of ADP fnp-2993 43 113 385 385 NUM fnp-2993 43 114 covid-19 covid-19 PROPN fnp-2993 43 115 patients patient NOUN fnp-2993 43 116 had have VERB fnp-2993 43 117 gustatory gustatory ADJ fnp-2993 43 118 dysfunction dysfunction NOUN fnp-2993 43 119 and and CCONJ fnp-2993 43 120 85.6 85.6 NUM fnp-2993 43 121 % % NOUN fnp-2993 43 122 of of ADP fnp-2993 43 123 417 417 NUM fnp-2993 43 124 covid-19 covid-19 PROPN fnp-2993 43 125 patients patient NOUN fnp-2993 43 126 had have VERB fnp-2993 43 127 olfactory olfactory ADJ fnp-2993 43 128 dysfunction.45 dysfunction.45 NOUN fnp-2993 43 129 in in ADP fnp-2993 43 130 a a DET fnp-2993 43 131 california california PROPN fnp-2993 43 132 study study NOUN fnp-2993 43 133 , , PUNCT fnp-2993 43 134 71 71 NUM fnp-2993 43 135 % % NOUN fnp-2993 43 136 of of ADP fnp-2993 43 137 59 59 NUM fnp-2993 43 138 covid-19 covid-19 PROPN fnp-2993 43 139 patients patient NOUN fnp-2993 43 140 recorded record VERB fnp-2993 43 141 ageusia ageusia NOUN fnp-2993 43 142 and and CCONJ fnp-2993 43 143 68 68 NUM fnp-2993 43 144 % % NOUN fnp-2993 43 145 reported report VERB fnp-2993 43 146 anosmia.46 anosmia.46 NOUN fnp-2993 43 147 olfactory olfactory NOUN fnp-2993 43 148 and and CCONJ fnp-2993 43 149 gustatory gustatory ADJ fnp-2993 43 150 dysfunction dysfunction NOUN fnp-2993 43 151 in in ADP fnp-2993 43 152 covid-19 covid-19 PROPN fnp-2993 43 153 typically typically ADV fnp-2993 43 154 resolves resolve VERB fnp-2993 43 155 after after ADP fnp-2993 43 156 17 17 NUM fnp-2993 43 157 to to PART fnp-2993 43 158 30 30 NUM fnp-2993 43 159 days day NOUN fnp-2993 43 160 from from ADP fnp-2993 43 161 initial initial ADJ fnp-2993 43 162 onset.49,50 onset.49,50 NOUN fnp-2993 43 163 although although SCONJ fnp-2993 43 164 long long ADJ fnp-2993 43 165 term term NOUN fnp-2993 43 166 follow follow NOUN fnp-2993 43 167 - - PUNCT fnp-2993 43 168 up up NOUN fnp-2993 43 169 is be AUX fnp-2993 43 170 generally generally ADV fnp-2993 43 171 lacking,51 lacking,51 NOUN fnp-2993 43 172 one one NUM fnp-2993 43 173 study study NOUN fnp-2993 43 174 reports report NOUN fnp-2993 43 175 resolution resolution NOUN fnp-2993 43 176 rates rate NOUN fnp-2993 43 177 at at ADP fnp-2993 43 178 day day NOUN fnp-2993 43 179 30 30 NUM fnp-2993 43 180 in in ADP fnp-2993 43 181 home home NOUN fnp-2993 43 182 - - PUNCT fnp-2993 43 183 quarantined quarantine VERB fnp-2993 43 184 covid-19 covid-19 PROPN fnp-2993 43 185 patients patient NOUN fnp-2993 43 186 of of ADP fnp-2993 43 187 87 87 NUM fnp-2993 43 188 % % NOUN fnp-2993 43 189 for for ADP fnp-2993 43 190 olfactory olfactory ADJ fnp-2993 43 191 dysfunction dysfunction NOUN fnp-2993 43 192 and and CCONJ fnp-2993 43 193 82 82 NUM fnp-2993 43 194 % % NOUN fnp-2993 43 195 for for ADP fnp-2993 43 196 gustatory gustatory NOUN fnp-2993 43 197 dysfunction.52 dysfunction.52 ADJ fnp-2993 43 198 presence presence NOUN fnp-2993 43 199 of of ADP fnp-2993 43 200 sars sar NOUN fnp-2993 43 201 - - PUNCT fnp-2993 43 202 cov-2 cov-2 NOUN fnp-2993 43 203 virions virion NOUN fnp-2993 43 204 in in ADP fnp-2993 43 205 the the DET fnp-2993 43 206 olfactory olfactory NOUN fnp-2993 43 207 neuroepithelium neuroepithelium NOUN fnp-2993 43 208 of of ADP fnp-2993 43 209 the the DET fnp-2993 43 210 nasal nasal ADJ fnp-2993 43 211 mucosa mucosa PROPN fnp-2993 43 212 as as ADV fnp-2993 43 213 well well ADV fnp-2993 43 214 as as ADP fnp-2993 43 215 in in ADP fnp-2993 43 216 the the DET fnp-2993 43 217 olfactory olfactory NOUN fnp-2993 43 218 bulb bulb NOUN fnp-2993 43 219 has have AUX fnp-2993 43 220 been be AUX fnp-2993 43 221 documented53,54 documented53,54 NOUN fnp-2993 43 222 though though SCONJ fnp-2993 43 223 the the DET fnp-2993 43 224 exact exact ADJ fnp-2993 43 225 basis basis NOUN fnp-2993 43 226 for for ADP fnp-2993 43 227 olfactory olfactory ADJ fnp-2993 43 228 dysfunction dysfunction NOUN fnp-2993 43 229 and and CCONJ fnp-2993 43 230 recovery recovery NOUN fnp-2993 43 231 remains remain VERB fnp-2993 43 232 to to PART fnp-2993 43 233 be be AUX fnp-2993 43 234 resolved resolve VERB fnp-2993 43 235 . . PUNCT fnp-2993 44 1 stroke stroke NOUN fnp-2993 44 2 stroke stroke PROPN fnp-2993 44 3 is be AUX fnp-2993 44 4 the the DET fnp-2993 44 5 most most ADV fnp-2993 44 6 common common ADJ fnp-2993 44 7 debilitating debilitating ADJ fnp-2993 44 8 neurological neurological ADJ fnp-2993 44 9 disorder disorder NOUN fnp-2993 44 10 associated associate VERB fnp-2993 44 11 with with ADP fnp-2993 44 12 covid-19 covid-19 PROPN fnp-2993 44 13 and and CCONJ fnp-2993 44 14 has have VERB fnp-2993 44 15 a a DET fnp-2993 44 16 predilection predilection NOUN fnp-2993 44 17 for for ADP fnp-2993 44 18 males male NOUN fnp-2993 44 19 and and CCONJ fnp-2993 44 20 the the DET fnp-2993 44 21 elderly elderly ADJ fnp-2993 44 22 . . PUNCT fnp-2993 45 1 two two NUM fnp-2993 45 2 retrospective retrospective ADJ fnp-2993 45 3 new new PROPN fnp-2993 45 4 york york PROPN fnp-2993 45 5 studies study NOUN fnp-2993 45 6 reported report VERB fnp-2993 45 7 respectively respectively ADV fnp-2993 45 8 that that SCONJ fnp-2993 45 9 1.6 1.6 NUM fnp-2993 45 10 % % NOUN fnp-2993 45 11 of of ADP fnp-2993 45 12 1,916 1,916 NUM fnp-2993 45 13 patients patient NOUN fnp-2993 45 14 with with ADP fnp-2993 45 15 hospitalizations hospitalization NOUN fnp-2993 45 16 or or CCONJ fnp-2993 45 17 emergency emergency NOUN fnp-2993 45 18 department department NOUN fnp-2993 45 19 visits visit NOUN fnp-2993 45 20 for for ADP fnp-2993 45 21 covid-19 covid-19 PROPN fnp-2993 45 22 and and CCONJ fnp-2993 45 23 0.9 0.9 NUM fnp-2993 45 24 % % NOUN fnp-2993 45 25 of of ADP fnp-2993 45 26 3,556 3,556 NUM fnp-2993 45 27 hospitalized hospitalize VERB fnp-2993 45 28 covid-19 covid-19 PROPN fnp-2993 45 29 patients patient NOUN fnp-2993 45 30 had have AUX fnp-2993 45 31 radiologically radiologically ADV fnp-2993 45 32 - - PUNCT fnp-2993 45 33 confirmed confirm VERB fnp-2993 45 34 ischemic ischemic ADJ fnp-2993 45 35 infarcts.55,56 infarcts.55,56 NOUN fnp-2993 45 36 cryptogenic cryptogenic ADJ fnp-2993 45 37 strokes stroke NOUN fnp-2993 45 38 were be AUX fnp-2993 45 39 twice twice ADV fnp-2993 45 40 as as ADV fnp-2993 45 41 common common ADJ fnp-2993 45 42 in in ADP fnp-2993 45 43 hospitalized hospitalize VERB fnp-2993 45 44 covid-19 covid-19 PROPN fnp-2993 45 45 patients patient NOUN fnp-2993 45 46 compared compare VERB fnp-2993 45 47 to to ADP fnp-2993 45 48 either either CCONJ fnp-2993 45 49 contemporary contemporary ADJ fnp-2993 45 50 or or CCONJ fnp-2993 45 51 historical historical ADJ fnp-2993 45 52 controls.56 controls.56 NOUN fnp-2993 45 53 a a DET fnp-2993 45 54 third third ADJ fnp-2993 45 55 new new PROPN fnp-2993 45 56 york york PROPN fnp-2993 45 57 retrospective retrospective ADJ fnp-2993 45 58 study study NOUN fnp-2993 45 59 found find VERB fnp-2993 45 60 1.1 1.1 NUM fnp-2993 45 61 % % NOUN fnp-2993 45 62 of of ADP fnp-2993 45 63 3,218 3,218 NUM fnp-2993 45 64 covid-19 covid-19 PROPN fnp-2993 45 65 patients patient NOUN fnp-2993 45 66 had have VERB fnp-2993 45 67 strokes stroke NOUN fnp-2993 45 68 ; ; PUNCT fnp-2993 45 69 in in ADP fnp-2993 45 70 the the DET fnp-2993 45 71 small small ADJ fnp-2993 45 72 subset subset NOUN fnp-2993 45 73 with with ADP fnp-2993 45 74 acute acute ADJ fnp-2993 45 75 neuroimaging neuroimaging NOUN fnp-2993 45 76 , , PUNCT fnp-2993 45 77 68.5 68.5 NUM fnp-2993 45 78 % % NOUN fnp-2993 45 79 of of ADP fnp-2993 45 80 strokes stroke NOUN fnp-2993 45 81 were be AUX fnp-2993 45 82 ischemic ischemic ADJ fnp-2993 45 83 ( ( PUNCT fnp-2993 45 84 44.5 44.5 NUM fnp-2993 45 85 % % NOUN fnp-2993 45 86 large large ADJ fnp-2993 45 87 vessel vessel NOUN fnp-2993 45 88 , , PUNCT fnp-2993 45 89 24 24 NUM fnp-2993 45 90 % % NOUN fnp-2993 45 91 lacunar lacunar NOUN fnp-2993 45 92 ) ) PUNCT fnp-2993 45 93 and and CCONJ fnp-2993 45 94 24 24 NUM fnp-2993 45 95 % % NOUN fnp-2993 45 96 were be AUX fnp-2993 45 97 hemorrhagic.57 hemorrhagic.57 PROPN fnp-2993 45 98 a a DET fnp-2993 45 99 retrospective retrospective ADJ fnp-2993 45 100 chinese chinese ADJ fnp-2993 45 101 study study NOUN fnp-2993 45 102 of of ADP fnp-2993 45 103 214 214 NUM fnp-2993 45 104 covid-19 covid-19 PROPN fnp-2993 45 105 patients patient NOUN fnp-2993 45 106 reported report VERB fnp-2993 45 107 strokes stroke NOUN fnp-2993 45 108 in in ADP fnp-2993 45 109 six six NUM fnp-2993 45 110 patients patient NOUN fnp-2993 45 111 ( ( PUNCT fnp-2993 45 112 2.8%).44 2.8%).44 NUM fnp-2993 45 113 a a DET fnp-2993 45 114 small small ADJ fnp-2993 45 115 american american ADJ fnp-2993 45 116 case case NOUN fnp-2993 45 117 series series NOUN fnp-2993 45 118 reported report VERB fnp-2993 45 119 large large ADJ fnp-2993 45 120 vessel vessel NOUN fnp-2993 45 121 ischemic ischemic ADJ fnp-2993 45 122 strokes stroke NOUN fnp-2993 45 123 in in ADP fnp-2993 45 124 five five NUM fnp-2993 45 125 covid-19 covid-19 PROPN fnp-2993 45 126 patients patient NOUN fnp-2993 45 127 younger young ADJ fnp-2993 45 128 than than ADP fnp-2993 45 129 50 50 NUM fnp-2993 45 130 , , PUNCT fnp-2993 45 131 four four NUM fnp-2993 45 132 of of ADP fnp-2993 45 133 whom whom PRON fnp-2993 45 134 had have VERB fnp-2993 45 135 no no DET fnp-2993 45 136 prior prior ADJ fnp-2993 45 137 history history NOUN fnp-2993 45 138 of of ADP fnp-2993 45 139 stroke.58 stroke.58 PROPN fnp-2993 45 140 for for ADP fnp-2993 45 141 comparison comparison NOUN fnp-2993 45 142 , , PUNCT fnp-2993 45 143 the the DET fnp-2993 45 144 average average ADJ fnp-2993 45 145 incidence incidence NOUN fnp-2993 45 146 of of ADP fnp-2993 45 147 stroke stroke NOUN fnp-2993 45 148 among among ADP fnp-2993 45 149 patients patient NOUN fnp-2993 45 150 admitted admit VERB fnp-2993 45 151 through through ADP fnp-2993 45 152 a a DET fnp-2993 45 153 u.s u.s PROPN fnp-2993 45 154 . . PROPN fnp-2993 45 155 emergency emergency PROPN fnp-2993 45 156 department department PROPN fnp-2993 45 157 prior prior ADV fnp-2993 45 158 to to ADP fnp-2993 45 159 the the DET fnp-2993 45 160 pandemic pandemic NOUN fnp-2993 45 161 was be AUX fnp-2993 45 162 approximately approximately ADV fnp-2993 45 163 3.2%.59 3.2%.59 NUM fnp-2993 45 164 of of ADP fnp-2993 45 165 patients patient NOUN fnp-2993 45 166 who who PRON fnp-2993 45 167 visited visit VERB fnp-2993 45 168 emergency emergency NOUN fnp-2993 45 169 departments department NOUN fnp-2993 45 170 or or CCONJ fnp-2993 45 171 were be AUX fnp-2993 45 172 hospitalized hospitalize VERB fnp-2993 45 173 , , PUNCT fnp-2993 45 174 only only ADV fnp-2993 45 175 0.2 0.2 NUM fnp-2993 45 176 % % NOUN fnp-2993 45 177 of of ADP fnp-2993 45 178 1486 1486 NUM fnp-2993 45 179 influenza influenza NOUN fnp-2993 45 180 patients patient NOUN fnp-2993 45 181 had have VERB fnp-2993 45 182 ischemic ischemic ADJ fnp-2993 45 183 infarcts infarct NOUN fnp-2993 45 184 which which PRON fnp-2993 45 185 was be AUX fnp-2993 45 186 significantly significantly ADV fnp-2993 45 187 less less ADJ fnp-2993 45 188 than than ADP fnp-2993 45 189 covid-19 covid-19 PROPN fnp-2993 45 190 patients patient NOUN fnp-2993 45 191 even even ADV fnp-2993 45 192 after after ADP fnp-2993 45 193 adjusting adjust VERB fnp-2993 45 194 for for ADP fnp-2993 45 195 age age NOUN fnp-2993 45 196 , , PUNCT fnp-2993 45 197 sex sex NOUN fnp-2993 45 198 and and CCONJ fnp-2993 45 199 , , PUNCT fnp-2993 45 200 race.55 race.55 NOUN fnp-2993 45 201 in in ADP fnp-2993 45 202 another another DET fnp-2993 45 203 new new PROPN fnp-2993 45 204 york york PROPN fnp-2993 45 205 study study NOUN fnp-2993 45 206 , , PUNCT fnp-2993 45 207 33 33 NUM fnp-2993 45 208 out out ADP fnp-2993 45 209 of of ADP fnp-2993 45 210 755 755 NUM fnp-2993 45 211 ( ( PUNCT fnp-2993 45 212 4.4 4.4 NUM fnp-2993 45 213 % % NOUN fnp-2993 45 214 ) ) PUNCT fnp-2993 46 1 covid-19 covid-19 PROPN fnp-2993 46 2 patients patient NOUN fnp-2993 46 3 with with ADP fnp-2993 46 4 neuroimaging neuroimaging NOUN fnp-2993 46 5 had have VERB fnp-2993 46 6 evidence evidence NOUN fnp-2993 46 7 of of ADP fnp-2993 46 8 intracranial intracranial ADJ fnp-2993 46 9 hemorrhage hemorrhage NOUN fnp-2993 46 10 not not PART fnp-2993 46 11 associated associate VERB fnp-2993 46 12 with with ADP fnp-2993 46 13 trauma trauma NOUN fnp-2993 46 14 , , PUNCT fnp-2993 46 15 brain brain NOUN fnp-2993 46 16 metastases metastasis NOUN fnp-2993 46 17 , , PUNCT fnp-2993 46 18 or or CCONJ fnp-2993 46 19 tumor tumor NOUN fnp-2993 46 20 resection.60 resection.60 NOUN fnp-2993 46 21 parenchymal parenchymal ADJ fnp-2993 46 22 hemorrhages hemorrhage NOUN fnp-2993 46 23 with with ADP fnp-2993 46 24 mass mass ADJ fnp-2993 46 25 effect effect NOUN fnp-2993 46 26 and and CCONJ fnp-2993 46 27 herniation herniation NOUN fnp-2993 46 28 were be AUX fnp-2993 46 29 present present ADJ fnp-2993 46 30 in in ADP fnp-2993 46 31 five five NUM fnp-2993 46 32 patients patient NOUN fnp-2993 46 33 , , PUNCT fnp-2993 46 34 punctate punctate VERB fnp-2993 46 35 hemorrhages hemorrhage NOUN fnp-2993 46 36 in in ADP fnp-2993 46 37 seven seven NUM fnp-2993 46 38 , , PUNCT fnp-2993 46 39 small small ADJ fnp-2993 46 40 to to PART fnp-2993 46 41 moderate moderate ADJ fnp-2993 46 42 sized sized ADJ fnp-2993 46 43 hemorrhages hemorrhage NOUN fnp-2993 46 44 in in ADP fnp-2993 46 45 17 17 NUM fnp-2993 46 46 , , PUNCT fnp-2993 46 47 and and CCONJ fnp-2993 46 48 large large ADJ fnp-2993 46 49 single single ADJ fnp-2993 46 50 site site NOUN fnp-2993 46 51 hemorrhages hemorrhage NOUN fnp-2993 46 52 without without ADP fnp-2993 46 53 herniation herniation NOUN fnp-2993 46 54 in in ADP fnp-2993 46 55 four.60 four.60 PROPN fnp-2993 46 56 twenty twenty NUM fnp-2993 46 57 - - PUNCT fnp-2993 46 58 six six NUM fnp-2993 46 59 of of ADP fnp-2993 46 60 the the DET fnp-2993 46 61 33 33 NUM fnp-2993 46 62 intracranial intracranial ADJ fnp-2993 46 63 hemorrhages hemorrhage NOUN fnp-2993 46 64 occurred occur VERB fnp-2993 46 65 as as ADP fnp-2993 46 66 a a DET fnp-2993 46 67 transformation transformation NOUN fnp-2993 46 68 of of ADP fnp-2993 46 69 an an DET fnp-2993 46 70 ischemic ischemic ADJ fnp-2993 46 71 infarct.60 infarct.60 NOUN fnp-2993 46 72 of of ADP fnp-2993 46 73 the the DET fnp-2993 46 74 five five NUM fnp-2993 46 75 patients patient NOUN fnp-2993 46 76 with with ADP fnp-2993 46 77 parenchymal parenchymal ADJ fnp-2993 46 78 hemorrhages hemorrhage NOUN fnp-2993 46 79 , , PUNCT fnp-2993 46 80 four four NUM fnp-2993 46 81 had have VERB fnp-2993 46 82 high high ADJ fnp-2993 46 83 partial partial ADJ fnp-2993 46 84 thromboplastin thromboplastin NOUN fnp-2993 46 85 time time NOUN fnp-2993 46 86 or or CCONJ fnp-2993 46 87 anti anti ADJ fnp-2993 46 88 - - ADJ fnp-2993 46 89 factor factor ADJ fnp-2993 46 90 xa xa NOUN fnp-2993 46 91 in in ADP fnp-2993 46 92 the the DET fnp-2993 46 93 72 72 NUM fnp-2993 46 94 hours hour NOUN fnp-2993 46 95 before before ADP fnp-2993 46 96 the the DET fnp-2993 46 97 intracranial intracranial ADJ fnp-2993 46 98 hemorrhage.60 hemorrhage.60 ADJ fnp-2993 46 99 advanced advanced ADJ fnp-2993 46 100 age age NOUN fnp-2993 46 101 , , PUNCT fnp-2993 46 102 cardiovascular cardiovascular ADJ fnp-2993 46 103 disease disease NOUN fnp-2993 46 104 , , PUNCT fnp-2993 46 105 cerebrovascular cerebrovascular ADJ fnp-2993 46 106 disease disease NOUN fnp-2993 46 107 , , PUNCT fnp-2993 46 108 diabetes diabetes NOUN fnp-2993 46 109 , , PUNCT fnp-2993 46 110 chronic chronic ADJ fnp-2993 46 111 respiratory respiratory ADJ fnp-2993 46 112 disease disease NOUN fnp-2993 46 113 , , PUNCT fnp-2993 46 114 hypertension hypertension NOUN fnp-2993 46 115 , , PUNCT fnp-2993 46 116 obesity obesity NOUN fnp-2993 46 117 , , PUNCT fnp-2993 46 118 smoking smoking NOUN fnp-2993 46 119 , , PUNCT fnp-2993 46 120 and and CCONJ fnp-2993 46 121 cancer cancer NOUN fnp-2993 46 122 are be AUX fnp-2993 46 123 risk risk NOUN fnp-2993 46 124 factors factor NOUN fnp-2993 46 125 for for ADP fnp-2993 46 126 severe severe ADJ fnp-2993 46 127 covid-19 covid-19 PROPN fnp-2993 46 128 disease disease NOUN fnp-2993 46 129 or or CCONJ fnp-2993 46 130 poor poor ADJ fnp-2993 46 131 outcome.61–67 outcome.61–67 NOUN fnp-2993 46 132 in in ADP fnp-2993 46 133 a a DET fnp-2993 46 134 canadian canadian ADJ fnp-2993 46 135 study study NOUN fnp-2993 46 136 , , PUNCT fnp-2993 46 137 critically critically ADV fnp-2993 46 138 ill ill ADJ fnp-2993 46 139 covid-19 covid-19 PROPN fnp-2993 46 140 patients patient NOUN fnp-2993 46 141 with with ADP fnp-2993 46 142 blood blood NOUN fnp-2993 46 143 groups group NOUN fnp-2993 46 144 a a PRON fnp-2993 46 145 and and CCONJ fnp-2993 46 146 ab ab PROPN fnp-2993 46 147 were be AUX fnp-2993 46 148 more more ADV fnp-2993 46 149 likely likely ADJ fnp-2993 46 150 to to PART fnp-2993 46 151 require require VERB fnp-2993 46 152 ventilation ventilation NOUN fnp-2993 46 153 , , PUNCT fnp-2993 46 154 continuous continuous ADJ fnp-2993 46 155 renal renal ADJ fnp-2993 46 156 replacement replacement NOUN fnp-2993 46 157 therapy therapy NOUN fnp-2993 46 158 , , PUNCT fnp-2993 46 159 and and CCONJ fnp-2993 46 160 prolonged prolong VERB fnp-2993 46 161 intensive intensive ADJ fnp-2993 46 162 care care NOUN fnp-2993 46 163 unit unit NOUN fnp-2993 46 164 admission.68 admission.68 NOUN fnp-2993 46 165 in in ADP fnp-2993 46 166 contrast contrast NOUN fnp-2993 46 167 , , PUNCT fnp-2993 46 168 an an DET fnp-2993 46 169 earlier early ADJ fnp-2993 46 170 american american PROPN fnp-2993 46 171 covid-19 covid-19 PROPN fnp-2993 46 172 study study NOUN fnp-2993 46 173 did do AUX fnp-2993 46 174 not not PART fnp-2993 46 175 show show VERB fnp-2993 46 176 an an DET fnp-2993 46 177 association association NOUN fnp-2993 46 178 between between ADP fnp-2993 46 179 specific specific ADJ fnp-2993 46 180 blood blood NOUN fnp-2993 46 181 groups group NOUN fnp-2993 46 182 and and CCONJ fnp-2993 46 183 either either CCONJ fnp-2993 46 184 ventilation ventilation NOUN fnp-2993 46 185 or or CCONJ fnp-2993 46 186 death.69 death.69 NOUN fnp-2993 46 187 differences difference NOUN fnp-2993 46 188 in in ADP fnp-2993 46 189 cohorts cohort NOUN fnp-2993 46 190 including include VERB fnp-2993 46 191 mortality mortality NOUN fnp-2993 46 192 rates rate NOUN fnp-2993 46 193 may may AUX fnp-2993 46 194 account account VERB fnp-2993 46 195 for for ADP fnp-2993 46 196 the the DET fnp-2993 46 197 contradictory contradictory ADJ fnp-2993 46 198 findings.68 findings.68 NOUN fnp-2993 46 199 it it PRON fnp-2993 46 200 can can AUX fnp-2993 46 201 not not PART fnp-2993 46 202 escape escape VERB fnp-2993 46 203 notice notice NOUN fnp-2993 46 204 that that SCONJ fnp-2993 46 205 a a DET fnp-2993 46 206 number number NOUN fnp-2993 46 207 of of ADP fnp-2993 46 208 the the DET fnp-2993 46 209 aforementioned aforementioned ADJ fnp-2993 46 210 covid-19 covid-19 PROPN fnp-2993 46 211 prognostic prognostic ADJ fnp-2993 46 212 factors factor NOUN fnp-2993 46 213 are be AUX fnp-2993 46 214 associated associate VERB fnp-2993 46 215 with with ADP fnp-2993 46 216 atherosclerosis atherosclerosis NOUN fnp-2993 46 217 and and CCONJ fnp-2993 46 218 arteriolosclerosis arteriolosclerosis NOUN fnp-2993 46 219 that that SCONJ fnp-2993 46 220 , , PUNCT fnp-2993 46 221 in in ADP fnp-2993 46 222 the the DET fnp-2993 46 223 setting setting NOUN fnp-2993 46 224 of of ADP fnp-2993 46 225 covid-19 covid-19 PROPN fnp-2993 46 226 respiratory respiratory ADJ fnp-2993 46 227 compromise compromise NOUN fnp-2993 46 228 and and CCONJ fnp-2993 46 229 coagulopathy coagulopathy ADJ fnp-2993 46 230 , , PUNCT fnp-2993 46 231 may may AUX fnp-2993 46 232 contribute contribute VERB fnp-2993 46 233 to to ADP fnp-2993 46 234 strokes stroke NOUN fnp-2993 46 235 . . PUNCT fnp-2993 47 1 guillain guillain NOUN fnp-2993 47 2 - - PUNCT fnp-2993 47 3 barré barré PROPN fnp-2993 47 4 syndrome syndrome PROPN fnp-2993 47 5 gbs gbs PROPN fnp-2993 47 6 is be AUX fnp-2993 47 7 an an DET fnp-2993 47 8 uncommon uncommon ADJ fnp-2993 47 9 , , PUNCT fnp-2993 47 10 immune immune NOUN fnp-2993 47 11 - - PUNCT fnp-2993 47 12 mediated mediate VERB fnp-2993 47 13 demyelinating demyelinate VERB fnp-2993 47 14 disease disease NOUN fnp-2993 47 15 of of ADP fnp-2993 47 16 the the DET fnp-2993 47 17 peripheral peripheral ADJ fnp-2993 47 18 nerves nerve NOUN fnp-2993 47 19 that that PRON fnp-2993 47 20 often often ADV fnp-2993 47 21 follows follow VERB fnp-2993 47 22 viral viral ADJ fnp-2993 47 23 infections infection NOUN fnp-2993 47 24 . . PUNCT fnp-2993 48 1 common common ADJ fnp-2993 48 2 presenting presenting NOUN fnp-2993 48 3 symptoms symptom NOUN fnp-2993 48 4 in in ADP fnp-2993 48 5 covid-19 covid-19 PROPN fnp-2993 48 6 patients patient NOUN fnp-2993 48 7 include include VERB fnp-2993 48 8 symmetrical symmetrical ADJ fnp-2993 48 9 flaccid flaccid ADJ fnp-2993 48 10 quadriparesis quadriparesis NOUN fnp-2993 48 11 , , PUNCT fnp-2993 48 12 ataxia ataxia ADJ fnp-2993 48 13 , , PUNCT fnp-2993 48 14 facial facial ADJ fnp-2993 48 15 weakness weakness NOUN fnp-2993 48 16 , , PUNCT fnp-2993 48 17 respiratory respiratory ADJ fnp-2993 48 18 failure failure NOUN fnp-2993 48 19 , , PUNCT fnp-2993 48 20 and and CCONJ fnp-2993 48 21 lower low ADJ fnp-2993 48 22 paresthesia.70–72 paresthesia.70–72 PRON fnp-2993 48 23 rt rt NOUN fnp-2993 48 24 - - PUNCT fnp-2993 48 25 pcr pcr NOUN fnp-2993 48 26 of of ADP fnp-2993 48 27 nasopharyngeal nasopharyngeal ADJ fnp-2993 48 28 swabs swab NOUN fnp-2993 48 29 tested test VERB fnp-2993 48 30 positive positive ADJ fnp-2993 48 31 for for ADP fnp-2993 48 32 sars sar NOUN fnp-2993 48 33 - - PUNCT fnp-2993 48 34 cov-2 cov-2 X fnp-2993 48 35 but but CCONJ fnp-2993 48 36 csf csf NOUN fnp-2993 48 37 was be AUX fnp-2993 48 38 negative negative ADJ fnp-2993 48 39 for for ADP fnp-2993 48 40 tested test VERB fnp-2993 48 41 patients.73–75 patients.73–75 PUNCT fnp-2993 48 42 gbs gbs PROPN fnp-2993 48 43 symptoms symptom NOUN fnp-2993 48 44 tend tend VERB fnp-2993 48 45 to to PART fnp-2993 48 46 emerge emerge VERB fnp-2993 48 47 between between ADP fnp-2993 48 48 day day NOUN fnp-2993 48 49 five five NUM fnp-2993 48 50 to to PART fnp-2993 48 51 10 10 NUM fnp-2993 48 52 after after ADP fnp-2993 48 53 covid-19 covid-19 PROPN fnp-2993 48 54 symptom symptom NOUN fnp-2993 48 55 onset.71 onset.71 NOUN fnp-2993 48 56 over over ADP fnp-2993 48 57 30 30 NUM fnp-2993 48 58 cases case NOUN fnp-2993 48 59 of of ADP fnp-2993 48 60 gbs gbs PROPN fnp-2993 48 61 have have AUX fnp-2993 48 62 been be AUX fnp-2993 48 63 reported.73–76 reported.73–76 NUM fnp-2993 48 64 one one NUM fnp-2993 48 65 proposed propose VERB fnp-2993 48 66 mechanism mechanism NOUN fnp-2993 48 67 is be AUX fnp-2993 48 68 an an DET fnp-2993 48 69 autoimmune autoimmune ADJ fnp-2993 48 70 hyperreaction hyperreaction NOUN fnp-2993 48 71 , , PUNCT fnp-2993 48 72 triggering trigger VERB fnp-2993 48 73 release release NOUN fnp-2993 48 74 of of ADP fnp-2993 48 75 pro pro ADJ fnp-2993 48 76 - - ADJ fnp-2993 48 77 inflammatory inflammatory ADJ fnp-2993 48 78 mediators mediator NOUN fnp-2993 48 79 such such ADJ fnp-2993 48 80 as as ADP fnp-2993 48 81 interleukin interleukin NOUN fnp-2993 48 82 ( ( PUNCT fnp-2993 48 83 il)-6 il)-6 NUM fnp-2993 48 84 , , PUNCT fnp-2993 48 85 that that PRON fnp-2993 48 86 cause cause VERB fnp-2993 48 87 autoimmune autoimmune ADJ fnp-2993 48 88 demyelination demyelination NOUN fnp-2993 48 89 or or CCONJ fnp-2993 48 90 axonal axonal ADJ fnp-2993 48 91 damage damage NOUN fnp-2993 48 92 . . PUNCT fnp-2993 49 1 alternatively alternatively ADV fnp-2993 49 2 in in ADP fnp-2993 49 3 some some DET fnp-2993 49 4 cases case NOUN fnp-2993 49 5 , , PUNCT fnp-2993 49 6 sars sar NOUN fnp-2993 49 7 - - PUNCT fnp-2993 49 8 cov-2 cov-2 NUM fnp-2993 49 9 may may AUX fnp-2993 49 10 induce induce VERB fnp-2993 49 11 production production NOUN fnp-2993 49 12 of of ADP fnp-2993 49 13 antibodies antibody NOUN fnp-2993 49 14 targeting target VERB fnp-2993 49 15 gangliosides ganglioside NOUN fnp-2993 49 16 , , PUNCT fnp-2993 49 17 leading lead VERB fnp-2993 49 18 to to ADP fnp-2993 49 19 peripheral peripheral ADJ fnp-2993 49 20 neuropathy.72,77 neuropathy.72,77 NOUN fnp-2993 49 21 covid-19 covid-19 PROPN fnp-2993 49 22 associated associate VERB fnp-2993 49 23 miller miller PROPN fnp-2993 49 24 fisher fisher PROPN fnp-2993 49 25 syndrome syndrome PROPN fnp-2993 49 26 ( ( PUNCT fnp-2993 49 27 mfs mfs PROPN fnp-2993 49 28 ) ) PUNCT fnp-2993 49 29 , , PUNCT fnp-2993 49 30 a a DET fnp-2993 49 31 variant variant NOUN fnp-2993 49 32 of of ADP fnp-2993 49 33 gbs gbs PROPN fnp-2993 49 34 with with ADP fnp-2993 49 35 ophthalmoplegia ophthalmoplegia PROPN fnp-2993 49 36 , , PUNCT fnp-2993 49 37 areflexia areflexia NOUN fnp-2993 49 38 , , PUNCT fnp-2993 49 39 and and CCONJ fnp-2993 49 40 ataxia ataxia NOUN fnp-2993 49 41 , , PUNCT fnp-2993 49 42 and and CCONJ fnp-2993 49 43 polyneuritis polyneuritis PROPN fnp-2993 49 44 cranialis cranialis X fnp-2993 49 45 ( ( PUNCT fnp-2993 49 46 pnc pnc PROPN fnp-2993 49 47 ) ) PUNCT fnp-2993 49 48 , , PUNCT fnp-2993 49 49 a a DET fnp-2993 49 50 gbs gbs PROPN fnp-2993 49 51 variant variant NOUN fnp-2993 49 52 with with ADP fnp-2993 49 53 multiple multiple ADJ fnp-2993 49 54 cranial cranial ADJ fnp-2993 49 55 neuropathies neuropathy NOUN fnp-2993 49 56 , , PUNCT fnp-2993 49 57 have have AUX fnp-2993 49 58 been be AUX fnp-2993 49 59 reported.78 reported.78 VERB fnp-2993 49 60 meningitis meningitis NOUN fnp-2993 49 61 and and CCONJ fnp-2993 49 62 encephalitis encephalitis ADJ fnp-2993 49 63 covid-19 covid-19 PROPN fnp-2993 49 64 associated associate VERB fnp-2993 49 65 meningitis meningitis NOUN fnp-2993 49 66 has have AUX fnp-2993 49 67 only only ADV fnp-2993 49 68 infrequently infrequently ADV fnp-2993 49 69 been be AUX fnp-2993 49 70 reported report VERB fnp-2993 49 71 but but CCONJ fnp-2993 49 72 one one NUM fnp-2993 49 73 case case NOUN fnp-2993 49 74 highlights highlight VERB fnp-2993 49 75 the the DET fnp-2993 49 76 need need NOUN fnp-2993 49 77 for for ADP fnp-2993 49 78 csf csf ADJ fnp-2993 49 79 testing testing NOUN fnp-2993 49 80 if if SCONJ fnp-2993 49 81 suspected.33 suspected.33 NOUN fnp-2993 49 82 a a DET fnp-2993 49 83 24 24 NUM fnp-2993 49 84 - - PUNCT fnp-2993 49 85 year year NOUN fnp-2993 49 86 - - PUNCT fnp-2993 49 87 old old ADJ fnp-2993 49 88 japanese japanese ADJ fnp-2993 49 89 male male NOUN fnp-2993 49 90 presented present VERB fnp-2993 49 91 with with ADP fnp-2993 49 92 headache headache NOUN fnp-2993 49 93 , , PUNCT fnp-2993 49 94 generalized generalized ADJ fnp-2993 49 95 fatigue fatigue NOUN fnp-2993 49 96 and and CCONJ fnp-2993 49 97 fever fever NOUN fnp-2993 49 98 . . PUNCT fnp-2993 50 1 nine nine NUM fnp-2993 50 2 days day NOUN fnp-2993 50 3 after after ADP fnp-2993 50 4 onset onset NOUN fnp-2993 50 5 of of ADP fnp-2993 50 6 typical typical ADJ fnp-2993 50 7 covid-19 covid-19 PROPN fnp-2993 50 8 symptoms symptom NOUN fnp-2993 50 9 , , PUNCT fnp-2993 50 10 the the DET fnp-2993 50 11 patient patient NOUN fnp-2993 50 12 had have AUX fnp-2993 50 13 altered alter VERB fnp-2993 50 14 mental mental ADJ fnp-2993 50 15 status status NOUN fnp-2993 50 16 , , PUNCT fnp-2993 50 17 transient transient VERB fnp-2993 50 18 generalized generalized ADJ fnp-2993 50 19 seizures seizure NOUN fnp-2993 50 20 , , PUNCT fnp-2993 50 21 and and CCONJ fnp-2993 50 22 neck neck NOUN fnp-2993 50 23 stiffness stiffness NOUN fnp-2993 50 24 . . PUNCT fnp-2993 51 1 brain brain NOUN fnp-2993 51 2 magnetic magnetic ADJ fnp-2993 51 3 resonance resonance NOUN fnp-2993 51 4 imaging imaging NOUN fnp-2993 51 5 ( ( PUNCT fnp-2993 51 6 mri mri NOUN fnp-2993 51 7 ) ) PUNCT fnp-2993 51 8 showed show VERB fnp-2993 51 9 hyperintensities hyperintensitie NOUN fnp-2993 51 10 along along ADP fnp-2993 51 11 the the DET fnp-2993 51 12 lateral lateral ADJ fnp-2993 51 13 ventricle ventricle NOUN fnp-2993 51 14 and and CCONJ fnp-2993 51 15 in in ADP fnp-2993 51 16 the the DET fnp-2993 51 17 medial medial ADJ fnp-2993 51 18 temporal temporal ADJ fnp-2993 51 19 lobe lobe NOUN fnp-2993 51 20 including include VERB fnp-2993 51 21 the the DET fnp-2993 51 22 hippocampus hippocampus NOUN fnp-2993 51 23 . . PUNCT fnp-2993 52 1 sars sars PROPN fnp-2993 52 2 - - PUNCT fnp-2993 52 3 cov-2 cov-2 NOUN fnp-2993 52 4 rna rna NOUN fnp-2993 52 5 was be AUX fnp-2993 52 6 not not PART fnp-2993 52 7 detected detect VERB fnp-2993 52 8 by by ADP fnp-2993 52 9 rt rt NOUN fnp-2993 52 10 - - PUNCT fnp-2993 52 11 pcr pcr PROPN fnp-2993 52 12 in in ADP fnp-2993 52 13 a a DET fnp-2993 52 14 nasopharyngeal nasopharyngeal ADJ fnp-2993 52 15 swab swab NOUN fnp-2993 52 16 but but CCONJ fnp-2993 52 17 was be AUX fnp-2993 52 18 in in ADP fnp-2993 52 19 csf.33 csf.33 PROPN fnp-2993 52 20 autopsies autopsy NOUN fnp-2993 52 21 performed perform VERB fnp-2993 52 22 on on ADP fnp-2993 52 23 covid-19 covid-19 PROPN fnp-2993 52 24 patients patient NOUN fnp-2993 52 25 have have AUX fnp-2993 52 26 suggested suggest VERB fnp-2993 52 27 meningoencephalitis meningoencephalitis NOUN fnp-2993 52 28 in in ADP fnp-2993 52 29 some some DET fnp-2993 52 30 cases case NOUN fnp-2993 52 31 and and CCONJ fnp-2993 52 32 these these PRON fnp-2993 52 33 are be AUX fnp-2993 52 34 discussed discuss VERB fnp-2993 52 35 in in ADP fnp-2993 52 36 section section NOUN fnp-2993 52 37 8.79 8.79 NUM fnp-2993 52 38 other other ADJ fnp-2993 52 39 disorders disorder NOUN fnp-2993 52 40 a a DET fnp-2993 52 41 brazilian brazilian ADJ fnp-2993 52 42 study study NOUN fnp-2993 52 43 reported report VERB fnp-2993 52 44 central central ADJ fnp-2993 52 45 venous venous ADJ fnp-2993 52 46 thrombosis thrombosis NOUN fnp-2993 52 47 ( ( PUNCT fnp-2993 52 48 cvt cvt PROPN fnp-2993 52 49 ) ) PUNCT fnp-2993 52 50 in in ADP fnp-2993 52 51 three three NUM fnp-2993 52 52 previously previously ADV fnp-2993 52 53 healthy healthy ADJ fnp-2993 52 54 covid-19 covid-19 PROPN fnp-2993 52 55 patients patient NOUN fnp-2993 52 56 younger young ADJ fnp-2993 52 57 than than ADP fnp-2993 52 58 41 41 NUM fnp-2993 52 59 years year NOUN fnp-2993 52 60 , , PUNCT fnp-2993 52 61 underscoring underscore VERB fnp-2993 52 62 the the DET fnp-2993 52 63 need need NOUN fnp-2993 52 64 for for ADP fnp-2993 52 65 awareness awareness NOUN fnp-2993 52 66 of of ADP fnp-2993 52 67 a a DET fnp-2993 52 68 hypercoagulable hypercoagulable ADJ fnp-2993 52 69 state state NOUN fnp-2993 52 70 in in ADP fnp-2993 52 71 covid-19 covid-19 PROPN fnp-2993 52 72 even even ADV fnp-2993 52 73 in in ADP fnp-2993 52 74 this this DET fnp-2993 52 75 age age NOUN fnp-2993 52 76 group.80 group.80 ADJ fnp-2993 52 77 acute acute NOUN fnp-2993 52 78 hemorrhagic hemorrhagic NOUN fnp-2993 52 79 necrotizing necrotizing NOUN fnp-2993 52 80 encephalopathy encephalopathy NOUN fnp-2993 52 81 , , PUNCT fnp-2993 52 82 an an DET fnp-2993 52 83 uncommon uncommon ADJ fnp-2993 52 84 complication complication NOUN fnp-2993 52 85 characterized characterize VERB fnp-2993 52 86 by by ADP fnp-2993 52 87 multifocal multifocal ADJ fnp-2993 52 88 symmetric symmetric ADJ fnp-2993 52 89 brain brain NOUN fnp-2993 52 90 lesions lesion NOUN fnp-2993 52 91 including include VERB fnp-2993 52 92 bilateral bilateral ADJ fnp-2993 52 93 thalamic thalamic ADJ fnp-2993 52 94 lesions lesion NOUN fnp-2993 52 95 , , PUNCT fnp-2993 52 96 has have AUX fnp-2993 52 97 been be AUX fnp-2993 52 98 associated associate VERB fnp-2993 52 99 with with ADP fnp-2993 52 100 covid-19 covid-19 PROPN fnp-2993 52 101 , , PUNCT fnp-2993 52 102 though though SCONJ fnp-2993 52 103 rarely.81,82 rarely.81,82 NOUN fnp-2993 52 104 this this DET fnp-2993 52 105 complication complication NOUN fnp-2993 52 106 may may AUX fnp-2993 52 107 be be AUX fnp-2993 52 108 caused cause VERB fnp-2993 52 109 by by ADP fnp-2993 52 110 blood blood NOUN fnp-2993 52 111 - - PUNCT fnp-2993 52 112 brain brain NOUN fnp-2993 52 113 - - PUNCT fnp-2993 52 114 barrier barrier NOUN fnp-2993 52 115 disruption disruption NOUN fnp-2993 52 116 related relate VERB fnp-2993 52 117 to to ADP fnp-2993 52 118 intracranial intracranial ADJ fnp-2993 52 119 cytokine cytokine NOUN fnp-2993 52 120 storms.81 storms.81 NOUN fnp-2993 52 121 covid-19 covid-19 PROPN fnp-2993 52 122 associated associate VERB fnp-2993 52 123 cases case NOUN fnp-2993 52 124 of of ADP fnp-2993 52 125 adem adem PROPN fnp-2993 52 126 - - PUNCT fnp-2993 52 127 like like ADJ fnp-2993 52 128 disease disease NOUN fnp-2993 52 129 and and CCONJ fnp-2993 52 130 autoimmune autoimmune NOUN fnp-2993 52 131 encephalitis encephalitis NOUN fnp-2993 52 132 have have AUX fnp-2993 52 133 been be AUX fnp-2993 52 134 documented.72,83 documented.72,83 NOUN fnp-2993 52 135 8 8 NUM fnp-2993 52 136 . . PUNCT fnp-2993 53 1 neuropathological neuropathological ADJ fnp-2993 53 2 findings finding NOUN fnp-2993 53 3 and and CCONJ fnp-2993 53 4 neuropathogenesis neuropathogenesis NOUN fnp-2993 53 5 of of ADP fnp-2993 53 6 covid-19 covid-19 PROPN fnp-2993 53 7 to to PART fnp-2993 53 8 examine examine VERB fnp-2993 53 9 the the DET fnp-2993 53 10 spectrum spectrum NOUN fnp-2993 53 11 of of ADP fnp-2993 53 12 covid-19 covid-19 PROPN fnp-2993 53 13 neuropathology neuropathology NOUN fnp-2993 53 14 , , PUNCT fnp-2993 53 15 we we PRON fnp-2993 53 16 reviewed review VERB fnp-2993 53 17 20 20 NUM fnp-2993 53 18 papers paper NOUN fnp-2993 53 19 encompassing encompass VERB fnp-2993 53 20 184 184 NUM fnp-2993 53 21 patients patient NOUN fnp-2993 53 22 with with ADP fnp-2993 53 23 tissue tissue NOUN fnp-2993 53 24 - - PUNCT fnp-2993 53 25 based base VERB fnp-2993 53 26 neuropathological neuropathological ADJ fnp-2993 53 27 analyses analysis NOUN fnp-2993 53 28 including include VERB fnp-2993 53 29 101 101 NUM fnp-2993 53 30 cases case NOUN fnp-2993 53 31 analyzed analyze VERB fnp-2993 53 32 by by ADP fnp-2993 53 33 rt rt PROPN fnp-2993 53 34 - - PUNCT fnp-2993 53 35 pcr pcr PROPN fnp-2993 53 36 for for ADP fnp-2993 53 37 sars sar NOUN fnp-2993 53 38 - - PUNCT fnp-2993 53 39 cov-2 cov-2 NUM fnp-2993 53 40 and and CCONJ fnp-2993 53 41 83 83 NUM fnp-2993 53 42 cases case NOUN fnp-2993 53 43 by by ADP fnp-2993 53 44 immunohistochemistry immunohistochemistry NOUN fnp-2993 53 45 ( ( PUNCT fnp-2993 53 46 ihc ihc PROPN fnp-2993 53 47 ) ) PUNCT fnp-2993 53 48 ( ( PUNCT fnp-2993 53 49 table table NOUN fnp-2993 53 50 1).25,53,79,83–99 1).25,53,79,83–99 NUM fnp-2993 53 51 all all DET fnp-2993 53 52 cases case NOUN fnp-2993 53 53 are be AUX fnp-2993 53 54 autopsies autopsy NOUN fnp-2993 53 55 except except SCONJ fnp-2993 53 56 for for ADP fnp-2993 53 57 four four NUM fnp-2993 53 58 biopsies biopsy NOUN fnp-2993 53 59 and and CCONJ fnp-2993 53 60 one one NUM fnp-2993 53 61 case case NOUN fnp-2993 53 62 of of ADP fnp-2993 53 63 unspecified unspecified ADJ fnp-2993 53 64 type type NOUN fnp-2993 53 65 . . PUNCT fnp-2993 54 1 the the DET fnp-2993 54 2 range range NOUN fnp-2993 54 3 of of ADP fnp-2993 54 4 histologic histologic ADJ fnp-2993 54 5 findings finding NOUN fnp-2993 54 6 is be AUX fnp-2993 54 7 broad broad ADJ fnp-2993 54 8 and and CCONJ fnp-2993 54 9 in in ADP fnp-2993 54 10 part part NOUN fnp-2993 54 11 reflects reflect VERB fnp-2993 54 12 the the DET fnp-2993 54 13 heterogeneity heterogeneity NOUN fnp-2993 54 14 of of ADP fnp-2993 54 15 neurological neurological ADJ fnp-2993 54 16 findings finding NOUN fnp-2993 54 17 . . PUNCT fnp-2993 55 1 the the DET fnp-2993 55 2 most most ADV fnp-2993 55 3 frequent frequent ADJ fnp-2993 55 4 findings finding NOUN fnp-2993 55 5 ( ( PUNCT fnp-2993 55 6 table table NOUN fnp-2993 55 7 1 1 NUM fnp-2993 55 8 ) ) PUNCT fnp-2993 55 9 include include VERB fnp-2993 55 10 microglial microglial ADJ fnp-2993 55 11 activation activation NOUN fnp-2993 55 12 with with ADP fnp-2993 55 13 microglial microglial ADJ fnp-2993 55 14 nodules nodule NOUN fnp-2993 55 15 in in ADP fnp-2993 55 16 a a DET fnp-2993 55 17 likely likely ADJ fnp-2993 55 18 underestimated underestimate VERB fnp-2993 55 19 subset subset NOUN fnp-2993 55 20 ; ; PUNCT fnp-2993 55 21 lymphoid lymphoid ADJ fnp-2993 55 22 inflammation inflammation NOUN fnp-2993 55 23 including include VERB fnp-2993 55 24 perivascular perivascular ADJ fnp-2993 55 25 lymphocytosis lymphocytosis NOUN fnp-2993 55 26 ( ( PUNCT fnp-2993 55 27 figure figure NOUN fnp-2993 55 28 3a 3a NUM fnp-2993 55 29 ) ) PUNCT fnp-2993 55 30 , , PUNCT fnp-2993 55 31 parenchymal parenchymal ADJ fnp-2993 55 32 lymphocytic lymphocytic ADJ fnp-2993 55 33 infiltration infiltration NOUN fnp-2993 55 34 , , PUNCT fnp-2993 55 35 and and CCONJ fnp-2993 55 36 leptomeningeal leptomeningeal ADJ fnp-2993 55 37 lymphocytic lymphocytic ADJ fnp-2993 55 38 inflammation inflammation NOUN fnp-2993 55 39 ; ; PUNCT fnp-2993 55 40 hypoxic hypoxic ADJ fnp-2993 55 41 - - PUNCT fnp-2993 55 42 ischemic ischemic ADJ fnp-2993 55 43 changes change NOUN fnp-2993 55 44 ( ( PUNCT fnp-2993 55 45 figure figure NOUN fnp-2993 55 46 3b 3b NUM fnp-2993 55 47 ) ) PUNCT fnp-2993 55 48 ; ; PUNCT fnp-2993 55 49 astrogliosis astrogliosis NOUN fnp-2993 55 50 ; ; PUNCT fnp-2993 55 51 acute acute ADJ fnp-2993 55 52 / / SYM fnp-2993 55 53 subacute subacute NOUN fnp-2993 55 54 brain brain NOUN fnp-2993 55 55 infarcts infarct NOUN fnp-2993 55 56 ; ; PUNCT fnp-2993 55 57 primary primary ADJ fnp-2993 55 58 hemorrhage hemorrhage NOUN fnp-2993 55 59 ; ; PUNCT fnp-2993 55 60 and and CCONJ fnp-2993 55 61 microthrombi microthrombi NOUN fnp-2993 55 62 . . PUNCT fnp-2993 56 1 it it PRON fnp-2993 56 2 should should AUX fnp-2993 56 3 be be AUX fnp-2993 56 4 noted note VERB fnp-2993 56 5 that that SCONJ fnp-2993 56 6 the the DET fnp-2993 56 7 prevalence prevalence NOUN fnp-2993 56 8 of of ADP fnp-2993 56 9 detected detect VERB fnp-2993 56 10 lymphoid lymphoid ADJ fnp-2993 56 11 inflammation inflammation NOUN fnp-2993 56 12 and and CCONJ fnp-2993 56 13 microglial microglial ADJ fnp-2993 56 14 nodules nodule NOUN fnp-2993 56 15 is be AUX fnp-2993 56 16 high high ADJ fnp-2993 56 17 in in ADP fnp-2993 56 18 papers paper NOUN fnp-2993 56 19 with with ADP fnp-2993 56 20 immunohistochemical immunohistochemical ADJ fnp-2993 56 21 studies study NOUN fnp-2993 56 22 and and CCONJ fnp-2993 56 23 low low ADJ fnp-2993 56 24 in in ADP fnp-2993 56 25 those those PRON fnp-2993 56 26 without without ADP fnp-2993 56 27 . . PUNCT fnp-2993 57 1 table table NOUN fnp-2993 57 2 1 1 NUM fnp-2993 57 3 : : PUNCT fnp-2993 57 4 neuropathological neuropathological ADJ fnp-2993 57 5 findings finding NOUN fnp-2993 57 6 in in ADP fnp-2993 57 7 covid-19 covid-19 PROPN fnp-2993 57 8 brain brain NOUN fnp-2993 57 9 tissue tissue NOUN fnp-2993 57 10 table table NOUN fnp-2993 57 11 1 1 NUM fnp-2993 57 12 : : PUNCT fnp-2993 57 13 some some DET fnp-2993 57 14 histologic histologic ADJ fnp-2993 57 15 findings finding NOUN fnp-2993 57 16 are be AUX fnp-2993 57 17 likely likely ADJ fnp-2993 57 18 to to PART fnp-2993 57 19 be be AUX fnp-2993 57 20 under under ADV fnp-2993 57 21 - - PUNCT fnp-2993 57 22 reported report VERB fnp-2993 57 23 as as ADP fnp-2993 57 24 reviewed review VERB fnp-2993 57 25 studies study NOUN fnp-2993 57 26 are be AUX fnp-2993 57 27 variable variable ADJ fnp-2993 57 28 in in ADP fnp-2993 57 29 their their PRON fnp-2993 57 30 focus focus NOUN fnp-2993 57 31 . . PUNCT fnp-2993 58 1 * * PUNCT fnp-2993 58 2 only only ADV fnp-2993 58 3 studies study NOUN fnp-2993 58 4 tabulating tabulate VERB fnp-2993 58 5 the the DET fnp-2993 58 6 prevalence prevalence NOUN fnp-2993 58 7 of of ADP fnp-2993 58 8 microglial microglial ADJ fnp-2993 58 9 nodules nodule NOUN fnp-2993 58 10 are be AUX fnp-2993 58 11 included include VERB fnp-2993 58 12 . . PUNCT fnp-2993 59 1 studies study NOUN fnp-2993 59 2 mentioning mention VERB fnp-2993 59 3 microglial microglial ADJ fnp-2993 59 4 nodules nodule NOUN fnp-2993 59 5 in in ADP fnp-2993 59 6 their their PRON fnp-2993 59 7 case case NOUN fnp-2993 59 8 series series NOUN fnp-2993 59 9 but but CCONJ fnp-2993 59 10 not not PART fnp-2993 59 11 enumerating enumerate VERB fnp-2993 59 12 the the DET fnp-2993 59 13 frequency frequency NOUN fnp-2993 59 14 are be AUX fnp-2993 59 15 excluded exclude VERB fnp-2993 59 16 . . PUNCT fnp-2993 60 1 figure figure NOUN fnp-2993 60 2 3 3 NUM fnp-2993 60 3 : : PUNCT fnp-2993 60 4 representative representative ADJ fnp-2993 60 5 covid-19 covid-19 PROPN fnp-2993 60 6 histopathology histopathology NOUN fnp-2993 60 7 : : PUNCT fnp-2993 60 8 a. a. NOUN fnp-2993 60 9 mild mild ADJ fnp-2993 60 10 perivascular perivascular ADJ fnp-2993 60 11 lymphoid lymphoid ADJ fnp-2993 60 12 inflammation inflammation NOUN fnp-2993 60 13 , , PUNCT fnp-2993 60 14 400x 400x NUM fnp-2993 60 15 ( ( PUNCT fnp-2993 60 16 arrow arrow NOUN fnp-2993 60 17 ) ) PUNCT fnp-2993 60 18 ; ; PUNCT fnp-2993 60 19 b. b. PROPN fnp-2993 60 20 eosinophilia eosinophilia PROPN fnp-2993 60 21 in in ADP fnp-2993 60 22 purkinje purkinje PROPN fnp-2993 60 23 cells cell NOUN fnp-2993 60 24 compatible compatible ADJ fnp-2993 60 25 with with ADP fnp-2993 60 26 acute acute ADJ fnp-2993 60 27 hypoxic hypoxic ADJ fnp-2993 60 28 - - PUNCT fnp-2993 60 29 ischemic ischemic ADJ fnp-2993 60 30 change change NOUN fnp-2993 60 31 , , PUNCT fnp-2993 60 32 200x 200x NUM fnp-2993 60 33 ( ( PUNCT fnp-2993 60 34 arrows arrow NOUN fnp-2993 60 35 ) ) PUNCT fnp-2993 60 36 ; ; PUNCT fnp-2993 60 37 c. c. PROPN fnp-2993 60 38 subacute subacute VERB fnp-2993 60 39 infarct infarct NOUN fnp-2993 60 40 of of ADP fnp-2993 60 41 anterior anterior ADJ fnp-2993 60 42 pituitary pituitary ADJ fnp-2993 60 43 gland gland NOUN fnp-2993 60 44 , , PUNCT fnp-2993 60 45 100x 100x NUM fnp-2993 60 46 ( ( PUNCT fnp-2993 60 47 arrows arrow NOUN fnp-2993 60 48 ) ) PUNCT fnp-2993 60 49 ; ; PUNCT fnp-2993 60 50 d. d. PROPN fnp-2993 60 51 alzheimer alzheimer PROPN fnp-2993 60 52 type type PROPN fnp-2993 60 53 ii ii PROPN fnp-2993 60 54 astrocytes astrocyte NOUN fnp-2993 60 55 in in ADP fnp-2993 60 56 basal basal ADJ fnp-2993 60 57 ganglia ganglion NOUN fnp-2993 60 58 , , PUNCT fnp-2993 60 59 400x 400x NUM fnp-2993 60 60 ( ( PUNCT fnp-2993 60 61 circle circle PROPN fnp-2993 60 62 ) ) PUNCT fnp-2993 60 63 . . PUNCT fnp-2993 61 1 sars sar NOUN fnp-2993 61 2 - - PUNCT fnp-2993 61 3 cov-2 cov-2 NUM fnp-2993 61 4 is be AUX fnp-2993 61 5 detectable detectable ADJ fnp-2993 61 6 in in ADP fnp-2993 61 7 central central ADJ fnp-2993 61 8 nervous nervous ADJ fnp-2993 61 9 system system NOUN fnp-2993 61 10 tissue tissue NOUN fnp-2993 61 11 at at ADV fnp-2993 61 12 least least ADV fnp-2993 61 13 three three NUM fnp-2993 61 14 routes route NOUN fnp-2993 61 15 of of ADP fnp-2993 61 16 cns cns NOUN fnp-2993 61 17 infection infection NOUN fnp-2993 61 18 by by ADP fnp-2993 61 19 sars sar NOUN fnp-2993 61 20 - - PUNCT fnp-2993 61 21 cov-2 cov-2 PART fnp-2993 61 22 have have AUX fnp-2993 61 23 been be AUX fnp-2993 61 24 proposed propose VERB fnp-2993 61 25 : : PUNCT fnp-2993 61 26 retrograde retrograde ADJ fnp-2993 61 27 transmission transmission NOUN fnp-2993 61 28 via via ADP fnp-2993 61 29 olfactory olfactory ADJ fnp-2993 61 30 sensory sensory ADJ fnp-2993 61 31 neurons neuron NOUN fnp-2993 61 32 , , PUNCT fnp-2993 61 33 infiltration infiltration NOUN fnp-2993 61 34 of of ADP fnp-2993 61 35 immune immune ADJ fnp-2993 61 36 cells cell NOUN fnp-2993 61 37 , , PUNCT fnp-2993 61 38 and and CCONJ fnp-2993 61 39 entry entry NOUN fnp-2993 61 40 across across ADP fnp-2993 61 41 the the DET fnp-2993 61 42 blood blood NOUN fnp-2993 61 43 - - PUNCT fnp-2993 61 44 brain brain NOUN fnp-2993 61 45 barrier.100,101 barrier.100,101 NOUN fnp-2993 61 46 the the DET fnp-2993 61 47 prevalence prevalence NOUN fnp-2993 61 48 of of ADP fnp-2993 61 49 anosmia anosmia NOUN fnp-2993 61 50 and and CCONJ fnp-2993 61 51 ageusia ageusia NOUN fnp-2993 61 52 in in ADP fnp-2993 61 53 covid-19 covid-19 PROPN fnp-2993 61 54 patients patient NOUN fnp-2993 61 55 led lead VERB fnp-2993 61 56 to to ADP fnp-2993 61 57 the the DET fnp-2993 61 58 theory theory NOUN fnp-2993 61 59 that that SCONJ fnp-2993 61 60 sars sar NOUN fnp-2993 61 61 - - PUNCT fnp-2993 61 62 cov-2 cov-2 PART fnp-2993 61 63 enters enter VERB fnp-2993 61 64 the the DET fnp-2993 61 65 brain brain NOUN fnp-2993 61 66 via via ADP fnp-2993 61 67 infection infection NOUN fnp-2993 61 68 of of ADP fnp-2993 61 69 neurons neuron NOUN fnp-2993 61 70 in in ADP fnp-2993 61 71 the the DET fnp-2993 61 72 olfactory olfactory NOUN fnp-2993 61 73 neuroepithelium neuroepithelium NOUN fnp-2993 61 74 ( ( PUNCT fnp-2993 61 75 which which PRON fnp-2993 61 76 resides reside VERB fnp-2993 61 77 in in ADP fnp-2993 61 78 the the DET fnp-2993 61 79 mucosa mucosa NOUN fnp-2993 61 80 of of ADP fnp-2993 61 81 the the DET fnp-2993 61 82 nasal nasal ADJ fnp-2993 61 83 cavity cavity NOUN fnp-2993 61 84 ) ) PUNCT fnp-2993 61 85 and and CCONJ fnp-2993 61 86 from from ADP fnp-2993 61 87 there there ADV fnp-2993 61 88 to to ADP fnp-2993 61 89 the the DET fnp-2993 61 90 olfactory olfactory NOUN fnp-2993 61 91 bulb bulb NOUN fnp-2993 61 92 and and CCONJ fnp-2993 61 93 then then ADV fnp-2993 61 94 to to ADP fnp-2993 61 95 other other ADJ fnp-2993 61 96 brain brain NOUN fnp-2993 61 97 regions region NOUN fnp-2993 61 98 . . PUNCT fnp-2993 62 1 this this DET fnp-2993 62 2 olfactory olfactory ADJ fnp-2993 62 3 route route NOUN fnp-2993 62 4 is be AUX fnp-2993 62 5 used use VERB fnp-2993 62 6 by by ADP fnp-2993 62 7 other other ADJ fnp-2993 62 8 coronaviruses coronaviruse NOUN fnp-2993 62 9 , , PUNCT fnp-2993 62 10 such such ADJ fnp-2993 62 11 as as ADP fnp-2993 62 12 sars sar NOUN fnp-2993 62 13 - - PUNCT fnp-2993 62 14 cov102 cov102 PROPN fnp-2993 62 15 and and CCONJ fnp-2993 62 16 mers mer NOUN fnp-2993 62 17 - - PUNCT fnp-2993 62 18 cov.103 cov.103 NOUN fnp-2993 62 19 covid-19 covid-19 PROPN fnp-2993 62 20 patients patient NOUN fnp-2993 62 21 frequently frequently ADV fnp-2993 62 22 display display VERB fnp-2993 62 23 mri mri NOUN fnp-2993 62 24 hyperintensity hyperintensity NOUN fnp-2993 62 25 in in ADP fnp-2993 62 26 the the DET fnp-2993 62 27 olfactory olfactory NOUN fnp-2993 62 28 cortex.104 cortex.104 VERB fnp-2993 62 29 the the DET fnp-2993 62 30 ace2 ace2 PROPN fnp-2993 62 31 receptor receptor NOUN fnp-2993 62 32 , , PUNCT fnp-2993 62 33 used use VERB fnp-2993 62 34 by by ADP fnp-2993 62 35 sars sar NOUN fnp-2993 62 36 - - PUNCT fnp-2993 62 37 cov-2 cov-2 NOUN fnp-2993 62 38 for for ADP fnp-2993 62 39 cellular cellular ADJ fnp-2993 62 40 entry entry NOUN fnp-2993 62 41 , , PUNCT fnp-2993 62 42 is be AUX fnp-2993 62 43 expressed express VERB fnp-2993 62 44 in in ADP fnp-2993 62 45 sustentacular sustentacular ADJ fnp-2993 62 46 cells cell NOUN fnp-2993 62 47 and and CCONJ fnp-2993 62 48 stem stem NOUN fnp-2993 62 49 cells cell NOUN fnp-2993 62 50 of of ADP fnp-2993 62 51 the the DET fnp-2993 62 52 nasal nasal PROPN fnp-2993 62 53 olfactory olfactory PROPN fnp-2993 62 54 epithelium.23,105 epithelium.23,105 PROPN fnp-2993 62 55 while while SCONJ fnp-2993 62 56 one one NUM fnp-2993 62 57 study study NOUN fnp-2993 62 58 suggests suggest VERB fnp-2993 62 59 olfactory olfactory ADJ fnp-2993 62 60 neurons neuron NOUN fnp-2993 62 61 themselves themselves PRON fnp-2993 62 62 do do AUX fnp-2993 62 63 not not PART fnp-2993 62 64 express express VERB fnp-2993 62 65 the the DET fnp-2993 62 66 ace2 ace2 PROPN fnp-2993 62 67 receptor,23 receptor,23 NOUN fnp-2993 62 68 another another DET fnp-2993 62 69 report report NOUN fnp-2993 62 70 contradicts contradict VERB fnp-2993 62 71 this this DET fnp-2993 62 72 finding.106 finding.106 NOUN fnp-2993 62 73 besides besides SCONJ fnp-2993 62 74 technical technical ADJ fnp-2993 62 75 sensitivity sensitivity NOUN fnp-2993 62 76 issues issue NOUN fnp-2993 62 77 , , PUNCT fnp-2993 62 78 it it PRON fnp-2993 62 79 may may AUX fnp-2993 62 80 be be AUX fnp-2993 62 81 that that SCONJ fnp-2993 62 82 the the DET fnp-2993 62 83 expression expression NOUN fnp-2993 62 84 levels level NOUN fnp-2993 62 85 of of ADP fnp-2993 62 86 the the DET fnp-2993 62 87 ace2 ace2 NOUN fnp-2993 62 88 receptor receptor NOUN fnp-2993 62 89 and and CCONJ fnp-2993 62 90 other other ADJ fnp-2993 62 91 receptors receptor NOUN fnp-2993 62 92 differ differ VERB fnp-2993 62 93 under under ADP fnp-2993 62 94 inflammatory inflammatory ADJ fnp-2993 62 95 conditions condition NOUN fnp-2993 62 96 as as SCONJ fnp-2993 62 97 compared compare VERB fnp-2993 62 98 to to ADP fnp-2993 62 99 physiologic physiologic ADJ fnp-2993 62 100 conditions condition NOUN fnp-2993 62 101 . . PUNCT fnp-2993 63 1 viral viral ADJ fnp-2993 63 2 particles particle NOUN fnp-2993 63 3 have have AUX fnp-2993 63 4 been be AUX fnp-2993 63 5 detected detect VERB fnp-2993 63 6 by by ADP fnp-2993 63 7 electron electron NOUN fnp-2993 63 8 microscopy microscopy NOUN fnp-2993 63 9 and and CCONJ fnp-2993 63 10 ihc ihc PROPN fnp-2993 63 11 in in ADP fnp-2993 63 12 the the DET fnp-2993 63 13 olfactory olfactory ADJ fnp-2993 63 14 epithelium54 epithelium54 NOUN fnp-2993 63 15 as as ADV fnp-2993 63 16 well well ADV fnp-2993 63 17 as as ADP fnp-2993 63 18 by by ADP fnp-2993 63 19 electron electron NOUN fnp-2993 63 20 microscopy microscopy NOUN fnp-2993 63 21 in in ADP fnp-2993 63 22 olfactory olfactory ADJ fnp-2993 63 23 neurons neuron NOUN fnp-2993 63 24 of of ADP fnp-2993 63 25 the the DET fnp-2993 63 26 nasal nasal ADJ fnp-2993 63 27 mucosa mucosa NOUN fnp-2993 63 28 at at ADP fnp-2993 63 29 autopsy.53 autopsy.53 PROPN fnp-2993 63 30 morbini morbini PROPN fnp-2993 63 31 and and CCONJ fnp-2993 63 32 colleagues colleague NOUN fnp-2993 63 33 report report VERB fnp-2993 63 34 ultrastructural ultrastructural ADJ fnp-2993 63 35 evidence evidence NOUN fnp-2993 63 36 of of ADP fnp-2993 63 37 sars sar NOUN fnp-2993 63 38 - - PUNCT fnp-2993 63 39 cov-2 cov-2 NOUN fnp-2993 63 40 particles particle NOUN fnp-2993 63 41 in in ADP fnp-2993 63 42 the the DET fnp-2993 63 43 olfactory olfactory NOUN fnp-2993 63 44 bulb bulb NOUN fnp-2993 63 45 of of ADP fnp-2993 63 46 a a DET fnp-2993 63 47 covid-19 covid-19 PROPN fnp-2993 63 48 patient.54 patient.54 PROPN fnp-2993 63 49 a a DET fnp-2993 63 50 second second ADJ fnp-2993 63 51 theory theory NOUN fnp-2993 63 52 posits posit NOUN fnp-2993 63 53 that that SCONJ fnp-2993 63 54 sars sar NOUN fnp-2993 63 55 - - PUNCT fnp-2993 63 56 cov-2 cov-2 NUM fnp-2993 63 57 may may AUX fnp-2993 63 58 infect infect VERB fnp-2993 63 59 immune immune ADJ fnp-2993 63 60 cells cell NOUN fnp-2993 63 61 that that PRON fnp-2993 63 62 cross cross VERB fnp-2993 63 63 the the DET fnp-2993 63 64 blood blood NOUN fnp-2993 63 65 - - PUNCT fnp-2993 63 66 brain brain NOUN fnp-2993 63 67 barrier barrier NOUN fnp-2993 63 68 and and CCONJ fnp-2993 63 69 deliver deliver VERB fnp-2993 63 70 virus virus NOUN fnp-2993 63 71 into into ADP fnp-2993 63 72 the the DET fnp-2993 63 73 brain brain NOUN fnp-2993 63 74 . . PUNCT fnp-2993 64 1 this this DET fnp-2993 64 2 mechanism mechanism NOUN fnp-2993 64 3 is be AUX fnp-2993 64 4 well well ADV fnp-2993 64 5 described describe VERB fnp-2993 64 6 in in ADP fnp-2993 64 7 hiv.107 hiv.107 PROPN fnp-2993 64 8 white white ADJ fnp-2993 64 9 blood blood NOUN fnp-2993 64 10 cells cell NOUN fnp-2993 64 11 including include VERB fnp-2993 64 12 lymphocytes lymphocyte NOUN fnp-2993 64 13 and and CCONJ fnp-2993 64 14 monocytes monocyte VERB fnp-2993 64 15 express express VERB fnp-2993 64 16 the the DET fnp-2993 64 17 ace2 ace2 NOUN fnp-2993 64 18 receptor.108,109 receptor.108,109 ADJ fnp-2993 64 19 infection infection NOUN fnp-2993 64 20 of of ADP fnp-2993 64 21 immune immune ADJ fnp-2993 64 22 cells cell NOUN fnp-2993 64 23 by by ADP fnp-2993 64 24 sars sar NOUN fnp-2993 64 25 - - PUNCT fnp-2993 64 26 cov-2 cov-2 PART fnp-2993 64 27 is be AUX fnp-2993 64 28 an an DET fnp-2993 64 29 active active ADJ fnp-2993 64 30 area area NOUN fnp-2993 64 31 of of ADP fnp-2993 64 32 study study NOUN fnp-2993 64 33 . . PUNCT fnp-2993 65 1 finally finally ADV fnp-2993 65 2 , , PUNCT fnp-2993 65 3 the the DET fnp-2993 65 4 third third ADJ fnp-2993 65 5 theory theory NOUN fnp-2993 65 6 extends extend VERB fnp-2993 65 7 the the DET fnp-2993 65 8 well well ADV fnp-2993 65 9 documented document VERB fnp-2993 65 10 behavior behavior NOUN fnp-2993 65 11 of of ADP fnp-2993 65 12 encephalitic encephalitic ADJ fnp-2993 65 13 blood blood NOUN fnp-2993 65 14 - - PUNCT fnp-2993 65 15 borne bear VERB fnp-2993 65 16 coronaviruses coronaviruse NOUN fnp-2993 65 17 to to PART fnp-2993 65 18 enter enter VERB fnp-2993 65 19 through through ADP fnp-2993 65 20 the the DET fnp-2993 65 21 blood blood NOUN fnp-2993 65 22 - - PUNCT fnp-2993 65 23 brain brain NOUN fnp-2993 65 24 barrier barrier NOUN fnp-2993 65 25 via via ADP fnp-2993 65 26 infection infection NOUN fnp-2993 65 27 of of ADP fnp-2993 65 28 vessel vessel NOUN fnp-2993 65 29 wall wall PROPN fnp-2993 65 30 cells.110 cells.110 PROPN fnp-2993 65 31 histologically histologically ADV fnp-2993 65 32 , , PUNCT fnp-2993 65 33 on on ADP fnp-2993 65 34 routine routine ADJ fnp-2993 65 35 hematoxylinand hematoxylinand ADJ fnp-2993 65 36 eosin eosin NOUN fnp-2993 65 37 - - PUNCT fnp-2993 65 38 stained stain VERB fnp-2993 65 39 slides slide NOUN fnp-2993 65 40 , , PUNCT fnp-2993 65 41 neither neither PRON fnp-2993 65 42 viral viral ADJ fnp-2993 65 43 inclusions inclusion NOUN fnp-2993 65 44 nor nor CCONJ fnp-2993 65 45 specific specific ADJ fnp-2993 65 46 cellular cellular ADJ fnp-2993 65 47 changes change NOUN fnp-2993 65 48 recognizable recognizable ADJ fnp-2993 65 49 as as SCONJ fnp-2993 65 50 direct direct ADJ fnp-2993 65 51 viral viral ADJ fnp-2993 65 52 infection infection NOUN fnp-2993 65 53 have have AUX fnp-2993 65 54 been be AUX fnp-2993 65 55 reported report VERB fnp-2993 65 56 . . PUNCT fnp-2993 66 1 however however ADV fnp-2993 66 2 , , PUNCT fnp-2993 66 3 sars sar NOUN fnp-2993 66 4 - - PUNCT fnp-2993 66 5 cov-2 cov-2 PART fnp-2993 66 6 has have AUX fnp-2993 66 7 been be AUX fnp-2993 66 8 detected detect VERB fnp-2993 66 9 in in ADP fnp-2993 66 10 the the DET fnp-2993 66 11 brain brain NOUN fnp-2993 66 12 by by ADP fnp-2993 66 13 rt rt PROPN fnp-2993 66 14 - - PUNCT fnp-2993 66 15 pcr pcr PROPN fnp-2993 66 16 , , PUNCT fnp-2993 66 17 ihc ihc PROPN fnp-2993 66 18 , , PUNCT fnp-2993 66 19 and and CCONJ fnp-2993 66 20 electron electron NOUN fnp-2993 66 21 microscopy microscopy NOUN fnp-2993 66 22 . . PUNCT fnp-2993 67 1 as as ADV fnp-2993 67 2 many many ADJ fnp-2993 67 3 as as ADP fnp-2993 67 4 54 54 NUM fnp-2993 67 5 out out ADP fnp-2993 67 6 of of ADP fnp-2993 67 7 101 101 NUM fnp-2993 67 8 ( ( PUNCT fnp-2993 67 9 53.5 53.5 NUM fnp-2993 67 10 % % NOUN fnp-2993 67 11 ) ) PUNCT fnp-2993 67 12 cases case NOUN fnp-2993 67 13 were be AUX fnp-2993 67 14 positive positive ADJ fnp-2993 67 15 for for ADP fnp-2993 67 16 sars sar NOUN fnp-2993 67 17 - - PUNCT fnp-2993 67 18 cov-2 cov-2 NOUN fnp-2993 67 19 in in ADP fnp-2993 67 20 the the DET fnp-2993 67 21 brain brain NOUN fnp-2993 67 22 by by ADP fnp-2993 67 23 rt rt PROPN fnp-2993 67 24 - - PUNCT fnp-2993 67 25 pcr pcr PROPN fnp-2993 67 26 and and CCONJ fnp-2993 67 27 23 23 NUM fnp-2993 67 28 out out ADP fnp-2993 67 29 of of ADP fnp-2993 67 30 83 83 NUM fnp-2993 67 31 ( ( PUNCT fnp-2993 67 32 27.7 27.7 NUM fnp-2993 67 33 % % NOUN fnp-2993 67 34 ) ) PUNCT fnp-2993 67 35 cases case NOUN fnp-2993 67 36 were be AUX fnp-2993 67 37 positive positive ADJ fnp-2993 67 38 by by ADP fnp-2993 67 39 ihc ihc PROPN fnp-2993 67 40 ( ( PUNCT fnp-2993 67 41 table table NOUN fnp-2993 67 42 1 1 NUM fnp-2993 67 43 ) ) PUNCT fnp-2993 67 44 . . PUNCT fnp-2993 68 1 in in ADP fnp-2993 68 2 some some DET fnp-2993 68 3 cases case NOUN fnp-2993 68 4 , , PUNCT fnp-2993 68 5 copies copy NOUN fnp-2993 68 6 of of ADP fnp-2993 68 7 virus virus NOUN fnp-2993 68 8 detected detect VERB fnp-2993 68 9 by by ADP fnp-2993 68 10 rt rt PROPN fnp-2993 68 11 - - PUNCT fnp-2993 68 12 pcr pcr PROPN fnp-2993 68 13 were be AUX fnp-2993 68 14 low low ADJ fnp-2993 68 15 in in ADP fnp-2993 68 16 number number NOUN fnp-2993 68 17 and and CCONJ fnp-2993 68 18 the the DET fnp-2993 68 19 detection detection NOUN fnp-2993 68 20 of of ADP fnp-2993 68 21 virus virus NOUN fnp-2993 68 22 in in ADP fnp-2993 68 23 blood blood NOUN fnp-2993 68 24 or or CCONJ fnp-2993 68 25 blood blood NOUN fnp-2993 68 26 cells cell NOUN fnp-2993 68 27 within within ADP fnp-2993 68 28 intracerebral intracerebral ADJ fnp-2993 68 29 vasculature vasculature NOUN fnp-2993 68 30 rather rather ADV fnp-2993 68 31 than than ADP fnp-2993 68 32 brain brain NOUN fnp-2993 68 33 cells cell NOUN fnp-2993 68 34 was be AUX fnp-2993 68 35 a a DET fnp-2993 68 36 possibility possibility NOUN fnp-2993 68 37 . . PUNCT fnp-2993 69 1 however however ADV fnp-2993 69 2 , , PUNCT fnp-2993 69 3 ihc ihc PROPN fnp-2993 69 4 has have AUX fnp-2993 69 5 confirmed confirm VERB fnp-2993 69 6 the the DET fnp-2993 69 7 presence presence NOUN fnp-2993 69 8 of of ADP fnp-2993 69 9 viral viral ADJ fnp-2993 69 10 antigens antigen NOUN fnp-2993 69 11 in in ADP fnp-2993 69 12 autopsy autopsy ADJ fnp-2993 69 13 brain brain NOUN fnp-2993 69 14 cells cell NOUN fnp-2993 69 15 . . PUNCT fnp-2993 70 1 of of ADP fnp-2993 70 2 note note NOUN fnp-2993 70 3 , , PUNCT fnp-2993 70 4 antibodies antibodie VERB fnp-2993 70 5 against against ADP fnp-2993 70 6 sars sar NOUN fnp-2993 70 7 - - PUNCT fnp-2993 70 8 cov-2 cov-2 NOUN fnp-2993 70 9 spike spike ADJ fnp-2993 70 10 protein protein NOUN fnp-2993 70 11 were be AUX fnp-2993 70 12 more more ADV fnp-2993 70 13 effective effective ADJ fnp-2993 70 14 in in ADP fnp-2993 70 15 detecting detect VERB fnp-2993 70 16 viral viral ADJ fnp-2993 70 17 antigens antigen NOUN fnp-2993 70 18 than than ADP fnp-2993 70 19 those those PRON fnp-2993 70 20 targeted target VERB fnp-2993 70 21 against against ADP fnp-2993 70 22 nucleocapsid nucleocapsid ADJ fnp-2993 70 23 protein25,87,97 protein25,87,97 NOUN fnp-2993 70 24 ( ( PUNCT fnp-2993 70 25 supplementary supplementary ADJ fnp-2993 70 26 table table NOUN fnp-2993 70 27 a a PRON fnp-2993 70 28 ) ) PUNCT fnp-2993 70 29 . . PUNCT fnp-2993 71 1 importantly importantly ADV fnp-2993 71 2 , , PUNCT fnp-2993 71 3 staining stain VERB fnp-2993 71 4 using use VERB fnp-2993 71 5 both both DET fnp-2993 71 6 anti anti ADJ fnp-2993 71 7 - - ADJ fnp-2993 71 8 spike spike ADJ fnp-2993 71 9 and and CCONJ fnp-2993 71 10 anti anti ADJ fnp-2993 71 11 - - ADJ fnp-2993 71 12 nucleocapsid nucleocapsid ADJ fnp-2993 71 13 antibodies antibody NOUN fnp-2993 71 14 may may AUX fnp-2993 71 15 be be AUX fnp-2993 71 16 more more ADV fnp-2993 71 17 sensitive sensitive ADJ fnp-2993 71 18 than than ADP fnp-2993 71 19 either either ADV fnp-2993 71 20 alone alone ADJ fnp-2993 71 21 as as ADP fnp-2993 71 22 , , PUNCT fnp-2993 71 23 in in ADP fnp-2993 71 24 a a DET fnp-2993 71 25 few few ADJ fnp-2993 71 26 cases case NOUN fnp-2993 71 27 , , PUNCT fnp-2993 71 28 nucleocapsid nucleocapsid ADJ fnp-2993 71 29 protein protein NOUN fnp-2993 71 30 was be AUX fnp-2993 71 31 detected detect VERB fnp-2993 71 32 while while SCONJ fnp-2993 71 33 spike spike ADJ fnp-2993 71 34 protein protein NOUN fnp-2993 71 35 was be AUX fnp-2993 71 36 not not PART fnp-2993 71 37 . . PUNCT fnp-2993 72 1 whether whether SCONJ fnp-2993 72 2 this this DET fnp-2993 72 3 finding finding NOUN fnp-2993 72 4 is be AUX fnp-2993 72 5 a a DET fnp-2993 72 6 technical technical ADJ fnp-2993 72 7 issue issue NOUN fnp-2993 72 8 related relate VERB fnp-2993 72 9 to to ADP fnp-2993 72 10 the the DET fnp-2993 72 11 quality quality NOUN fnp-2993 72 12 of of ADP fnp-2993 72 13 the the DET fnp-2993 72 14 antibodies antibody NOUN fnp-2993 72 15 or or CCONJ fnp-2993 72 16 the the DET fnp-2993 72 17 intrinsic intrinsic ADJ fnp-2993 72 18 accessibility accessibility NOUN fnp-2993 72 19 of of ADP fnp-2993 72 20 the the DET fnp-2993 72 21 relevant relevant ADJ fnp-2993 72 22 epitopes epitope NOUN fnp-2993 72 23 or or CCONJ fnp-2993 72 24 both both PRON fnp-2993 72 25 is be AUX fnp-2993 72 26 unresolved unresolved ADJ fnp-2993 72 27 . . PUNCT fnp-2993 73 1 staining stain VERB fnp-2993 73 2 of of ADP fnp-2993 73 3 virus virus NOUN fnp-2993 73 4 localizes localize VERB fnp-2993 73 5 in in ADP fnp-2993 73 6 scattered scatter VERB fnp-2993 73 7 cortical cortical ADJ fnp-2993 73 8 neurons neuron NOUN fnp-2993 73 9 and and CCONJ fnp-2993 73 10 endothelial endothelial NOUN fnp-2993 73 11 cells,87 cells,87 NOUN fnp-2993 73 12 as as ADV fnp-2993 73 13 well well ADV fnp-2993 73 14 as as ADP fnp-2993 73 15 brainstem brainstem NOUN fnp-2993 73 16 cranial cranial ADJ fnp-2993 73 17 nerve nerve NOUN fnp-2993 73 18 roots root NOUN fnp-2993 73 19 and and CCONJ fnp-2993 73 20 isolated isolated ADJ fnp-2993 73 21 cells cell NOUN fnp-2993 73 22 ( ( PUNCT fnp-2993 73 23 cell cell NOUN fnp-2993 73 24 type type NOUN fnp-2993 73 25 unclear unclear ADJ fnp-2993 73 26 ) ) PUNCT fnp-2993 73 27 in in ADP fnp-2993 73 28 the the DET fnp-2993 73 29 medulla medulla NOUN fnp-2993 73 30 oblongata oblongata NOUN fnp-2993 73 31 ; ; PUNCT fnp-2993 73 32 the the DET fnp-2993 73 33 images image NOUN fnp-2993 73 34 of of ADP fnp-2993 73 35 the the DET fnp-2993 73 36 isolated isolate VERB fnp-2993 73 37 cells cell NOUN fnp-2993 73 38 had have VERB fnp-2993 73 39 a a DET fnp-2993 73 40 striking striking ADJ fnp-2993 73 41 lack lack NOUN fnp-2993 73 42 of of ADP fnp-2993 73 43 attendant attendant ADJ fnp-2993 73 44 chronic chronic ADJ fnp-2993 73 45 inflammation.25 inflammation.25 NOUN fnp-2993 73 46 this this DET fnp-2993 73 47 disconnect disconnect NOUN fnp-2993 73 48 between between ADP fnp-2993 73 49 viral viral ADJ fnp-2993 73 50 infection infection NOUN fnp-2993 73 51 and and CCONJ fnp-2993 73 52 inflammation inflammation NOUN fnp-2993 73 53 raises raise VERB fnp-2993 73 54 the the DET fnp-2993 73 55 question question NOUN fnp-2993 73 56 of of ADP fnp-2993 73 57 immune immune ADJ fnp-2993 73 58 evasion evasion NOUN fnp-2993 73 59 . . PUNCT fnp-2993 74 1 one one NUM fnp-2993 74 2 case case NOUN fnp-2993 74 3 exhibited exhibit VERB fnp-2993 74 4 viral viral ADJ fnp-2993 74 5 staining stain VERB fnp-2993 74 6 around around ADP fnp-2993 74 7 the the DET fnp-2993 74 8 edges edge NOUN fnp-2993 74 9 of of ADP fnp-2993 74 10 subcortical subcortical ADJ fnp-2993 74 11 white white ADJ fnp-2993 74 12 matter matter NOUN fnp-2993 74 13 microinfarcts.87 microinfarcts.87 VERB fnp-2993 74 14 the the DET fnp-2993 74 15 immunostaining immunostaining NOUN fnp-2993 74 16 pattern pattern NOUN fnp-2993 74 17 consists consist VERB fnp-2993 74 18 of of ADP fnp-2993 74 19 diffuse diffuse NOUN fnp-2993 74 20 cytoplasmic cytoplasmic ADJ fnp-2993 74 21 and and CCONJ fnp-2993 74 22 perinuclear perinuclear ADJ fnp-2993 74 23 positivity positivity NOUN fnp-2993 74 24 with with ADP fnp-2993 74 25 small small ADJ fnp-2993 74 26 concentrated concentrated ADJ fnp-2993 74 27 foci focus NOUN fnp-2993 74 28 possibly possibly ADV fnp-2993 74 29 representing represent VERB fnp-2993 74 30 viral viral ADJ fnp-2993 74 31 inclusion inclusion NOUN fnp-2993 74 32 bodies.87 bodies.87 PROPN fnp-2993 74 33 meinhardt meinhardt ADJ fnp-2993 74 34 and and CCONJ fnp-2993 74 35 colleagues colleague NOUN fnp-2993 74 36 , , PUNCT fnp-2993 74 37 using use VERB fnp-2993 74 38 in in ADP fnp-2993 74 39 situ situ ADJ fnp-2993 74 40 hybridization hybridization NOUN fnp-2993 74 41 ( ( PUNCT fnp-2993 74 42 ish ish PROPN fnp-2993 74 43 ) ) PUNCT fnp-2993 74 44 , , PUNCT fnp-2993 74 45 identified identify VERB fnp-2993 74 46 sars sar NOUN fnp-2993 74 47 - - PUNCT fnp-2993 74 48 cov-2 cov-2 NOUN fnp-2993 74 49 in in ADP fnp-2993 74 50 the the DET fnp-2993 74 51 olfactory olfactory NOUN fnp-2993 74 52 epithelium epithelium NOUN fnp-2993 74 53 and and CCONJ fnp-2993 74 54 mucus.53 mucus.53 NOUN fnp-2993 74 55 lastly lastly ADV fnp-2993 74 56 , , PUNCT fnp-2993 74 57 viral viral ADJ fnp-2993 74 58 particles particle NOUN fnp-2993 74 59 compatible compatible ADJ fnp-2993 74 60 with with ADP fnp-2993 74 61 sars sar NOUN fnp-2993 74 62 - - PUNCT fnp-2993 74 63 cov-2 cov-2 PART fnp-2993 74 64 have have AUX fnp-2993 74 65 been be AUX fnp-2993 74 66 identified identify VERB fnp-2993 74 67 by by ADP fnp-2993 74 68 electron electron NOUN fnp-2993 74 69 microscopy microscopy NOUN fnp-2993 74 70 in in ADP fnp-2993 74 71 olfactory olfactory ADJ fnp-2993 74 72 bulb bulb NOUN fnp-2993 74 73 and and CCONJ fnp-2993 75 1 frontal frontal ADJ fnp-2993 75 2 lobe lobe NOUN fnp-2993 75 3 tissue.54,96 tissue.54,96 NOUN fnp-2993 75 4 to to ADP fnp-2993 75 5 date date NOUN fnp-2993 75 6 , , PUNCT fnp-2993 75 7 regions region NOUN fnp-2993 75 8 in in ADP fnp-2993 75 9 which which PRON fnp-2993 75 10 sars sar NOUN fnp-2993 75 11 - - PUNCT fnp-2993 75 12 cov-2 cov-2 PART fnp-2993 75 13 have have AUX fnp-2993 75 14 been be AUX fnp-2993 75 15 detected detect VERB fnp-2993 75 16 by by ADP fnp-2993 75 17 ihc ihc PROPN fnp-2993 75 18 , , PUNCT fnp-2993 75 19 rt rt PROPN fnp-2993 75 20 - - PUNCT fnp-2993 75 21 pcr pcr ADJ fnp-2993 75 22 , , PUNCT fnp-2993 75 23 or or CCONJ fnp-2993 75 24 electron electron NOUN fnp-2993 75 25 microscopy microscopy NOUN fnp-2993 75 26 relevant relevant ADJ fnp-2993 75 27 to to ADP fnp-2993 75 28 the the DET fnp-2993 75 29 cns cns PROPN fnp-2993 75 30 include include VERB fnp-2993 75 31 cornea cornea PROPN fnp-2993 75 32 , , PUNCT fnp-2993 75 33 conjunctiva conjunctiva NOUN fnp-2993 75 34 , , PUNCT fnp-2993 75 35 olfactory olfactory ADJ fnp-2993 75 36 epithelium epithelium NOUN fnp-2993 75 37 , , PUNCT fnp-2993 75 38 olfactory olfactory NOUN fnp-2993 75 39 bulb bulb NOUN fnp-2993 75 40 , , PUNCT fnp-2993 75 41 olfactory olfactory ADJ fnp-2993 75 42 tubercle tubercle NOUN fnp-2993 75 43 , , PUNCT fnp-2993 75 44 frontal frontal ADJ fnp-2993 75 45 lobe lobe NOUN fnp-2993 75 46 , , PUNCT fnp-2993 75 47 cerebellum cerebellum NOUN fnp-2993 75 48 , , PUNCT fnp-2993 75 49 medulla medulla NOUN fnp-2993 75 50 oblongata oblongata NOUN fnp-2993 75 51 , , PUNCT fnp-2993 75 52 cranial cranial ADJ fnp-2993 75 53 nerves nerve NOUN fnp-2993 75 54 and and CCONJ fnp-2993 75 55 trigeminal trigeminal ADJ fnp-2993 75 56 ganglion ganglion NOUN fnp-2993 75 57 . . PUNCT fnp-2993 76 1 most most ADJ fnp-2993 76 2 investigations investigation NOUN fnp-2993 76 3 studied study VERB fnp-2993 76 4 limited limited ADJ fnp-2993 76 5 areas area NOUN fnp-2993 76 6 of of ADP fnp-2993 76 7 brain brain NOUN fnp-2993 76 8 or or CCONJ fnp-2993 76 9 did do AUX fnp-2993 76 10 not not PART fnp-2993 76 11 specify specify VERB fnp-2993 76 12 the the DET fnp-2993 76 13 origin origin NOUN fnp-2993 76 14 of of ADP fnp-2993 76 15 cerebral cerebral ADJ fnp-2993 76 16 cortex cortex NOUN fnp-2993 76 17 tissue tissue NOUN fnp-2993 76 18 . . PUNCT fnp-2993 77 1 additional additional ADJ fnp-2993 77 2 studies study NOUN fnp-2993 77 3 are be AUX fnp-2993 77 4 needed need VERB fnp-2993 77 5 to to PART fnp-2993 77 6 better well ADV fnp-2993 77 7 establish establish VERB fnp-2993 77 8 the the DET fnp-2993 77 9 frequency frequency NOUN fnp-2993 77 10 and and CCONJ fnp-2993 77 11 extent extent NOUN fnp-2993 77 12 of of ADP fnp-2993 77 13 direct direct ADJ fnp-2993 77 14 infection infection NOUN fnp-2993 77 15 in in ADP fnp-2993 77 16 the the DET fnp-2993 77 17 cns cns NOUN fnp-2993 77 18 . . PUNCT fnp-2993 78 1 as as SCONJ fnp-2993 78 2 some some DET fnp-2993 78 3 patients patient NOUN fnp-2993 78 4 have have VERB fnp-2993 78 5 " " PUNCT fnp-2993 78 6 long long ADJ fnp-2993 78 7 covid covid NOUN fnp-2993 78 8 ” " PUNCT fnp-2993 78 9 wherein wherein SCONJ fnp-2993 78 10 they they PRON fnp-2993 78 11 have have AUX fnp-2993 78 12 persistent persistent ADJ fnp-2993 78 13 symptoms symptom NOUN fnp-2993 78 14 for for ADP fnp-2993 78 15 months month NOUN fnp-2993 78 16 , , PUNCT fnp-2993 78 17 whether whether SCONJ fnp-2993 78 18 and and CCONJ fnp-2993 78 19 how how SCONJ fnp-2993 78 20 sars sar NOUN fnp-2993 78 21 - - PUNCT fnp-2993 78 22 cov-2 cov-2 PART fnp-2993 78 23 may may AUX fnp-2993 78 24 persist persist VERB fnp-2993 78 25 in in ADP fnp-2993 78 26 the the DET fnp-2993 78 27 brain brain NOUN fnp-2993 78 28 will will AUX fnp-2993 78 29 need need VERB fnp-2993 78 30 to to PART fnp-2993 78 31 be be AUX fnp-2993 78 32 evaluated evaluate VERB fnp-2993 78 33 in in ADP fnp-2993 78 34 the the DET fnp-2993 78 35 future future NOUN fnp-2993 78 36 . . PUNCT fnp-2993 79 1 chronic chronic ADJ fnp-2993 79 2 inflammatory inflammatory ADJ fnp-2993 79 3 and and CCONJ fnp-2993 79 4 reactive reactive ADJ fnp-2993 79 5 glial glial ADJ fnp-2993 79 6 changes change NOUN fnp-2993 79 7 microgliosis microgliosis NOUN fnp-2993 79 8 and and CCONJ fnp-2993 79 9 astrocytosis astrocytosis NOUN fnp-2993 79 10 are be AUX fnp-2993 79 11 common common ADJ fnp-2993 79 12 in in ADP fnp-2993 79 13 covid-19 covid-19 PROPN fnp-2993 79 14 brains brain NOUN fnp-2993 79 15 including include VERB fnp-2993 79 16 in in ADP fnp-2993 79 17 the the DET fnp-2993 79 18 olfactory olfactory NOUN fnp-2993 79 19 bulb.25 bulb.25 PROPN fnp-2993 79 20 lymphoid lymphoid ADJ fnp-2993 79 21 inflammation inflammation NOUN fnp-2993 79 22 , , PUNCT fnp-2993 79 23 which which PRON fnp-2993 79 24 tends tend VERB fnp-2993 79 25 to to PART fnp-2993 79 26 be be AUX fnp-2993 79 27 minimal minimal ADJ fnp-2993 79 28 or or CCONJ fnp-2993 79 29 mild mild ADJ fnp-2993 79 30 in in ADP fnp-2993 79 31 many many ADJ fnp-2993 79 32 cases case NOUN fnp-2993 79 33 , , PUNCT fnp-2993 79 34 is be AUX fnp-2993 79 35 not not PART fnp-2993 79 36 uncommon uncommon ADJ fnp-2993 79 37 particularly particularly ADV fnp-2993 79 38 in in ADP fnp-2993 79 39 the the DET fnp-2993 79 40 medulla medulla NOUN fnp-2993 79 41 oblongata oblongata NOUN fnp-2993 79 42 and and CCONJ fnp-2993 79 43 if if SCONJ fnp-2993 79 44 ihc ihc PROPN fnp-2993 79 45 is be AUX fnp-2993 79 46 used use VERB fnp-2993 79 47 for for ADP fnp-2993 79 48 detection.25 detection.25 NOUN fnp-2993 79 49 in in ADP fnp-2993 79 50 many many ADJ fnp-2993 79 51 studies study NOUN fnp-2993 79 52 that that PRON fnp-2993 79 53 did do AUX fnp-2993 79 54 not not PART fnp-2993 79 55 use use VERB fnp-2993 79 56 ihc ihc PROPN fnp-2993 79 57 , , PUNCT fnp-2993 79 58 lymphoid lymphoid ADJ fnp-2993 79 59 inflammation inflammation NOUN fnp-2993 79 60 was be AUX fnp-2993 79 61 reported report VERB fnp-2993 79 62 as as ADP fnp-2993 79 63 absent absent ADJ fnp-2993 79 64 or or CCONJ fnp-2993 79 65 infrequent infrequent ADJ fnp-2993 79 66 ; ; PUNCT fnp-2993 79 67 this this PRON fnp-2993 79 68 is be AUX fnp-2993 79 69 concordant concordant ADJ fnp-2993 79 70 with with ADP fnp-2993 79 71 our our PRON fnp-2993 79 72 experience experience NOUN fnp-2993 79 73 and and CCONJ fnp-2993 79 74 anecdotally anecdotally ADV fnp-2993 79 75 with with ADP fnp-2993 79 76 that that PRON fnp-2993 79 77 of of ADP fnp-2993 79 78 colleagues colleague NOUN fnp-2993 79 79 in in ADP fnp-2993 79 80 asia asia PROPN fnp-2993 79 81 and and CCONJ fnp-2993 79 82 in in ADP fnp-2993 79 83 the the DET fnp-2993 79 84 united united PROPN fnp-2993 79 85 states states PROPN fnp-2993 79 86 ( ( PUNCT fnp-2993 79 87 personal personal ADJ fnp-2993 79 88 communication communication NOUN fnp-2993 79 89 ) ) PUNCT fnp-2993 79 90 . . PUNCT fnp-2993 80 1 a a DET fnp-2993 80 2 substantial substantial ADJ fnp-2993 80 3 portion portion NOUN fnp-2993 80 4 of of ADP fnp-2993 80 5 these these DET fnp-2993 80 6 reactive reactive ADJ fnp-2993 80 7 changes change NOUN fnp-2993 80 8 may may AUX fnp-2993 80 9 be be AUX fnp-2993 80 10 secondary secondary ADJ fnp-2993 80 11 to to ADP fnp-2993 80 12 systemic systemic ADJ fnp-2993 80 13 issues issue NOUN fnp-2993 80 14 ( ( PUNCT fnp-2993 80 15 e.g. e.g. ADV fnp-2993 80 16 sepsis sepsis NOUN fnp-2993 80 17 ) ) PUNCT fnp-2993 80 18 or or CCONJ fnp-2993 80 19 other other ADJ fnp-2993 80 20 neuropathology neuropathology NOUN fnp-2993 80 21 ( ( PUNCT fnp-2993 80 22 infarcts infarct NOUN fnp-2993 80 23 , , PUNCT fnp-2993 80 24 hemorrhages hemorrhage NOUN fnp-2993 80 25 , , PUNCT fnp-2993 80 26 etc etc X fnp-2993 80 27 . . X fnp-2993 80 28 ) ) PUNCT fnp-2993 81 1 rather rather ADV fnp-2993 81 2 than than ADP fnp-2993 81 3 a a DET fnp-2993 81 4 response response NOUN fnp-2993 81 5 to to ADP fnp-2993 81 6 direct direct ADJ fnp-2993 81 7 infection infection NOUN fnp-2993 81 8 . . PUNCT fnp-2993 82 1 microgliosis microgliosis NOUN fnp-2993 82 2 and and CCONJ fnp-2993 82 3 chronic chronic ADJ fnp-2993 82 4 inflammation inflammation NOUN fnp-2993 82 5 did do AUX fnp-2993 82 6 not not PART fnp-2993 82 7 correlate correlate VERB fnp-2993 82 8 with with ADP fnp-2993 82 9 the the DET fnp-2993 82 10 severity severity NOUN fnp-2993 82 11 of of ADP fnp-2993 82 12 covid-19 covid-19 PROPN fnp-2993 82 13 disease disease NOUN fnp-2993 82 14 nor nor CCONJ fnp-2993 82 15 were be AUX fnp-2993 82 16 there there PRON fnp-2993 82 17 any any DET fnp-2993 82 18 discernible discernible ADJ fnp-2993 82 19 neuropathological neuropathological ADJ fnp-2993 82 20 differences difference NOUN fnp-2993 82 21 in in ADP fnp-2993 82 22 patients patient NOUN fnp-2993 82 23 from from ADP fnp-2993 82 24 nursing nursing NOUN fnp-2993 82 25 homes home NOUN fnp-2993 82 26 , , PUNCT fnp-2993 82 27 hospital hospital NOUN fnp-2993 82 28 wards ward NOUN fnp-2993 82 29 , , PUNCT fnp-2993 82 30 or or CCONJ fnp-2993 82 31 intensive intensive ADJ fnp-2993 82 32 care care NOUN fnp-2993 82 33 units.25 units.25 NOUN fnp-2993 82 34 furthermore furthermore ADV fnp-2993 82 35 , , PUNCT fnp-2993 82 36 microglial microglial ADJ fnp-2993 82 37 activation activation NOUN fnp-2993 82 38 , , PUNCT fnp-2993 82 39 perivascular perivascular ADJ fnp-2993 82 40 lymphocytosis lymphocytosis NOUN fnp-2993 82 41 , , PUNCT fnp-2993 82 42 and and CCONJ fnp-2993 82 43 leptomeningeal leptomeningeal ADJ fnp-2993 82 44 lymphocytic lymphocytic ADJ fnp-2993 82 45 infiltration infiltration NOUN fnp-2993 82 46 is be AUX fnp-2993 82 47 observed observe VERB fnp-2993 82 48 to to ADP fnp-2993 82 49 similar similar ADJ fnp-2993 82 50 degrees degree NOUN fnp-2993 82 51 in in ADP fnp-2993 82 52 the the DET fnp-2993 82 53 control control NOUN fnp-2993 82 54 brains brain NOUN fnp-2993 82 55 of of ADP fnp-2993 82 56 septic septic ADJ fnp-2993 82 57 ( ( PUNCT fnp-2993 82 58 non non ADJ fnp-2993 82 59 - - ADJ fnp-2993 82 60 covid-19 covid-19 ADJ fnp-2993 82 61 ) ) PUNCT fnp-2993 82 62 patients patient NOUN fnp-2993 82 63 when when SCONJ fnp-2993 82 64 compared compare VERB fnp-2993 82 65 to to ADP fnp-2993 82 66 covid-19 covid-19 PROPN fnp-2993 82 67 patients.86 patients.86 VERB fnp-2993 82 68 some some DET fnp-2993 82 69 cases case NOUN fnp-2993 82 70 present present ADJ fnp-2993 82 71 findings finding NOUN fnp-2993 82 72 compatible compatible ADJ fnp-2993 82 73 with with ADP fnp-2993 82 74 viral viral ADJ fnp-2993 82 75 meningoencephalitis meningoencephalitis NOUN fnp-2993 82 76 including include VERB fnp-2993 82 77 parenchymal parenchymal ADJ fnp-2993 82 78 lymphocytic lymphocytic ADJ fnp-2993 82 79 clustering clustering NOUN fnp-2993 82 80 around around ADP fnp-2993 82 81 microglial microglial ADJ fnp-2993 82 82 nodules nodule NOUN fnp-2993 82 83 , , PUNCT fnp-2993 82 84 concomitant concomitant ADJ fnp-2993 82 85 leptomeningeal leptomeningeal ADJ fnp-2993 82 86 lymphocytic lymphocytic ADJ fnp-2993 82 87 inflammation inflammation NOUN fnp-2993 82 88 , , PUNCT fnp-2993 82 89 and and CCONJ fnp-2993 82 90 even even ADV fnp-2993 82 91 neuronophagy neuronophagy ADJ fnp-2993 82 92 . . PUNCT fnp-2993 83 1 in in ADP fnp-2993 83 2 the the DET fnp-2993 83 3 study study NOUN fnp-2993 83 4 by by ADP fnp-2993 83 5 matschke matschke NOUN fnp-2993 83 6 and and CCONJ fnp-2993 83 7 colleagues colleague NOUN fnp-2993 83 8 , , PUNCT fnp-2993 83 9 four four NUM fnp-2993 83 10 out out ADP fnp-2993 83 11 of of ADP fnp-2993 83 12 16 16 NUM fnp-2993 83 13 cases case NOUN fnp-2993 83 14 immunopositive immunopositive ADJ fnp-2993 83 15 for for ADP fnp-2993 83 16 sars sar NOUN fnp-2993 83 17 - - PUNCT fnp-2993 83 18 cov-2 cov-2 PART fnp-2993 83 19 had have VERB fnp-2993 83 20 10 10 NUM fnp-2993 83 21 to to PART fnp-2993 83 22 49 49 NUM fnp-2993 83 23 cd8 cd8 NOUN fnp-2993 83 24 + + PROPN fnp-2993 83 25 cytotoxic cytotoxic ADJ fnp-2993 83 26 t t NOUN fnp-2993 83 27 lymphocytes lymphocyte NOUN fnp-2993 83 28 per per ADP fnp-2993 83 29 high high ADJ fnp-2993 83 30 power power NOUN fnp-2993 83 31 field field NOUN fnp-2993 83 32 in in ADP fnp-2993 83 33 at at ADV fnp-2993 83 34 least least ADV fnp-2993 83 35 three three NUM fnp-2993 83 36 fields field NOUN fnp-2993 83 37 in in ADP fnp-2993 83 38 the the DET fnp-2993 83 39 medulla medulla NOUN fnp-2993 83 40 oblongata.25 oblongata.25 NOUN fnp-2993 83 41 the the DET fnp-2993 83 42 observed observed ADJ fnp-2993 83 43 lymphocytes lymphocyte NOUN fnp-2993 83 44 tended tend VERB fnp-2993 83 45 to to PART fnp-2993 83 46 cluster cluster VERB fnp-2993 83 47 near near ADP fnp-2993 83 48 activated activate VERB fnp-2993 83 49 microglial microglial ADJ fnp-2993 83 50 nodules,25 nodules,25 NOUN fnp-2993 83 51 as as ADP fnp-2993 83 52 commonly commonly ADV fnp-2993 83 53 seen see VERB fnp-2993 83 54 in in ADP fnp-2993 83 55 viral viral ADJ fnp-2993 83 56 encephalitis encephalitis NOUN fnp-2993 83 57 . . PUNCT fnp-2993 84 1 rt rt ADJ fnp-2993 84 2 - - PUNCT fnp-2993 84 3 pcr pcr ADJ fnp-2993 84 4 detected detect VERB fnp-2993 84 5 sars sar NOUN fnp-2993 84 6 - - PUNCT fnp-2993 84 7 cov-2 cov-2 NOUN fnp-2993 84 8 rna rna NOUN fnp-2993 84 9 in in ADP fnp-2993 84 10 three three NUM fnp-2993 84 11 out out ADP fnp-2993 84 12 of of ADP fnp-2993 84 13 the the DET fnp-2993 84 14 four four NUM fnp-2993 84 15 cases.25 cases.25 NOUN fnp-2993 84 16 three three NUM fnp-2993 84 17 studies study NOUN fnp-2993 84 18 report report NOUN fnp-2993 84 19 neuronophagy neuronophagy VERB fnp-2993 84 20 in in ADP fnp-2993 84 21 the the DET fnp-2993 84 22 medulla medulla NOUN fnp-2993 84 23 associated associate VERB fnp-2993 84 24 with with ADP fnp-2993 84 25 histiocytic histiocytic ADJ fnp-2993 84 26 and and CCONJ fnp-2993 84 27 lymphocytic lymphocytic ADJ fnp-2993 84 28 parenchymal parenchymal ADJ fnp-2993 84 29 infiltration.25,84,89 infiltration.25,84,89 PROPN fnp-2993 84 30 von von NOUN fnp-2993 84 31 weyhern weyhern NOUN fnp-2993 84 32 and and CCONJ fnp-2993 84 33 colleagues colleague NOUN fnp-2993 84 34 report report VERB fnp-2993 84 35 six six NUM fnp-2993 84 36 cases case NOUN fnp-2993 84 37 of of ADP fnp-2993 84 38 perivascular perivascular ADJ fnp-2993 84 39 and and CCONJ fnp-2993 84 40 parenchymal parenchymal ADJ fnp-2993 84 41 lymphocytosis lymphocytosis NOUN fnp-2993 84 42 with with ADP fnp-2993 84 43 neuronal neuronal ADJ fnp-2993 84 44 loss loss NOUN fnp-2993 84 45 and and CCONJ fnp-2993 84 46 axon axon NOUN fnp-2993 84 47 degeneration degeneration NOUN fnp-2993 84 48 in in ADP fnp-2993 84 49 the the DET fnp-2993 84 50 brainstem brainstem NOUN fnp-2993 84 51 , , PUNCT fnp-2993 84 52 which which PRON fnp-2993 84 53 the the DET fnp-2993 84 54 authors author NOUN fnp-2993 84 55 determined determine VERB fnp-2993 84 56 to to PART fnp-2993 84 57 be be AUX fnp-2993 84 58 adequate adequate ADJ fnp-2993 84 59 to to PART fnp-2993 84 60 diagnose diagnose VERB fnp-2993 84 61 sars sar NOUN fnp-2993 84 62 - - PUNCT fnp-2993 84 63 cov-2 cov-2 NOUN fnp-2993 84 64 viral viral ADJ fnp-2993 84 65 encephalitis.79 encephalitis.79 NOUN fnp-2993 84 66 in in ADP fnp-2993 84 67 the the DET fnp-2993 84 68 same same ADJ fnp-2993 84 69 study study NOUN fnp-2993 84 70 , , PUNCT fnp-2993 84 71 five five NUM fnp-2993 84 72 of of ADP fnp-2993 84 73 the the DET fnp-2993 84 74 six six NUM fnp-2993 84 75 cases case NOUN fnp-2993 84 76 had have VERB fnp-2993 84 77 concomitant concomitant ADJ fnp-2993 84 78 meningitis.79 meningitis.79 NOUN fnp-2993 84 79 respiratory respiratory ADJ fnp-2993 84 80 and and CCONJ fnp-2993 84 81 cardiovascular cardiovascular ADJ fnp-2993 84 82 control control NOUN fnp-2993 84 83 centers center NOUN fnp-2993 84 84 of of ADP fnp-2993 84 85 the the DET fnp-2993 84 86 medulla medulla NOUN fnp-2993 84 87 may may AUX fnp-2993 84 88 be be AUX fnp-2993 84 89 affected.53 affected.53 NOUN fnp-2993 84 90 while while SCONJ fnp-2993 84 91 the the DET fnp-2993 84 92 majority majority NOUN fnp-2993 84 93 of of ADP fnp-2993 84 94 covid-19 covid-19 PROPN fnp-2993 84 95 patients patient NOUN fnp-2993 84 96 with with ADP fnp-2993 84 97 neurological neurological ADJ fnp-2993 84 98 manifestations manifestation NOUN fnp-2993 84 99 do do AUX fnp-2993 84 100 not not PART fnp-2993 84 101 have have VERB fnp-2993 84 102 detectable detectable ADJ fnp-2993 84 103 sars sar NOUN fnp-2993 84 104 - - PUNCT fnp-2993 84 105 cov-2 cov-2 NOUN fnp-2993 84 106 rna rna NOUN fnp-2993 84 107 in in ADP fnp-2993 84 108 csf csf NOUN fnp-2993 84 109 by by ADP fnp-2993 84 110 rt rt PROPN fnp-2993 84 111 - - PUNCT fnp-2993 84 112 pcr,111–113 pcr,111–113 NOUN fnp-2993 84 113 exceptions exception NOUN fnp-2993 84 114 to to ADP fnp-2993 84 115 this this DET fnp-2993 84 116 trend trend NOUN fnp-2993 84 117 have have AUX fnp-2993 84 118 been be AUX fnp-2993 84 119 reported report VERB fnp-2993 84 120 in in ADP fnp-2993 84 121 at at ADV fnp-2993 84 122 least least ADV fnp-2993 84 123 four four NUM fnp-2993 84 124 covid-19 covid-19 PROPN fnp-2993 84 125 patients.33,114–116 patients.33,114–116 ADJ fnp-2993 84 126 anti anti ADJ fnp-2993 84 127 - - ADJ fnp-2993 84 128 sars sar NOUN fnp-2993 84 129 - - PUNCT fnp-2993 84 130 cov-2 cov-2 NOUN fnp-2993 84 131 antibodies antibody NOUN fnp-2993 84 132 were be AUX fnp-2993 84 133 detected detect VERB fnp-2993 84 134 in in ADP fnp-2993 84 135 the the DET fnp-2993 84 136 csf csf NOUN fnp-2993 84 137 of of ADP fnp-2993 84 138 one one NUM fnp-2993 84 139 covid-19 covid-19 PROPN fnp-2993 84 140 patient patient NOUN fnp-2993 84 141 suggesting suggest VERB fnp-2993 84 142 an an DET fnp-2993 84 143 immune immune ADJ fnp-2993 84 144 response response NOUN fnp-2993 84 145 to to ADP fnp-2993 84 146 viral viral ADJ fnp-2993 84 147 infection.87 infection.87 NOUN fnp-2993 84 148 it it PRON fnp-2993 84 149 appears appear VERB fnp-2993 84 150 therefore therefore ADV fnp-2993 84 151 that that SCONJ fnp-2993 84 152 histologically histologically ADV fnp-2993 84 153 documentable documentable ADJ fnp-2993 84 154 cases case NOUN fnp-2993 84 155 of of ADP fnp-2993 84 156 sars sar NOUN fnp-2993 84 157 - - PUNCT fnp-2993 84 158 cov-2 cov-2 NOUN fnp-2993 84 159 encephalitis encephalitis NOUN fnp-2993 84 160 and/or and/or CCONJ fnp-2993 84 161 meningitis meningitis NOUN fnp-2993 84 162 do do AUX fnp-2993 84 163 occur occur VERB fnp-2993 84 164 , , PUNCT fnp-2993 84 165 with with ADP fnp-2993 84 166 a a DET fnp-2993 84 167 tendency tendency NOUN fnp-2993 84 168 to to PART fnp-2993 84 169 involve involve VERB fnp-2993 84 170 the the DET fnp-2993 84 171 brainstem brainstem NOUN fnp-2993 84 172 . . PUNCT fnp-2993 85 1 as as SCONJ fnp-2993 85 2 only only ADV fnp-2993 85 3 a a DET fnp-2993 85 4 few few ADJ fnp-2993 85 5 series series NOUN fnp-2993 85 6 report report VERB fnp-2993 85 7 the the DET fnp-2993 85 8 majority majority NOUN fnp-2993 85 9 of of ADP fnp-2993 85 10 brainstem brainstem NOUN fnp-2993 85 11 microglial microglial ADJ fnp-2993 85 12 encephalitis encephalitis ADJ fnp-2993 85 13 cases case NOUN fnp-2993 85 14 , , PUNCT fnp-2993 85 15 the the DET fnp-2993 85 16 question question NOUN fnp-2993 85 17 arises arise VERB fnp-2993 85 18 as as ADP fnp-2993 85 19 to to ADP fnp-2993 85 20 whether whether SCONJ fnp-2993 85 21 particular particular ADJ fnp-2993 85 22 viral viral ADJ fnp-2993 85 23 strains strain NOUN fnp-2993 85 24 , , PUNCT fnp-2993 85 25 therapeutic therapeutic ADJ fnp-2993 85 26 approaches approach NOUN fnp-2993 85 27 , , PUNCT fnp-2993 85 28 genetic genetic ADJ fnp-2993 85 29 background background NOUN fnp-2993 85 30 or or CCONJ fnp-2993 85 31 detection detection NOUN fnp-2993 85 32 methods method NOUN fnp-2993 85 33 are be AUX fnp-2993 85 34 responsible responsible ADJ fnp-2993 85 35 for for ADP fnp-2993 85 36 its its PRON fnp-2993 85 37 apparent apparent ADJ fnp-2993 85 38 absence absence NOUN fnp-2993 85 39 or or CCONJ fnp-2993 85 40 paucity paucity NOUN fnp-2993 85 41 in in ADP fnp-2993 85 42 the the DET fnp-2993 85 43 majority majority NOUN fnp-2993 85 44 of of ADP fnp-2993 85 45 studies study NOUN fnp-2993 85 46 . . PUNCT fnp-2993 86 1 autoimmune autoimmune PROPN fnp-2993 86 2 mediated mediate VERB fnp-2993 86 3 inflammation inflammation NOUN fnp-2993 86 4 may may AUX fnp-2993 86 5 also also ADV fnp-2993 86 6 occur occur VERB fnp-2993 86 7 . . PUNCT fnp-2993 87 1 autoimmune autoimmune ADJ fnp-2993 87 2 encephalitis encephalitis PROPN fnp-2993 87 3 , , PUNCT fnp-2993 87 4 adem adem PROPN fnp-2993 87 5 , , PUNCT fnp-2993 87 6 and and CCONJ fnp-2993 87 7 acute acute ADJ fnp-2993 87 8 necrotizing necrotizing NOUN fnp-2993 87 9 encephalopathy encephalopathy NOUN fnp-2993 87 10 have have AUX fnp-2993 87 11 also also ADV fnp-2993 87 12 been be AUX fnp-2993 87 13 reported report VERB fnp-2993 87 14 clinically clinically ADV fnp-2993 87 15 though though SCONJ fnp-2993 87 16 histopathologic histopathologic ADJ fnp-2993 87 17 evaluation evaluation NOUN fnp-2993 87 18 has have AUX fnp-2993 87 19 been be AUX fnp-2993 87 20 limited limit VERB fnp-2993 87 21 . . PUNCT fnp-2993 88 1 adem adem PROPN fnp-2993 88 2 - - PUNCT fnp-2993 88 3 like like ADJ fnp-2993 88 4 pathology pathology NOUN fnp-2993 88 5 has have AUX fnp-2993 88 6 been be AUX fnp-2993 88 7 reported report VERB fnp-2993 88 8 in in ADP fnp-2993 88 9 one one NUM fnp-2993 88 10 autopsy autopsy ADJ fnp-2993 88 11 case.83 case.83 PROPN fnp-2993 88 12 microthrombi microthrombi NOUN fnp-2993 88 13 , , PUNCT fnp-2993 88 14 infarcts infarct VERB fnp-2993 88 15 , , PUNCT fnp-2993 88 16 hemorrhages hemorrhage NOUN fnp-2993 88 17 , , PUNCT fnp-2993 88 18 and and CCONJ fnp-2993 88 19 “ " PUNCT fnp-2993 88 20 neutrophilic neutrophilic ADJ fnp-2993 88 21 plugs plug NOUN fnp-2993 88 22 ” " PUNCT fnp-2993 88 23 sars sar NOUN fnp-2993 88 24 - - PUNCT fnp-2993 88 25 cov-2 cov-2 NUM fnp-2993 88 26 may may AUX fnp-2993 88 27 induce induce VERB fnp-2993 88 28 a a DET fnp-2993 88 29 cytokine cytokine NOUN fnp-2993 88 30 storm storm NOUN fnp-2993 88 31 , , PUNCT fnp-2993 88 32 a a DET fnp-2993 88 33 severe severe ADJ fnp-2993 88 34 hyperimmune hyperimmune NOUN fnp-2993 88 35 reaction reaction NOUN fnp-2993 88 36 characterized characterize VERB fnp-2993 88 37 by by ADP fnp-2993 88 38 excessive excessive ADJ fnp-2993 88 39 and and CCONJ fnp-2993 88 40 rapid rapid ADJ fnp-2993 88 41 release release NOUN fnp-2993 88 42 of of ADP fnp-2993 88 43 cytokines cytokine NOUN fnp-2993 88 44 such such ADJ fnp-2993 88 45 as as ADP fnp-2993 88 46 il-6 il-6 NUM fnp-2993 88 47 and and CCONJ fnp-2993 88 48 il-1β il-1β PROPN fnp-2993 88 49 into into ADP fnp-2993 88 50 the the DET fnp-2993 88 51 blood.117,118 blood.117,118 PROPN fnp-2993 88 52 il-6 il-6 NOUN fnp-2993 88 53 activates activate VERB fnp-2993 88 54 the the DET fnp-2993 88 55 coagulation coagulation NOUN fnp-2993 88 56 system system NOUN fnp-2993 88 57 and and CCONJ fnp-2993 88 58 increases increase VERB fnp-2993 88 59 vascular vascular ADJ fnp-2993 88 60 permeability119 permeability119 PROPN fnp-2993 88 61 which which PRON fnp-2993 88 62 , , PUNCT fnp-2993 88 63 in in ADP fnp-2993 88 64 combination combination NOUN fnp-2993 88 65 with with ADP fnp-2993 88 66 viral viral ADJ fnp-2993 88 67 endotheliopathy,120 endotheliopathy,120 PROPN fnp-2993 88 68 may may AUX fnp-2993 88 69 account account VERB fnp-2993 88 70 for for ADP fnp-2993 88 71 the the DET fnp-2993 88 72 well well ADV fnp-2993 88 73 documented document VERB fnp-2993 88 74 covid-19 covid-19 PROPN fnp-2993 88 75 associated associate VERB fnp-2993 88 76 coagulopathy.41,121 coagulopathy.41,121 ADJ fnp-2993 88 77 sars sar NOUN fnp-2993 88 78 - - PUNCT fnp-2993 88 79 cov-2 cov-2 PART fnp-2993 88 80 has have AUX fnp-2993 88 81 been be AUX fnp-2993 88 82 detected detect VERB fnp-2993 88 83 within within ADP fnp-2993 88 84 cerebral cerebral ADJ fnp-2993 88 85 endothelial endothelial ADJ fnp-2993 88 86 cells cell NOUN fnp-2993 88 87 by by ADP fnp-2993 88 88 ihc ihc PROPN fnp-2993 88 89 and and CCONJ fnp-2993 88 90 electron electron PROPN fnp-2993 88 91 microscopy.87,96 microscopy.87,96 NOUN fnp-2993 88 92 hypercoagulability hypercoagulability NOUN fnp-2993 88 93 , , PUNCT fnp-2993 88 94 in in ADP fnp-2993 88 95 turn turn NOUN fnp-2993 88 96 , , PUNCT fnp-2993 88 97 results result NOUN fnp-2993 88 98 in in ADP fnp-2993 88 99 histologic histologic ADJ fnp-2993 88 100 findings finding NOUN fnp-2993 88 101 of of ADP fnp-2993 88 102 microthrombi microthrombi NOUN fnp-2993 88 103 , , PUNCT fnp-2993 88 104 infarcts infarct VERB fnp-2993 88 105 , , PUNCT fnp-2993 88 106 and and CCONJ fnp-2993 88 107 hemorrhages hemorrhage NOUN fnp-2993 88 108 . . PUNCT fnp-2993 89 1 also also ADV fnp-2993 89 2 , , PUNCT fnp-2993 89 3 il-1β il-1β PROPN fnp-2993 89 4 plays play VERB fnp-2993 89 5 a a DET fnp-2993 89 6 major major ADJ fnp-2993 89 7 role role NOUN fnp-2993 89 8 in in ADP fnp-2993 89 9 triggering trigger VERB fnp-2993 89 10 vascular vascular ADJ fnp-2993 89 11 “ " PUNCT fnp-2993 89 12 neutrophilic neutrophilic ADJ fnp-2993 89 13 plugs plug NOUN fnp-2993 89 14 ” " PUNCT fnp-2993 89 15 containing contain VERB fnp-2993 89 16 neutrophils neutrophil NOUN fnp-2993 89 17 and/or and/or CCONJ fnp-2993 89 18 platelets platelet VERB fnp-2993 89 19 as as ADV fnp-2993 89 20 well well ADV fnp-2993 89 21 as as ADP fnp-2993 89 22 neutrophil neutrophil ADJ fnp-2993 89 23 extracellular extracellular ADJ fnp-2993 89 24 traps trap NOUN fnp-2993 89 25 , , PUNCT fnp-2993 89 26 a a DET fnp-2993 89 27 mesh mesh NOUN fnp-2993 89 28 of of ADP fnp-2993 89 29 deoxynucleic deoxynucleic VERB fnp-2993 89 30 acid acid NOUN fnp-2993 89 31 ( ( PUNCT fnp-2993 89 32 dna)-rich dna)-rich PROPN fnp-2993 89 33 material material NOUN fnp-2993 89 34 coated coat VERB fnp-2993 89 35 with with ADP fnp-2993 89 36 antimicrobials antimicrobial NOUN fnp-2993 89 37 that that PRON fnp-2993 89 38 entrap entrap VERB fnp-2993 89 39 and and CCONJ fnp-2993 89 40 kill kill VERB fnp-2993 89 41 microbes.122 microbes.122 NOUN fnp-2993 89 42 these these DET fnp-2993 89 43 “ " PUNCT fnp-2993 89 44 neutrophilic neutrophilic ADJ fnp-2993 89 45 plugs plug NOUN fnp-2993 89 46 ” " PUNCT fnp-2993 89 47 have have AUX fnp-2993 89 48 been be AUX fnp-2993 89 49 found find VERB fnp-2993 89 50 in in ADP fnp-2993 89 51 the the DET fnp-2993 89 52 brain brain NOUN fnp-2993 89 53 as as ADV fnp-2993 89 54 well well ADV fnp-2993 89 55 as as ADP fnp-2993 89 56 the the DET fnp-2993 89 57 lungs lung NOUN fnp-2993 89 58 , , PUNCT fnp-2993 89 59 heart heart NOUN fnp-2993 89 60 , , PUNCT fnp-2993 89 61 kidneys kidney NOUN fnp-2993 89 62 , , PUNCT fnp-2993 89 63 and and CCONJ fnp-2993 89 64 liver liver NOUN fnp-2993 89 65 of of ADP fnp-2993 89 66 covid-19 covid-19 PROPN fnp-2993 89 67 patients patient NOUN fnp-2993 89 68 who who PRON fnp-2993 89 69 come come VERB fnp-2993 89 70 to to ADP fnp-2993 89 71 autopsy.88 autopsy.88 PROPN fnp-2993 89 72 approximately approximately ADV fnp-2993 89 73 1.6 1.6 NUM fnp-2993 89 74 % % NOUN fnp-2993 89 75 of of ADP fnp-2993 89 76 cases case NOUN fnp-2993 89 77 have have VERB fnp-2993 89 78 “ " PUNCT fnp-2993 89 79 neutrophilic neutrophilic ADJ fnp-2993 89 80 plugs plug NOUN fnp-2993 89 81 ” " PUNCT fnp-2993 89 82 in in ADP fnp-2993 89 83 the the DET fnp-2993 89 84 brain brain NOUN fnp-2993 89 85 ( ( PUNCT fnp-2993 89 86 table table NOUN fnp-2993 89 87 1 1 NUM fnp-2993 89 88 ) ) PUNCT fnp-2993 89 89 though though SCONJ fnp-2993 89 90 this this DET fnp-2993 89 91 percentage percentage NOUN fnp-2993 89 92 is be AUX fnp-2993 89 93 likely likely ADJ fnp-2993 89 94 an an DET fnp-2993 89 95 underestimate underestimate ADJ fnp-2993 89 96 as as SCONJ fnp-2993 89 97 pathologists pathologist NOUN fnp-2993 89 98 do do AUX fnp-2993 89 99 not not PART fnp-2993 89 100 typically typically ADV fnp-2993 89 101 evaluate evaluate VERB fnp-2993 89 102 for for ADP fnp-2993 89 103 these these DET fnp-2993 89 104 structures structure NOUN fnp-2993 89 105 . . PUNCT fnp-2993 90 1 pneumonia pneumonia NOUN fnp-2993 90 2 and and CCONJ fnp-2993 90 3 ards ard VERB fnp-2993 90 4 with with ADP fnp-2993 90 5 resultant resultant NOUN fnp-2993 90 6 hypoxemia hypoxemia NOUN fnp-2993 90 7 as as ADV fnp-2993 90 8 well well ADV fnp-2993 90 9 as as ADP fnp-2993 90 10 pre pre ADJ fnp-2993 90 11 - - ADJ fnp-2993 90 12 existing exist VERB fnp-2993 90 13 arteriosclerosis arteriosclerosis NOUN fnp-2993 90 14 are be AUX fnp-2993 90 15 also also ADV fnp-2993 90 16 likely likely ADV fnp-2993 90 17 contributory contributory NOUN fnp-2993 90 18 to to ADP fnp-2993 90 19 the the DET fnp-2993 90 20 cerebral cerebral ADJ fnp-2993 90 21 infarcts infarct NOUN fnp-2993 90 22 . . PUNCT fnp-2993 91 1 in in ADP fnp-2993 91 2 addition addition NOUN fnp-2993 91 3 to to ADP fnp-2993 91 4 cerebral cerebral ADJ fnp-2993 91 5 infarcts infarct NOUN fnp-2993 91 6 , , PUNCT fnp-2993 91 7 we we PRON fnp-2993 91 8 have have AUX fnp-2993 91 9 noted note VERB fnp-2993 91 10 occasional occasional ADJ fnp-2993 91 11 cases case NOUN fnp-2993 91 12 of of ADP fnp-2993 91 13 pituitary pituitary ADJ fnp-2993 91 14 infarcts infarct NOUN fnp-2993 91 15 ( ( PUNCT fnp-2993 91 16 figure figure NOUN fnp-2993 91 17 3c 3c NUM fnp-2993 91 18 ) ) PUNCT fnp-2993 91 19 in in ADP fnp-2993 91 20 our our PRON fnp-2993 91 21 covid-19 covid-19 PROPN fnp-2993 91 22 autopsies autopsy NOUN fnp-2993 91 23 . . PUNCT fnp-2993 92 1 numerous numerous ADJ fnp-2993 92 2 extramedullary extramedullary ADJ fnp-2993 92 3 megakaryocytes megakaryocyte NOUN fnp-2993 92 4 were be AUX fnp-2993 92 5 present present ADJ fnp-2993 92 6 in in ADP fnp-2993 92 7 subacute subacute ADJ fnp-2993 92 8 cerebral cerebral ADJ fnp-2993 92 9 infarcts infarct NOUN fnp-2993 92 10 of of ADP fnp-2993 92 11 one one NUM fnp-2993 92 12 covid-19 covid-19 PROPN fnp-2993 92 13 patient.84 patient.84 PROPN fnp-2993 92 14 alzheimer alzheimer PROPN fnp-2993 92 15 type type PROPN fnp-2993 92 16 ii ii PROPN fnp-2993 92 17 astrocytosis astrocytosis NOUN fnp-2993 92 18 alzheimer alzheimer PROPN fnp-2993 92 19 type type PROPN fnp-2993 92 20 ii ii PROPN fnp-2993 92 21 astrocytosis astrocytosis NOUN fnp-2993 92 22 ( ( PUNCT fnp-2993 92 23 figure figure NOUN fnp-2993 92 24 3d 3d NUM fnp-2993 92 25 ) ) PUNCT fnp-2993 92 26 characteristic characteristic NOUN fnp-2993 92 27 of of ADP fnp-2993 92 28 hepatic hepatic ADJ fnp-2993 92 29 encephalopathy encephalopathy NOUN fnp-2993 92 30 has have AUX fnp-2993 92 31 been be AUX fnp-2993 92 32 reported.89,97 reported.89,97 NOUN fnp-2993 92 33 the the DET fnp-2993 92 34 reports report NOUN fnp-2993 92 35 do do AUX fnp-2993 92 36 not not PART fnp-2993 92 37 specify specify VERB fnp-2993 92 38 whether whether SCONJ fnp-2993 92 39 the the DET fnp-2993 92 40 frequency frequency NOUN fnp-2993 92 41 of of ADP fnp-2993 92 42 the the DET fnp-2993 92 43 alzheimer alzheimer PROPN fnp-2993 92 44 type type PROPN fnp-2993 92 45 ii ii PROPN fnp-2993 92 46 astrocytes astrocyte NOUN fnp-2993 92 47 reaches reach VERB fnp-2993 92 48 a a DET fnp-2993 92 49 threshold threshold NOUN fnp-2993 92 50 of of ADP fnp-2993 92 51 five five NUM fnp-2993 92 52 or or CCONJ fnp-2993 92 53 more more ADJ fnp-2993 92 54 per per ADP fnp-2993 92 55 20 20 NUM fnp-2993 92 56 high high ADJ fnp-2993 92 57 power power NOUN fnp-2993 92 58 fields field NOUN fnp-2993 92 59 , , PUNCT fnp-2993 92 60 the the DET fnp-2993 92 61 cutoff cutoff NOUN fnp-2993 92 62 suggested suggest VERB fnp-2993 92 63 by by ADP fnp-2993 92 64 agarwal agarwal PROPN fnp-2993 92 65 and and CCONJ fnp-2993 92 66 colleagues colleague NOUN fnp-2993 92 67 for for ADP fnp-2993 92 68 hepatic hepatic ADJ fnp-2993 92 69 encephalopathy.123 encephalopathy.123 NOUN fnp-2993 92 70 in in ADP fnp-2993 92 71 a a DET fnp-2993 92 72 paper paper NOUN fnp-2993 92 73 by by ADP fnp-2993 92 74 solomon solomon PROPN fnp-2993 92 75 and and CCONJ fnp-2993 92 76 colleagues colleague NOUN fnp-2993 92 77 , , PUNCT fnp-2993 92 78 four four NUM fnp-2993 92 79 out out ADP fnp-2993 92 80 of of ADP fnp-2993 92 81 four four NUM fnp-2993 92 82 cases case NOUN fnp-2993 92 83 with with ADP fnp-2993 92 84 alzheimer alzheimer PROPN fnp-2993 92 85 type type PROPN fnp-2993 92 86 ii ii PROPN fnp-2993 92 87 astrocytes astrocyte NOUN fnp-2993 92 88 had have VERB fnp-2993 92 89 chronic chronic ADJ fnp-2993 92 90 liver liver NOUN fnp-2993 92 91 disease disease NOUN fnp-2993 92 92 or or CCONJ fnp-2993 92 93 alcohol alcohol NOUN fnp-2993 92 94 use use NOUN fnp-2993 92 95 disorder.97 disorder.97 NOUN fnp-2993 92 96 the the DET fnp-2993 92 97 relative relative ADJ fnp-2993 92 98 contribution contribution NOUN fnp-2993 92 99 of of ADP fnp-2993 92 100 hepatic hepatic ADJ fnp-2993 92 101 encephalopathy encephalopathy NOUN fnp-2993 92 102 to to ADP fnp-2993 92 103 cases case NOUN fnp-2993 92 104 currently currently ADV fnp-2993 92 105 ascribed ascribe VERB fnp-2993 92 106 as as ADP fnp-2993 92 107 septic septic ADJ fnp-2993 92 108 or or CCONJ fnp-2993 92 109 para para NOUN fnp-2993 92 110 - - PUNCT fnp-2993 92 111 infectious infectious ADJ fnp-2993 92 112 encephalopathy encephalopathy NOUN fnp-2993 92 113 remains remain VERB fnp-2993 92 114 to to PART fnp-2993 92 115 be be AUX fnp-2993 92 116 seen see VERB fnp-2993 92 117 . . PUNCT fnp-2993 93 1 9 9 X fnp-2993 93 2 . . X fnp-2993 93 3 conclusions conclusion NOUN fnp-2993 93 4 systemic systemic ADJ fnp-2993 93 5 dysfunction dysfunction NOUN fnp-2993 93 6 and and CCONJ fnp-2993 93 7 viral viral ADJ fnp-2993 93 8 infection infection NOUN fnp-2993 93 9 of of ADP fnp-2993 93 10 the the DET fnp-2993 93 11 cns cns NOUN fnp-2993 93 12 can can AUX fnp-2993 93 13 cause cause VERB fnp-2993 93 14 a a DET fnp-2993 93 15 wide wide ADJ fnp-2993 93 16 range range NOUN fnp-2993 93 17 of of ADP fnp-2993 93 18 covid-19 covid-19 PROPN fnp-2993 93 19 related relate VERB fnp-2993 93 20 neuropathological neuropathological ADJ fnp-2993 93 21 changes change NOUN fnp-2993 93 22 . . PUNCT fnp-2993 94 1 the the DET fnp-2993 94 2 incidence incidence NOUN fnp-2993 94 3 of of ADP fnp-2993 94 4 neuropathological neuropathological ADJ fnp-2993 94 5 findings finding NOUN fnp-2993 94 6 should should AUX fnp-2993 94 7 be be AUX fnp-2993 94 8 viewed view VERB fnp-2993 94 9 with with ADP fnp-2993 94 10 caution caution NOUN fnp-2993 94 11 given give VERB fnp-2993 94 12 great great ADJ fnp-2993 94 13 variability variability NOUN fnp-2993 94 14 in in ADP fnp-2993 94 15 what what PRON fnp-2993 94 16 tissues tissue NOUN fnp-2993 94 17 were be AUX fnp-2993 94 18 studied study VERB fnp-2993 94 19 and and CCONJ fnp-2993 94 20 what what DET fnp-2993 94 21 types type NOUN fnp-2993 94 22 of of ADP fnp-2993 94 23 ancillary ancillary ADJ fnp-2993 94 24 studies study NOUN fnp-2993 94 25 were be AUX fnp-2993 94 26 ( ( PUNCT fnp-2993 94 27 or or CCONJ fnp-2993 94 28 were be AUX fnp-2993 94 29 not not PART fnp-2993 94 30 ) ) PUNCT fnp-2993 94 31 performed perform VERB fnp-2993 94 32 . . PUNCT fnp-2993 95 1 inflammatory inflammatory ADJ fnp-2993 95 2 changes change NOUN fnp-2993 95 3 were be AUX fnp-2993 95 4 reported report VERB fnp-2993 95 5 in in ADP fnp-2993 95 6 a a DET fnp-2993 95 7 high high ADJ fnp-2993 95 8 percentage percentage NOUN fnp-2993 95 9 of of ADP fnp-2993 95 10 cases case NOUN fnp-2993 95 11 in in ADP fnp-2993 95 12 some some DET fnp-2993 95 13 series series NOUN fnp-2993 95 14 but but CCONJ fnp-2993 95 15 not not PART fnp-2993 95 16 in in ADP fnp-2993 95 17 others other NOUN fnp-2993 95 18 , , PUNCT fnp-2993 95 19 at at ADP fnp-2993 95 20 least least ADJ fnp-2993 95 21 in in ADP fnp-2993 95 22 part part NOUN fnp-2993 95 23 due due ADP fnp-2993 95 24 to to ADP fnp-2993 95 25 the the DET fnp-2993 95 26 use use NOUN fnp-2993 95 27 of of ADP fnp-2993 95 28 immunostaining immunostaining NOUN fnp-2993 95 29 ; ; PUNCT fnp-2993 95 30 however however ADV fnp-2993 95 31 , , PUNCT fnp-2993 95 32 the the DET fnp-2993 95 33 lack lack NOUN fnp-2993 95 34 of of ADP fnp-2993 95 35 controls control NOUN fnp-2993 95 36 in in ADP fnp-2993 95 37 most most ADJ fnp-2993 95 38 of of ADP fnp-2993 95 39 these these DET fnp-2993 95 40 studies study NOUN fnp-2993 95 41 limit limit VERB fnp-2993 95 42 interpretation interpretation NOUN fnp-2993 95 43 of of ADP fnp-2993 95 44 these these DET fnp-2993 95 45 findings finding NOUN fnp-2993 95 46 . . PUNCT fnp-2993 96 1 selection selection NOUN fnp-2993 96 2 or or CCONJ fnp-2993 96 3 referral referral ADJ fnp-2993 96 4 bias bias NOUN fnp-2993 96 5 , , PUNCT fnp-2993 96 6 the the DET fnp-2993 96 7 decedent decedent NOUN fnp-2993 96 8 ’s ’s PART fnp-2993 96 9 co co NOUN fnp-2993 96 10 - - NOUN fnp-2993 96 11 morbidities morbidity NOUN fnp-2993 96 12 , , PUNCT fnp-2993 96 13 therapies therapy NOUN fnp-2993 96 14 given give VERB fnp-2993 96 15 , , PUNCT fnp-2993 96 16 patient patient NOUN fnp-2993 96 17 ’s ’s NOUN fnp-2993 96 18 genetic genetic ADJ fnp-2993 96 19 background background NOUN fnp-2993 96 20 , , PUNCT fnp-2993 96 21 immune immune ADJ fnp-2993 96 22 status status NOUN fnp-2993 96 23 , , PUNCT fnp-2993 96 24 immunization immunization NOUN fnp-2993 96 25 status status NOUN fnp-2993 96 26 and and CCONJ fnp-2993 96 27 perhaps perhaps ADV fnp-2993 96 28 viral viral ADJ fnp-2993 96 29 strains strain NOUN fnp-2993 96 30 of of ADP fnp-2993 96 31 sars sar NOUN fnp-2993 96 32 - - PUNCT fnp-2993 96 33 cov-2 cov-2 NUM fnp-2993 96 34 may may AUX fnp-2993 96 35 also also ADV fnp-2993 96 36 contribute contribute VERB fnp-2993 96 37 to to ADP fnp-2993 96 38 differences difference NOUN fnp-2993 96 39 and and CCONJ fnp-2993 96 40 will will AUX fnp-2993 96 41 need need VERB fnp-2993 96 42 to to PART fnp-2993 96 43 be be AUX fnp-2993 96 44 dissected dissect VERB fnp-2993 96 45 out out ADP fnp-2993 96 46 in in ADP fnp-2993 96 47 the the DET fnp-2993 96 48 future future NOUN fnp-2993 96 49 . . PUNCT fnp-2993 97 1 whether whether SCONJ fnp-2993 97 2 or or CCONJ fnp-2993 97 3 how how SCONJ fnp-2993 97 4 much much ADJ fnp-2993 97 5 of of ADP fnp-2993 97 6 the the DET fnp-2993 97 7 inflammatory inflammatory ADJ fnp-2993 97 8 changes change NOUN fnp-2993 97 9 seen see VERB fnp-2993 97 10 are be AUX fnp-2993 97 11 due due ADJ fnp-2993 97 12 to to ADP fnp-2993 97 13 autoimmune autoimmune ADJ fnp-2993 97 14 phenomena phenomenon NOUN fnp-2993 97 15 versus versus ADP fnp-2993 97 16 direct direct ADJ fnp-2993 97 17 viral viral ADJ fnp-2993 97 18 infection infection NOUN fnp-2993 97 19 or or CCONJ fnp-2993 97 20 other other ADJ fnp-2993 97 21 causes cause NOUN fnp-2993 97 22 remains remain VERB fnp-2993 97 23 to to PART fnp-2993 97 24 be be AUX fnp-2993 97 25 resolved resolve VERB fnp-2993 97 26 . . PUNCT fnp-2993 98 1 the the DET fnp-2993 98 2 presence presence NOUN fnp-2993 98 3 of of ADP fnp-2993 98 4 microglial microglial ADJ fnp-2993 98 5 nodules nodule NOUN fnp-2993 98 6 and and CCONJ fnp-2993 98 7 detectable detectable ADJ fnp-2993 98 8 virus virus NOUN fnp-2993 98 9 are be AUX fnp-2993 98 10 indicative indicative ADJ fnp-2993 98 11 of of ADP fnp-2993 98 12 viral viral ADJ fnp-2993 98 13 meningoencephalitis meningoencephalitis NOUN fnp-2993 98 14 in in ADP fnp-2993 98 15 some some DET fnp-2993 98 16 cases case NOUN fnp-2993 98 17 ; ; PUNCT fnp-2993 98 18 a a DET fnp-2993 98 19 predilection predilection NOUN fnp-2993 98 20 for for ADP fnp-2993 98 21 the the DET fnp-2993 98 22 medulla medulla NOUN fnp-2993 98 23 perhaps perhaps ADV fnp-2993 98 24 with with ADP fnp-2993 98 25 compromise compromise NOUN fnp-2993 98 26 of of ADP fnp-2993 98 27 respiratory respiratory ADJ fnp-2993 98 28 and and CCONJ fnp-2993 98 29 cardiovascular cardiovascular ADJ fnp-2993 98 30 control control NOUN fnp-2993 98 31 centers center NOUN fnp-2993 98 32 may may AUX fnp-2993 98 33 compound compound VERB fnp-2993 98 34 the the DET fnp-2993 98 35 covid-19 covid-19 PROPN fnp-2993 98 36 patient patient NOUN fnp-2993 98 37 ’s ’ VERB fnp-2993 98 38 often often ADV fnp-2993 98 39 already already ADV fnp-2993 98 40 tenuous tenuous ADJ fnp-2993 98 41 cardiorespiratory cardiorespiratory NOUN fnp-2993 98 42 function function NOUN fnp-2993 98 43 . . PUNCT fnp-2993 99 1 while while SCONJ fnp-2993 99 2 there there PRON fnp-2993 99 3 is be VERB fnp-2993 99 4 evidence evidence NOUN fnp-2993 99 5 for for ADP fnp-2993 99 6 an an DET fnp-2993 99 7 olfactory olfactory ADJ fnp-2993 99 8 route route NOUN fnp-2993 99 9 of of ADP fnp-2993 99 10 infection infection NOUN fnp-2993 99 11 , , PUNCT fnp-2993 99 12 it it PRON fnp-2993 99 13 is be AUX fnp-2993 99 14 unclear unclear ADJ fnp-2993 99 15 whether whether SCONJ fnp-2993 99 16 this this PRON fnp-2993 99 17 is be AUX fnp-2993 99 18 the the DET fnp-2993 99 19 major major ADJ fnp-2993 99 20 mechanism mechanism NOUN fnp-2993 99 21 of of ADP fnp-2993 99 22 cns cns NOUN fnp-2993 99 23 infection infection NOUN fnp-2993 99 24 given give VERB fnp-2993 99 25 that that SCONJ fnp-2993 99 26 the the DET fnp-2993 99 27 virus virus NOUN fnp-2993 99 28 is be AUX fnp-2993 99 29 rarely rarely ADV fnp-2993 99 30 detectable detectable ADJ fnp-2993 99 31 in in ADP fnp-2993 99 32 the the DET fnp-2993 99 33 olfactory olfactory NOUN fnp-2993 99 34 bulb bulb NOUN fnp-2993 99 35 . . PUNCT fnp-2993 100 1 cerebral cerebral ADJ fnp-2993 100 2 endothelial endothelial ADJ fnp-2993 100 3 infection infection NOUN fnp-2993 100 4 is be AUX fnp-2993 100 5 also also ADV fnp-2993 100 6 present present ADJ fnp-2993 100 7 and and CCONJ fnp-2993 100 8 a a DET fnp-2993 100 9 hematogenous hematogenous ADJ fnp-2993 100 10 route route NOUN fnp-2993 100 11 of of ADP fnp-2993 100 12 infection infection NOUN fnp-2993 100 13 is be AUX fnp-2993 100 14 therefore therefore ADV fnp-2993 100 15 plausible plausible ADJ fnp-2993 100 16 perhaps perhaps ADV fnp-2993 100 17 even even ADV fnp-2993 100 18 common common ADJ fnp-2993 100 19 . . PUNCT fnp-2993 101 1 data datum NOUN fnp-2993 101 2 on on ADP fnp-2993 101 3 where where SCONJ fnp-2993 101 4 the the DET fnp-2993 101 5 virus virus NOUN fnp-2993 101 6 is be AUX fnp-2993 101 7 detectable detectable ADJ fnp-2993 101 8 in in ADP fnp-2993 101 9 the the DET fnp-2993 101 10 brain brain NOUN fnp-2993 101 11 is be AUX fnp-2993 101 12 limited limit VERB fnp-2993 101 13 as as SCONJ fnp-2993 101 14 studies study NOUN fnp-2993 101 15 have have AUX fnp-2993 101 16 focused focus VERB fnp-2993 101 17 on on ADP fnp-2993 101 18 the the DET fnp-2993 101 19 frontal frontal ADJ fnp-2993 101 20 lobe lobe NOUN fnp-2993 101 21 and and CCONJ fnp-2993 101 22 brainstem brainstem NOUN fnp-2993 101 23 . . PUNCT fnp-2993 102 1 it it PRON fnp-2993 102 2 would would AUX fnp-2993 102 3 not not PART fnp-2993 102 4 be be AUX fnp-2993 102 5 surprising surprising ADJ fnp-2993 102 6 to to PART fnp-2993 102 7 find find VERB fnp-2993 102 8 a a DET fnp-2993 102 9 greater great ADJ fnp-2993 102 10 extent extent NOUN fnp-2993 102 11 of of ADP fnp-2993 102 12 infection infection NOUN fnp-2993 102 13 than than SCONJ fnp-2993 102 14 currently currently ADV fnp-2993 102 15 confirmed confirm VERB fnp-2993 102 16 . . PUNCT fnp-2993 103 1 it it PRON fnp-2993 103 2 should should AUX fnp-2993 103 3 be be AUX fnp-2993 103 4 kept keep VERB fnp-2993 103 5 in in ADP fnp-2993 103 6 mind mind NOUN fnp-2993 103 7 that that SCONJ fnp-2993 103 8 the the DET fnp-2993 103 9 sensitivity sensitivity NOUN fnp-2993 103 10 of of ADP fnp-2993 103 11 virus virus NOUN fnp-2993 103 12 detection detection NOUN fnp-2993 103 13 is be AUX fnp-2993 103 14 suboptimal suboptimal ADJ fnp-2993 103 15 given give VERB fnp-2993 103 16 that that SCONJ fnp-2993 103 17 most most ADJ fnp-2993 103 18 samples sample NOUN fnp-2993 103 19 are be AUX fnp-2993 103 20 derived derive VERB fnp-2993 103 21 from from ADP fnp-2993 103 22 autopsies autopsy NOUN fnp-2993 103 23 . . PUNCT fnp-2993 104 1 lastly lastly ADV fnp-2993 104 2 , , PUNCT fnp-2993 104 3 it it PRON fnp-2993 104 4 is be AUX fnp-2993 104 5 notable notable ADJ fnp-2993 104 6 that that SCONJ fnp-2993 104 7 inflammation inflammation NOUN fnp-2993 104 8 does do AUX fnp-2993 104 9 not not PART fnp-2993 104 10 always always ADV fnp-2993 104 11 coincide coincide VERB fnp-2993 104 12 with with ADP fnp-2993 104 13 virus virus NOUN fnp-2993 104 14 localization localization NOUN fnp-2993 104 15 , , PUNCT fnp-2993 104 16 raising raise VERB fnp-2993 104 17 the the DET fnp-2993 104 18 concern concern NOUN fnp-2993 104 19 that that SCONJ fnp-2993 104 20 the the DET fnp-2993 104 21 virus virus NOUN fnp-2993 104 22 may may AUX fnp-2993 104 23 be be AUX fnp-2993 104 24 evading evade VERB fnp-2993 104 25 the the DET fnp-2993 104 26 immune immune ADJ fnp-2993 104 27 response response NOUN fnp-2993 104 28 in in ADP fnp-2993 104 29 the the DET fnp-2993 104 30 cns cns NOUN fnp-2993 104 31 . . PUNCT fnp-2993 105 1 whether whether SCONJ fnp-2993 105 2 the the DET fnp-2993 105 3 cns cns NOUN fnp-2993 105 4 is be AUX fnp-2993 105 5 a a DET fnp-2993 105 6 potential potential ADJ fnp-2993 105 7 long long ADJ fnp-2993 105 8 - - PUNCT fnp-2993 105 9 term term NOUN fnp-2993 105 10 reservoir reservoir NOUN fnp-2993 105 11 of of ADP fnp-2993 105 12 virus virus NOUN fnp-2993 105 13 and and CCONJ fnp-2993 105 14 a a DET fnp-2993 105 15 contributor contributor NOUN fnp-2993 105 16 to to ADP fnp-2993 105 17 “ " PUNCT fnp-2993 105 18 long long ADJ fnp-2993 105 19 covid covid NOUN fnp-2993 105 20 ” " PUNCT fnp-2993 105 21 remains remain VERB fnp-2993 105 22 to to PART fnp-2993 105 23 be be AUX fnp-2993 105 24 seen see VERB fnp-2993 105 25 . . PUNCT fnp-2993 106 1 lastly lastly ADV fnp-2993 106 2 , , PUNCT fnp-2993 106 3 increased increase VERB fnp-2993 106 4 risk risk NOUN fnp-2993 106 5 for for ADP fnp-2993 106 6 vascular vascular ADJ fnp-2993 106 7 dementia dementia NOUN fnp-2993 106 8 or or CCONJ fnp-2993 106 9 neurodegenerative neurodegenerative ADJ fnp-2993 106 10 disorders disorder NOUN fnp-2993 106 11 are be AUX fnp-2993 106 12 hypothetical hypothetical ADJ fnp-2993 106 13 concerns concern NOUN fnp-2993 106 14 that that PRON fnp-2993 106 15 may may AUX fnp-2993 106 16 need need VERB fnp-2993 106 17 to to PART fnp-2993 106 18 be be AUX fnp-2993 106 19 addressed address VERB fnp-2993 106 20 at at ADP fnp-2993 106 21 a a DET fnp-2993 106 22 later later ADJ fnp-2993 106 23 time time NOUN fnp-2993 106 24 . . PUNCT fnp-2993 107 1 funding fund VERB fnp-2993 107 2 this this DET fnp-2993 107 3 work work NOUN fnp-2993 107 4 was be AUX fnp-2993 107 5 supported support VERB fnp-2993 107 6 in in ADP fnp-2993 107 7 part part NOUN fnp-2993 107 8 by by ADP fnp-2993 107 9 nimh nimh PROPN fnp-2993 107 10 2u24mh10092 2u24mh10092 PUNCT fnp-2993 107 11 and and CCONJ fnp-2993 107 12 u01 u01 PROPN fnp-2993 107 13 mh083500 mh083500 PROPN fnp-2993 107 14 ( ( PUNCT fnp-2993 107 15 s. s. PROPN fnp-2993 107 16 magaki magaki PROPN fnp-2993 107 17 , , PUNCT fnp-2993 107 18 e. e. PROPN fnp-2993 107 19 singer singer PROPN fnp-2993 107 20 , , PUNCT fnp-2993 107 21 w. w. PROPN fnp-2993 107 22 yong yong PROPN fnp-2993 107 23 ) ) PUNCT fnp-2993 107 24 and and CCONJ fnp-2993 107 25 in in ADP fnp-2993 107 26 part part NOUN fnp-2993 107 27 by by ADP fnp-2993 107 28 the the DET fnp-2993 107 29 ucla ucla NOUN fnp-2993 107 30 broad broad ADJ fnp-2993 107 31 stem stem NOUN fnp-2993 107 32 cell cell NOUN fnp-2993 107 33 research research NOUN fnp-2993 107 34 center center NOUN fnp-2993 107 35 covid covid VERB fnp-2993 107 36 19 19 NUM fnp-2993 107 37 research research NOUN fnp-2993 107 38 award award NOUN fnp-2993 107 39 ocrc ocrc NOUN fnp-2993 107 40 # # SYM fnp-2993 107 41 20 20 NUM fnp-2993 107 42 - - SYM fnp-2993 107 43 70 70 NUM fnp-2993 107 44 ( ( PUNCT fnp-2993 107 45 h.v h.v NOUN fnp-2993 107 46 . . PROPN fnp-2993 107 47 vinters vinter NOUN fnp-2993 107 48 , , PUNCT fnp-2993 107 49 s. s. PROPN fnp-2993 107 50 magaki magaki PROPN fnp-2993 107 51 , , PUNCT fnp-2993 107 52 and and CCONJ fnp-2993 107 53 t. t. PROPN fnp-2993 107 54 zhang zhang PROPN fnp-2993 107 55 ) ) PUNCT fnp-2993 107 56 . . PUNCT fnp-2993 108 1 references reference NOUN fnp-2993 108 2 1 1 NUM fnp-2993 108 3 . . PUNCT fnp-2993 108 4 naming name VERB fnp-2993 108 5 the the DET fnp-2993 108 6 coronavirus coronavirus NOUN fnp-2993 108 7 disease disease NOUN fnp-2993 108 8 ( ( PUNCT fnp-2993 108 9 covid-19 covid-19 PROPN fnp-2993 108 10 ) ) PUNCT fnp-2993 108 11 and and CCONJ fnp-2993 108 12 the the DET fnp-2993 108 13 virus virus NOUN fnp-2993 108 14 that that PRON fnp-2993 108 15 causes cause VERB fnp-2993 108 16 it it PRON fnp-2993 108 17 . . PUNCT fnp-2993 109 1 world world NOUN fnp-2993 109 2 health health PROPN fnp-2993 109 3 organization organization PROPN fnp-2993 109 4 . . PUNCT fnp-2993 110 1 accessed access VERB fnp-2993 110 2 october october PROPN fnp-2993 110 3 21 21 NUM fnp-2993 110 4 , , PUNCT fnp-2993 110 5 2020 2020 NUM fnp-2993 110 6 . . PUNCT fnp-2993 111 1 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it PROPN fnp-2993 111 2 2 2 NUM fnp-2993 111 3 . . X fnp-2993 111 4 weekly weekly ADJ fnp-2993 111 5 epidemiological epidemiological ADJ fnp-2993 111 6 update update NOUN fnp-2993 111 7 29 29 NUM fnp-2993 111 8 december december PROPN fnp-2993 111 9 2020 2020 NUM fnp-2993 111 10 . . PUNCT fnp-2993 112 1 world world PROPN fnp-2993 112 2 health health PROPN fnp-2993 112 3 organization organization PROPN fnp-2993 112 4 . . PUNCT fnp-2993 113 1 accessed access VERB fnp-2993 113 2 december december PROPN fnp-2993 113 3 30 30 NUM fnp-2993 113 4 , , PUNCT fnp-2993 113 5 2020 2020 NUM fnp-2993 113 6 . . PUNCT fnp-2993 114 1 https://www.who.int/publications/m/item/weekly-epidemiological-update---29-december-2020 https://www.who.int/publications/m/item/weekly-epidemiological-update---29-december-2020 PRON fnp-2993 114 2 3 3 X fnp-2993 114 3 . . PUNCT fnp-2993 114 4 ye ye PRON fnp-2993 114 5 zw zw PROPN fnp-2993 114 6 , , PUNCT fnp-2993 114 7 yuan yuan PROPN fnp-2993 114 8 s s PROPN fnp-2993 114 9 , , PUNCT fnp-2993 114 10 yuen yuen PROPN fnp-2993 114 11 ks ks PROPN fnp-2993 114 12 , , PUNCT fnp-2993 114 13 fung fung PROPN fnp-2993 114 14 sy sy PROPN fnp-2993 114 15 , , PUNCT fnp-2993 114 16 chan chan PROPN fnp-2993 114 17 cp cp PROPN fnp-2993 114 18 , , PUNCT fnp-2993 114 19 jin jin PROPN fnp-2993 114 20 dy dy X fnp-2993 114 21 . . PROPN fnp-2993 115 1 zoonotic zoonotic ADJ fnp-2993 115 2 origins origin NOUN fnp-2993 115 3 of of ADP fnp-2993 115 4 human human ADJ fnp-2993 115 5 coronaviruses coronaviruse NOUN fnp-2993 115 6 . . PUNCT fnp-2993 116 1 int int NOUN fnp-2993 116 2 j j PROPN fnp-2993 116 3 biol biol PROPN fnp-2993 116 4 sci sci PROPN fnp-2993 116 5 . . PUNCT fnp-2993 117 1 2020;16(10):1686 2020;16(10):1686 NUM fnp-2993 117 2 - - SYM fnp-2993 117 3 1697 1697 NUM fnp-2993 117 4 . . PUNCT fnp-2993 118 1 doi:10.7150 doi:10.7150 PROPN fnp-2993 118 2 / / SYM fnp-2993 118 3 ijbs.45472 ijbs.45472 PROPN fnp-2993 118 4 4 4 NUM fnp-2993 118 5 . . PUNCT fnp-2993 118 6 zhu zhu PROPN fnp-2993 118 7 n n CCONJ fnp-2993 118 8 , , PUNCT fnp-2993 118 9 zhang zhang PROPN fnp-2993 118 10 d d PROPN fnp-2993 118 11 , , PUNCT fnp-2993 118 12 wang wang PROPN fnp-2993 118 13 w w PROPN fnp-2993 118 14 , , PUNCT fnp-2993 118 15 et et PROPN fnp-2993 118 16 al al PROPN fnp-2993 118 17 . . PUNCT fnp-2993 119 1 a a DET fnp-2993 119 2 novel novel ADJ fnp-2993 119 3 coronavirus coronavirus NOUN fnp-2993 119 4 from from ADP fnp-2993 119 5 patients patient NOUN fnp-2993 119 6 with with ADP fnp-2993 119 7 pneumonia pneumonia NOUN fnp-2993 119 8 in in ADP fnp-2993 119 9 china china PROPN fnp-2993 119 10 , , PUNCT fnp-2993 119 11 2019 2019 NUM fnp-2993 119 12 . . PUNCT fnp-2993 120 1 n n X fnp-2993 120 2 engl engl PROPN fnp-2993 120 3 j j PROPN fnp-2993 120 4 med med PROPN fnp-2993 120 5 . . PUNCT fnp-2993 121 1 2020;382(8):727 2020;382(8):727 NUM fnp-2993 121 2 - - SYM fnp-2993 121 3 733 733 NUM fnp-2993 121 4 . . PUNCT fnp-2993 122 1 doi:10.1056 doi:10.1056 PROPN fnp-2993 122 2 / / SYM fnp-2993 122 3 nejmoa2001017 nejmoa2001017 PROPN fnp-2993 122 4 5 5 NUM fnp-2993 122 5 . . PUNCT fnp-2993 123 1 caly caly PROPN fnp-2993 123 2 l l PROPN fnp-2993 123 3 , , PUNCT fnp-2993 123 4 druce druce PROPN fnp-2993 123 5 j j PROPN fnp-2993 123 6 , , PUNCT fnp-2993 123 7 roberts roberts PROPN fnp-2993 123 8 j j PROPN fnp-2993 123 9 , , PUNCT fnp-2993 123 10 et et PROPN fnp-2993 123 11 al al PROPN fnp-2993 123 12 . . PUNCT fnp-2993 123 13 isolation isolation NOUN fnp-2993 123 14 and and CCONJ fnp-2993 123 15 rapid rapid ADJ fnp-2993 123 16 sharing sharing NOUN fnp-2993 123 17 of of ADP fnp-2993 123 18 the the DET fnp-2993 123 19 2019 2019 NUM fnp-2993 123 20 novel novel ADJ fnp-2993 123 21 coronavirus coronavirus NOUN fnp-2993 123 22 ( ( PUNCT fnp-2993 123 23 sars sar NOUN fnp-2993 123 24 - - PUNCT fnp-2993 123 25 cov-2 cov-2 NOUN fnp-2993 123 26 ) ) PUNCT fnp-2993 123 27 from from ADP fnp-2993 123 28 the the DET fnp-2993 123 29 first first ADJ fnp-2993 123 30 patient patient NOUN fnp-2993 123 31 diagnosed diagnose VERB fnp-2993 123 32 with with ADP fnp-2993 123 33 covid-19 covid-19 PROPN fnp-2993 123 34 in in ADP fnp-2993 123 35 australia australia PROPN fnp-2993 123 36 . . PUNCT fnp-2993 124 1 med med PROPN fnp-2993 124 2 j j PROPN fnp-2993 124 3 aust aust PROPN fnp-2993 124 4 . . PUNCT fnp-2993 125 1 2020;212(10):459 2020;212(10):459 PROPN fnp-2993 125 2 - - SYM fnp-2993 125 3 462 462 NUM fnp-2993 125 4 . . PUNCT fnp-2993 126 1 doi:10.5694 doi:10.5694 NOUN fnp-2993 126 2 / / SYM fnp-2993 126 3 mja2.50569 mja2.50569 PROPN fnp-2993 126 4 6 6 NUM fnp-2993 126 5 . . PUNCT fnp-2993 127 1 gulholm gulholm PROPN fnp-2993 127 2 t t PROPN fnp-2993 127 3 , , PUNCT fnp-2993 127 4 basile basile PROPN fnp-2993 127 5 k k PROPN fnp-2993 127 6 , , PUNCT fnp-2993 127 7 kok kok PROPN fnp-2993 127 8 j j PROPN fnp-2993 127 9 , , PUNCT fnp-2993 127 10 chen chen PROPN fnp-2993 127 11 s s PROPN fnp-2993 127 12 , , PUNCT fnp-2993 127 13 rawlinson rawlinson PROPN fnp-2993 127 14 w. w. PROPN fnp-2993 127 15 laboratory laboratory PROPN fnp-2993 127 16 diagnosis diagnosis NOUN fnp-2993 127 17 of of ADP fnp-2993 127 18 severe severe ADJ fnp-2993 127 19 acute acute ADJ fnp-2993 127 20 respiratory respiratory ADJ fnp-2993 127 21 syndrome syndrome NOUN fnp-2993 127 22 coronavirus coronavirus NOUN fnp-2993 127 23 2 2 NUM fnp-2993 127 24 . . PUNCT fnp-2993 127 25 pathology pathology NOUN fnp-2993 127 26 . . PUNCT fnp-2993 128 1 2020;52(7):745 2020;52(7):745 PROPN fnp-2993 128 2 - - PUNCT fnp-2993 128 3 753 753 NUM fnp-2993 128 4 . . PUNCT fnp-2993 129 1 doi:10.1016 doi:10.1016 PROPN fnp-2993 129 2 / / SYM fnp-2993 129 3 j.pathol.2020.09.011 j.pathol.2020.09.011 PROPN fnp-2993 129 4 7 7 X fnp-2993 129 5 . . PUNCT fnp-2993 129 6 koyama koyama PROPN fnp-2993 129 7 t t PROPN fnp-2993 129 8 , , PUNCT fnp-2993 129 9 platt platt PROPN fnp-2993 129 10 d d PROPN fnp-2993 129 11 , , PUNCT fnp-2993 129 12 parida parida PROPN fnp-2993 129 13 l. l. PROPN fnp-2993 129 14 variant variant PROPN fnp-2993 129 15 analysis analysis NOUN fnp-2993 129 16 of of ADP fnp-2993 129 17 sars sar NOUN fnp-2993 129 18 - - PUNCT fnp-2993 129 19 cov-2 cov-2 NOUN fnp-2993 129 20 genomes genome NOUN fnp-2993 129 21 . . PUNCT fnp-2993 130 1 bull bull PROPN fnp-2993 130 2 world world PROPN fnp-2993 130 3 health health NOUN fnp-2993 130 4 organ organ NOUN fnp-2993 130 5 . . PUNCT fnp-2993 131 1 2020;98(7):495 2020;98(7):495 NUM fnp-2993 131 2 - - PUNCT fnp-2993 131 3 504 504 NUM fnp-2993 131 4 . . PUNCT fnp-2993 131 5 doi:10.2471 doi:10.2471 NOUN fnp-2993 131 6 / / SYM fnp-2993 131 7 blt.20.253591 blt.20.253591 PROPN fnp-2993 131 8 8 8 NUM fnp-2993 131 9 . . PUNCT fnp-2993 131 10 naqvi naqvi PROPN fnp-2993 131 11 aat aat PROPN fnp-2993 131 12 , , PUNCT fnp-2993 131 13 fatima fatima PROPN fnp-2993 131 14 k k PROPN fnp-2993 131 15 , , PUNCT fnp-2993 131 16 mohammad mohammad PROPN fnp-2993 131 17 t t PROPN fnp-2993 131 18 , , PUNCT fnp-2993 131 19 et et PROPN fnp-2993 131 20 al al PROPN fnp-2993 131 21 . . PUNCT fnp-2993 132 1 insights insight NOUN fnp-2993 132 2 into into ADP fnp-2993 132 3 sars sar NOUN fnp-2993 132 4 - - PUNCT fnp-2993 132 5 cov-2 cov-2 NOUN fnp-2993 132 6 genome genome NOUN fnp-2993 132 7 , , PUNCT fnp-2993 132 8 structure structure NOUN fnp-2993 132 9 , , PUNCT fnp-2993 132 10 evolution evolution NOUN fnp-2993 132 11 , , PUNCT fnp-2993 132 12 pathogenesis pathogenesis NOUN fnp-2993 132 13 and and CCONJ fnp-2993 132 14 therapies therapy NOUN fnp-2993 132 15 : : PUNCT fnp-2993 132 16 structural structural ADJ fnp-2993 132 17 genomics genomics NOUN fnp-2993 132 18 approach approach NOUN fnp-2993 132 19 . . PUNCT fnp-2993 133 1 biochim biochim PROPN fnp-2993 133 2 biophys biophy NOUN fnp-2993 133 3 acta acta PROPN fnp-2993 133 4 mol mol ADP fnp-2993 133 5 basis basis NOUN fnp-2993 133 6 dis dis PROPN fnp-2993 133 7 . . PUNCT fnp-2993 134 1 2020;1866(10):165878 2020;1866(10):165878 X fnp-2993 134 2 . . PUNCT fnp-2993 135 1 doi:10.1016 doi:10.1016 PROPN fnp-2993 135 2 / / SYM fnp-2993 135 3 j.bbadis.2020.165878 j.bbadis.2020.165878 ADJ fnp-2993 135 4 9 9 NUM fnp-2993 135 5 . . PUNCT fnp-2993 135 6 ou ou PROPN fnp-2993 135 7 x x PROPN fnp-2993 135 8 , , PUNCT fnp-2993 135 9 liu liu PROPN fnp-2993 135 10 y y PROPN fnp-2993 135 11 , , PUNCT fnp-2993 135 12 lei lei X fnp-2993 135 13 x x NOUN fnp-2993 135 14 , , PUNCT fnp-2993 135 15 et et PROPN fnp-2993 135 16 al al PROPN fnp-2993 135 17 . . PUNCT fnp-2993 135 18 characterization characterization NOUN fnp-2993 135 19 of of ADP fnp-2993 135 20 spike spike ADJ fnp-2993 135 21 glycoprotein glycoprotein NOUN fnp-2993 135 22 of of ADP fnp-2993 135 23 sars sar NOUN fnp-2993 135 24 - - PUNCT fnp-2993 135 25 cov-2 cov-2 NOUN fnp-2993 135 26 on on ADP fnp-2993 135 27 virus virus NOUN fnp-2993 135 28 entry entry NOUN fnp-2993 135 29 and and CCONJ fnp-2993 135 30 its its PRON fnp-2993 135 31 immune immune ADJ fnp-2993 135 32 cross cross NOUN fnp-2993 135 33 - - NOUN fnp-2993 135 34 reactivity reactivity NOUN fnp-2993 135 35 with with ADP fnp-2993 135 36 sars sar NOUN fnp-2993 135 37 - - PUNCT fnp-2993 135 38 cov cov NOUN fnp-2993 135 39 . . PUNCT fnp-2993 136 1 nat nat PROPN fnp-2993 136 2 commun commun PROPN fnp-2993 136 3 . . PUNCT fnp-2993 137 1 2020;11(1 2020;11(1 NUM fnp-2993 137 2 ) ) PUNCT fnp-2993 137 3 . . PUNCT fnp-2993 138 1 doi:10.1038 doi:10.1038 NOUN fnp-2993 138 2 / / SYM fnp-2993 138 3 s41467 s41467 NOUN fnp-2993 138 4 - - PUNCT fnp-2993 138 5 020 020 NUM fnp-2993 138 6 - - PUNCT fnp-2993 138 7 15562 15562 NUM fnp-2993 138 8 - - SYM fnp-2993 138 9 9 9 NUM fnp-2993 138 10 10 10 NUM fnp-2993 138 11 . . PUNCT fnp-2993 139 1 pachetti pachetti PROPN fnp-2993 139 2 m m PROPN fnp-2993 139 3 , , PUNCT fnp-2993 139 4 marini marini PROPN fnp-2993 139 5 b b PROPN fnp-2993 139 6 , , PUNCT fnp-2993 139 7 benedetti benedetti PROPN fnp-2993 139 8 f f PROPN fnp-2993 139 9 , , PUNCT fnp-2993 139 10 et et PROPN fnp-2993 139 11 al al PROPN fnp-2993 139 12 . . PUNCT fnp-2993 140 1 emerging emerge VERB fnp-2993 140 2 sars sar NOUN fnp-2993 140 3 - - PUNCT fnp-2993 140 4 cov-2 cov-2 NOUN fnp-2993 140 5 mutation mutation NOUN fnp-2993 140 6 hot hot ADJ fnp-2993 140 7 spots spot NOUN fnp-2993 140 8 include include VERB fnp-2993 140 9 a a DET fnp-2993 140 10 novel novel ADJ fnp-2993 140 11 rna rna NOUN fnp-2993 140 12 - - PUNCT fnp-2993 140 13 dependent dependent ADJ fnp-2993 140 14 - - PUNCT fnp-2993 140 15 rna rna NOUN fnp-2993 140 16 polymerase polymerase NOUN fnp-2993 140 17 variant variant NOUN fnp-2993 140 18 . . PUNCT fnp-2993 141 1 j j PROPN fnp-2993 141 2 transl transl PROPN fnp-2993 141 3 med med PROPN fnp-2993 141 4 . . PUNCT fnp-2993 142 1 2020;18(1):1 2020;18(1):1 NUM fnp-2993 142 2 - - SYM fnp-2993 142 3 9 9 NUM fnp-2993 142 4 . . PUNCT fnp-2993 142 5 doi:10.1186 doi:10.1186 PROPN fnp-2993 142 6 / / SYM fnp-2993 142 7 s12967 s12967 NOUN fnp-2993 142 8 - - PUNCT fnp-2993 142 9 020 020 NUM fnp-2993 142 10 - - PUNCT fnp-2993 142 11 02344 02344 NUM fnp-2993 142 12 - - SYM fnp-2993 142 13 6 6 NUM fnp-2993 142 14 11 11 NUM fnp-2993 142 15 . . PUNCT fnp-2993 143 1 day day PROPN fnp-2993 143 2 t t PROPN fnp-2993 143 3 , , PUNCT fnp-2993 143 4 gandon gandon NOUN fnp-2993 143 5 s s PROPN fnp-2993 143 6 , , PUNCT fnp-2993 143 7 lion lion PROPN fnp-2993 143 8 s s PROPN fnp-2993 143 9 , , PUNCT fnp-2993 143 10 otto otto PROPN fnp-2993 143 11 sp sp PROPN fnp-2993 143 12 . . PROPN fnp-2993 144 1 on on ADP fnp-2993 144 2 the the DET fnp-2993 144 3 evolutionary evolutionary ADJ fnp-2993 144 4 epidemiology epidemiology NOUN fnp-2993 144 5 of of ADP fnp-2993 144 6 sars sar NOUN fnp-2993 144 7 - - PUNCT fnp-2993 144 8 cov-2 cov-2 NOUN fnp-2993 144 9 . . PUNCT fnp-2993 145 1 curr curr PROPN fnp-2993 145 2 biol biol PROPN fnp-2993 145 3 . . PUNCT fnp-2993 146 1 2020;30(15):r849 2020;30(15):r849 X fnp-2993 146 2 - - PUNCT fnp-2993 146 3 r857 r857 PROPN fnp-2993 146 4 . . PUNCT fnp-2993 146 5 doi:10.1016 doi:10.1016 PROPN fnp-2993 146 6 / / SYM fnp-2993 146 7 j.cub.2020.06.031 j.cub.2020.06.031 PROPN fnp-2993 146 8 12 12 NUM fnp-2993 146 9 . . PUNCT fnp-2993 147 1 rowland rowland PROPN fnp-2993 147 2 - - PUNCT fnp-2993 147 3 jones jones PROPN fnp-2993 147 4 s s PROPN fnp-2993 147 5 , , PUNCT fnp-2993 147 6 andrews andrews PROPN fnp-2993 147 7 sm sm PROPN fnp-2993 147 8 . . PUNCT fnp-2993 148 1 recent recent ADJ fnp-2993 148 2 advances advance NOUN fnp-2993 148 3 in in ADP fnp-2993 148 4 understanding understand VERB fnp-2993 148 5 hiv hiv PROPN fnp-2993 148 6 evolution evolution NOUN fnp-2993 148 7 . . PUNCT fnp-2993 149 1 f1000research f1000research PROPN fnp-2993 149 2 . . PUNCT fnp-2993 150 1 2017;6(0):1 2017;6(0):1 NUM fnp-2993 150 2 - - PUNCT fnp-2993 150 3 7 7 NUM fnp-2993 150 4 . . PUNCT fnp-2993 150 5 doi:10.12688 doi:10.12688 PROPN fnp-2993 150 6 / / SYM fnp-2993 150 7 f1000research.10876.1 f1000research.10876.1 NOUN fnp-2993 150 8 13 13 NUM fnp-2993 150 9 . . PUNCT fnp-2993 151 1 nobusawa nobusawa PROPN fnp-2993 151 2 e e PROPN fnp-2993 151 3 , , PUNCT fnp-2993 151 4 sato sato PROPN fnp-2993 151 5 k. k. PROPN fnp-2993 151 6 comparison comparison NOUN fnp-2993 151 7 of of ADP fnp-2993 151 8 the the DET fnp-2993 151 9 mutation mutation NOUN fnp-2993 151 10 rates rate NOUN fnp-2993 151 11 of of ADP fnp-2993 151 12 human human ADJ fnp-2993 151 13 influenza influenza NOUN fnp-2993 151 14 a a DET fnp-2993 151 15 and and CCONJ fnp-2993 151 16 b b NOUN fnp-2993 151 17 viruses virus NOUN fnp-2993 151 18 . . PUNCT fnp-2993 152 1 j j PROPN fnp-2993 152 2 virol virol NOUN fnp-2993 152 3 . . PUNCT fnp-2993 153 1 2006;80(7):3675 2006;80(7):3675 NUM fnp-2993 153 2 - - SYM fnp-2993 153 3 3678 3678 NUM fnp-2993 153 4 . . PUNCT fnp-2993 154 1 doi:10.1128 doi:10.1128 NOUN fnp-2993 154 2 / / SYM fnp-2993 154 3 jvi.80.7.3675 jvi.80.7.3675 NOUN fnp-2993 154 4 - - PUNCT fnp-2993 154 5 3678.2006 3678.2006 NUM fnp-2993 154 6 14 14 NUM fnp-2993 154 7 . . PUNCT fnp-2993 155 1 gheblawi gheblawi PROPN fnp-2993 155 2 m m PROPN fnp-2993 155 3 , , PUNCT fnp-2993 155 4 wang wang PROPN fnp-2993 155 5 k k PROPN fnp-2993 155 6 , , PUNCT fnp-2993 155 7 viveiros viveiro NOUN fnp-2993 155 8 a a PRON fnp-2993 155 9 , , PUNCT fnp-2993 155 10 et et PROPN fnp-2993 155 11 al al PROPN fnp-2993 155 12 . . PUNCT fnp-2993 155 13 angiotensin angiotensin NOUN fnp-2993 155 14 - - PUNCT fnp-2993 155 15 converting convert VERB fnp-2993 155 16 enzyme enzyme NOUN fnp-2993 155 17 2 2 NUM fnp-2993 155 18 : : PUNCT fnp-2993 155 19 sars sar NOUN fnp-2993 155 20 - - PUNCT fnp-2993 155 21 cov-2 cov-2 NOUN fnp-2993 155 22 receptor receptor NOUN fnp-2993 155 23 and and CCONJ fnp-2993 155 24 regulator regulator NOUN fnp-2993 155 25 of of ADP fnp-2993 155 26 the the DET fnp-2993 155 27 renin renin ADJ fnp-2993 155 28 - - PUNCT fnp-2993 155 29 angiotensin angiotensin NOUN fnp-2993 155 30 system system NOUN fnp-2993 155 31 : : PUNCT fnp-2993 155 32 celebrating celebrate VERB fnp-2993 155 33 the the DET fnp-2993 155 34 20th 20th ADJ fnp-2993 155 35 anniversary anniversary NOUN fnp-2993 155 36 of of ADP fnp-2993 155 37 the the DET fnp-2993 155 38 discovery discovery NOUN fnp-2993 155 39 of of ADP fnp-2993 155 40 ace2 ace2 PROPN fnp-2993 155 41 . . PUNCT fnp-2993 156 1 circ circ PROPN fnp-2993 156 2 res re NOUN fnp-2993 156 3 . . PUNCT fnp-2993 157 1 2020;126(10):1456 2020;126(10):1456 PRON fnp-2993 157 2 - - SYM fnp-2993 157 3 1474 1474 NUM fnp-2993 157 4 . . PUNCT fnp-2993 158 1 doi:10.1161 doi:10.1161 NOUN fnp-2993 158 2 / / SYM fnp-2993 158 3 circresaha.120.317015 circresaha.120.317015 PROPN fnp-2993 158 4 15 15 NUM fnp-2993 158 5 . . PUNCT fnp-2993 159 1 wang wang PROPN fnp-2993 159 2 k k PROPN fnp-2993 159 3 , , PUNCT fnp-2993 159 4 chen chen PROPN fnp-2993 159 5 w w PROPN fnp-2993 159 6 , , PUNCT fnp-2993 159 7 zhang zhang PROPN fnp-2993 159 8 z z PROPN fnp-2993 159 9 , , PUNCT fnp-2993 159 10 et et PROPN fnp-2993 159 11 al al PROPN fnp-2993 159 12 . . PUNCT fnp-2993 160 1 cd147 cd147 PROPN fnp-2993 160 2 - - PUNCT fnp-2993 160 3 spike spike NOUN fnp-2993 160 4 protein protein NOUN fnp-2993 160 5 is be AUX fnp-2993 160 6 a a DET fnp-2993 160 7 novel novel ADJ fnp-2993 160 8 route route NOUN fnp-2993 160 9 for for ADP fnp-2993 160 10 sars sar NOUN fnp-2993 160 11 - - PUNCT fnp-2993 160 12 cov-2 cov-2 PART fnp-2993 160 13 infection infection NOUN fnp-2993 160 14 to to ADP fnp-2993 160 15 host host NOUN fnp-2993 160 16 cells cell NOUN fnp-2993 160 17 . . PUNCT fnp-2993 161 1 signal signal PROPN fnp-2993 161 2 transduct transduct NOUN fnp-2993 161 3 target target NOUN fnp-2993 161 4 ther ther ADV fnp-2993 161 5 . . PUNCT fnp-2993 162 1 2020;5(1):283 2020;5(1):283 X fnp-2993 162 2 . . PUNCT fnp-2993 162 3 doi:10.1038 doi:10.1038 NOUN fnp-2993 162 4 / / SYM fnp-2993 162 5 s41392 s41392 VERB fnp-2993 162 6 - - PUNCT fnp-2993 162 7 020 020 NUM fnp-2993 162 8 - - PUNCT fnp-2993 162 9 00426 00426 NUM fnp-2993 162 10 - - PUNCT fnp-2993 162 11 x x SYM fnp-2993 162 12 16 16 NUM fnp-2993 162 13 . . PUNCT fnp-2993 163 1 fernández fernández PROPN fnp-2993 163 2 - - PUNCT fnp-2993 163 3 atucha atucha PROPN fnp-2993 163 4 a a PRON fnp-2993 163 5 , , PUNCT fnp-2993 163 6 izagirre izagirre VERB fnp-2993 163 7 a a DET fnp-2993 163 8 , , PUNCT fnp-2993 163 9 fraile fraile NOUN fnp-2993 163 10 - - PUNCT fnp-2993 163 11 bermúdez bermúdez PROPN fnp-2993 163 12 ab ab PROPN fnp-2993 163 13 , , PUNCT fnp-2993 163 14 et et PROPN fnp-2993 163 15 al al PROPN fnp-2993 163 16 . . PROPN fnp-2993 164 1 sex sex NOUN fnp-2993 164 2 differences difference NOUN fnp-2993 164 3 in in ADP fnp-2993 164 4 the the DET fnp-2993 164 5 aging age VERB fnp-2993 164 6 pattern pattern NOUN fnp-2993 164 7 of of ADP fnp-2993 164 8 renin renin ADJ fnp-2993 164 9 - - PUNCT fnp-2993 164 10 angiotensin angiotensin NOUN fnp-2993 164 11 system system NOUN fnp-2993 164 12 serum serum NOUN fnp-2993 164 13 peptidases peptidase NOUN fnp-2993 164 14 . . PUNCT fnp-2993 165 1 biol biol PROPN fnp-2993 165 2 sex sex NOUN fnp-2993 165 3 differ differ NOUN fnp-2993 165 4 . . PUNCT fnp-2993 166 1 2017;8(1 2017;8(1 NUM fnp-2993 166 2 ) ) PUNCT fnp-2993 166 3 . . PUNCT fnp-2993 167 1 doi:10.1186 doi:10.1186 PROPN fnp-2993 167 2 / / SYM fnp-2993 167 3 s13293 s13293 NOUN fnp-2993 167 4 - - PUNCT fnp-2993 167 5 017 017 NUM fnp-2993 167 6 - - PUNCT fnp-2993 167 7 0128 0128 NUM fnp-2993 167 8 - - SYM fnp-2993 167 9 8 8 NUM fnp-2993 167 10 17 17 NUM fnp-2993 167 11 . . PUNCT fnp-2993 168 1 hu hu PROPN fnp-2993 168 2 y y PROPN fnp-2993 168 3 , , PUNCT fnp-2993 168 4 li li PROPN fnp-2993 168 5 x x PROPN fnp-2993 168 6 , , PUNCT fnp-2993 168 7 wu wu PROPN fnp-2993 168 8 n n CCONJ fnp-2993 168 9 , , PUNCT fnp-2993 168 10 wang wang PROPN fnp-2993 168 11 n n PROPN fnp-2993 168 12 , , PUNCT fnp-2993 168 13 qui qui X fnp-2993 168 14 c c PROPN fnp-2993 168 15 , , PUNCT fnp-2993 168 16 li li PROPN fnp-2993 168 17 j. j. PROPN fnp-2993 168 18 study study PROPN fnp-2993 168 19 on on ADP fnp-2993 168 20 the the DET fnp-2993 168 21 correlation correlation NOUN fnp-2993 168 22 among among ADP fnp-2993 168 23 sex sex NOUN fnp-2993 168 24 , , PUNCT fnp-2993 168 25 age age NOUN fnp-2993 168 26 , , PUNCT fnp-2993 168 27 and and CCONJ fnp-2993 168 28 the the DET fnp-2993 168 29 activity activity NOUN fnp-2993 168 30 of of ADP fnp-2993 168 31 ace ace NOUN fnp-2993 168 32 , , PUNCT fnp-2993 168 33 ace2 ace2 NOUN fnp-2993 168 34 and and CCONJ fnp-2993 168 35 the the DET fnp-2993 168 36 ratio ratio NOUN fnp-2993 168 37 of of ADP fnp-2993 168 38 ace ace NOUN fnp-2993 168 39 / / SYM fnp-2993 168 40 ace2 ace2 PROPN fnp-2993 168 41 . . PUNCT fnp-2993 169 1 j j PROPN fnp-2993 169 2 qiqihar qiqihar PROPN fnp-2993 169 3 med med PROPN fnp-2993 169 4 coll coll PROPN fnp-2993 169 5 . . PUNCT fnp-2993 170 1 2018;39(8):884 2018;39(8):884 NUM fnp-2993 170 2 - - PUNCT fnp-2993 170 3 887 887 NUM fnp-2993 170 4 . . PUNCT fnp-2993 170 5 doi:10.3969 doi:10.3969 NOUN fnp-2993 170 6 / / SYM fnp-2993 170 7 j.issn.1002 j.issn.1002 PROPN fnp-2993 170 8 - - PUNCT fnp-2993 170 9 1256.2018.08.005 1256.2018.08.005 PROPN fnp-2993 170 10 18 18 NUM fnp-2993 170 11 . . PUNCT fnp-2993 171 1 liu liu PROPN fnp-2993 171 2 y y PROPN fnp-2993 171 3 , , PUNCT fnp-2993 171 4 zhao zhao PROPN fnp-2993 171 5 l l PROPN fnp-2993 171 6 , , PUNCT fnp-2993 171 7 zhang zhang PROPN fnp-2993 171 8 q q PROPN fnp-2993 171 9 , , PUNCT fnp-2993 171 10 zhang zhang PROPN fnp-2993 171 11 l l PROPN fnp-2993 171 12 , , PUNCT fnp-2993 171 13 ren ren PROPN fnp-2993 171 14 g. g. PROPN fnp-2993 171 15 effect effect NOUN fnp-2993 171 16 of of ADP fnp-2993 171 17 long long ADJ fnp-2993 171 18 - - PUNCT fnp-2993 171 19 term term NOUN fnp-2993 171 20 smoking smoking NOUN fnp-2993 171 21 on on ADP fnp-2993 171 22 expressiong expressiong NOUN fnp-2993 171 23 of of ADP fnp-2993 171 24 serum serum NOUN fnp-2993 171 25 ace ace NOUN fnp-2993 171 26 and and CCONJ fnp-2993 171 27 ace2 ace2 NOUN fnp-2993 171 28 as as ADV fnp-2993 171 29 well well ADV fnp-2993 171 30 as as ADP fnp-2993 171 31 its its PRON fnp-2993 171 32 significance significance NOUN fnp-2993 171 33 . . PUNCT fnp-2993 172 1 j j PROPN fnp-2993 172 2 taishan taishan PROPN fnp-2993 172 3 med med PROPN fnp-2993 172 4 coll coll PROPN fnp-2993 172 5 . . PUNCT fnp-2993 173 1 2019;40(4):258 2019;40(4):258 PROPN fnp-2993 173 2 - - PUNCT fnp-2993 173 3 260 260 NUM fnp-2993 173 4 . . PUNCT fnp-2993 173 5 doi:10.3969 doi:10.3969 NOUN fnp-2993 173 6 / / SYM fnp-2993 173 7 j.issn.1004 j.issn.1004 NOUN fnp-2993 173 8 - - PUNCT fnp-2993 173 9 7115.2019.04.007 7115.2019.04.007 PROPN fnp-2993 173 10 19 19 NUM fnp-2993 173 11 . . PUNCT fnp-2993 173 12 smith smith PROPN fnp-2993 173 13 jc jc PROPN fnp-2993 173 14 , , PUNCT fnp-2993 173 15 sausville sausville PROPN fnp-2993 173 16 el el PROPN fnp-2993 173 17 , , PUNCT fnp-2993 173 18 girish girish PROPN fnp-2993 173 19 v v PROPN fnp-2993 173 20 , , PUNCT fnp-2993 173 21 et et PROPN fnp-2993 173 22 al al PROPN fnp-2993 173 23 . . PUNCT fnp-2993 173 24 cigarette cigarette PROPN fnp-2993 173 25 smoke smoke NOUN fnp-2993 173 26 exposure exposure NOUN fnp-2993 173 27 and and CCONJ fnp-2993 173 28 inflammatory inflammatory ADJ fnp-2993 173 29 signaling signal VERB fnp-2993 173 30 increase increase NOUN fnp-2993 173 31 the the DET fnp-2993 173 32 expression expression NOUN fnp-2993 173 33 of of ADP fnp-2993 173 34 the the DET fnp-2993 173 35 sars sar NOUN fnp-2993 173 36 - - PUNCT fnp-2993 173 37 cov-2 cov-2 NOUN fnp-2993 173 38 receptor receptor NOUN fnp-2993 173 39 ace2 ace2 NOUN fnp-2993 173 40 in in ADP fnp-2993 173 41 the the DET fnp-2993 173 42 respiratory respiratory ADJ fnp-2993 173 43 tract tract NOUN fnp-2993 173 44 . . PUNCT fnp-2993 174 1 dev dev NOUN fnp-2993 174 2 cell cell NOUN fnp-2993 174 3 . . PUNCT fnp-2993 175 1 2020;53(5):514 2020;53(5):514 NOUN fnp-2993 175 2 - - SYM fnp-2993 175 3 529.e3 529.e3 NUM fnp-2993 175 4 . . PUNCT fnp-2993 176 1 doi doi NOUN fnp-2993 176 2 : : PUNCT fnp-2993 176 3 https://doi.org/10.1016 https://doi.org/10.1016 PROPN fnp-2993 176 4 / / SYM fnp-2993 176 5 j.devcel.2020.05.012 j.devcel.2020.05.012 PROPN fnp-2993 176 6 20 20 NUM fnp-2993 176 7 . . PUNCT fnp-2993 177 1 bernardi bernardi PROPN fnp-2993 177 2 s s PROPN fnp-2993 177 3 , , PUNCT fnp-2993 177 4 toffoli toffoli PROPN fnp-2993 177 5 b b NUM fnp-2993 177 6 , , PUNCT fnp-2993 177 7 zennaro zennaro NOUN fnp-2993 177 8 c c PROPN fnp-2993 177 9 , , PUNCT fnp-2993 177 10 et et PROPN fnp-2993 177 11 al al PROPN fnp-2993 177 12 . . PROPN fnp-2993 177 13 high high ADJ fnp-2993 177 14 - - PUNCT fnp-2993 177 15 salt salt NOUN fnp-2993 177 16 diet diet NOUN fnp-2993 177 17 increases increase VERB fnp-2993 177 18 glomerular glomerular ADJ fnp-2993 177 19 ace ace NOUN fnp-2993 177 20 / / SYM fnp-2993 177 21 ace2 ace2 NOUN fnp-2993 177 22 ratio ratio NOUN fnp-2993 177 23 leading lead VERB fnp-2993 177 24 to to ADP fnp-2993 177 25 oxidative oxidative ADJ fnp-2993 177 26 stress stress NOUN fnp-2993 177 27 and and CCONJ fnp-2993 177 28 kidney kidney NOUN fnp-2993 177 29 damage damage NOUN fnp-2993 177 30 . . PUNCT fnp-2993 178 1 nephrol nephrol ADJ fnp-2993 178 2 dial dial NOUN fnp-2993 178 3 transplant transplant NOUN fnp-2993 178 4 . . PUNCT fnp-2993 179 1 2012;27(5):1793 2012;27(5):1793 NUM fnp-2993 179 2 - - SYM fnp-2993 179 3 1800 1800 NUM fnp-2993 179 4 . . PUNCT fnp-2993 180 1 doi:10.1093 doi:10.1093 NOUN fnp-2993 180 2 / / SYM fnp-2993 180 3 ndt ndt PROPN fnp-2993 180 4 / / SYM fnp-2993 180 5 gfr600 gfr600 PROPN fnp-2993 180 6 21 21 NUM fnp-2993 180 7 . . PUNCT fnp-2993 181 1 lavrentyev lavrentyev ADV fnp-2993 181 2 en en PROPN fnp-2993 181 3 , , PUNCT fnp-2993 181 4 malik malik PROPN fnp-2993 181 5 ku ku PROPN fnp-2993 181 6 . . PROPN fnp-2993 181 7 high high ADJ fnp-2993 181 8 glucose glucose NOUN fnp-2993 181 9 - - PUNCT fnp-2993 181 10 induced induce VERB fnp-2993 181 11 nox1 nox1 ADJ fnp-2993 181 12 - - PUNCT fnp-2993 181 13 derived derive VERB fnp-2993 181 14 superoxides superoxide NOUN fnp-2993 181 15 downregulate downregulate PROPN fnp-2993 181 16 pkc pkc PROPN fnp-2993 181 17 - - PUNCT fnp-2993 181 18 βii βii NOUN fnp-2993 181 19 , , PUNCT fnp-2993 181 20 which which PRON fnp-2993 181 21 subsequently subsequently ADV fnp-2993 181 22 decreases decrease VERB fnp-2993 181 23 ace2 ace2 NOUN fnp-2993 181 24 expression expression NOUN fnp-2993 181 25 and and CCONJ fnp-2993 181 26 ang(1 ang(1 NOUN fnp-2993 181 27 - - PUNCT fnp-2993 181 28 7 7 NUM fnp-2993 181 29 ) ) PUNCT fnp-2993 181 30 formation formation NOUN fnp-2993 181 31 in in ADP fnp-2993 181 32 rat rat NOUN fnp-2993 181 33 vsmcs vsmcs NOUN fnp-2993 181 34 . . PUNCT fnp-2993 182 1 am be AUX fnp-2993 182 2 j j PROPN fnp-2993 182 3 physiol physiol PROPN fnp-2993 182 4 hear hear VERB fnp-2993 182 5 circ circ PROPN fnp-2993 182 6 physiol physiol PROPN fnp-2993 182 7 . . PUNCT fnp-2993 183 1 2009;296(1):106 2009;296(1):106 NUM fnp-2993 183 2 - - SYM fnp-2993 183 3 118 118 NUM fnp-2993 183 4 . . PUNCT fnp-2993 183 5 doi:10.1152 doi:10.1152 NOUN fnp-2993 183 6 / / SYM fnp-2993 183 7 ajpheart.00239.2008 ajpheart.00239.2008 NOUN fnp-2993 183 8 22 22 NUM fnp-2993 183 9 . . PUNCT fnp-2993 184 1 xia xia PROPN fnp-2993 184 2 h h PROPN fnp-2993 184 3 , , PUNCT fnp-2993 184 4 lazartigues lazartigue NOUN fnp-2993 184 5 e. e. PROPN fnp-2993 184 6 angiotensin angiotensin PROPN fnp-2993 184 7 - - PUNCT fnp-2993 184 8 converting convert VERB fnp-2993 184 9 enzyme enzyme NOUN fnp-2993 184 10 2 2 NUM fnp-2993 184 11 in in ADP fnp-2993 184 12 the the DET fnp-2993 184 13 brain brain NOUN fnp-2993 184 14 : : PUNCT fnp-2993 184 15 properties property NOUN fnp-2993 184 16 and and CCONJ fnp-2993 184 17 future future ADJ fnp-2993 184 18 directions direction NOUN fnp-2993 184 19 . . PUNCT fnp-2993 185 1 j j PROPN fnp-2993 185 2 neurochem neurochem PROPN fnp-2993 185 3 . . PUNCT fnp-2993 186 1 2008;107(6):1482 2008;107(6):1482 NUM fnp-2993 186 2 - - SYM fnp-2993 186 3 1494 1494 NUM fnp-2993 186 4 . . PUNCT fnp-2993 187 1 doi:10.1111 doi:10.1111 PROPN fnp-2993 187 2 / / SYM fnp-2993 187 3 j.1471 j.1471 PROPN fnp-2993 187 4 - - PUNCT fnp-2993 187 5 4159.2008.05723.x 4159.2008.05723.x PROPN fnp-2993 187 6 23 23 NUM fnp-2993 187 7 . . PUNCT fnp-2993 188 1 brann brann PROPN fnp-2993 188 2 d d PROPN fnp-2993 188 3 , , PUNCT fnp-2993 188 4 tsukahara tsukahara PROPN fnp-2993 188 5 t t PROPN fnp-2993 188 6 , , PUNCT fnp-2993 188 7 weinreb weinreb PROPN fnp-2993 188 8 c c AUX fnp-2993 188 9 , , PUNCT fnp-2993 188 10 et et PROPN fnp-2993 188 11 al al PROPN fnp-2993 188 12 . . PUNCT fnp-2993 189 1 non non ADJ fnp-2993 189 2 - - ADJ fnp-2993 189 3 neuronal neuronal ADJ fnp-2993 189 4 expression expression NOUN fnp-2993 189 5 of of ADP fnp-2993 189 6 sars sar NOUN fnp-2993 189 7 - - PUNCT fnp-2993 189 8 cov-2 cov-2 NOUN fnp-2993 189 9 entry entry NOUN fnp-2993 189 10 genes gene NOUN fnp-2993 189 11 in in ADP fnp-2993 189 12 the the DET fnp-2993 189 13 olfactory olfactory ADJ fnp-2993 189 14 system system NOUN fnp-2993 189 15 suggests suggest VERB fnp-2993 189 16 mechanisms mechanism NOUN fnp-2993 189 17 underlying underlie VERB fnp-2993 189 18 covid-19 covid-19 PROPN fnp-2993 189 19 - - PUNCT fnp-2993 189 20 associated associate VERB fnp-2993 189 21 anosmia anosmia NOUN fnp-2993 189 22 . . PUNCT fnp-2993 190 1 sci sci PROPN fnp-2993 190 2 adv adv PROPN fnp-2993 190 3 . . PUNCT fnp-2993 191 1 2020;6(31):eabc5801 2020;6(31):eabc5801 PROPN fnp-2993 191 2 . . PUNCT fnp-2993 191 3 doi:10.1126 doi:10.1126 PROPN fnp-2993 191 4 / / SYM fnp-2993 191 5 sciadv.abc5801 sciadv.abc5801 PROPN fnp-2993 191 6 24 24 NUM fnp-2993 191 7 . . PUNCT fnp-2993 192 1 chen chen PROPN fnp-2993 192 2 m m PROPN fnp-2993 192 3 , , PUNCT fnp-2993 192 4 shen shen PROPN fnp-2993 192 5 w w PROPN fnp-2993 192 6 , , PUNCT fnp-2993 192 7 rowan rowan PROPN fnp-2993 192 8 nr nr PROPN fnp-2993 192 9 , , PUNCT fnp-2993 192 10 et et PROPN fnp-2993 192 11 al al PROPN fnp-2993 192 12 . . PROPN fnp-2993 192 13 elevated elevate VERB fnp-2993 192 14 ace2 ace2 NOUN fnp-2993 192 15 expression expression NOUN fnp-2993 192 16 in in ADP fnp-2993 192 17 the the DET fnp-2993 192 18 olfactory olfactory NOUN fnp-2993 192 19 neuroepithelium neuroepithelium NOUN fnp-2993 192 20 : : PUNCT fnp-2993 192 21 implications implication NOUN fnp-2993 192 22 for for ADP fnp-2993 192 23 anosmia anosmia NOUN fnp-2993 192 24 and and CCONJ fnp-2993 192 25 upper upper ADJ fnp-2993 192 26 respiratory respiratory ADJ fnp-2993 192 27 sars sar NOUN fnp-2993 192 28 - - PUNCT fnp-2993 192 29 cov-2 cov-2 NOUN fnp-2993 192 30 entry entry NOUN fnp-2993 192 31 and and CCONJ fnp-2993 192 32 replication replication NOUN fnp-2993 192 33 . . PUNCT fnp-2993 193 1 eur eur PROPN fnp-2993 193 2 respir respir PROPN fnp-2993 193 3 j. j. PROPN fnp-2993 193 4 2020;56(3):2001948 2020;56(3):2001948 PROPN fnp-2993 193 5 . . PUNCT fnp-2993 194 1 doi:10.1183/13993003.01948 doi:10.1183/13993003.01948 NOUN fnp-2993 194 2 - - PUNCT fnp-2993 194 3 2020 2020 NUM fnp-2993 194 4 25 25 NUM fnp-2993 194 5 . . PUNCT fnp-2993 195 1 matschke matschke PROPN fnp-2993 195 2 j j PROPN fnp-2993 195 3 , , PUNCT fnp-2993 195 4 lütgehetmann lütgehetmann PROPN fnp-2993 195 5 m m PROPN fnp-2993 195 6 , , PUNCT fnp-2993 195 7 hagel hagel PROPN fnp-2993 195 8 c c AUX fnp-2993 195 9 , , PUNCT fnp-2993 195 10 et et PROPN fnp-2993 195 11 al al PROPN fnp-2993 195 12 . . PROPN fnp-2993 195 13 neuropathology neuropathology NOUN fnp-2993 195 14 of of ADP fnp-2993 195 15 patients patient NOUN fnp-2993 195 16 with with ADP fnp-2993 195 17 covid-19 covid-19 PROPN fnp-2993 195 18 in in ADP fnp-2993 195 19 germany germany PROPN fnp-2993 195 20 : : PUNCT fnp-2993 195 21 a a DET fnp-2993 195 22 post post ADJ fnp-2993 195 23 - - ADJ fnp-2993 195 24 mortem mortem ADJ fnp-2993 195 25 case case NOUN fnp-2993 195 26 series series NOUN fnp-2993 195 27 . . PUNCT fnp-2993 196 1 lancet lancet PROPN fnp-2993 196 2 neurol neurol PROPN fnp-2993 196 3 . . PUNCT fnp-2993 197 1 2020;19(11 2020;19(11 NUM fnp-2993 197 2 ) ) PUNCT fnp-2993 197 3 . . PUNCT fnp-2993 198 1 doi:10.1016 doi:10.1016 PROPN fnp-2993 198 2 / / SYM fnp-2993 198 3 s1474 s1474 PROPN fnp-2993 198 4 - - PROPN fnp-2993 198 5 4422(20)30308 4422(20)30308 NUM fnp-2993 198 6 - - PUNCT fnp-2993 198 7 2 2 NUM fnp-2993 198 8 26 26 NUM fnp-2993 198 9 . . PUNCT fnp-2993 199 1 wang wang PROPN fnp-2993 199 2 k k PROPN fnp-2993 199 3 , , PUNCT fnp-2993 199 4 chen chen PROPN fnp-2993 199 5 w w PROPN fnp-2993 199 6 , , PUNCT fnp-2993 199 7 zhou zhou PROPN fnp-2993 199 8 y y PROPN fnp-2993 199 9 sen sen PROPN fnp-2993 199 10 , , PUNCT fnp-2993 199 11 et et PROPN fnp-2993 199 12 al al PROPN fnp-2993 199 13 . . PUNCT fnp-2993 200 1 sars sars PROPN fnp-2993 200 2 - - PUNCT fnp-2993 200 3 cov-2 cov-2 PART fnp-2993 200 4 invades invade VERB fnp-2993 200 5 host host NOUN fnp-2993 200 6 cells cell NOUN fnp-2993 200 7 via via ADP fnp-2993 200 8 a a DET fnp-2993 200 9 novel novel ADJ fnp-2993 200 10 route route NOUN fnp-2993 200 11 : : PUNCT fnp-2993 200 12 cd147 cd147 PROPN fnp-2993 200 13 - - PUNCT fnp-2993 200 14 spike spike NOUN fnp-2993 200 15 protein protein NOUN fnp-2993 200 16 . . PUNCT fnp-2993 201 1 biorxiv biorxiv PROPN fnp-2993 201 2 . . PUNCT fnp-2993 202 1 published publish VERB fnp-2993 202 2 online online ADJ fnp-2993 202 3 january january PROPN fnp-2993 202 4 1 1 NUM fnp-2993 202 5 , , PUNCT fnp-2993 202 6 2020:2020.03.14.988345 2020:2020.03.14.988345 NUM fnp-2993 202 7 . . PUNCT fnp-2993 202 8 doi:10.1101/2020.03.14.988345 doi:10.1101/2020.03.14.988345 PROPN fnp-2993 202 9 27 27 NUM fnp-2993 202 10 . . PUNCT fnp-2993 203 1 cantuti cantuti PROPN fnp-2993 203 2 - - PUNCT fnp-2993 203 3 castelvetri castelvetri NOUN fnp-2993 203 4 l l NOUN fnp-2993 203 5 , , PUNCT fnp-2993 203 6 ojha ojha PROPN fnp-2993 203 7 r r PROPN fnp-2993 203 8 , , PUNCT fnp-2993 203 9 pedro pedro PROPN fnp-2993 203 10 ld ld PROPN fnp-2993 203 11 , , PUNCT fnp-2993 203 12 et et PROPN fnp-2993 203 13 al al PROPN fnp-2993 203 14 . . PUNCT fnp-2993 204 1 neuropilin-1 neuropilin-1 PROPN fnp-2993 204 2 facilitates facilitate VERB fnp-2993 204 3 sars sar NOUN fnp-2993 204 4 - - PUNCT fnp-2993 204 5 cov-2 cov-2 NOUN fnp-2993 204 6 cell cell NOUN fnp-2993 204 7 entry entry NOUN fnp-2993 204 8 and and CCONJ fnp-2993 204 9 provides provide VERB fnp-2993 204 10 a a DET fnp-2993 204 11 possible possible ADJ fnp-2993 204 12 pathway pathway NOUN fnp-2993 204 13 into into ADP fnp-2993 204 14 the the DET fnp-2993 204 15 central central ADJ fnp-2993 204 16 nervous nervous ADJ fnp-2993 204 17 system system NOUN fnp-2993 204 18 . . PUNCT fnp-2993 205 1 biorxiv biorxiv NOUN fnp-2993 205 2 . . PUNCT fnp-2993 206 1 published publish VERB fnp-2993 206 2 online online ADJ fnp-2993 206 3 january january PROPN fnp-2993 206 4 1 1 NUM fnp-2993 206 5 , , PUNCT fnp-2993 206 6 2020:2020.06.07.137802 2020:2020.06.07.137802 NUM fnp-2993 206 7 . . PUNCT fnp-2993 206 8 doi:10.1101/2020.06.07.137802 doi:10.1101/2020.06.07.137802 PROPN fnp-2993 206 9 28 28 NUM fnp-2993 206 10 . . PUNCT fnp-2993 207 1 hoffmann hoffmann PROPN fnp-2993 207 2 m m PROPN fnp-2993 207 3 , , PUNCT fnp-2993 207 4 kleine kleine PROPN fnp-2993 207 5 - - PUNCT fnp-2993 207 6 weber weber PROPN fnp-2993 207 7 h h PROPN fnp-2993 207 8 , , PUNCT fnp-2993 207 9 schroeder schroeder PROPN fnp-2993 207 10 s s PROPN fnp-2993 207 11 , , PUNCT fnp-2993 207 12 et et PROPN fnp-2993 207 13 al al PROPN fnp-2993 207 14 . . PUNCT fnp-2993 208 1 sars sars PROPN fnp-2993 208 2 - - PUNCT fnp-2993 208 3 cov-2 cov-2 PART fnp-2993 208 4 cell cell NOUN fnp-2993 208 5 entry entry NOUN fnp-2993 208 6 depends depend VERB fnp-2993 208 7 on on ADP fnp-2993 208 8 ace2 ace2 NOUN fnp-2993 208 9 and and CCONJ fnp-2993 208 10 tmprss2 tmprss2 ADV fnp-2993 208 11 and and CCONJ fnp-2993 208 12 is be AUX fnp-2993 208 13 blocked block VERB fnp-2993 208 14 by by ADP fnp-2993 208 15 a a DET fnp-2993 208 16 clinically clinically ADV fnp-2993 208 17 proven prove VERB fnp-2993 208 18 protease protease NOUN fnp-2993 208 19 inhibitor inhibitor NOUN fnp-2993 208 20 . . PUNCT fnp-2993 209 1 cell cell NOUN fnp-2993 209 2 . . PUNCT fnp-2993 210 1 2020;181(2):271 2020;181(2):271 NOUN fnp-2993 210 2 - - SYM fnp-2993 210 3 280.e8 280.e8 NUM fnp-2993 210 4 . . PUNCT fnp-2993 211 1 doi:10.1016 doi:10.1016 PROPN fnp-2993 211 2 / / SYM fnp-2993 211 3 j.cell.2020.02.052 j.cell.2020.02.052 PROPN fnp-2993 211 4 29 29 NUM fnp-2993 211 5 . . PUNCT fnp-2993 212 1 zang zang PROPN fnp-2993 212 2 r r PROPN fnp-2993 212 3 , , PUNCT fnp-2993 212 4 gomez gomez PROPN fnp-2993 212 5 castro castro PROPN fnp-2993 212 6 mf mf VERB fnp-2993 212 7 , , PUNCT fnp-2993 212 8 mccune mccune PROPN fnp-2993 212 9 bt bt PROPN fnp-2993 212 10 , , PUNCT fnp-2993 212 11 et et PROPN fnp-2993 212 12 al al PROPN fnp-2993 212 13 . . PUNCT fnp-2993 213 1 tmprss2 tmprss2 PROPN fnp-2993 213 2 and and CCONJ fnp-2993 213 3 tmprss4 tmprss4 PROPN fnp-2993 213 4 promote promote VERB fnp-2993 213 5 sars sar NOUN fnp-2993 213 6 - - PUNCT fnp-2993 213 7 cov-2 cov-2 PART fnp-2993 213 8 infection infection NOUN fnp-2993 213 9 of of ADP fnp-2993 213 10 human human ADJ fnp-2993 213 11 small small ADJ fnp-2993 213 12 intestinal intestinal ADJ fnp-2993 213 13 enterocytes enterocyte NOUN fnp-2993 213 14 . . PUNCT fnp-2993 214 1 sci sci PROPN fnp-2993 214 2 immunol immunol NOUN fnp-2993 214 3 . . PUNCT fnp-2993 215 1 2020;5(47):eabc3582 2020;5(47):eabc3582 NOUN fnp-2993 215 2 . . PUNCT fnp-2993 215 3 doi:10.1126 doi:10.1126 PROPN fnp-2993 215 4 / / SYM fnp-2993 215 5 sciimmunol.abc3582 sciimmunol.abc3582 PROPN fnp-2993 215 6 30 30 NUM fnp-2993 215 7 . . PUNCT fnp-2993 216 1 covid-19 covid-19 PROPN fnp-2993 216 2 rt rt PROPN fnp-2993 216 3 - - PUNCT fnp-2993 216 4 pcr pcr PROPN fnp-2993 216 5 test test NOUN fnp-2993 216 6 emergency emergency NOUN fnp-2993 216 7 use use NOUN fnp-2993 216 8 authorization authorization NOUN fnp-2993 216 9 ( ( PUNCT fnp-2993 216 10 eua eua PROPN fnp-2993 216 11 ) ) PUNCT fnp-2993 216 12 summary summary NOUN fnp-2993 216 13 . . PUNCT fnp-2993 217 1 laboratory laboratory NOUN fnp-2993 217 2 corporation corporation PROPN fnp-2993 217 3 of of ADP fnp-2993 217 4 america america PROPN fnp-2993 217 5 . . PUNCT fnp-2993 218 1 accessed access VERB fnp-2993 218 2 september september PROPN fnp-2993 218 3 2 2 NUM fnp-2993 218 4 , , PUNCT fnp-2993 218 5 2020 2020 NUM fnp-2993 218 6 . . PUNCT fnp-2993 219 1 https://www.fda.gov/media/136151/download https://www.fda.gov/media/136151/download X fnp-2993 220 1 31 31 NUM fnp-2993 220 2 . . PUNCT fnp-2993 221 1 long long ADJ fnp-2993 221 2 c c NOUN fnp-2993 221 3 , , PUNCT fnp-2993 221 4 xu xu PROPN fnp-2993 222 1 h h PROPN fnp-2993 222 2 , , PUNCT fnp-2993 222 3 shen shen PROPN fnp-2993 222 4 q q PROPN fnp-2993 222 5 , , PUNCT fnp-2993 222 6 et et PROPN fnp-2993 222 7 al al PROPN fnp-2993 222 8 . . PUNCT fnp-2993 222 9 diagnosis diagnosis NOUN fnp-2993 222 10 of of ADP fnp-2993 222 11 the the DET fnp-2993 222 12 coronavirus coronavirus NOUN fnp-2993 222 13 disease disease NOUN fnp-2993 222 14 ( ( PUNCT fnp-2993 222 15 covid-19 covid-19 PROPN fnp-2993 222 16 ): ): PUNCT fnp-2993 222 17 rrt rrt NOUN fnp-2993 222 18 - - ADJ fnp-2993 222 19 pcr pcr ADJ fnp-2993 222 20 or or CCONJ fnp-2993 222 21 ct ct NUM fnp-2993 222 22 ? ? PUNCT fnp-2993 223 1 eur eur PROPN fnp-2993 223 2 j j PROPN fnp-2993 223 3 radiol radiol NOUN fnp-2993 223 4 . . PUNCT fnp-2993 224 1 2020;126:108961 2020;126:108961 NUM fnp-2993 224 2 . . PUNCT fnp-2993 224 3 doi:10.1016 doi:10.1016 PROPN fnp-2993 224 4 / / SYM fnp-2993 224 5 j.ejrad.2020.108961 j.ejrad.2020.108961 PROPN fnp-2993 224 6 32 32 NUM fnp-2993 224 7 . . PUNCT fnp-2993 225 1 ai ai PROPN fnp-2993 225 2 t t PROPN fnp-2993 225 3 , , PUNCT fnp-2993 225 4 yang yang PROPN fnp-2993 225 5 z z PROPN fnp-2993 225 6 , , PUNCT fnp-2993 225 7 hou hou PROPN fnp-2993 225 8 h h PROPN fnp-2993 225 9 , , PUNCT fnp-2993 225 10 et et PROPN fnp-2993 226 1 al al PROPN fnp-2993 226 2 . . PUNCT fnp-2993 226 3 correlation correlation NOUN fnp-2993 226 4 of of ADP fnp-2993 226 5 chest chest NOUN fnp-2993 226 6 ct ct PROPN fnp-2993 226 7 and and CCONJ fnp-2993 226 8 rt rt ADJ fnp-2993 226 9 - - PUNCT fnp-2993 226 10 pcr pcr ADJ fnp-2993 226 11 testing testing NOUN fnp-2993 226 12 in in ADP fnp-2993 226 13 coronavirus coronavirus NOUN fnp-2993 226 14 disease disease NOUN fnp-2993 226 15 2019 2019 NUM fnp-2993 226 16 ( ( PUNCT fnp-2993 226 17 covid-19 covid-19 PROPN fnp-2993 226 18 ) ) PUNCT fnp-2993 226 19 in in ADP fnp-2993 226 20 china china PROPN fnp-2993 226 21 : : PUNCT fnp-2993 226 22 a a DET fnp-2993 226 23 report report NOUN fnp-2993 226 24 of of ADP fnp-2993 226 25 1014 1014 NUM fnp-2993 226 26 cases case NOUN fnp-2993 226 27 . . PUNCT fnp-2993 227 1 radiology radiology NOUN fnp-2993 227 2 . . PUNCT fnp-2993 228 1 2020;296(2):e32 2020;296(2):e32 NOUN fnp-2993 228 2 - - PUNCT fnp-2993 228 3 e40 e40 PROPN fnp-2993 228 4 . . PUNCT fnp-2993 229 1 doi:10.1148 doi:10.1148 PROPN fnp-2993 229 2 / / SYM fnp-2993 229 3 radiol.2020200642 radiol.2020200642 PROPN fnp-2993 229 4 33 33 NUM fnp-2993 229 5 . . PUNCT fnp-2993 230 1 moriguchi moriguchi PROPN fnp-2993 230 2 t t PROPN fnp-2993 230 3 , , PUNCT fnp-2993 230 4 harii harii PROPN fnp-2993 230 5 n n CCONJ fnp-2993 230 6 , , PUNCT fnp-2993 230 7 goto goto PROPN fnp-2993 230 8 j j PROPN fnp-2993 230 9 , , PUNCT fnp-2993 230 10 et et PROPN fnp-2993 230 11 al al PROPN fnp-2993 230 12 . . PUNCT fnp-2993 231 1 a a DET fnp-2993 231 2 first first ADJ fnp-2993 231 3 case case NOUN fnp-2993 231 4 of of ADP fnp-2993 231 5 meningitis meningitis NOUN fnp-2993 231 6 / / SYM fnp-2993 231 7 encephalitis encephalitis NOUN fnp-2993 231 8 associated associate VERB fnp-2993 231 9 with with ADP fnp-2993 231 10 sars sar NOUN fnp-2993 231 11 - - PUNCT fnp-2993 231 12 coronavirus-2 coronavirus-2 NUM fnp-2993 231 13 . . PUNCT fnp-2993 232 1 int int PROPN fnp-2993 232 2 j j PROPN fnp-2993 232 3 infect infect VERB fnp-2993 232 4 dis dis PROPN fnp-2993 232 5 . . PUNCT fnp-2993 233 1 2020;94:55 2020;94:55 NUM fnp-2993 233 2 - - SYM fnp-2993 233 3 58 58 NUM fnp-2993 233 4 . . PUNCT fnp-2993 234 1 doi:10.1016 doi:10.1016 PROPN fnp-2993 234 2 / / SYM fnp-2993 234 3 j.ijid.2020.03.062 j.ijid.2020.03.062 PROPN fnp-2993 234 4 34 34 NUM fnp-2993 234 5 . . PUNCT fnp-2993 235 1 perera perera PROPN fnp-2993 235 2 rapm rapm NOUN fnp-2993 235 3 , , PUNCT fnp-2993 235 4 tso tso PROPN fnp-2993 235 5 e e PROPN fnp-2993 235 6 , , PUNCT fnp-2993 235 7 tsang tsang PROPN fnp-2993 235 8 oty oty PROPN fnp-2993 235 9 , , PUNCT fnp-2993 235 10 et et PROPN fnp-2993 235 11 al al PROPN fnp-2993 235 12 . . PUNCT fnp-2993 236 1 sars sars PROPN fnp-2993 236 2 - - PUNCT fnp-2993 236 3 cov-2 cov-2 PART fnp-2993 236 4 virus virus NOUN fnp-2993 236 5 culture culture NOUN fnp-2993 236 6 and and CCONJ fnp-2993 236 7 subgenomic subgenomic ADJ fnp-2993 236 8 rna rna NOUN fnp-2993 236 9 for for ADP fnp-2993 236 10 respiratory respiratory ADJ fnp-2993 236 11 specimens specimen NOUN fnp-2993 236 12 from from ADP fnp-2993 236 13 patients patient NOUN fnp-2993 236 14 with with ADP fnp-2993 236 15 mild mild ADJ fnp-2993 236 16 coronavirus coronavirus NOUN fnp-2993 236 17 disease disease NOUN fnp-2993 236 18 . . PUNCT fnp-2993 237 1 emerg emerg PROPN fnp-2993 237 2 infect infect NOUN fnp-2993 237 3 dis dis PROPN fnp-2993 237 4 j. j. PROPN fnp-2993 237 5 2020;26(11):2701 2020;26(11):2701 PROPN fnp-2993 237 6 . . PUNCT fnp-2993 237 7 doi:10.3201 doi:10.3201 NOUN fnp-2993 237 8 / / SYM fnp-2993 237 9 eid2611.203219 eid2611.203219 NUM fnp-2993 237 10 35 35 NUM fnp-2993 237 11 . . PUNCT fnp-2993 238 1 dai dai PROPN fnp-2993 238 2 w w PROPN fnp-2993 238 3 - - PUNCT fnp-2993 238 4 c c PROPN fnp-2993 238 5 , , PUNCT fnp-2993 238 6 zhang zhang PROPN fnp-2993 238 7 hw hw PROPN fnp-2993 238 8 , , PUNCT fnp-2993 238 9 yu yu PROPN fnp-2993 238 10 j j PROPN fnp-2993 238 11 , , PUNCT fnp-2993 238 12 et et PROPN fnp-2993 238 13 al al PROPN fnp-2993 238 14 . . PROPN fnp-2993 239 1 ct ct PROPN fnp-2993 239 2 imaging imaging NOUN fnp-2993 239 3 and and CCONJ fnp-2993 239 4 differential differential ADJ fnp-2993 239 5 diagnosis diagnosis NOUN fnp-2993 239 6 of of ADP fnp-2993 239 7 covid-19 covid-19 PROPN fnp-2993 239 8 . . PUNCT fnp-2993 240 1 can can AUX fnp-2993 240 2 assoc assoc VERB fnp-2993 240 3 radiol radiol PROPN fnp-2993 240 4 j. j. PROPN fnp-2993 240 5 2020;71(2):195 2020;71(2):195 PROPN fnp-2993 240 6 - - PUNCT fnp-2993 240 7 200 200 NUM fnp-2993 240 8 . . PUNCT fnp-2993 241 1 doi:10.1177/0846537120913033 doi:10.1177/0846537120913033 VERB fnp-2993 241 2 36 36 NUM fnp-2993 241 3 . . PUNCT fnp-2993 242 1 guo guo PROPN fnp-2993 242 2 l l PROPN fnp-2993 242 3 , , PUNCT fnp-2993 242 4 ren ren PROPN fnp-2993 242 5 l l PROPN fnp-2993 242 6 , , PUNCT fnp-2993 242 7 yang yang PROPN fnp-2993 242 8 s s PROPN fnp-2993 242 9 , , PUNCT fnp-2993 242 10 et et PROPN fnp-2993 242 11 al al PROPN fnp-2993 242 12 . . PUNCT fnp-2993 242 13 profiling profile VERB fnp-2993 242 14 early early ADJ fnp-2993 242 15 humoral humoral ADJ fnp-2993 242 16 response response NOUN fnp-2993 242 17 to to PART fnp-2993 242 18 diagnose diagnose VERB fnp-2993 242 19 novel novel ADJ fnp-2993 242 20 coronavirus coronavirus NOUN fnp-2993 242 21 disease disease NOUN fnp-2993 242 22 ( ( PUNCT fnp-2993 242 23 covid-19 covid-19 PROPN fnp-2993 242 24 ) ) PUNCT fnp-2993 242 25 . . PUNCT fnp-2993 243 1 clin clin PROPN fnp-2993 243 2 infect infect PROPN fnp-2993 243 3 dis dis PROPN fnp-2993 243 4 an an DET fnp-2993 243 5 off off ADJ fnp-2993 243 6 publ publ NOUN fnp-2993 243 7 infect infect ADJ fnp-2993 243 8 dis dis PROPN fnp-2993 243 9 soc soc PROPN fnp-2993 243 10 am be AUX fnp-2993 243 11 . . PUNCT fnp-2993 244 1 published publish VERB fnp-2993 244 2 online online ADJ fnp-2993 244 3 march march PROPN fnp-2993 244 4 2020 2020 NUM fnp-2993 244 5 . . PUNCT fnp-2993 245 1 doi:10.1093 doi:10.1093 NOUN fnp-2993 245 2 / / SYM fnp-2993 245 3 cid cid PROPN fnp-2993 245 4 / / SYM fnp-2993 245 5 ciaa310 ciaa310 PROPN fnp-2993 245 6 37 37 NUM fnp-2993 245 7 . . PUNCT fnp-2993 246 1 gauger gauger PROPN fnp-2993 246 2 pc pc PROPN fnp-2993 246 3 , , PUNCT fnp-2993 246 4 vincent vincent PROPN fnp-2993 246 5 al al PROPN fnp-2993 246 6 . . PROPN fnp-2993 246 7 serum serum PROPN fnp-2993 246 8 virus virus PROPN fnp-2993 246 9 neutralization neutralization NOUN fnp-2993 246 10 assay assay VERB fnp-2993 246 11 for for ADP fnp-2993 246 12 detection detection NOUN fnp-2993 246 13 and and CCONJ fnp-2993 246 14 quantitation quantitation NOUN fnp-2993 246 15 of of ADP fnp-2993 246 16 serum serum NOUN fnp-2993 246 17 neutralizing neutralize VERB fnp-2993 246 18 antibodies antibody NOUN fnp-2993 246 19 to to PART fnp-2993 246 20 influenza influenza VERB fnp-2993 246 21 a a DET fnp-2993 246 22 virus virus NOUN fnp-2993 246 23 in in ADP fnp-2993 246 24 swine swine PROPN fnp-2993 246 25 . . PUNCT fnp-2993 247 1 methods method NOUN fnp-2993 247 2 mol mol ADP fnp-2993 247 3 biol biol PROPN fnp-2993 247 4 . . PUNCT fnp-2993 248 1 2020;2123:321 2020;2123:321 NUM fnp-2993 248 2 - - SYM fnp-2993 248 3 333 333 NUM fnp-2993 248 4 . . PUNCT fnp-2993 249 1 doi:10.1007/978 doi:10.1007/978 ADJ fnp-2993 249 2 - - PUNCT fnp-2993 249 3 1 1 NUM fnp-2993 249 4 - - PUNCT fnp-2993 249 5 0716 0716 NUM fnp-2993 249 6 - - PUNCT fnp-2993 249 7 0346 0346 NUM fnp-2993 249 8 - - PUNCT fnp-2993 249 9 8_23 8_23 NUM fnp-2993 249 10 38 38 NUM fnp-2993 249 11 . . PUNCT fnp-2993 250 1 okba okba PROPN fnp-2993 251 1 nma nma PROPN fnp-2993 251 2 , , PUNCT fnp-2993 251 3 müller müller PROPN fnp-2993 251 4 ma ma PROPN fnp-2993 251 5 , , PUNCT fnp-2993 251 6 li li PROPN fnp-2993 251 7 w w PROPN fnp-2993 251 8 , , PUNCT fnp-2993 251 9 et et PROPN fnp-2993 251 10 al al PROPN fnp-2993 251 11 . . PROPN fnp-2993 252 1 severe severe ADJ fnp-2993 252 2 acute acute ADJ fnp-2993 252 3 respiratory respiratory ADJ fnp-2993 252 4 syndrome syndrome NOUN fnp-2993 252 5 coronavirus coronavirus NOUN fnp-2993 252 6 2 2 NUM fnp-2993 252 7 - - PUNCT fnp-2993 252 8 specific specific ADJ fnp-2993 252 9 antibody antibody NOUN fnp-2993 252 10 responses response NOUN fnp-2993 252 11 in in ADP fnp-2993 252 12 coronavirus coronavirus NOUN fnp-2993 252 13 disease disease NOUN fnp-2993 252 14 2019 2019 NUM fnp-2993 252 15 patients patient NOUN fnp-2993 252 16 . . PUNCT fnp-2993 253 1 emerg emerg PROPN fnp-2993 253 2 infect infect PROPN fnp-2993 253 3 dis dis PROPN fnp-2993 253 4 . . PUNCT fnp-2993 254 1 2020;26(7 2020;26(7 NUM fnp-2993 254 2 ) ) PUNCT fnp-2993 254 3 . . PUNCT fnp-2993 255 1 doi:10.3201 doi:10.3201 NOUN fnp-2993 255 2 / / SYM fnp-2993 255 3 eid2607.200841 eid2607.200841 PROPN fnp-2993 255 4 39 39 NUM fnp-2993 255 5 . . PUNCT fnp-2993 256 1 sun sun PROPN fnp-2993 256 2 b b PROPN fnp-2993 256 3 , , PUNCT fnp-2993 256 4 feng feng PROPN fnp-2993 256 5 y y PROPN fnp-2993 256 6 , , PUNCT fnp-2993 256 7 mo mo PROPN fnp-2993 256 8 x x PROPN fnp-2993 256 9 , , PUNCT fnp-2993 256 10 et et PROPN fnp-2993 256 11 al al PROPN fnp-2993 256 12 . . PUNCT fnp-2993 257 1 kinetics kinetic NOUN fnp-2993 257 2 of of ADP fnp-2993 257 3 sars sar NOUN fnp-2993 257 4 - - PUNCT fnp-2993 257 5 cov-2 cov-2 NOUN fnp-2993 257 6 specific specific ADJ fnp-2993 257 7 igm igm NOUN fnp-2993 257 8 and and CCONJ fnp-2993 257 9 igg igg PROPN fnp-2993 257 10 responses response NOUN fnp-2993 257 11 in in ADP fnp-2993 257 12 covid-19 covid-19 PROPN fnp-2993 257 13 patients patient NOUN fnp-2993 257 14 . . PUNCT fnp-2993 258 1 emerg emerg PROPN fnp-2993 258 2 microbes microbe NOUN fnp-2993 258 3 infect infect VERB fnp-2993 258 4 . . PUNCT fnp-2993 259 1 2020;9(1):940 2020;9(1):940 NUM fnp-2993 259 2 - - SYM fnp-2993 259 3 948 948 NUM fnp-2993 259 4 . . PUNCT fnp-2993 260 1 doi:10.1080/22221751.2020.1762515 doi:10.1080/22221751.2020.1762515 PROPN fnp-2993 260 2 40 40 NUM fnp-2993 260 3 . . PUNCT fnp-2993 261 1 krammer krammer PROPN fnp-2993 261 2 f f PROPN fnp-2993 261 3 , , PUNCT fnp-2993 261 4 simon simon PROPN fnp-2993 261 5 v. v. ADP fnp-2993 261 6 serology serology NOUN fnp-2993 261 7 assays assay NOUN fnp-2993 261 8 to to PART fnp-2993 261 9 manage manage VERB fnp-2993 261 10 covid-19 covid-19 PROPN fnp-2993 261 11 . . PUNCT fnp-2993 261 12 science science PROPN fnp-2993 261 13 . . PUNCT fnp-2993 262 1 2020;368(6495):1060 2020;368(6495):1060 NUM fnp-2993 262 2 - - PUNCT fnp-2993 262 3 1061 1061 NUM fnp-2993 262 4 . . PUNCT fnp-2993 263 1 doi:10.1126 doi:10.1126 PROPN fnp-2993 263 2 / / SYM fnp-2993 263 3 science.abc1227 science.abc1227 PROPN fnp-2993 263 4 41 41 NUM fnp-2993 263 5 . . PUNCT fnp-2993 264 1 wiersinga wiersinga PROPN fnp-2993 264 2 wj wj PROPN fnp-2993 264 3 , , PUNCT fnp-2993 264 4 rhodes rhode VERB fnp-2993 264 5 a a PRON fnp-2993 264 6 , , PUNCT fnp-2993 264 7 cheng cheng PROPN fnp-2993 264 8 ac ac PROPN fnp-2993 264 9 , , PUNCT fnp-2993 264 10 peacock peacock NOUN fnp-2993 264 11 sj sj PROPN fnp-2993 264 12 , , PUNCT fnp-2993 264 13 prescott prescott PROPN fnp-2993 264 14 hc hc PROPN fnp-2993 264 15 . . PROPN fnp-2993 264 16 pathophysiology pathophysiology NOUN fnp-2993 264 17 , , PUNCT fnp-2993 264 18 transmission transmission NOUN fnp-2993 264 19 , , PUNCT fnp-2993 264 20 diagnosis diagnosis NOUN fnp-2993 264 21 , , PUNCT fnp-2993 264 22 and and CCONJ fnp-2993 264 23 treatment treatment NOUN fnp-2993 264 24 of of ADP fnp-2993 264 25 coronavirus coronavirus NOUN fnp-2993 264 26 disease disease NOUN fnp-2993 264 27 2019 2019 NUM fnp-2993 264 28 ( ( PUNCT fnp-2993 264 29 covid-19 covid-19 PROPN fnp-2993 264 30 ): ): PUNCT fnp-2993 264 31 a a DET fnp-2993 264 32 review review NOUN fnp-2993 264 33 . . PUNCT fnp-2993 265 1 jama jama PROPN fnp-2993 265 2 . . PUNCT fnp-2993 266 1 2020;324(8):782 2020;324(8):782 NUM fnp-2993 266 2 - - SYM fnp-2993 266 3 793 793 NUM fnp-2993 266 4 . . PUNCT fnp-2993 267 1 doi:10.1001 doi:10.1001 PROPN fnp-2993 267 2 / / SYM fnp-2993 267 3 jama.2020.12839 jama.2020.12839 PROPN fnp-2993 267 4 42 42 NUM fnp-2993 267 5 . . PUNCT fnp-2993 268 1 xu xu PROPN fnp-2993 269 1 z z PROPN fnp-2993 269 2 , , PUNCT fnp-2993 269 3 shi shi PROPN fnp-2993 269 4 l l PROPN fnp-2993 269 5 , , PUNCT fnp-2993 269 6 wang wang PROPN fnp-2993 269 7 y y PROPN fnp-2993 269 8 , , PUNCT fnp-2993 269 9 et et PROPN fnp-2993 269 10 al al PROPN fnp-2993 269 11 . . PUNCT fnp-2993 270 1 pathological pathological ADJ fnp-2993 270 2 findings finding NOUN fnp-2993 270 3 of of ADP fnp-2993 270 4 covid-19 covid-19 PROPN fnp-2993 270 5 associated associate VERB fnp-2993 270 6 with with ADP fnp-2993 270 7 acute acute ADJ fnp-2993 270 8 respiratory respiratory ADJ fnp-2993 270 9 distress distress NOUN fnp-2993 270 10 syndrome syndrome NOUN fnp-2993 270 11 . . PUNCT fnp-2993 271 1 lancet lancet PROPN fnp-2993 271 2 respir respir VERB fnp-2993 271 3 med me VERB fnp-2993 271 4 . . PUNCT fnp-2993 272 1 2020;8(4):420 2020;8(4):420 NUM fnp-2993 272 2 - - SYM fnp-2993 272 3 422 422 NUM fnp-2993 272 4 . . PUNCT fnp-2993 272 5 doi:10.1016 doi:10.1016 PROPN fnp-2993 272 6 / / SYM fnp-2993 272 7 s2213 s2213 PROPN fnp-2993 272 8 - - PUNCT fnp-2993 272 9 2600(20)30076 2600(20)30076 NUM fnp-2993 272 10 - - PUNCT fnp-2993 272 11 x x SYM fnp-2993 272 12 43 43 NUM fnp-2993 272 13 . . PUNCT fnp-2993 273 1 jose jose PROPN fnp-2993 273 2 rj rj PROPN fnp-2993 273 3 , , PUNCT fnp-2993 273 4 manuel manuel PROPN fnp-2993 273 5 a. a. PROPN fnp-2993 273 6 covid-19 covid-19 PROPN fnp-2993 273 7 cytokine cytokine NOUN fnp-2993 273 8 storm storm NOUN fnp-2993 273 9 : : PUNCT fnp-2993 273 10 the the DET fnp-2993 273 11 interplay interplay NOUN fnp-2993 273 12 between between ADP fnp-2993 273 13 inflammation inflammation NOUN fnp-2993 273 14 and and CCONJ fnp-2993 273 15 coagulation coagulation NOUN fnp-2993 273 16 . . PUNCT fnp-2993 274 1 lancet lancet PROPN fnp-2993 274 2 respir respir VERB fnp-2993 274 3 med med ADJ fnp-2993 274 4 . . PUNCT fnp-2993 275 1 2020;8(6):e46 2020;8(6):e46 PROPN fnp-2993 275 2 - - PUNCT fnp-2993 275 3 e47 e47 PROPN fnp-2993 275 4 . . PUNCT fnp-2993 276 1 doi:10.1016 doi:10.1016 PROPN fnp-2993 276 2 / / SYM fnp-2993 276 3 s2213 s2213 PROPN fnp-2993 276 4 - - PUNCT fnp-2993 276 5 2600(20)30216 2600(20)30216 NUM fnp-2993 276 6 - - SYM fnp-2993 276 7 2 2 NUM fnp-2993 276 8 44 44 NUM fnp-2993 276 9 . . PUNCT fnp-2993 276 10 mao mao PROPN fnp-2993 277 1 l l NOUN fnp-2993 277 2 , , PUNCT fnp-2993 277 3 jin jin PROPN fnp-2993 277 4 h h PROPN fnp-2993 277 5 , , PUNCT fnp-2993 277 6 wang wang PROPN fnp-2993 277 7 m m PROPN fnp-2993 277 8 , , PUNCT fnp-2993 277 9 et et PROPN fnp-2993 277 10 al al PROPN fnp-2993 277 11 . . PUNCT fnp-2993 277 12 neurologic neurologic ADJ fnp-2993 277 13 manifestations manifestation NOUN fnp-2993 277 14 of of ADP fnp-2993 277 15 hospitalized hospitalize VERB fnp-2993 277 16 patients patient NOUN fnp-2993 277 17 with with ADP fnp-2993 277 18 coronavirus coronavirus NOUN fnp-2993 277 19 disease disease NOUN fnp-2993 277 20 2019 2019 NUM fnp-2993 277 21 in in ADP fnp-2993 277 22 wuhan wuhan PROPN fnp-2993 277 23 , , PUNCT fnp-2993 277 24 china china PROPN fnp-2993 277 25 . . PUNCT fnp-2993 278 1 jama jama PROPN fnp-2993 278 2 neurol neurol PROPN fnp-2993 278 3 . . PUNCT fnp-2993 279 1 2020;77(6):683 2020;77(6):683 NUM fnp-2993 279 2 - - PUNCT fnp-2993 279 3 690 690 NUM fnp-2993 279 4 . . PUNCT fnp-2993 280 1 doi:10.1001 doi:10.1001 PROPN fnp-2993 280 2 / / SYM fnp-2993 280 3 jamaneurol.2020.1127 jamaneurol.2020.1127 PROPN fnp-2993 280 4 45 45 NUM fnp-2993 280 5 . . PUNCT fnp-2993 281 1 lechien lechien PROPN fnp-2993 281 2 jr jr PROPN fnp-2993 281 3 , , PUNCT fnp-2993 281 4 chiesa chiesa NOUN fnp-2993 281 5 - - PUNCT fnp-2993 281 6 estomba estomba NOUN fnp-2993 281 7 cm cm NOUN fnp-2993 281 8 , , PUNCT fnp-2993 281 9 de de PROPN fnp-2993 281 10 siati siati PROPN fnp-2993 281 11 dr dr PROPN fnp-2993 281 12 , , PUNCT fnp-2993 281 13 et et PROPN fnp-2993 281 14 al al PROPN fnp-2993 281 15 . . PROPN fnp-2993 281 16 olfactory olfactory NOUN fnp-2993 281 17 and and CCONJ fnp-2993 281 18 gustatory gustatory NOUN fnp-2993 281 19 dysfunctions dysfunction NOUN fnp-2993 281 20 as as ADP fnp-2993 281 21 a a DET fnp-2993 281 22 clinical clinical ADJ fnp-2993 281 23 presentation presentation NOUN fnp-2993 281 24 of of ADP fnp-2993 281 25 mild mild ADJ fnp-2993 281 26 - - PUNCT fnp-2993 281 27 to to ADP fnp-2993 281 28 - - PUNCT fnp-2993 281 29 moderate moderate ADJ fnp-2993 281 30 forms form NOUN fnp-2993 281 31 of of ADP fnp-2993 281 32 the the DET fnp-2993 281 33 coronavirus coronavirus NOUN fnp-2993 281 34 disease disease NOUN fnp-2993 281 35 ( ( PUNCT fnp-2993 281 36 covid-19 covid-19 PROPN fnp-2993 281 37 ): ): PUNCT fnp-2993 281 38 a a DET fnp-2993 281 39 multicenter multicenter ADJ fnp-2993 281 40 european european ADJ fnp-2993 281 41 study study NOUN fnp-2993 281 42 . . PUNCT fnp-2993 282 1 eur eur PROPN fnp-2993 282 2 arch arch PROPN fnp-2993 282 3 oto oto PROPN fnp-2993 282 4 - - PUNCT fnp-2993 282 5 rhino rhino NOUN fnp-2993 282 6 - - NOUN fnp-2993 282 7 laryngology laryngology NOUN fnp-2993 282 8 . . PUNCT fnp-2993 283 1 2020;277(8):2251 2020;277(8):2251 NUM fnp-2993 283 2 - - SYM fnp-2993 283 3 2261 2261 NUM fnp-2993 283 4 . . PUNCT fnp-2993 284 1 doi:10.1007 doi:10.1007 NOUN fnp-2993 284 2 / / SYM fnp-2993 284 3 s00405 s00405 NOUN fnp-2993 284 4 - - PUNCT fnp-2993 284 5 020 020 NUM fnp-2993 284 6 - - PUNCT fnp-2993 284 7 05965 05965 NUM fnp-2993 284 8 - - SYM fnp-2993 284 9 1 1 NUM fnp-2993 284 10 46 46 NUM fnp-2993 284 11 . . PUNCT fnp-2993 285 1 yan yan PROPN fnp-2993 285 2 ch ch PROPN fnp-2993 285 3 , , PUNCT fnp-2993 285 4 faraji faraji PROPN fnp-2993 285 5 f f PROPN fnp-2993 285 6 , , PUNCT fnp-2993 285 7 prajapati prajapati PROPN fnp-2993 285 8 dp dp PROPN fnp-2993 285 9 , , PUNCT fnp-2993 285 10 boone boone PROPN fnp-2993 285 11 ce ce PROPN fnp-2993 285 12 , , PUNCT fnp-2993 285 13 deconde deconde VERB fnp-2993 285 14 as as ADP fnp-2993 285 15 . . PUNCT fnp-2993 285 16 association association NOUN fnp-2993 285 17 of of ADP fnp-2993 285 18 chemosensory chemosensory ADJ fnp-2993 285 19 dysfunction dysfunction NOUN fnp-2993 285 20 and and CCONJ fnp-2993 285 21 covid-19 covid-19 PROPN fnp-2993 285 22 in in ADP fnp-2993 285 23 patients patient NOUN fnp-2993 285 24 presenting present VERB fnp-2993 285 25 with with ADP fnp-2993 285 26 influenza influenza NOUN fnp-2993 285 27 - - PUNCT fnp-2993 285 28 like like ADJ fnp-2993 285 29 symptoms symptom NOUN fnp-2993 285 30 . . PUNCT fnp-2993 286 1 int int PROPN fnp-2993 286 2 forum forum PROPN fnp-2993 286 3 allergy allergy PROPN fnp-2993 286 4 rhinol rhinol PROPN fnp-2993 286 5 . . PUNCT fnp-2993 287 1 2020;10(7):806 2020;10(7):806 NUM fnp-2993 287 2 - - NUM fnp-2993 287 3 813 813 NUM fnp-2993 287 4 . . PUNCT fnp-2993 288 1 doi:10.1002 doi:10.1002 NOUN fnp-2993 288 2 / / SYM fnp-2993 288 3 alr.22579 alr.22579 NUM fnp-2993 288 4 47 47 NUM fnp-2993 288 5 . . PUNCT fnp-2993 289 1 helms helms PROPN fnp-2993 289 2 j j PROPN fnp-2993 289 3 , , PUNCT fnp-2993 289 4 kremer kremer PROPN fnp-2993 289 5 s s PROPN fnp-2993 289 6 , , PUNCT fnp-2993 289 7 merdji merdji PROPN fnp-2993 289 8 h h PROPN fnp-2993 289 9 , , PUNCT fnp-2993 289 10 et et PROPN fnp-2993 289 11 al al PROPN fnp-2993 289 12 . . PROPN fnp-2993 290 1 neurologic neurologic ADJ fnp-2993 290 2 features feature NOUN fnp-2993 290 3 in in ADP fnp-2993 290 4 severe severe ADJ fnp-2993 290 5 sars sar NOUN fnp-2993 290 6 - - PUNCT fnp-2993 290 7 cov-2 cov-2 NOUN fnp-2993 290 8 infection infection NOUN fnp-2993 290 9 . . PUNCT fnp-2993 291 1 n n PROPN fnp-2993 291 2 engl engl PROPN fnp-2993 291 3 j j PROPN fnp-2993 291 4 med med PROPN fnp-2993 291 5 . . PUNCT fnp-2993 292 1 2020;382(21):2268 2020;382(21):2268 NUM fnp-2993 292 2 - - SYM fnp-2993 292 3 2270 2270 NUM fnp-2993 292 4 . . PUNCT fnp-2993 293 1 doi:10.1056 doi:10.1056 PROPN fnp-2993 293 2 / / SYM fnp-2993 293 3 nejmc2008597 nejmc2008597 PROPN fnp-2993 293 4 48 48 NUM fnp-2993 293 5 . . PUNCT fnp-2993 294 1 paterson paterson PROPN fnp-2993 294 2 rw rw PROPN fnp-2993 294 3 , , PUNCT fnp-2993 294 4 brown brown PROPN fnp-2993 294 5 rl rl PROPN fnp-2993 294 6 , , PUNCT fnp-2993 294 7 benjamin benjamin PROPN fnp-2993 294 8 l l PROPN fnp-2993 294 9 , , PUNCT fnp-2993 294 10 et et PROPN fnp-2993 294 11 al al PROPN fnp-2993 294 12 . . PUNCT fnp-2993 295 1 the the DET fnp-2993 295 2 emerging emerge VERB fnp-2993 295 3 spectrum spectrum NOUN fnp-2993 295 4 of of ADP fnp-2993 295 5 covid-19 covid-19 PROPN fnp-2993 295 6 neurology neurology NOUN fnp-2993 295 7 : : PUNCT fnp-2993 295 8 clinical clinical ADJ fnp-2993 295 9 , , PUNCT fnp-2993 295 10 radiological radiological ADJ fnp-2993 295 11 and and CCONJ fnp-2993 295 12 laboratory laboratory NOUN fnp-2993 295 13 findings finding NOUN fnp-2993 295 14 . . PUNCT fnp-2993 296 1 brain brain NOUN fnp-2993 296 2 . . PUNCT fnp-2993 297 1 2020;143(10):3104 2020;143(10):3104 X fnp-2993 297 2 - - SYM fnp-2993 297 3 3120 3120 NUM fnp-2993 297 4 . . PUNCT fnp-2993 298 1 doi:10.1093 doi:10.1093 NOUN fnp-2993 298 2 / / SYM fnp-2993 298 3 brain brain PROPN fnp-2993 298 4 / / SYM fnp-2993 298 5 awaa240 awaa240 PROPN fnp-2993 298 6 49 49 NUM fnp-2993 298 7 . . PUNCT fnp-2993 299 1 paolo paolo PROPN fnp-2993 299 2 g. g. PROPN fnp-2993 299 3 does do AUX fnp-2993 299 4 covid-19 covid-19 PROPN fnp-2993 299 5 cause cause VERB fnp-2993 299 6 permanent permanent ADJ fnp-2993 299 7 damage damage NOUN fnp-2993 299 8 to to ADP fnp-2993 299 9 olfactory olfactory NOUN fnp-2993 299 10 and and CCONJ fnp-2993 299 11 gustatory gustatory NOUN fnp-2993 299 12 function function NOUN fnp-2993 299 13 ? ? PUNCT fnp-2993 300 1 med med ADJ fnp-2993 300 2 hypotheses hypothesis NOUN fnp-2993 300 3 . . PUNCT fnp-2993 301 1 2020;143:110086 2020;143:110086 NUM fnp-2993 301 2 . . PUNCT fnp-2993 301 3 doi:10.1016 doi:10.1016 PROPN fnp-2993 301 4 / / SYM fnp-2993 301 5 j.mehy.2020.110086 j.mehy.2020.110086 PROPN fnp-2993 301 6 50 50 NUM fnp-2993 301 7 . . PUNCT fnp-2993 302 1 hopkins hopkins PROPN fnp-2993 302 2 c c PROPN fnp-2993 302 3 , , PUNCT fnp-2993 302 4 surda surda PROPN fnp-2993 302 5 p p NOUN fnp-2993 302 6 , , PUNCT fnp-2993 302 7 whitehead whitehead PROPN fnp-2993 302 8 e e PROPN fnp-2993 302 9 , , PUNCT fnp-2993 302 10 kumar kumar PROPN fnp-2993 302 11 bn bn PROPN fnp-2993 302 12 . . PROPN fnp-2993 303 1 early early ADJ fnp-2993 303 2 recovery recovery NOUN fnp-2993 303 3 following follow VERB fnp-2993 303 4 new new ADJ fnp-2993 303 5 onset onset NOUN fnp-2993 303 6 anosmia anosmia NOUN fnp-2993 303 7 during during ADP fnp-2993 303 8 the the DET fnp-2993 303 9 covid-19 covid-19 PROPN fnp-2993 303 10 pandemic pandemic NOUN fnp-2993 303 11 – – PUNCT fnp-2993 303 12 an an DET fnp-2993 303 13 observational observational ADJ fnp-2993 303 14 cohort cohort NOUN fnp-2993 303 15 study study NOUN fnp-2993 303 16 . . PUNCT fnp-2993 304 1 j j PROPN fnp-2993 304 2 otolaryngol otolaryngol PROPN fnp-2993 304 3 head head NOUN fnp-2993 304 4 neck neck NOUN fnp-2993 304 5 surg surg NOUN fnp-2993 304 6 . . PUNCT fnp-2993 305 1 2020;49(1):26 2020;49(1):26 X fnp-2993 305 2 . . PUNCT fnp-2993 305 3 doi:10.1186 doi:10.1186 PROPN fnp-2993 305 4 / / SYM fnp-2993 305 5 s40463 s40463 PROPN fnp-2993 305 6 - - PUNCT fnp-2993 305 7 020 020 NUM fnp-2993 305 8 - - PUNCT fnp-2993 305 9 00423 00423 NUM fnp-2993 305 10 - - SYM fnp-2993 305 11 8 8 NUM fnp-2993 305 12 51 51 NUM fnp-2993 305 13 . . PUNCT fnp-2993 305 14 whitcroft whitcroft PROPN fnp-2993 305 15 kl kl PROPN fnp-2993 305 16 , , PUNCT fnp-2993 305 17 hummel hummel PROPN fnp-2993 305 18 t. t. PROPN fnp-2993 305 19 olfactory olfactory ADJ fnp-2993 305 20 dysfunction dysfunction NOUN fnp-2993 305 21 in in ADP fnp-2993 305 22 covid-19 covid-19 PROPN fnp-2993 305 23 : : PUNCT fnp-2993 305 24 diagnosis diagnosis NOUN fnp-2993 305 25 and and CCONJ fnp-2993 305 26 management management NOUN fnp-2993 305 27 . . PUNCT fnp-2993 306 1 jama jama PROPN fnp-2993 306 2 . . PUNCT fnp-2993 307 1 2020;323(24):2512 2020;323(24):2512 X fnp-2993 307 2 - - SYM fnp-2993 307 3 2514 2514 NUM fnp-2993 307 4 . . PUNCT fnp-2993 308 1 doi:10.1001 doi:10.1001 PROPN fnp-2993 308 2 / / SYM fnp-2993 308 3 jama.2020.8391 jama.2020.8391 PROPN fnp-2993 308 4 52 52 NUM fnp-2993 308 5 . . PUNCT fnp-2993 309 1 paderno paderno PROPN fnp-2993 309 2 a a PRON fnp-2993 309 3 , , PUNCT fnp-2993 309 4 mattavelli mattavelli PROPN fnp-2993 309 5 d d PROPN fnp-2993 309 6 , , PUNCT fnp-2993 309 7 rampinelli rampinelli PROPN fnp-2993 309 8 v v PROPN fnp-2993 309 9 , , PUNCT fnp-2993 309 10 et et PROPN fnp-2993 309 11 al al PROPN fnp-2993 309 12 . . PROPN fnp-2993 310 1 olfactory olfactory PROPN fnp-2993 310 2 and and CCONJ fnp-2993 310 3 gustatory gustatory NOUN fnp-2993 310 4 outcomes outcome NOUN fnp-2993 310 5 in in ADP fnp-2993 310 6 covid-19 covid-19 PROPN fnp-2993 310 7 : : PUNCT fnp-2993 310 8 a a DET fnp-2993 310 9 prospective prospective ADJ fnp-2993 310 10 evaluation evaluation NOUN fnp-2993 310 11 in in ADP fnp-2993 310 12 nonhospitalized nonhospitalize VERB fnp-2993 310 13 subjects subject NOUN fnp-2993 310 14 . . PUNCT fnp-2993 311 1 otolaryngol otolaryngol ADJ fnp-2993 311 2 head head NOUN fnp-2993 311 3 neck neck NOUN fnp-2993 311 4 surg surg NOUN fnp-2993 311 5 . . PUNCT fnp-2993 312 1 2020;163(6):1144 2020;163(6):1144 NUM fnp-2993 312 2 - - SYM fnp-2993 312 3 1149 1149 NUM fnp-2993 312 4 . . PUNCT fnp-2993 313 1 doi:10.1177/0194599820939538 doi:10.1177/0194599820939538 VERB fnp-2993 313 2 53 53 NUM fnp-2993 313 3 . . PUNCT fnp-2993 314 1 meinhardt meinhardt PROPN fnp-2993 314 2 j j PROPN fnp-2993 314 3 , , PUNCT fnp-2993 314 4 radke radke PROPN fnp-2993 314 5 j j PROPN fnp-2993 314 6 , , PUNCT fnp-2993 314 7 dittmayer dittmayer PROPN fnp-2993 314 8 c c X fnp-2993 314 9 , , PUNCT fnp-2993 314 10 et et PROPN fnp-2993 314 11 al al PROPN fnp-2993 314 12 . . PROPN fnp-2993 314 13 olfactory olfactory PROPN fnp-2993 314 14 transmucosal transmucosal PROPN fnp-2993 314 15 sars sars PROPN fnp-2993 314 16 - - PUNCT fnp-2993 314 17 cov-2 cov-2 PART fnp-2993 314 18 invasion invasion NOUN fnp-2993 314 19 as as ADP fnp-2993 314 20 a a DET fnp-2993 314 21 port port NOUN fnp-2993 314 22 of of ADP fnp-2993 314 23 central central ADJ fnp-2993 314 24 nervous nervous ADJ fnp-2993 314 25 system system NOUN fnp-2993 314 26 entry entry NOUN fnp-2993 314 27 in in ADP fnp-2993 314 28 individuals individual NOUN fnp-2993 314 29 with with ADP fnp-2993 314 30 covid-19 covid-19 PROPN fnp-2993 314 31 . . PUNCT fnp-2993 315 1 nat nat PROPN fnp-2993 315 2 neurosci neurosci PROPN fnp-2993 315 3 . . PUNCT fnp-2993 315 4 published publish VERB fnp-2993 315 5 online online ADJ fnp-2993 315 6 2020 2020 NUM fnp-2993 315 7 . . PUNCT fnp-2993 316 1 doi:10.1038 doi:10.1038 NOUN fnp-2993 316 2 / / SYM fnp-2993 316 3 s41593 s41593 PROPN fnp-2993 316 4 - - PUNCT fnp-2993 316 5 020 020 NUM fnp-2993 316 6 - - PUNCT fnp-2993 316 7 00758 00758 NUM fnp-2993 316 8 - - SYM fnp-2993 316 9 5 5 NUM fnp-2993 316 10 54 54 NUM fnp-2993 316 11 . . PUNCT fnp-2993 317 1 morbini morbini PROPN fnp-2993 317 2 p p NOUN fnp-2993 317 3 , , PUNCT fnp-2993 317 4 benazzo benazzo PROPN fnp-2993 317 5 m m PROPN fnp-2993 317 6 , , PUNCT fnp-2993 317 7 verga verga PROPN fnp-2993 317 8 l l PROPN fnp-2993 317 9 , , PUNCT fnp-2993 317 10 et et PROPN fnp-2993 317 11 al al PROPN fnp-2993 317 12 . . PUNCT fnp-2993 318 1 ultrastructural ultrastructural ADJ fnp-2993 318 2 evidence evidence NOUN fnp-2993 318 3 of of ADP fnp-2993 318 4 direct direct ADJ fnp-2993 318 5 viral viral ADJ fnp-2993 318 6 damage damage NOUN fnp-2993 318 7 to to ADP fnp-2993 318 8 the the DET fnp-2993 318 9 olfactory olfactory NOUN fnp-2993 318 10 complex complex NOUN fnp-2993 318 11 in in ADP fnp-2993 318 12 patients patient NOUN fnp-2993 318 13 testing test VERB fnp-2993 318 14 positive positive ADJ fnp-2993 318 15 for for ADP fnp-2993 318 16 sars sar NOUN fnp-2993 318 17 - - PUNCT fnp-2993 318 18 cov-2 cov-2 NOUN fnp-2993 318 19 . . PUNCT fnp-2993 319 1 jama jama PROPN fnp-2993 319 2 otolaryngol otolaryngol PROPN fnp-2993 319 3 neck neck NOUN fnp-2993 319 4 surg surg NOUN fnp-2993 319 5 . . PUNCT fnp-2993 320 1 2020;146(10):972 2020;146(10):972 NUM fnp-2993 320 2 - - SYM fnp-2993 320 3 973 973 NUM fnp-2993 320 4 . . PUNCT fnp-2993 321 1 doi:10.1001 doi:10.1001 PROPN fnp-2993 321 2 / / SYM fnp-2993 321 3 jamaoto.2020.2366 jamaoto.2020.2366 PROPN fnp-2993 321 4 55 55 NUM fnp-2993 321 5 . . PUNCT fnp-2993 322 1 merkler merkler NOUN fnp-2993 322 2 ae ae PROPN fnp-2993 322 3 , , PUNCT fnp-2993 322 4 parikh parikh PROPN fnp-2993 322 5 ns ns PROPN fnp-2993 322 6 , , PUNCT fnp-2993 322 7 mir mir PROPN fnp-2993 322 8 s s X fnp-2993 322 9 , , PUNCT fnp-2993 322 10 et et PROPN fnp-2993 322 11 al al PROPN fnp-2993 322 12 . . PROPN fnp-2993 322 13 risk risk NOUN fnp-2993 322 14 of of ADP fnp-2993 322 15 ischemic ischemic ADJ fnp-2993 322 16 stroke stroke NOUN fnp-2993 322 17 in in ADP fnp-2993 322 18 patients patient NOUN fnp-2993 322 19 with with ADP fnp-2993 322 20 coronavirus coronavirus NOUN fnp-2993 322 21 disease disease NOUN fnp-2993 322 22 2019 2019 NUM fnp-2993 322 23 ( ( PUNCT fnp-2993 322 24 covid-19 covid-19 PROPN fnp-2993 322 25 ) ) PUNCT fnp-2993 322 26 vs vs ADP fnp-2993 322 27 patients patient NOUN fnp-2993 322 28 with with ADP fnp-2993 322 29 influenza influenza NOUN fnp-2993 322 30 . . PUNCT fnp-2993 323 1 jama jama PROPN fnp-2993 323 2 neurol neurol PROPN fnp-2993 323 3 . . PUNCT fnp-2993 324 1 2020;77(11):1–7 2020;77(11):1–7 X fnp-2993 324 2 . . PUNCT fnp-2993 325 1 doi:10.1001 doi:10.1001 PROPN fnp-2993 325 2 / / SYM fnp-2993 325 3 jamaneurol.2020.2730 jamaneurol.2020.2730 PROPN fnp-2993 325 4 56 56 NUM fnp-2993 325 5 . . PUNCT fnp-2993 326 1 yaghi yaghi PROPN fnp-2993 326 2 s s PROPN fnp-2993 326 3 , , PUNCT fnp-2993 326 4 ishida ishida PROPN fnp-2993 326 5 k k PROPN fnp-2993 326 6 , , PUNCT fnp-2993 326 7 torres torre VERB fnp-2993 326 8 j j PROPN fnp-2993 326 9 , , PUNCT fnp-2993 326 10 et et PROPN fnp-2993 326 11 al al PROPN fnp-2993 326 12 . . PUNCT fnp-2993 327 1 sars sars PROPN fnp-2993 327 2 - - PUNCT fnp-2993 327 3 cov-2 cov-2 PUNCT fnp-2993 327 4 and and CCONJ fnp-2993 327 5 stroke stroke NOUN fnp-2993 327 6 in in ADP fnp-2993 327 7 a a DET fnp-2993 327 8 new new PROPN fnp-2993 327 9 york york PROPN fnp-2993 327 10 healthcare healthcare PROPN fnp-2993 327 11 system system NOUN fnp-2993 327 12 . . PUNCT fnp-2993 328 1 stroke stroke NOUN fnp-2993 328 2 . . PUNCT fnp-2993 329 1 2020;51(7):2002 2020;51(7):2002 NUM fnp-2993 329 2 - - SYM fnp-2993 329 3 2011 2011 NUM fnp-2993 329 4 . . PUNCT fnp-2993 330 1 doi:10.1161 doi:10.1161 ADJ fnp-2993 330 2 / / SYM fnp-2993 330 3 strokeaha.120.030335 strokeaha.120.030335 NOUN fnp-2993 330 4 57 57 NUM fnp-2993 330 5 . . PUNCT fnp-2993 331 1 jain jain PROPN fnp-2993 331 2 r r PROPN fnp-2993 331 3 , , PUNCT fnp-2993 331 4 young young ADJ fnp-2993 331 5 m m PROPN fnp-2993 331 6 , , PUNCT fnp-2993 331 7 dogra dogra PROPN fnp-2993 331 8 s s PROPN fnp-2993 331 9 , , PUNCT fnp-2993 331 10 et et PROPN fnp-2993 331 11 al al PROPN fnp-2993 331 12 . . PUNCT fnp-2993 332 1 covid-19 covid-19 PROPN fnp-2993 332 2 related relate VERB fnp-2993 332 3 neuroimaging neuroimaging NOUN fnp-2993 332 4 findings finding NOUN fnp-2993 332 5 : : PUNCT fnp-2993 332 6 a a DET fnp-2993 332 7 signal signal NOUN fnp-2993 332 8 of of ADP fnp-2993 332 9 thromboembolic thromboembolic ADJ fnp-2993 332 10 complications complication NOUN fnp-2993 332 11 and and CCONJ fnp-2993 332 12 a a DET fnp-2993 332 13 strong strong ADJ fnp-2993 332 14 prognostic prognostic ADJ fnp-2993 332 15 marker marker NOUN fnp-2993 332 16 of of ADP fnp-2993 332 17 poor poor ADJ fnp-2993 332 18 patient patient ADJ fnp-2993 332 19 outcome outcome NOUN fnp-2993 332 20 . . PUNCT fnp-2993 333 1 j j PROPN fnp-2993 333 2 neurol neurol PROPN fnp-2993 333 3 sci sci PROPN fnp-2993 333 4 . . PUNCT fnp-2993 333 5 2020;414:116923 2020;414:116923 NUM fnp-2993 333 6 . . PUNCT fnp-2993 334 1 doi:10.1016 doi:10.1016 PROPN fnp-2993 334 2 / / SYM fnp-2993 334 3 j.jns.2020.116923 j.jns.2020.116923 PROPN fnp-2993 334 4 58 58 NUM fnp-2993 334 5 . . PUNCT fnp-2993 335 1 oxley oxley PROPN fnp-2993 335 2 tj tj PROPN fnp-2993 335 3 , , PUNCT fnp-2993 335 4 mocco mocco PROPN fnp-2993 335 5 j j PROPN fnp-2993 335 6 , , PUNCT fnp-2993 335 7 majidi majidi PROPN fnp-2993 335 8 s s PART fnp-2993 335 9 , , PUNCT fnp-2993 335 10 et et PROPN fnp-2993 335 11 al al PROPN fnp-2993 335 12 . . PUNCT fnp-2993 336 1 large large ADJ fnp-2993 336 2 - - PUNCT fnp-2993 336 3 vessel vessel NOUN fnp-2993 336 4 stroke stroke NOUN fnp-2993 336 5 as as ADP fnp-2993 336 6 a a DET fnp-2993 336 7 presenting present VERB fnp-2993 336 8 feature feature NOUN fnp-2993 336 9 of of ADP fnp-2993 336 10 covid-19 covid-19 PROPN fnp-2993 336 11 in in ADP fnp-2993 336 12 the the DET fnp-2993 336 13 young young NOUN fnp-2993 336 14 . . PUNCT fnp-2993 337 1 n n PROPN fnp-2993 337 2 engl engl PROPN fnp-2993 337 3 j j PROPN fnp-2993 337 4 med med PROPN fnp-2993 337 5 . . PUNCT fnp-2993 338 1 2020;382(20):e60 2020;382(20):e60 NUM fnp-2993 338 2 - - PUNCT fnp-2993 338 3 e60 e60 NOUN fnp-2993 338 4 . . PUNCT fnp-2993 338 5 doi:10.1056 doi:10.1056 PROPN fnp-2993 338 6 / / SYM fnp-2993 338 7 nejmc2009787 nejmc2009787 PROPN fnp-2993 338 8 59 59 NUM fnp-2993 338 9 . . PUNCT fnp-2993 339 1 national national PROPN fnp-2993 339 2 hospital hospital PROPN fnp-2993 339 3 ambulatory ambulatory ADJ fnp-2993 339 4 medical medical ADJ fnp-2993 339 5 care care NOUN fnp-2993 339 6 survey survey NOUN fnp-2993 339 7 : : PUNCT fnp-2993 339 8 2017 2017 NUM fnp-2993 339 9 emergency emergency NOUN fnp-2993 339 10 department department NOUN fnp-2993 339 11 summary summary NOUN fnp-2993 339 12 tables table NOUN fnp-2993 339 13 . . PUNCT fnp-2993 340 1 centers center NOUN fnp-2993 340 2 for for ADP fnp-2993 340 3 disease disease NOUN fnp-2993 340 4 control control NOUN fnp-2993 340 5 and and CCONJ fnp-2993 340 6 prevention prevention NOUN fnp-2993 340 7 . . PUNCT fnp-2993 341 1 accessed access VERB fnp-2993 341 2 january january PROPN fnp-2993 341 3 10 10 NUM fnp-2993 341 4 , , PUNCT fnp-2993 341 5 2021 2021 NUM fnp-2993 341 6 . . PUNCT fnp-2993 342 1 https://www.cdc.gov/nchs/data/nhamcs/web_tables/2017_ed_web_tables-508.pdf https://www.cdc.gov/nchs/data/nhamcs/web_tables/2017_ed_web_tables-508.pdf PROPN fnp-2993 342 2 60 60 PROPN fnp-2993 342 3 . . PUNCT fnp-2993 343 1 dogra dogra PROPN fnp-2993 343 2 s s PROPN fnp-2993 343 3 , , PUNCT fnp-2993 343 4 jain jain PROPN fnp-2993 343 5 r r PROPN fnp-2993 343 6 , , PUNCT fnp-2993 343 7 cao cao PROPN fnp-2993 343 8 m m PROPN fnp-2993 343 9 , , PUNCT fnp-2993 343 10 et et PROPN fnp-2993 343 11 al al PROPN fnp-2993 343 12 . . PROPN fnp-2993 343 13 hemorrhagic hemorrhagic PROPN fnp-2993 343 14 stroke stroke NOUN fnp-2993 343 15 and and CCONJ fnp-2993 343 16 anticoagulation anticoagulation NOUN fnp-2993 343 17 in in ADP fnp-2993 343 18 covid-19 covid-19 PROPN fnp-2993 343 19 . . PUNCT fnp-2993 344 1 j j PROPN fnp-2993 344 2 stroke stroke PROPN fnp-2993 344 3 cerebrovasc cerebrovasc PROPN fnp-2993 344 4 dis dis PROPN fnp-2993 344 5 . . PUNCT fnp-2993 345 1 2020;29(8):104984 2020;29(8):104984 PROPN fnp-2993 345 2 . . PUNCT fnp-2993 346 1 doi doi NOUN fnp-2993 346 2 : : PUNCT fnp-2993 346 3 https://doi.org/10.1016 https://doi.org/10.1016 PROPN fnp-2993 346 4 / / SYM fnp-2993 346 5 j.jstrokecerebrovasdis.2020.104984 j.jstrokecerebrovasdis.2020.104984 PROPN fnp-2993 346 6 61 61 NUM fnp-2993 346 7 . . PUNCT fnp-2993 347 1 wu wu PROPN fnp-2993 347 2 z z PROPN fnp-2993 347 3 , , PUNCT fnp-2993 347 4 mcgoogan mcgoogan PROPN fnp-2993 347 5 jm jm PROPN fnp-2993 347 6 . . PROPN fnp-2993 347 7 characteristics characteristic NOUN fnp-2993 347 8 of of ADP fnp-2993 347 9 and and CCONJ fnp-2993 347 10 important important ADJ fnp-2993 347 11 lessons lesson NOUN fnp-2993 347 12 from from ADP fnp-2993 347 13 the the DET fnp-2993 347 14 coronavirus coronavirus NOUN fnp-2993 347 15 disease disease NOUN fnp-2993 347 16 2019 2019 NUM fnp-2993 347 17 ( ( PUNCT fnp-2993 347 18 covid-19 covid-19 PROPN fnp-2993 347 19 ) ) PUNCT fnp-2993 347 20 outbreak outbreak NOUN fnp-2993 347 21 in in ADP fnp-2993 347 22 china china PROPN fnp-2993 347 23 : : PUNCT fnp-2993 347 24 summary summary NOUN fnp-2993 347 25 of of ADP fnp-2993 347 26 a a DET fnp-2993 347 27 report report NOUN fnp-2993 347 28 of of ADP fnp-2993 347 29 72 72 NUM fnp-2993 347 30     SPACE fnp-2993 347 31 314 314 NUM fnp-2993 347 32 cases case NOUN fnp-2993 347 33 from from ADP fnp-2993 347 34 the the DET fnp-2993 347 35 chinese chinese ADJ fnp-2993 347 36 center center NOUN fnp-2993 347 37 for for ADP fnp-2993 347 38 disease disease NOUN fnp-2993 347 39 control control NOUN fnp-2993 347 40 and and CCONJ fnp-2993 347 41 prevention prevention NOUN fnp-2993 347 42 . . PUNCT fnp-2993 348 1 jama jama PROPN fnp-2993 348 2 . . PUNCT fnp-2993 349 1 published publish VERB fnp-2993 349 2 online online ADJ fnp-2993 349 3 february february PROPN fnp-2993 349 4 2020 2020 NUM fnp-2993 349 5 . . PUNCT fnp-2993 350 1 doi:10.1001 doi:10.1001 PROPN fnp-2993 350 2 / / SYM fnp-2993 350 3 jama.2020.2648 jama.2020.2648 PROPN fnp-2993 350 4 62 62 NUM fnp-2993 350 5 . . PUNCT fnp-2993 351 1 yang yang PROPN fnp-2993 351 2 j j PROPN fnp-2993 351 3 , , PUNCT fnp-2993 351 4 zheng zheng PROPN fnp-2993 351 5 y y PROPN fnp-2993 351 6 , , PUNCT fnp-2993 351 7 gou gou PROPN fnp-2993 351 8 x x PROPN fnp-2993 351 9 , , PUNCT fnp-2993 351 10 et et PROPN fnp-2993 351 11 al al PROPN fnp-2993 351 12 . . PUNCT fnp-2993 352 1 prevalence prevalence NOUN fnp-2993 352 2 of of ADP fnp-2993 352 3 comorbidities comorbiditie NOUN fnp-2993 352 4 and and CCONJ fnp-2993 352 5 its its PRON fnp-2993 352 6 effects effect NOUN fnp-2993 352 7 in in ADP fnp-2993 352 8 patients patient NOUN fnp-2993 352 9 infected infect VERB fnp-2993 352 10 with with ADP fnp-2993 352 11 sars sar NOUN fnp-2993 352 12 - - PUNCT fnp-2993 352 13 cov-2 cov-2 NUM fnp-2993 352 14 : : PUNCT fnp-2993 352 15 a a DET fnp-2993 352 16 systematic systematic ADJ fnp-2993 352 17 review review NOUN fnp-2993 352 18 and and CCONJ fnp-2993 352 19 meta meta ADJ fnp-2993 352 20 - - PUNCT fnp-2993 352 21 analysis analysis NOUN fnp-2993 352 22 . . PUNCT fnp-2993 353 1 int int NOUN fnp-2993 353 2 j j PROPN fnp-2993 353 3 infect infect VERB fnp-2993 353 4 dis dis PROPN fnp-2993 353 5 ijid ijid VERB fnp-2993 353 6 off off ADP fnp-2993 353 7 publ publ NOUN fnp-2993 353 8 int int NOUN fnp-2993 353 9 soc soc NOUN fnp-2993 353 10 infect infect VERB fnp-2993 353 11 dis dis PROPN fnp-2993 353 12 . . PUNCT fnp-2993 354 1 2020;94:91 2020;94:91 NUM fnp-2993 354 2 - - SYM fnp-2993 354 3 95 95 NUM fnp-2993 354 4 . . PUNCT fnp-2993 355 1 doi:10.1016 doi:10.1016 PROPN fnp-2993 355 2 / / SYM fnp-2993 355 3 j.ijid.2020.03.017 j.ijid.2020.03.017 PROPN fnp-2993 355 4 63 63 NUM fnp-2993 355 5 . . PUNCT fnp-2993 356 1 chen chen PROPN fnp-2993 356 2 t t PROPN fnp-2993 356 3 , , PUNCT fnp-2993 356 4 wu wu PROPN fnp-2993 356 5 d d PROPN fnp-2993 356 6 , , PUNCT fnp-2993 356 7 chen chen PROPN fnp-2993 356 8 h h PROPN fnp-2993 356 9 , , PUNCT fnp-2993 356 10 et et PROPN fnp-2993 356 11 al al PROPN fnp-2993 356 12 . . PROPN fnp-2993 357 1 clinical clinical ADJ fnp-2993 357 2 characteristics characteristic NOUN fnp-2993 357 3 of of ADP fnp-2993 357 4 113 113 NUM fnp-2993 357 5 deceased deceased ADJ fnp-2993 357 6 patients patient NOUN fnp-2993 357 7 with with ADP fnp-2993 357 8 coronavirus coronavirus NOUN fnp-2993 357 9 disease disease NOUN fnp-2993 357 10 2019 2019 NUM fnp-2993 357 11 : : PUNCT fnp-2993 357 12 retrospective retrospective ADJ fnp-2993 357 13 study study NOUN fnp-2993 357 14 . . PUNCT fnp-2993 358 1 bmj bmj PROPN fnp-2993 358 2 . . PUNCT fnp-2993 359 1 2020;368 2020;368 NUM fnp-2993 359 2 : : PUNCT fnp-2993 359 3 m1091 m1091 ADJ fnp-2993 359 4 . . PUNCT fnp-2993 359 5 doi:10.1136 doi:10.1136 NOUN fnp-2993 359 6 / / SYM fnp-2993 359 7 bmj.m1091 bmj.m1091 NOUN fnp-2993 359 8 64 64 NUM fnp-2993 359 9 . . PUNCT fnp-2993 360 1 jordan jordan PROPN fnp-2993 360 2 re re PROPN fnp-2993 360 3 , , PUNCT fnp-2993 360 4 adab adab NOUN fnp-2993 360 5 p p X fnp-2993 360 6 , , PUNCT fnp-2993 360 7 cheng cheng PROPN fnp-2993 360 8 kk kk PROPN fnp-2993 360 9 . . PUNCT fnp-2993 361 1 covid-19 covid-19 PROPN fnp-2993 361 2 : : PUNCT fnp-2993 361 3 risk risk NOUN fnp-2993 361 4 factors factor NOUN fnp-2993 361 5 for for ADP fnp-2993 361 6 severe severe ADJ fnp-2993 361 7 disease disease NOUN fnp-2993 361 8 and and CCONJ fnp-2993 361 9 death death NOUN fnp-2993 361 10 . . PUNCT fnp-2993 362 1 bmj bmj PROPN fnp-2993 362 2 . . PUNCT fnp-2993 362 3 2020;368 2020;368 NUM fnp-2993 362 4 : : PUNCT fnp-2993 362 5 m1198 m1198 PROPN fnp-2993 362 6 . . PUNCT fnp-2993 362 7 doi:10.1136 doi:10.1136 PROPN fnp-2993 362 8 / / SYM fnp-2993 362 9 bmj.m1198 bmj.m1198 NOUN fnp-2993 362 10 65 65 NUM fnp-2993 362 11 . . PUNCT fnp-2993 363 1 wang wang PROPN fnp-2993 363 2 b b PROPN fnp-2993 363 3 , , PUNCT fnp-2993 363 4 li li PROPN fnp-2993 363 5 r r PROPN fnp-2993 363 6 , , PUNCT fnp-2993 363 7 lu lu PROPN fnp-2993 363 8 z z PROPN fnp-2993 363 9 , , PUNCT fnp-2993 363 10 huang huang PROPN fnp-2993 363 11 y. y. PROPN fnp-2993 363 12 does do AUX fnp-2993 363 13 comorbidity comorbidity NOUN fnp-2993 363 14 increase increase VERB fnp-2993 363 15 the the DET fnp-2993 363 16 risk risk NOUN fnp-2993 363 17 of of ADP fnp-2993 363 18 patients patient NOUN fnp-2993 363 19 with with ADP fnp-2993 363 20 covid-19 covid-19 PROPN fnp-2993 363 21 : : PUNCT fnp-2993 363 22 evidence evidence NOUN fnp-2993 363 23 from from ADP fnp-2993 363 24 meta meta ADJ fnp-2993 363 25 - - PUNCT fnp-2993 363 26 analysis analysis NOUN fnp-2993 363 27 . . PUNCT fnp-2993 364 1 aging aging NOUN fnp-2993 364 2 ( ( PUNCT fnp-2993 364 3 albany albany PROPN fnp-2993 364 4 ny ny PROPN fnp-2993 364 5 ) ) PUNCT fnp-2993 364 6 . . PUNCT fnp-2993 365 1 2020;12(7):6049 2020;12(7):6049 NUM fnp-2993 365 2 - - SYM fnp-2993 365 3 6057 6057 NUM fnp-2993 365 4 . . PUNCT fnp-2993 366 1 doi:10.18632 doi:10.18632 PROPN fnp-2993 366 2 / / SYM fnp-2993 366 3 aging.103000 aging.103000 PROPN fnp-2993 366 4 66 66 NUM fnp-2993 366 5 . . PUNCT fnp-2993 367 1 simonnet simonnet PROPN fnp-2993 367 2 a a PRON fnp-2993 367 3 , , PUNCT fnp-2993 367 4 chetboun chetboun NOUN fnp-2993 367 5 m m PROPN fnp-2993 367 6 , , PUNCT fnp-2993 367 7 poissy poissy PROPN fnp-2993 367 8 j j PROPN fnp-2993 367 9 , , PUNCT fnp-2993 367 10 et et PROPN fnp-2993 367 11 al al PROPN fnp-2993 367 12 . . PROPN fnp-2993 368 1 high high ADJ fnp-2993 368 2 prevalence prevalence NOUN fnp-2993 368 3 of of ADP fnp-2993 368 4 obesity obesity NOUN fnp-2993 368 5 in in ADP fnp-2993 368 6 severe severe ADJ fnp-2993 368 7 acute acute ADJ fnp-2993 368 8 respiratory respiratory ADJ fnp-2993 368 9 syndrome syndrome NOUN fnp-2993 368 10 coronavirus-2 coronavirus-2 NUM fnp-2993 368 11 ( ( PUNCT fnp-2993 368 12 sars sar NOUN fnp-2993 368 13 - - PUNCT fnp-2993 368 14 cov-2 cov-2 NOUN fnp-2993 368 15 ) ) PUNCT fnp-2993 368 16 requiring require VERB fnp-2993 368 17 invasive invasive ADJ fnp-2993 368 18 mechanical mechanical ADJ fnp-2993 368 19 ventilation ventilation NOUN fnp-2993 368 20 . . PUNCT fnp-2993 369 1 obesity obesity NOUN fnp-2993 369 2 ( ( PUNCT fnp-2993 369 3 silver silver ADJ fnp-2993 369 4 spring spring NOUN fnp-2993 369 5 ) ) PUNCT fnp-2993 369 6 . . PUNCT fnp-2993 370 1 2020;28(7):1195 2020;28(7):1195 NUM fnp-2993 370 2 - - SYM fnp-2993 370 3 1199 1199 NUM fnp-2993 370 4 . . PUNCT fnp-2993 371 1 doi:10.1002 doi:10.1002 NOUN fnp-2993 371 2 / / SYM fnp-2993 371 3 oby.22831 oby.22831 SYM fnp-2993 371 4 67 67 NUM fnp-2993 371 5 . . PUNCT fnp-2993 372 1 lighter light ADJ fnp-2993 372 2 j j PROPN fnp-2993 372 3 , , PUNCT fnp-2993 372 4 phillips phillips PROPN fnp-2993 372 5 m m PROPN fnp-2993 372 6 , , PUNCT fnp-2993 372 7 hochman hochman PROPN fnp-2993 372 8 s s PROPN fnp-2993 372 9 , , PUNCT fnp-2993 372 10 et et PROPN fnp-2993 372 11 al al PROPN fnp-2993 372 12 . . PROPN fnp-2993 372 13 obesity obesity NOUN fnp-2993 372 14 in in ADP fnp-2993 372 15 patients patient NOUN fnp-2993 372 16 younger young ADJ fnp-2993 372 17 than than ADP fnp-2993 372 18 60 60 NUM fnp-2993 372 19 years year NOUN fnp-2993 372 20 is be AUX fnp-2993 372 21 a a DET fnp-2993 372 22 risk risk NOUN fnp-2993 372 23 factor factor NOUN fnp-2993 372 24 for for ADP fnp-2993 372 25 covid-19 covid-19 PROPN fnp-2993 372 26 hospital hospital NOUN fnp-2993 372 27 admission admission NOUN fnp-2993 372 28 . . PUNCT fnp-2993 373 1 clin clin PROPN fnp-2993 373 2 infect infect PROPN fnp-2993 373 3 dis dis PROPN fnp-2993 373 4 . . PUNCT fnp-2993 373 5 published publish VERB fnp-2993 373 6 online online ADJ fnp-2993 373 7 april april PROPN fnp-2993 373 8 2020 2020 NUM fnp-2993 373 9 . . PUNCT fnp-2993 374 1 doi:10.1093 doi:10.1093 NOUN fnp-2993 374 2 / / SYM fnp-2993 374 3 cid cid PROPN fnp-2993 374 4 / / SYM fnp-2993 374 5 ciaa415 ciaa415 PROPN fnp-2993 374 6 68 68 NUM fnp-2993 374 7 . . PUNCT fnp-2993 375 1 hoiland hoiland NOUN fnp-2993 375 2 rl rl PROPN fnp-2993 375 3 , , PUNCT fnp-2993 375 4 fergusson fergusson PROPN fnp-2993 375 5 na na PROPN fnp-2993 375 6 , , PUNCT fnp-2993 375 7 mitra mitra PROPN fnp-2993 375 8 ar ar PROPN fnp-2993 375 9 , , PUNCT fnp-2993 375 10 et et PROPN fnp-2993 375 11 al al PROPN fnp-2993 375 12 . . PUNCT fnp-2993 376 1 the the DET fnp-2993 376 2 association association NOUN fnp-2993 376 3 of of ADP fnp-2993 376 4 abo abo ADJ fnp-2993 376 5 blood blood NOUN fnp-2993 376 6 group group NOUN fnp-2993 376 7 with with ADP fnp-2993 376 8 indices index NOUN fnp-2993 376 9 of of ADP fnp-2993 376 10 disease disease NOUN fnp-2993 376 11 severity severity NOUN fnp-2993 376 12 and and CCONJ fnp-2993 376 13 multiorgan multiorgan VERB fnp-2993 376 14 dysfunction dysfunction NOUN fnp-2993 376 15 in in ADP fnp-2993 376 16 covid-19 covid-19 PROPN fnp-2993 376 17 . . PUNCT fnp-2993 377 1 blood blood PROPN fnp-2993 377 2 adv adv PROPN fnp-2993 377 3 . . PUNCT fnp-2993 378 1 2020;4(20):4981 2020;4(20):4981 X fnp-2993 378 2 - - SYM fnp-2993 378 3 4989 4989 NUM fnp-2993 378 4 . . PUNCT fnp-2993 379 1 doi:10.1182 doi:10.1182 PROPN fnp-2993 379 2 / / SYM fnp-2993 379 3 bloodadvances.2020002623 bloodadvances.2020002623 PROPN fnp-2993 379 4 69 69 NUM fnp-2993 379 5 . . PUNCT fnp-2993 380 1 latz latz PROPN fnp-2993 380 2 ca ca PROPN fnp-2993 380 3 , , PUNCT fnp-2993 380 4 decarlo decarlo VERB fnp-2993 380 5 c c X fnp-2993 380 6 , , PUNCT fnp-2993 380 7 boitano boitano PROPN fnp-2993 380 8 l l PROPN fnp-2993 380 9 , , PUNCT fnp-2993 380 10 et et PROPN fnp-2993 380 11 al al PROPN fnp-2993 380 12 . . PUNCT fnp-2993 380 13 blood blood NOUN fnp-2993 380 14 type type NOUN fnp-2993 380 15 and and CCONJ fnp-2993 380 16 outcomes outcome NOUN fnp-2993 380 17 in in ADP fnp-2993 380 18 patients patient NOUN fnp-2993 380 19 with with ADP fnp-2993 380 20 covid-19 covid-19 PROPN fnp-2993 380 21 . . PUNCT fnp-2993 381 1 ann ann PROPN fnp-2993 381 2 hematol hematol NOUN fnp-2993 381 3 . . PUNCT fnp-2993 382 1 2020;99(9):2113 2020;99(9):2113 PROPN fnp-2993 382 2 - - SYM fnp-2993 382 3 2118 2118 NUM fnp-2993 382 4 . . PUNCT fnp-2993 383 1 doi:10.1007 doi:10.1007 VERB fnp-2993 383 2 / / SYM fnp-2993 383 3 s00277 s00277 NOUN fnp-2993 383 4 - - PUNCT fnp-2993 383 5 020 020 NUM fnp-2993 383 6 - - PUNCT fnp-2993 383 7 04169 04169 NUM fnp-2993 383 8 - - SYM fnp-2993 383 9 1 1 NUM fnp-2993 383 10 70 70 NUM fnp-2993 383 11 . . PUNCT fnp-2993 384 1 padroni padroni PROPN fnp-2993 384 2 m m PROPN fnp-2993 384 3 , , PUNCT fnp-2993 384 4 mastrangelo mastrangelo NOUN fnp-2993 384 5 v v NOUN fnp-2993 384 6 , , PUNCT fnp-2993 384 7 asioli asioli PROPN fnp-2993 384 8 gm gm PROPN fnp-2993 384 9 , , PUNCT fnp-2993 384 10 et et PROPN fnp-2993 384 11 al al PROPN fnp-2993 384 12 . . PROPN fnp-2993 384 13 guillain guillain PROPN fnp-2993 384 14 - - PUNCT fnp-2993 384 15 barré barré PROPN fnp-2993 384 16 syndrome syndrome NOUN fnp-2993 384 17 following follow VERB fnp-2993 384 18 covid-19 covid-19 PROPN fnp-2993 384 19 : : PUNCT fnp-2993 384 20 new new ADJ fnp-2993 384 21 infection infection NOUN fnp-2993 384 22 , , PUNCT fnp-2993 384 23 old old ADJ fnp-2993 384 24 complication complication NOUN fnp-2993 384 25 ? ? PUNCT fnp-2993 385 1 j j PROPN fnp-2993 385 2 neurol neurol NOUN fnp-2993 385 3 . . PUNCT fnp-2993 386 1 2020;(table 2020;(table NUM fnp-2993 386 2 1):1 1):1 NUM fnp-2993 386 3 - - SYM fnp-2993 386 4 3 3 NUM fnp-2993 386 5 . . PUNCT fnp-2993 386 6 doi:10.1007 doi:10.1007 VERB fnp-2993 386 7 / / SYM fnp-2993 386 8 s00415 s00415 NOUN fnp-2993 386 9 - - PUNCT fnp-2993 386 10 020 020 NUM fnp-2993 386 11 - - PUNCT fnp-2993 386 12 09849 09849 NUM fnp-2993 386 13 - - SYM fnp-2993 386 14 6 6 NUM fnp-2993 386 15 71 71 NUM fnp-2993 386 16 . . PUNCT fnp-2993 387 1 toscano toscano PROPN fnp-2993 387 2 g g PROPN fnp-2993 387 3 , , PUNCT fnp-2993 387 4 palmerini palmerini NOUN fnp-2993 387 5 f f PROPN fnp-2993 387 6 , , PUNCT fnp-2993 387 7 ravaglia ravaglia PROPN fnp-2993 387 8 s s PROPN fnp-2993 387 9 , , PUNCT fnp-2993 387 10 et et PROPN fnp-2993 387 11 al al PROPN fnp-2993 387 12 . . PROPN fnp-2993 387 13 guillain guillain PROPN fnp-2993 387 14 – – PUNCT fnp-2993 387 15 barré barré PROPN fnp-2993 387 16 syndrome syndrome PROPN fnp-2993 387 17 associated associate VERB fnp-2993 387 18 with with ADP fnp-2993 387 19 sars sar NOUN fnp-2993 387 20 - - PUNCT fnp-2993 387 21 cov-2 cov-2 NOUN fnp-2993 387 22 . . PUNCT fnp-2993 388 1 n n PROPN fnp-2993 388 2 engl engl PROPN fnp-2993 388 3 j j PROPN fnp-2993 388 4 med med PROPN fnp-2993 388 5 . . PUNCT fnp-2993 389 1 2020;382(26):2574 2020;382(26):2574 NUM fnp-2993 389 2 - - SYM fnp-2993 389 3 2576 2576 NUM fnp-2993 389 4 . . PUNCT fnp-2993 389 5 doi:10.1056 doi:10.1056 PROPN fnp-2993 389 6 / / SYM fnp-2993 389 7 nejmc2009191 nejmc2009191 PROPN fnp-2993 389 8 72 72 NUM fnp-2993 389 9 . . PUNCT fnp-2993 390 1 dalakas dalakas PROPN fnp-2993 390 2 mc mc PROPN fnp-2993 390 3 . . PROPN fnp-2993 390 4 guillain guillain PROPN fnp-2993 390 5 - - PUNCT fnp-2993 390 6 barré barré PROPN fnp-2993 390 7 syndrome syndrome NOUN fnp-2993 390 8 : : PUNCT fnp-2993 390 9 the the DET fnp-2993 390 10 first first ADJ fnp-2993 390 11 documented document VERB fnp-2993 390 12 covid-19 covid-19 PROPN fnp-2993 390 13 – – PUNCT fnp-2993 390 14 triggered trigger VERB fnp-2993 390 15 autoimmune autoimmune ADJ fnp-2993 390 16 neurologic neurologic ADJ fnp-2993 390 17 disease disease NOUN fnp-2993 390 18 . . PUNCT fnp-2993 391 1 neurol neurol PROPN fnp-2993 391 2 neuroimmunol neuroimmunol PROPN fnp-2993 391 3 neuroinflammation neuroinflammation PROPN fnp-2993 391 4 . . PUNCT fnp-2993 392 1 2020;7(5):e781 2020;7(5):e781 INTJ fnp-2993 392 2 . . PUNCT fnp-2993 393 1 doi:10.1212 doi:10.1212 PROPN fnp-2993 393 2 / / SYM fnp-2993 393 3 nxi.0000000000000781 nxi.0000000000000781 NUM fnp-2993 393 4 73 73 NUM fnp-2993 393 5 . . PUNCT fnp-2993 394 1 caress caress PROPN fnp-2993 394 2 jb jb PROPN fnp-2993 394 3 , , PUNCT fnp-2993 394 4 castoro castoro VERB fnp-2993 394 5 rj rj PROPN fnp-2993 394 6 , , PUNCT fnp-2993 394 7 simmons simmons PROPN fnp-2993 394 8 z z PROPN fnp-2993 394 9 , , PUNCT fnp-2993 394 10 et et PROPN fnp-2993 394 11 al al PROPN fnp-2993 394 12 . . PUNCT fnp-2993 395 1 covid-19 covid-19 PROPN fnp-2993 395 2 - - PUNCT fnp-2993 395 3 associated associate VERB fnp-2993 395 4 guillain guillain NOUN fnp-2993 395 5 - - PUNCT fnp-2993 395 6 barré barré NOUN fnp-2993 395 7 syndrome syndrome NOUN fnp-2993 395 8 : : PUNCT fnp-2993 395 9 the the DET fnp-2993 395 10 early early ADJ fnp-2993 395 11 pandemic pandemic ADJ fnp-2993 395 12 experience experience NOUN fnp-2993 395 13 . . PUNCT fnp-2993 396 1 muscle muscle NOUN fnp-2993 396 2 nerve nerve NOUN fnp-2993 396 3 . . PUNCT fnp-2993 397 1 2020;62(4):485 2020;62(4):485 NUM fnp-2993 397 2 - - PUNCT fnp-2993 397 3 491 491 NUM fnp-2993 397 4 . . PUNCT fnp-2993 398 1 doi:10.1002 doi:10.1002 NOUN fnp-2993 398 2 / / SYM fnp-2993 398 3 mus.27024 mus.27024 NUM fnp-2993 398 4 74 74 NUM fnp-2993 398 5 . . PUNCT fnp-2993 399 1 trujillo trujillo PROPN fnp-2993 399 2 gittermann gittermann PROPN fnp-2993 399 3 lm lm PROPN fnp-2993 399 4 , , PUNCT fnp-2993 399 5 valenzuela valenzuela PROPN fnp-2993 399 6 feris feris PROPN fnp-2993 399 7 sn sn PROPN fnp-2993 399 8 , , PUNCT fnp-2993 399 9 von von PROPN fnp-2993 399 10 oetinger oetinger PROPN fnp-2993 399 11 giacoman giacoman NOUN fnp-2993 399 12 a. a. NOUN fnp-2993 399 13 relation relation NOUN fnp-2993 399 14 between between ADP fnp-2993 399 15 covid-19 covid-19 PROPN fnp-2993 399 16 and and CCONJ fnp-2993 399 17 guillain guillain NOUN fnp-2993 399 18 - - PUNCT fnp-2993 399 19 barré barré PROPN fnp-2993 399 20 syndrome syndrome NOUN fnp-2993 399 21 in in ADP fnp-2993 399 22 adults adult NOUN fnp-2993 399 23 . . PUNCT fnp-2993 400 1 systematic systematic ADJ fnp-2993 400 2 review review NOUN fnp-2993 400 3 tt tt PROPN fnp-2993 400 4 relación relación PROPN fnp-2993 400 5 entre entre PROPN fnp-2993 400 6 covid-19 covid-19 PROPN fnp-2993 400 7 y y PROPN fnp-2993 400 8 síndrome síndrome PROPN fnp-2993 400 9 de de X fnp-2993 400 10 guillain guillain NOUN fnp-2993 400 11 - - PUNCT fnp-2993 400 12 barré barré PROPN fnp-2993 400 13 en en PROPN fnp-2993 400 14 adultos adultos PROPN fnp-2993 400 15 . . PUNCT fnp-2993 401 1 revisión revisión PROPN fnp-2993 401 2 sistemática sistemática PROPN fnp-2993 401 3 . . PUNCT fnp-2993 402 1 neurologia neurologia PROPN fnp-2993 402 2 . . PUNCT fnp-2993 403 1 2020;35(9):646 2020;35(9):646 PROPN fnp-2993 403 2 - - PUNCT fnp-2993 403 3 654 654 NUM fnp-2993 403 4 . . PUNCT fnp-2993 404 1 doi:10.1016 doi:10.1016 PROPN fnp-2993 404 2 / / SYM fnp-2993 404 3 j.nrl.2020.07.004 j.nrl.2020.07.004 NOUN fnp-2993 404 4 75 75 NUM fnp-2993 404 5 . . PUNCT fnp-2993 405 1 abu abu NOUN fnp-2993 405 2 - - PUNCT fnp-2993 405 3 rumeileh rumeileh PROPN fnp-2993 405 4 s s PROPN fnp-2993 405 5 , , PUNCT fnp-2993 405 6 abdelhak abdelhak VERB fnp-2993 405 7 a a PRON fnp-2993 405 8 , , PUNCT fnp-2993 405 9 foschi foschi NOUN fnp-2993 405 10 m m PROPN fnp-2993 405 11 , , PUNCT fnp-2993 405 12 tumani tumani PROPN fnp-2993 405 13 h h PROPN fnp-2993 405 14 , , PUNCT fnp-2993 405 15 otto otto PROPN fnp-2993 405 16 m. m. PROPN fnp-2993 405 17 guillain guillain PROPN fnp-2993 405 18 - - PUNCT fnp-2993 405 19 barré barré PROPN fnp-2993 405 20 syndrome syndrome PROPN fnp-2993 405 21 spectrum spectrum PROPN fnp-2993 405 22 associated associate VERB fnp-2993 405 23 with with ADP fnp-2993 405 24 covid-19 covid-19 PROPN fnp-2993 405 25 : : PUNCT fnp-2993 405 26 an an DET fnp-2993 405 27 up up ADP fnp-2993 405 28 - - PUNCT fnp-2993 405 29 to to ADP fnp-2993 405 30 - - PUNCT fnp-2993 405 31 date date NOUN fnp-2993 405 32 systematic systematic ADJ fnp-2993 405 33 review review NOUN fnp-2993 405 34 of of ADP fnp-2993 405 35 73 73 NUM fnp-2993 405 36 cases case NOUN fnp-2993 405 37 . . PUNCT fnp-2993 406 1 j j PROPN fnp-2993 406 2 neurol neurol PROPN fnp-2993 406 3 . . PUNCT fnp-2993 407 1 published publish VERB fnp-2993 407 2 online online ADJ fnp-2993 407 3 august august PROPN fnp-2993 407 4 25 25 NUM fnp-2993 407 5 , , PUNCT fnp-2993 407 6 2020:1 2020:1 NUM fnp-2993 407 7 - - SYM fnp-2993 407 8 38 38 NUM fnp-2993 407 9 . . PUNCT fnp-2993 408 1 doi:10.1007 doi:10.1007 VERB fnp-2993 408 2 / / SYM fnp-2993 409 1 s00415 s00415 NOUN fnp-2993 409 2 - - PUNCT fnp-2993 409 3 020 020 NUM fnp-2993 409 4 - - PUNCT fnp-2993 409 5 10124 10124 NUM fnp-2993 409 6 - - PUNCT fnp-2993 409 7 x x SYM fnp-2993 409 8 76 76 NUM fnp-2993 409 9 . . PUNCT fnp-2993 410 1 rahimi rahimi PROPN fnp-2993 410 2 k. k. PROPN fnp-2993 410 3 guillain guillain PROPN fnp-2993 410 4 - - PUNCT fnp-2993 410 5 barre barre NOUN fnp-2993 410 6 syndrome syndrome NOUN fnp-2993 410 7 during during ADP fnp-2993 410 8 covid-19 covid-19 PROPN fnp-2993 410 9 pandemic pandemic NOUN fnp-2993 410 10 : : PUNCT fnp-2993 410 11 an an DET fnp-2993 410 12 overview overview NOUN fnp-2993 410 13 of of ADP fnp-2993 410 14 the the DET fnp-2993 410 15 reports report NOUN fnp-2993 410 16 . . PUNCT fnp-2993 411 1 neurol neurol PROPN fnp-2993 411 2 sci sci PROPN fnp-2993 411 3 . . PUNCT fnp-2993 412 1 2020;41(11):3149 2020;41(11):3149 NUM fnp-2993 412 2 - - SYM fnp-2993 412 3 3156 3156 NUM fnp-2993 412 4 . . PUNCT fnp-2993 413 1 doi:10.1007 doi:10.1007 VERB fnp-2993 413 2 / / SYM fnp-2993 413 3 s10072 s10072 NOUN fnp-2993 413 4 - - PUNCT fnp-2993 413 5 020 020 NUM fnp-2993 413 6 - - PUNCT fnp-2993 413 7 04693 04693 NUM fnp-2993 413 8 - - SYM fnp-2993 413 9 y y PROPN fnp-2993 413 10 77 77 NUM fnp-2993 413 11 . . PUNCT fnp-2993 414 1 ehrenfeld ehrenfeld PROPN fnp-2993 414 2 m m PROPN fnp-2993 414 3 , , PUNCT fnp-2993 414 4 tincani tincani PROPN fnp-2993 414 5 a a X fnp-2993 414 6 , , PUNCT fnp-2993 414 7 andreoli andreoli PROPN fnp-2993 414 8 l l PROPN fnp-2993 414 9 , , PUNCT fnp-2993 414 10 et et PROPN fnp-2993 414 11 al al PROPN fnp-2993 414 12 . . PUNCT fnp-2993 414 13 covid-19 covid-19 PROPN fnp-2993 414 14 and and CCONJ fnp-2993 414 15 autoimmunity autoimmunity NOUN fnp-2993 414 16 . . PUNCT fnp-2993 415 1 autoimmun autoimmun PROPN fnp-2993 415 2 rev rev PROPN fnp-2993 415 3 . . PUNCT fnp-2993 416 1 2020;19(8):102597 2020;19(8):102597 NUM fnp-2993 416 2 . . PUNCT fnp-2993 416 3 doi:10.1016 doi:10.1016 PROPN fnp-2993 416 4 / / SYM fnp-2993 416 5 j.autrev.2020.102597 j.autrev.2020.102597 PROPN fnp-2993 416 6 78 78 NUM fnp-2993 416 7 . . PUNCT fnp-2993 417 1 gutiérrez gutiérrez NOUN fnp-2993 417 2 - - PUNCT fnp-2993 417 3 ortiz ortiz PROPN fnp-2993 417 4 c c PROPN fnp-2993 417 5 , , PUNCT fnp-2993 417 6 méndez méndez PROPN fnp-2993 417 7 a a NOUN fnp-2993 417 8 , , PUNCT fnp-2993 417 9 rodrigo rodrigo PROPN fnp-2993 417 10 - - PUNCT fnp-2993 417 11 rey rey PROPN fnp-2993 417 12 s s PROPN fnp-2993 417 13 , , PUNCT fnp-2993 417 14 et et PROPN fnp-2993 417 15 al al PROPN fnp-2993 417 16 . . PROPN fnp-2993 418 1 miller miller PROPN fnp-2993 418 2 fisher fisher PROPN fnp-2993 418 3 syndrome syndrome PROPN fnp-2993 418 4 and and CCONJ fnp-2993 418 5 polyneuritis polyneuritis PROPN fnp-2993 418 6 cranialis craniali NOUN fnp-2993 418 7 in in ADP fnp-2993 418 8 covid-19 covid-19 PROPN fnp-2993 418 9 . . PUNCT fnp-2993 418 10 neurology neurology NOUN fnp-2993 418 11 . . PUNCT fnp-2993 419 1 2020;241:10.1212 2020;241:10.1212 NUM fnp-2993 419 2 / / SYM fnp-2993 419 3 wnl.0000000000009619 wnl.0000000000009619 PROPN fnp-2993 419 4 . . PUNCT fnp-2993 420 1 doi:10.1212 doi:10.1212 PROPN fnp-2993 420 2 / / PROPN fnp-2993 420 3 wnl.0000000000009619 wnl.0000000000009619 PROPN fnp-2993 420 4 79 79 NUM fnp-2993 420 5 . . PUNCT fnp-2993 421 1 von von PROPN fnp-2993 421 2 weyhern weyhern PROPN fnp-2993 421 3 ch ch PROPN fnp-2993 421 4 , , PUNCT fnp-2993 421 5 kaufmann kaufmann PROPN fnp-2993 421 6 i i PROPN fnp-2993 421 7 , , PUNCT fnp-2993 421 8 neff neff PROPN fnp-2993 421 9 f f PROPN fnp-2993 421 10 , , PUNCT fnp-2993 421 11 kremer kremer PROPN fnp-2993 421 12 m. m. PROPN fnp-2993 421 13 early early ADJ fnp-2993 421 14 evidence evidence NOUN fnp-2993 421 15 of of ADP fnp-2993 421 16 pronounced pronounce VERB fnp-2993 421 17 brain brain NOUN fnp-2993 421 18 involvement involvement NOUN fnp-2993 421 19 in in ADP fnp-2993 421 20 fatal fatal ADJ fnp-2993 421 21 covid-19 covid-19 PROPN fnp-2993 421 22 outcomes outcome NOUN fnp-2993 421 23 . . PUNCT fnp-2993 422 1 lancet lancet PROPN fnp-2993 422 2 ( ( PUNCT fnp-2993 422 3 london london PROPN fnp-2993 422 4 , , PUNCT fnp-2993 422 5 england england PROPN fnp-2993 422 6 ) ) PUNCT fnp-2993 422 7 . . PUNCT fnp-2993 423 1 2020;395(10241):e109 2020;395(10241):e109 ADJ fnp-2993 423 2 . . PUNCT fnp-2993 424 1 doi:10.1016 doi:10.1016 PROPN fnp-2993 424 2 / / SYM fnp-2993 424 3 s0140 s0140 PROPN fnp-2993 424 4 - - PUNCT fnp-2993 424 5 6736(20)31282 6736(20)31282 PROPN fnp-2993 424 6 - - SYM fnp-2993 424 7 4 4 NUM fnp-2993 424 8 80 80 NUM fnp-2993 424 9 . . PUNCT fnp-2993 425 1 cavalcanti cavalcanti PROPN fnp-2993 425 2 d d PROPN fnp-2993 425 3 , , PUNCT fnp-2993 425 4 raz raz PROPN fnp-2993 425 5 e e PROPN fnp-2993 425 6 , , PUNCT fnp-2993 425 7 shapiro shapiro PROPN fnp-2993 425 8 m m PROPN fnp-2993 425 9 , , PUNCT fnp-2993 425 10 et et PROPN fnp-2993 425 11 al al PROPN fnp-2993 425 12 . . PROPN fnp-2993 425 13 cerebral cerebral ADJ fnp-2993 425 14 venous venous ADJ fnp-2993 425 15 thrombosis thrombosis NOUN fnp-2993 425 16 associated associate VERB fnp-2993 425 17 with with ADP fnp-2993 425 18 covid-19 covid-19 PROPN fnp-2993 425 19 . . PROPN fnp-2993 425 20 am be AUX fnp-2993 425 21 j j PROPN fnp-2993 425 22 neuroradiol neuroradiol PROPN fnp-2993 425 23 . . PUNCT fnp-2993 426 1 2020;41(8):1 2020;41(8):1 NUM fnp-2993 426 2 - - SYM fnp-2993 426 3 7 7 NUM fnp-2993 426 4 . . PUNCT fnp-2993 426 5 doi:10.3174 doi:10.3174 ADJ fnp-2993 426 6 / / SYM fnp-2993 426 7 ajnr.a6644 ajnr.a6644 PROPN fnp-2993 426 8 81 81 NUM fnp-2993 426 9 . . PUNCT fnp-2993 427 1 poyiadji poyiadji PROPN fnp-2993 427 2 n n PRON fnp-2993 427 3 , , PUNCT fnp-2993 427 4 shahin shahin PROPN fnp-2993 427 5 g g PROPN fnp-2993 427 6 , , PUNCT fnp-2993 427 7 noujaim noujaim ADJ fnp-2993 427 8 d d NOUN fnp-2993 427 9 , , PUNCT fnp-2993 427 10 stone stone NOUN fnp-2993 427 11 m m PROPN fnp-2993 427 12 , , PUNCT fnp-2993 427 13 patel patel PROPN fnp-2993 427 14 s s PART fnp-2993 427 15 , , PUNCT fnp-2993 427 16 griffith griffith PROPN fnp-2993 427 17 b. b. PROPN fnp-2993 427 18 covid-19 covid-19 PROPN fnp-2993 427 19 - - PUNCT fnp-2993 427 20 associated associate VERB fnp-2993 427 21 acute acute NOUN fnp-2993 427 22 hemorrhagic hemorrhagic NOUN fnp-2993 427 23 necrotizing necrotizing NOUN fnp-2993 427 24 encephalopathy encephalopathy NOUN fnp-2993 427 25 : : PUNCT fnp-2993 427 26 imaging imaging NOUN fnp-2993 427 27 features feature NOUN fnp-2993 427 28 . . PUNCT fnp-2993 428 1 radiology radiology NOUN fnp-2993 428 2 . . PUNCT fnp-2993 429 1 2020;296(2):e119 2020;296(2):e119 NUM fnp-2993 429 2 - - SYM fnp-2993 429 3 e120 e120 PROPN fnp-2993 429 4 . . PUNCT fnp-2993 430 1 doi:10.1148 doi:10.1148 NOUN fnp-2993 430 2 / / SYM fnp-2993 430 3 radiol.2020201187 radiol.2020201187 PROPN fnp-2993 430 4 82 82 PROPN fnp-2993 430 5 . . PUNCT fnp-2993 431 1 dixon dixon PROPN fnp-2993 431 2 l l PROPN fnp-2993 431 3 , , PUNCT fnp-2993 431 4 varley varley PROPN fnp-2993 431 5 j j PROPN fnp-2993 431 6 , , PUNCT fnp-2993 431 7 gontsarova gontsarova PROPN fnp-2993 431 8 a a X fnp-2993 431 9 , , PUNCT fnp-2993 431 10 et et PROPN fnp-2993 431 11 al al PROPN fnp-2993 431 12 . . PUNCT fnp-2993 432 1 covid-19 covid-19 PROPN fnp-2993 432 2 - - PUNCT fnp-2993 432 3 related relate VERB fnp-2993 432 4 acute acute ADJ fnp-2993 432 5 necrotizing necrotizing NOUN fnp-2993 432 6 encephalopathy encephalopathy NOUN fnp-2993 432 7 with with ADP fnp-2993 432 8 brain brain NOUN fnp-2993 432 9 stem stem NOUN fnp-2993 432 10 involvement involvement NOUN fnp-2993 432 11 in in ADP fnp-2993 432 12 a a DET fnp-2993 432 13 patient patient NOUN fnp-2993 432 14 with with ADP fnp-2993 432 15 aplastic aplastic ADJ fnp-2993 432 16 anemia anemia NOUN fnp-2993 432 17 . . PUNCT fnp-2993 433 1 neurol neurol PROPN fnp-2993 433 2 neuroimmunol neuroimmunol PROPN fnp-2993 433 3 neuroinflammation neuroinflammation PROPN fnp-2993 433 4 . . PUNCT fnp-2993 434 1 2020;7(5):e789 2020;7(5):e789 ADV fnp-2993 434 2 . . PUNCT fnp-2993 435 1 doi:10.1212 doi:10.1212 NOUN fnp-2993 435 2 / / SYM fnp-2993 435 3 nxi.0000000000000789 nxi.0000000000000789 SYM fnp-2993 435 4 83 83 NUM fnp-2993 435 5 . . PUNCT fnp-2993 436 1 reichard reichard PROPN fnp-2993 436 2 rr rr PROPN fnp-2993 436 3 , , PUNCT fnp-2993 436 4 kashani kashani PROPN fnp-2993 436 5 kb kb PROPN fnp-2993 436 6 , , PUNCT fnp-2993 436 7 boire boire X fnp-2993 436 8 na na PROPN fnp-2993 436 9 , , PUNCT fnp-2993 436 10 constantopoulos constantopoulos PROPN fnp-2993 436 11 e e PROPN fnp-2993 436 12 , , PUNCT fnp-2993 436 13 guo guo PROPN fnp-2993 436 14 y y PROPN fnp-2993 436 15 , , PUNCT fnp-2993 436 16 lucchinetti lucchinetti PROPN fnp-2993 436 17 cf cf NOUN fnp-2993 436 18 . . PUNCT fnp-2993 437 1 neuropathology neuropathology NOUN fnp-2993 437 2 of of ADP fnp-2993 437 3 covid-19 covid-19 PROPN fnp-2993 437 4 : : PUNCT fnp-2993 437 5 a a DET fnp-2993 437 6 spectrum spectrum NOUN fnp-2993 437 7 of of ADP fnp-2993 437 8 vascular vascular NOUN fnp-2993 437 9 and and CCONJ fnp-2993 437 10 acute acute ADJ fnp-2993 437 11 disseminated disseminate VERB fnp-2993 437 12 encephalomyelitis encephalomyelitis NOUN fnp-2993 437 13 ( ( PUNCT fnp-2993 437 14 adem)-like adem)-like ADP fnp-2993 437 15 pathology pathology NOUN fnp-2993 437 16 . . PUNCT fnp-2993 438 1 acta acta PROPN fnp-2993 438 2 neuropathol neuropathol PROPN fnp-2993 438 3 . . PUNCT fnp-2993 439 1 2020;140(1):1 2020;140(1):1 X fnp-2993 439 2 - - SYM fnp-2993 439 3 6 6 NUM fnp-2993 439 4 . . PUNCT fnp-2993 439 5 doi:10.1007 doi:10.1007 VERB fnp-2993 439 6 / / SYM fnp-2993 439 7 s00401 s00401 NOUN fnp-2993 439 8 - - PUNCT fnp-2993 439 9 020 020 NUM fnp-2993 439 10 - - PUNCT fnp-2993 439 11 02166 02166 NUM fnp-2993 439 12 - - SYM fnp-2993 439 13 2 2 NUM fnp-2993 439 14 84 84 NUM fnp-2993 439 15 . . PUNCT fnp-2993 440 1 jensen jensen PROPN fnp-2993 440 2 mp mp PROPN fnp-2993 440 3 , , PUNCT fnp-2993 440 4 le le X fnp-2993 440 5 quesne quesne PROPN fnp-2993 440 6 j j PROPN fnp-2993 440 7 , , PUNCT fnp-2993 440 8 officer officer NOUN fnp-2993 440 9 - - PUNCT fnp-2993 440 10 jones jones PROPN fnp-2993 440 11 l l PROPN fnp-2993 440 12 , , PUNCT fnp-2993 440 13 et et PROPN fnp-2993 440 14 al al PROPN fnp-2993 440 15 . . PUNCT fnp-2993 440 16 neuropathological neuropathological ADJ fnp-2993 440 17 findings finding NOUN fnp-2993 440 18 in in ADP fnp-2993 440 19 two two NUM fnp-2993 440 20 patients patient NOUN fnp-2993 440 21 with with ADP fnp-2993 440 22 fatal fatal ADJ fnp-2993 440 23 covid-19 covid-19 PROPN fnp-2993 440 24 . . PUNCT fnp-2993 440 25 neuropathol neuropathol PROPN fnp-2993 440 26 appl appl PROPN fnp-2993 440 27 neurobiol neurobiol PROPN fnp-2993 440 28 . . PUNCT fnp-2993 441 1 2020;n 2020;n NUM fnp-2993 441 2 / / SYM fnp-2993 441 3 a(n a(n NOUN fnp-2993 441 4 / / SYM fnp-2993 441 5 a a NOUN fnp-2993 441 6 ) ) PUNCT fnp-2993 441 7 . . PUNCT fnp-2993 442 1 doi:10.1111 doi:10.1111 PROPN fnp-2993 442 2 / / SYM fnp-2993 442 3 nan.12662 nan.12662 ADP fnp-2993 442 4 85 85 NUM fnp-2993 442 5 . . PUNCT fnp-2993 443 1 jaunmuktane jaunmuktane PROPN fnp-2993 443 2 z z PROPN fnp-2993 443 3 , , PUNCT fnp-2993 443 4 mahadeva mahadeva PROPN fnp-2993 443 5 u u PROPN fnp-2993 443 6 , , PUNCT fnp-2993 443 7 green green PROPN fnp-2993 443 8 a a X fnp-2993 443 9 , , PUNCT fnp-2993 443 10 et et PROPN fnp-2993 443 11 al al PROPN fnp-2993 443 12 . . PUNCT fnp-2993 443 13 microvascular microvascular ADJ fnp-2993 443 14 injury injury NOUN fnp-2993 443 15 and and CCONJ fnp-2993 443 16 hypoxic hypoxic ADJ fnp-2993 443 17 damage damage NOUN fnp-2993 443 18 : : PUNCT fnp-2993 443 19 emerging emerge VERB fnp-2993 443 20 neuropathological neuropathological ADJ fnp-2993 443 21 signatures signature NOUN fnp-2993 443 22 in in ADP fnp-2993 443 23 covid-19 covid-19 PROPN fnp-2993 443 24 . . PUNCT fnp-2993 444 1 acta acta PROPN fnp-2993 444 2 neuropathol neuropathol PROPN fnp-2993 444 3 . . PUNCT fnp-2993 445 1 2020;140(3):397 2020;140(3):397 NUM fnp-2993 445 2 - - SYM fnp-2993 445 3 400 400 NUM fnp-2993 445 4 . . PUNCT fnp-2993 446 1 doi:10.1007 doi:10.1007 VERB fnp-2993 446 2 / / SYM fnp-2993 446 3 s00401 s00401 NOUN fnp-2993 446 4 - - PUNCT fnp-2993 446 5 020 020 NUM fnp-2993 446 6 - - PUNCT fnp-2993 446 7 02190 02190 NUM fnp-2993 446 8 - - SYM fnp-2993 446 9 2 2 NUM fnp-2993 446 10 86 86 NUM fnp-2993 446 11 . . PUNCT fnp-2993 447 1 deigendesch deigendesch PROPN fnp-2993 447 2 n n CCONJ fnp-2993 447 3 , , PUNCT fnp-2993 447 4 sironi sironi PROPN fnp-2993 447 5 l l NOUN fnp-2993 447 6 , , PUNCT fnp-2993 447 7 kutza kutza X fnp-2993 447 8 m m PROPN fnp-2993 447 9 , , PUNCT fnp-2993 447 10 et et PROPN fnp-2993 447 11 al al PROPN fnp-2993 447 12 . . PROPN fnp-2993 447 13 correlates correlate VERB fnp-2993 447 14 of of ADP fnp-2993 447 15 critical critical ADJ fnp-2993 447 16 illness illness NOUN fnp-2993 447 17 - - PUNCT fnp-2993 447 18 related relate VERB fnp-2993 447 19 encephalopathy encephalopathy NOUN fnp-2993 447 20 predominate predominate ADJ fnp-2993 447 21 postmortem postmortem NOUN fnp-2993 447 22 covid-19 covid-19 PROPN fnp-2993 447 23 neuropathology neuropathology NOUN fnp-2993 447 24 . . PUNCT fnp-2993 448 1 acta acta PROPN fnp-2993 448 2 neuropathol neuropathol PROPN fnp-2993 448 3 . . PUNCT fnp-2993 449 1 2020;140(4):583 2020;140(4):583 NUM fnp-2993 449 2 - - SYM fnp-2993 449 3 586 586 NUM fnp-2993 449 4 . . PUNCT fnp-2993 449 5 doi:10.1007 doi:10.1007 VERB fnp-2993 449 6 / / SYM fnp-2993 449 7 s00401 s00401 NOUN fnp-2993 449 8 - - PUNCT fnp-2993 449 9 020 020 NUM fnp-2993 449 10 - - PUNCT fnp-2993 449 11 02213 02213 NUM fnp-2993 449 12 - - SYM fnp-2993 449 13 y y PROPN fnp-2993 449 14 87 87 NUM fnp-2993 449 15 . . PUNCT fnp-2993 450 1 song song PROPN fnp-2993 450 2 e e PROPN fnp-2993 450 3 , , PUNCT fnp-2993 450 4 zhang zhang PROPN fnp-2993 450 5 c c X fnp-2993 450 6 , , PUNCT fnp-2993 450 7 israelow israelow NOUN fnp-2993 450 8 b b NUM fnp-2993 450 9 , , PUNCT fnp-2993 450 10 et et PROPN fnp-2993 450 11 al al PROPN fnp-2993 450 12 . . PROPN fnp-2993 450 13 neuroinvasion neuroinvasion PROPN fnp-2993 450 14 of of ADP fnp-2993 450 15 sars sar NOUN fnp-2993 450 16 - - PUNCT fnp-2993 450 17 cov-2 cov-2 NOUN fnp-2993 450 18 in in ADP fnp-2993 450 19 human human ADJ fnp-2993 450 20 and and CCONJ fnp-2993 450 21 mouse mouse NOUN fnp-2993 450 22 brain brain NOUN fnp-2993 450 23 . . PUNCT fnp-2993 451 1 biorxiv biorxiv PROPN fnp-2993 451 2 . . PUNCT fnp-2993 452 1 published publish VERB fnp-2993 452 2 online online ADV fnp-2993 452 3 september september PROPN fnp-2993 452 4 8 8 NUM fnp-2993 452 5 , , PUNCT fnp-2993 452 6 2020:2020.06.25.169946 2020:2020.06.25.169946 NUM fnp-2993 452 7 . . PUNCT fnp-2993 453 1 doi:10.1101/2020.06.25.169946 doi:10.1101/2020.06.25.169946 PROPN fnp-2993 453 2 88 88 NUM fnp-2993 453 3 . . PUNCT fnp-2993 454 1 schurink schurink PROPN fnp-2993 454 2 b b PROPN fnp-2993 454 3 , , PUNCT fnp-2993 454 4 roos roo NOUN fnp-2993 454 5 e e NOUN fnp-2993 454 6 , , PUNCT fnp-2993 454 7 radonic radonic PROPN fnp-2993 454 8 t t PROPN fnp-2993 454 9 , , PUNCT fnp-2993 454 10 et et PROPN fnp-2993 454 11 al al PROPN fnp-2993 454 12 . . PROPN fnp-2993 454 13 viral viral ADJ fnp-2993 454 14 presence presence NOUN fnp-2993 454 15 and and CCONJ fnp-2993 454 16 immunopathology immunopathology NOUN fnp-2993 454 17 in in ADP fnp-2993 454 18 patients patient NOUN fnp-2993 454 19 with with ADP fnp-2993 454 20 lethal lethal ADJ fnp-2993 454 21 covid-19 covid-19 PROPN fnp-2993 454 22 : : PUNCT fnp-2993 454 23 a a DET fnp-2993 454 24 prospective prospective ADJ fnp-2993 454 25 autopsy autopsy ADJ fnp-2993 454 26 cohort cohort NOUN fnp-2993 454 27 study study NOUN fnp-2993 454 28 . . PUNCT fnp-2993 455 1 the the DET fnp-2993 455 2 lancet lancet PROPN fnp-2993 455 3 microbe microbe PROPN fnp-2993 455 4 . . PUNCT fnp-2993 456 1 2020;1(7):e290 2020;1(7):e290 NUM fnp-2993 456 2 - - PUNCT fnp-2993 456 3 e299 e299 PROPN fnp-2993 456 4 . . PUNCT fnp-2993 456 5 doi:10.1016 doi:10.1016 PROPN fnp-2993 456 6 / / SYM fnp-2993 456 7 s2666 s2666 PROPN fnp-2993 456 8 - - PUNCT fnp-2993 456 9 5247(20)30144 5247(20)30144 NUM fnp-2993 456 10 - - PUNCT fnp-2993 456 11 0 0 NUM fnp-2993 456 12 89 89 NUM fnp-2993 456 13 . . PUNCT fnp-2993 457 1 al al PROPN fnp-2993 457 2 - - PUNCT fnp-2993 457 3 dalahmah dalahmah PROPN fnp-2993 457 4 o o NOUN fnp-2993 457 5 , , PUNCT fnp-2993 457 6 thakur thakur PROPN fnp-2993 457 7 kt kt PROPN fnp-2993 457 8 , , PUNCT fnp-2993 457 9 nordvig nordvig ADP fnp-2993 457 10 as as ADP fnp-2993 457 11 , , PUNCT fnp-2993 457 12 et et PROPN fnp-2993 457 13 al al PROPN fnp-2993 457 14 . . PROPN fnp-2993 457 15 neuronophagia neuronophagia PROPN fnp-2993 457 16 and and CCONJ fnp-2993 457 17 microglial microglial ADJ fnp-2993 457 18 nodules nodule NOUN fnp-2993 457 19 in in ADP fnp-2993 457 20 a a DET fnp-2993 457 21 sars sar NOUN fnp-2993 457 22 - - PUNCT fnp-2993 457 23 cov-2 cov-2 NOUN fnp-2993 457 24 patient patient NOUN fnp-2993 457 25 with with ADP fnp-2993 457 26 cerebellar cerebellar ADJ fnp-2993 457 27 hemorrhage hemorrhage NOUN fnp-2993 457 28 . . PUNCT fnp-2993 458 1 acta acta PROPN fnp-2993 458 2 neuropathol neuropathol PROPN fnp-2993 458 3 commun commun PROPN fnp-2993 458 4 . . PUNCT fnp-2993 459 1 2020;8(1):147 2020;8(1):147 X fnp-2993 459 2 . . PUNCT fnp-2993 459 3 doi:10.1186 doi:10.1186 PROPN fnp-2993 459 4 / / SYM fnp-2993 459 5 s40478 s40478 PROPN fnp-2993 459 6 - - PUNCT fnp-2993 459 7 020 020 NUM fnp-2993 459 8 - - PUNCT fnp-2993 459 9 01024 01024 NUM fnp-2993 459 10 - - SYM fnp-2993 459 11 2 2 NUM fnp-2993 459 12 90 90 NUM fnp-2993 459 13 . . PUNCT fnp-2993 460 1 hernández hernández PROPN fnp-2993 460 2 - - PUNCT fnp-2993 460 3 fernández fernández PROPN fnp-2993 460 4 f f X fnp-2993 460 5 , , PUNCT fnp-2993 460 6 valencia valencia PROPN fnp-2993 460 7 hs hs PROPN fnp-2993 460 8 , , PUNCT fnp-2993 460 9 barbella barbella NOUN fnp-2993 460 10 - - PUNCT fnp-2993 460 11 aponte aponte PROPN fnp-2993 460 12 ra ra PROPN fnp-2993 460 13 , , PUNCT fnp-2993 460 14 et et PROPN fnp-2993 460 15 al al PROPN fnp-2993 460 16 . . PROPN fnp-2993 460 17 cerebrovascular cerebrovascular ADJ fnp-2993 460 18 disease disease NOUN fnp-2993 460 19 in in ADP fnp-2993 460 20 patients patient NOUN fnp-2993 460 21 with with ADP fnp-2993 460 22 covid-19 covid-19 PROPN fnp-2993 460 23 : : PUNCT fnp-2993 460 24 neuroimaging neuroimaging ADJ fnp-2993 460 25 , , PUNCT fnp-2993 460 26 histological histological ADJ fnp-2993 460 27 and and CCONJ fnp-2993 460 28 clinical clinical ADJ fnp-2993 460 29 description description NOUN fnp-2993 460 30 . . PUNCT fnp-2993 461 1 brain brain NOUN fnp-2993 461 2 . . PUNCT fnp-2993 462 1 2020;143(10):3089 2020;143(10):3089 NUM fnp-2993 462 2 - - PUNCT fnp-2993 462 3 3103 3103 NUM fnp-2993 462 4 . . PUNCT fnp-2993 463 1 doi:10.1093 doi:10.1093 NOUN fnp-2993 463 2 / / SYM fnp-2993 463 3 brain brain NOUN fnp-2993 463 4 / / SYM fnp-2993 463 5 awaa239 awaa239 PROPN fnp-2993 463 6 91 91 NUM fnp-2993 463 7 . . PUNCT fnp-2993 464 1 fabbri fabbri NOUN fnp-2993 464 2 vp vp PROPN fnp-2993 464 3 , , PUNCT fnp-2993 464 4 foschini foschini PROPN fnp-2993 464 5 mp mp PROPN fnp-2993 464 6 , , PUNCT fnp-2993 464 7 lazzarotto lazzarotto ADJ fnp-2993 464 8 t t PROPN fnp-2993 464 9 , , PUNCT fnp-2993 464 10 et et PROPN fnp-2993 464 11 al al PROPN fnp-2993 464 12 . . PROPN fnp-2993 465 1 brain brain PROPN fnp-2993 465 2 ischemic ischemic ADJ fnp-2993 465 3 injury injury NOUN fnp-2993 465 4 in in ADP fnp-2993 465 5 covid-19 covid-19 PROPN fnp-2993 465 6 - - PUNCT fnp-2993 465 7 infected infect VERB fnp-2993 465 8 patients patient NOUN fnp-2993 465 9 : : PUNCT fnp-2993 465 10 a a DET fnp-2993 465 11 series series NOUN fnp-2993 465 12 of of ADP fnp-2993 465 13 10 10 NUM fnp-2993 465 14 post post ADJ fnp-2993 465 15 - - ADJ fnp-2993 465 16 mortem mortem ADJ fnp-2993 465 17 cases case NOUN fnp-2993 465 18 . . PUNCT fnp-2993 466 1 brain brain NOUN fnp-2993 466 2 pathol pathol NOUN fnp-2993 466 3 . . PUNCT fnp-2993 467 1 published publish VERB fnp-2993 467 2 online online ADJ fnp-2993 467 3 october october PROPN fnp-2993 467 4 1 1 NUM fnp-2993 467 5 , , PUNCT fnp-2993 467 6 2020 2020 NUM fnp-2993 467 7 . . PUNCT fnp-2993 468 1 doi:10.1111 doi:10.1111 ADJ fnp-2993 468 2 / / SYM fnp-2993 468 3 bpa.12901 bpa.12901 ADP fnp-2993 468 4 92 92 NUM fnp-2993 468 5 . . PUNCT fnp-2993 469 1 patel patel PROPN fnp-2993 469 2 sd sd PROPN fnp-2993 469 3 , , PUNCT fnp-2993 469 4 kollar kollar ADJ fnp-2993 469 5 r r NOUN fnp-2993 469 6 , , PUNCT fnp-2993 469 7 troy troy NOUN fnp-2993 469 8 p p NOUN fnp-2993 469 9 , , PUNCT fnp-2993 469 10 et et PROPN fnp-2993 469 11 al al PROPN fnp-2993 469 12 . . PROPN fnp-2993 469 13 malignant malignant ADJ fnp-2993 469 14 cerebral cerebral ADJ fnp-2993 469 15 ischemia ischemia NOUN fnp-2993 469 16 in in ADP fnp-2993 469 17 a a DET fnp-2993 469 18 covid-19 covid-19 PROPN fnp-2993 469 19 infected infected ADJ fnp-2993 469 20 patient patient NOUN fnp-2993 469 21 : : PUNCT fnp-2993 469 22 case case NOUN fnp-2993 469 23 review review NOUN fnp-2993 469 24 and and CCONJ fnp-2993 469 25 histopathological histopathological ADJ fnp-2993 469 26 findings finding NOUN fnp-2993 469 27 . . PUNCT fnp-2993 470 1 j j PROPN fnp-2993 470 2 stroke stroke PROPN fnp-2993 470 3 cerebrovasc cerebrovasc PROPN fnp-2993 470 4 dis dis PROPN fnp-2993 470 5 . . PUNCT fnp-2993 471 1 2020;29(11):105231 2020;29(11):105231 X fnp-2993 471 2 . . PUNCT fnp-2993 471 3 doi:10.1016 doi:10.1016 PROPN fnp-2993 471 4 / / SYM fnp-2993 471 5 j.jstrokecerebrovasdis.2020.105231 j.jstrokecerebrovasdis.2020.105231 PROPN fnp-2993 471 6 93 93 NUM fnp-2993 471 7 . . PUNCT fnp-2993 472 1 patel patel PROPN fnp-2993 472 2 hn hn PROPN fnp-2993 472 3 , , PUNCT fnp-2993 472 4 syed sye VERB fnp-2993 472 5 a a PRON fnp-2993 472 6 , , PUNCT fnp-2993 472 7 lobel lobel PROPN fnp-2993 472 8 js js PROPN fnp-2993 472 9 , , PUNCT fnp-2993 472 10 et et PROPN fnp-2993 472 11 al al PROPN fnp-2993 472 12 . . PUNCT fnp-2993 473 1 cerebellar cerebellar ADJ fnp-2993 473 2 infarction infarction NOUN fnp-2993 473 3 requiring require VERB fnp-2993 473 4 surgical surgical ADJ fnp-2993 473 5 decompression decompression NOUN fnp-2993 473 6 in in ADP fnp-2993 473 7 patient patient NOUN fnp-2993 473 8 with with ADP fnp-2993 473 9 covid covid PROPN fnp-2993 473 10 19 19 NUM fnp-2993 473 11 pathological pathological ADJ fnp-2993 473 12 analysis analysis NOUN fnp-2993 473 13 and and CCONJ fnp-2993 473 14 brief brief ADJ fnp-2993 473 15 review review NOUN fnp-2993 473 16 . . PUNCT fnp-2993 474 1 interdiscip interdiscip PROPN fnp-2993 474 2 neurosurg neurosurg VERB fnp-2993 474 3 adv adv PROPN fnp-2993 474 4 tech tech NOUN fnp-2993 474 5 case case NOUN fnp-2993 474 6 manag manag NOUN fnp-2993 474 7 . . PUNCT fnp-2993 475 1 2020;22:100850 2020;22:100850 NUM fnp-2993 475 2 . . PUNCT fnp-2993 475 3 doi:10.1016 doi:10.1016 PROPN fnp-2993 475 4 / / SYM fnp-2993 475 5 j.inat.2020.100850 j.inat.2020.100850 PROPN fnp-2993 475 6 94 94 NUM fnp-2993 475 7 . . PUNCT fnp-2993 476 1 bryce bryce PROPN fnp-2993 476 2 c c PROPN fnp-2993 476 3 , , PUNCT fnp-2993 476 4 grimes grimes PROPN fnp-2993 476 5 z z PROPN fnp-2993 476 6 , , PUNCT fnp-2993 476 7 pujadas pujadas PROPN fnp-2993 476 8 e e NOUN fnp-2993 476 9 , , PUNCT fnp-2993 476 10 et et PROPN fnp-2993 476 11 al al PROPN fnp-2993 476 12 . . PROPN fnp-2993 476 13 pathophysiology pathophysiology PROPN fnp-2993 476 14 of of ADP fnp-2993 476 15 sars sar NOUN fnp-2993 476 16 - - PUNCT fnp-2993 476 17 cov-2 cov-2 NUM fnp-2993 476 18 : : PUNCT fnp-2993 476 19 targeting target VERB fnp-2993 476 20 of of ADP fnp-2993 476 21 endothelial endothelial ADJ fnp-2993 476 22 cells cell NOUN fnp-2993 476 23 renders render VERB fnp-2993 476 24 a a DET fnp-2993 476 25 complex complex ADJ fnp-2993 476 26 disease disease NOUN fnp-2993 476 27 with with ADP fnp-2993 476 28 thrombotic thrombotic ADJ fnp-2993 476 29 microangiopathy microangiopathy ADJ fnp-2993 476 30 and and CCONJ fnp-2993 476 31 aberrant aberrant ADJ fnp-2993 476 32 immune immune ADJ fnp-2993 476 33 response response NOUN fnp-2993 476 34 . . PUNCT fnp-2993 477 1 the the DET fnp-2993 477 2 mount mount PROPN fnp-2993 477 3 sinai sinai PROPN fnp-2993 477 4 covid-19 covid-19 PROPN fnp-2993 477 5 autopsy autopsy ADJ fnp-2993 477 6 experience experience NOUN fnp-2993 477 7 . . PUNCT fnp-2993 478 1 medrxiv medrxiv PROPN fnp-2993 478 2 . . PROPN fnp-2993 479 1 published publish VERB fnp-2993 479 2 online online ADJ fnp-2993 479 3 january january PROPN fnp-2993 479 4 1 1 NUM fnp-2993 479 5 , , PUNCT fnp-2993 479 6 2020:2020.05.18.20099960 2020:2020.05.18.20099960 X fnp-2993 479 7 . . PUNCT fnp-2993 480 1 doi:10.1101/2020.05.18.20099960 doi:10.1101/2020.05.18.20099960 PROPN fnp-2993 480 2 95 95 NUM fnp-2993 480 3 . . PUNCT fnp-2993 481 1 remmelink remmelink PROPN fnp-2993 481 2 m m PROPN fnp-2993 481 3 , , PUNCT fnp-2993 481 4 de de X fnp-2993 481 5 mendoca mendoca NOUN fnp-2993 481 6 r r NOUN fnp-2993 481 7 , , PUNCT fnp-2993 481 8 d’haene d’haene NOUN fnp-2993 481 9 n n CCONJ fnp-2993 481 10 , , PUNCT fnp-2993 481 11 et et PROPN fnp-2993 482 1 al al PROPN fnp-2993 482 2 . . PROPN fnp-2993 482 3 unspecific unspecific ADJ fnp-2993 482 4 post post ADJ fnp-2993 482 5 - - ADJ fnp-2993 482 6 mortem mortem ADJ fnp-2993 482 7 findings finding NOUN fnp-2993 482 8 despite despite SCONJ fnp-2993 482 9 multiorgan multiorgan NOUN fnp-2993 482 10 1 1 NUM fnp-2993 482 11 viral viral ADJ fnp-2993 482 12 spread spread NOUN fnp-2993 482 13 in in ADP fnp-2993 482 14 covid-19 covid-19 PROPN fnp-2993 482 15 patients patient NOUN fnp-2993 482 16 . . PUNCT fnp-2993 483 1 crit crit PROPN fnp-2993 483 2 care care NOUN fnp-2993 483 3 . . PUNCT fnp-2993 484 1 2020;21(1):495 2020;21(1):495 NUM fnp-2993 484 2 . . PUNCT fnp-2993 485 1 doi:10.1186 doi:10.1186 PROPN fnp-2993 485 2 / / SYM fnp-2993 485 3 s13054 s13054 NOUN fnp-2993 485 4 - - PUNCT fnp-2993 485 5 020 020 NUM fnp-2993 485 6 - - PUNCT fnp-2993 485 7 03218 03218 NUM fnp-2993 485 8 - - SYM fnp-2993 485 9 5 5 NUM fnp-2993 485 10 96 96 NUM fnp-2993 485 11 . . PUNCT fnp-2993 486 1 paniz paniz NOUN fnp-2993 486 2 - - PUNCT fnp-2993 486 3 mondolfi mondolfi NOUN fnp-2993 486 4 a a NOUN fnp-2993 486 5 , , PUNCT fnp-2993 486 6 bryce bryce PROPN fnp-2993 486 7 c c PROPN fnp-2993 486 8 , , PUNCT fnp-2993 486 9 grimes grimes PROPN fnp-2993 486 10 z z PROPN fnp-2993 486 11 , , PUNCT fnp-2993 486 12 et et PROPN fnp-2993 486 13 al al PROPN fnp-2993 486 14 . . PROPN fnp-2993 487 1 central central ADJ fnp-2993 487 2 nervous nervous ADJ fnp-2993 487 3 system system NOUN fnp-2993 487 4 involvement involvement NOUN fnp-2993 487 5 by by ADP fnp-2993 487 6 severe severe ADJ fnp-2993 487 7 acute acute ADJ fnp-2993 487 8 respiratory respiratory ADJ fnp-2993 487 9 syndrome syndrome NOUN fnp-2993 487 10 coronavirus-2 coronavirus-2 NUM fnp-2993 487 11 ( ( PUNCT fnp-2993 487 12 sars sar NOUN fnp-2993 487 13 - - PUNCT fnp-2993 487 14 cov-2 cov-2 NOUN fnp-2993 487 15 ) ) PUNCT fnp-2993 487 16 . . PUNCT fnp-2993 488 1 j j PROPN fnp-2993 488 2 med med PROPN fnp-2993 488 3 virol virol NOUN fnp-2993 488 4 . . PUNCT fnp-2993 489 1 2020;92(7):699 2020;92(7):699 NUM fnp-2993 489 2 - - SYM fnp-2993 489 3 702 702 NUM fnp-2993 489 4 . . PUNCT fnp-2993 489 5 doi:10.1002 doi:10.1002 NOUN fnp-2993 489 6 / / SYM fnp-2993 489 7 jmv.25915 jmv.25915 PROPN fnp-2993 489 8 97 97 NUM fnp-2993 489 9 . . PUNCT fnp-2993 490 1 solomon solomon PROPN fnp-2993 490 2 ih ih PROPN fnp-2993 490 3 , , PUNCT fnp-2993 490 4 normandin normandin NOUN fnp-2993 490 5 e e NOUN fnp-2993 490 6 , , PUNCT fnp-2993 490 7 bhattacharyya bhattacharyya PROPN fnp-2993 490 8 s s PROPN fnp-2993 490 9 , , PUNCT fnp-2993 490 10 et et PROPN fnp-2993 490 11 al al PROPN fnp-2993 490 12 . . PUNCT fnp-2993 491 1 neuropathological neuropathological ADJ fnp-2993 491 2 features feature NOUN fnp-2993 491 3 of of ADP fnp-2993 491 4 covid-19 covid-19 PROPN fnp-2993 491 5 . . PUNCT fnp-2993 492 1 n n PROPN fnp-2993 492 2 engl engl PROPN fnp-2993 492 3 j j PROPN fnp-2993 492 4 med med PROPN fnp-2993 492 5 . . PUNCT fnp-2993 492 6 2020;383(10):989 2020;383(10):989 NUM fnp-2993 492 7 - - SYM fnp-2993 492 8 992 992 NUM fnp-2993 492 9 . . PUNCT fnp-2993 492 10 doi:10.1056 doi:10.1056 PROPN fnp-2993 492 11 / / SYM fnp-2993 492 12 nejmc2019373 nejmc2019373 PROPN fnp-2993 492 13 98 98 NUM fnp-2993 492 14 . . PUNCT fnp-2993 493 1 hanley hanley PROPN fnp-2993 493 2 b b PROPN fnp-2993 493 3 , , PUNCT fnp-2993 493 4 naresh naresh PROPN fnp-2993 493 5 kn kn PROPN fnp-2993 493 6 , , PUNCT fnp-2993 493 7 roufosse roufosse NOUN fnp-2993 493 8 c c X fnp-2993 493 9 , , PUNCT fnp-2993 493 10 et et PROPN fnp-2993 493 11 al al PROPN fnp-2993 493 12 . . PUNCT fnp-2993 494 1 histopathological histopathological ADJ fnp-2993 494 2 findings finding NOUN fnp-2993 494 3 and and CCONJ fnp-2993 494 4 viral viral ADJ fnp-2993 494 5 tropism tropism NOUN fnp-2993 494 6 in in ADP fnp-2993 494 7 uk uk PROPN fnp-2993 494 8 patients patient NOUN fnp-2993 494 9 with with ADP fnp-2993 494 10 severe severe ADJ fnp-2993 494 11 fatal fatal ADJ fnp-2993 494 12 covid-19 covid-19 PROPN fnp-2993 494 13 : : PUNCT fnp-2993 494 14 a a DET fnp-2993 494 15 post post ADJ fnp-2993 494 16 - - ADJ fnp-2993 494 17 mortem mortem ADJ fnp-2993 494 18 study study NOUN fnp-2993 494 19 . . PUNCT fnp-2993 495 1 the the DET fnp-2993 495 2 lancet lancet PROPN fnp-2993 495 3 microbe microbe PROPN fnp-2993 495 4 . . PUNCT fnp-2993 496 1 2020;1(6):e245 2020;1(6):e245 NUM fnp-2993 496 2 - - PUNCT fnp-2993 496 3 e253 e253 PROPN fnp-2993 496 4 . . PUNCT fnp-2993 497 1 doi doi NOUN fnp-2993 497 2 : : PUNCT fnp-2993 497 3 https://doi.org/10.1016 https://doi.org/10.1016 PROPN fnp-2993 497 4 / / SYM fnp-2993 497 5 s2666 s2666 PROPN fnp-2993 497 6 - - PUNCT fnp-2993 497 7 5247(20)30115 5247(20)30115 NUM fnp-2993 497 8 - - SYM fnp-2993 497 9 4 4 NUM fnp-2993 497 10 99 99 NUM fnp-2993 497 11 . . PUNCT fnp-2993 498 1 kantonen kantonen PROPN fnp-2993 498 2 j j PROPN fnp-2993 498 3 , , PUNCT fnp-2993 498 4 mahzabin mahzabin PROPN fnp-2993 498 5 s s PROPN fnp-2993 498 6 , , PUNCT fnp-2993 498 7 mäyränpää mäyränpää PROPN fnp-2993 498 8 mi mi PROPN fnp-2993 498 9 , , PUNCT fnp-2993 498 10 et et PROPN fnp-2993 498 11 al al PROPN fnp-2993 498 12 . . PROPN fnp-2993 498 13 neuropathologic neuropathologic PROPN fnp-2993 498 14 features feature NOUN fnp-2993 498 15 of of ADP fnp-2993 498 16 four four NUM fnp-2993 498 17 autopsied autopsie VERB fnp-2993 498 18 covid-19 covid-19 PROPN fnp-2993 498 19 patients patient NOUN fnp-2993 498 20 . . PUNCT fnp-2993 499 1 brain brain NOUN fnp-2993 499 2 pathol pathol NOUN fnp-2993 499 3 . . PUNCT fnp-2993 499 4 published publish VERB fnp-2993 499 5 online online ADJ fnp-2993 499 6 august august PROPN fnp-2993 499 7 6 6 NUM fnp-2993 499 8 , , PUNCT fnp-2993 499 9 2020 2020 NUM fnp-2993 499 10 . . PUNCT fnp-2993 500 1 doi:10.1111 doi:10.1111 ADJ fnp-2993 500 2 / / SYM fnp-2993 500 3 bpa.12889 bpa.12889 PROPN fnp-2993 500 4 100 100 NUM fnp-2993 500 5 . . PUNCT fnp-2993 500 6 zubair zubair PROPN fnp-2993 500 7 as as ADP fnp-2993 500 8 , , PUNCT fnp-2993 500 9 mcalpine mcalpine PROPN fnp-2993 500 10 ls ls PROPN fnp-2993 500 11 , , PUNCT fnp-2993 500 12 gardin gardin PROPN fnp-2993 500 13 t t PROPN fnp-2993 500 14 , , PUNCT fnp-2993 500 15 farhadian farhadian PROPN fnp-2993 500 16 s s PROPN fnp-2993 500 17 , , PUNCT fnp-2993 500 18 kuruvilla kuruvilla PROPN fnp-2993 500 19 de de PROPN fnp-2993 500 20 , , PUNCT fnp-2993 500 21 spudich spudich NOUN fnp-2993 500 22 s. s. PROPN fnp-2993 500 23 neuropathogenesis neuropathogenesis PROPN fnp-2993 500 24 and and CCONJ fnp-2993 500 25 neurologic neurologic ADJ fnp-2993 500 26 manifestations manifestation NOUN fnp-2993 500 27 of of ADP fnp-2993 500 28 the the DET fnp-2993 500 29 coronaviruses coronaviruse NOUN fnp-2993 500 30 in in ADP fnp-2993 500 31 the the DET fnp-2993 500 32 age age NOUN fnp-2993 500 33 of of ADP fnp-2993 500 34 coronavirus coronavirus NOUN fnp-2993 500 35 disease disease NOUN fnp-2993 500 36 2019 2019 NUM fnp-2993 500 37 : : PUNCT fnp-2993 500 38 a a DET fnp-2993 500 39 review review NOUN fnp-2993 500 40 . . PUNCT fnp-2993 501 1 jama jama PROPN fnp-2993 501 2 neurol neurol PROPN fnp-2993 501 3 . . PUNCT fnp-2993 502 1 2020;77(8):1018 2020;77(8):1018 NOUN fnp-2993 502 2 - - SYM fnp-2993 502 3 1027 1027 NUM fnp-2993 502 4 . . PUNCT fnp-2993 503 1 doi:10.1001 doi:10.1001 PROPN fnp-2993 503 2 / / SYM fnp-2993 503 3 jamaneurol.2020.2065 jamaneurol.2020.2065 PROPN fnp-2993 503 4 101 101 NUM fnp-2993 503 5 . . PUNCT fnp-2993 504 1 iadecola iadecola PROPN fnp-2993 504 2 c c NOUN fnp-2993 504 3 , , PUNCT fnp-2993 504 4 anrather anrather PROPN fnp-2993 504 5 j j PROPN fnp-2993 504 6 , , PUNCT fnp-2993 504 7 kamel kamel PROPN fnp-2993 504 8 h. h. PROPN fnp-2993 504 9 effects effect NOUN fnp-2993 504 10 of of ADP fnp-2993 504 11 covid-19 covid-19 PROPN fnp-2993 504 12 on on ADP fnp-2993 504 13 the the DET fnp-2993 504 14 nervous nervous ADJ fnp-2993 504 15 system system NOUN fnp-2993 504 16 . . PUNCT fnp-2993 505 1 cell cell NOUN fnp-2993 505 2 . . PUNCT fnp-2993 506 1 2020;183(1):16 2020;183(1):16 NUM fnp-2993 506 2 - - PUNCT fnp-2993 506 3 27.e1 27.e1 PROPN fnp-2993 506 4 . . PUNCT fnp-2993 506 5 doi:10.1016 doi:10.1016 PROPN fnp-2993 506 6 / / SYM fnp-2993 506 7 j.cell.2020.08.028 j.cell.2020.08.028 PROPN fnp-2993 506 8 102 102 NUM fnp-2993 506 9 . . PUNCT fnp-2993 507 1 netland netland PROPN fnp-2993 507 2 j j PROPN fnp-2993 507 3 , , PUNCT fnp-2993 507 4 meyerholz meyerholz PROPN fnp-2993 507 5 dk dk PROPN fnp-2993 507 6 , , PUNCT fnp-2993 507 7 moore moore PROPN fnp-2993 507 8 s s PROPN fnp-2993 507 9 , , PUNCT fnp-2993 507 10 cassell cassell PROPN fnp-2993 507 11 m m PROPN fnp-2993 507 12 , , PUNCT fnp-2993 507 13 perlman perlman NOUN fnp-2993 507 14 s. s. PROPN fnp-2993 507 15 severe severe ADJ fnp-2993 507 16 acute acute ADJ fnp-2993 507 17 respiratory respiratory ADJ fnp-2993 507 18 syndrome syndrome NOUN fnp-2993 507 19 coronavirus coronavirus NOUN fnp-2993 507 20 infection infection NOUN fnp-2993 507 21 causes cause VERB fnp-2993 507 22 neuronal neuronal ADJ fnp-2993 507 23 death death NOUN fnp-2993 507 24 in in ADP fnp-2993 507 25 the the DET fnp-2993 507 26 absence absence NOUN fnp-2993 507 27 of of ADP fnp-2993 507 28 encephalitis encephalitis NOUN fnp-2993 507 29 in in ADP fnp-2993 507 30 mice mouse NOUN fnp-2993 507 31 transgenic transgenic NOUN fnp-2993 507 32 for for ADP fnp-2993 507 33 human human ADJ fnp-2993 507 34 ace2 ace2 NOUN fnp-2993 507 35 . . PUNCT fnp-2993 508 1 j j PROPN fnp-2993 508 2 virol virol PROPN fnp-2993 508 3 . . PUNCT fnp-2993 509 1 2008;82(15):7264 2008;82(15):7264 NUM fnp-2993 509 2 - - SYM fnp-2993 509 3 7275 7275 NUM fnp-2993 509 4 . . PUNCT fnp-2993 510 1 doi:10.1128 doi:10.1128 NOUN fnp-2993 510 2 / / SYM fnp-2993 510 3 jvi.00737 jvi.00737 NUM fnp-2993 510 4 - - SYM fnp-2993 510 5 08 08 NUM fnp-2993 510 6 103 103 NUM fnp-2993 510 7 . . PUNCT fnp-2993 511 1 hao hao PROPN fnp-2993 511 2 xy xy PROPN fnp-2993 511 3 , , PUNCT fnp-2993 511 4 lv lv PROPN fnp-2993 511 5 q q PROPN fnp-2993 511 6 , , PUNCT fnp-2993 511 7 li li PROPN fnp-2993 511 8 f f PROPN fnp-2993 511 9 di di PROPN fnp-2993 511 10 , , PUNCT fnp-2993 511 11 xu xu PROPN fnp-2993 511 12 yf yf PROPN fnp-2993 511 13 , , PUNCT fnp-2993 511 14 gao gao PROPN fnp-2993 511 15 h. h. PROPN fnp-2993 511 16 the the DET fnp-2993 511 17 characteristics characteristic NOUN fnp-2993 511 18 of of ADP fnp-2993 511 19 hdpp4 hdpp4 NOUN fnp-2993 511 20 transgenic transgenic NOUN fnp-2993 511 21 mice mouse NOUN fnp-2993 511 22 subjected subject VERB fnp-2993 511 23 to to PART fnp-2993 511 24 aerosol aerosol VERB fnp-2993 511 25 mers mer NOUN fnp-2993 511 26 coronavirus coronavirus NOUN fnp-2993 511 27 infection infection NOUN fnp-2993 511 28 via via ADP fnp-2993 511 29 an an DET fnp-2993 511 30 animal animal NOUN fnp-2993 511 31 nose nose NOUN fnp-2993 511 32 - - PUNCT fnp-2993 511 33 only only ADJ fnp-2993 511 34 exposure exposure NOUN fnp-2993 511 35 device device NOUN fnp-2993 511 36 . . PUNCT fnp-2993 512 1 anim anim NOUN fnp-2993 512 2 model model NOUN fnp-2993 512 3 exp exp PROPN fnp-2993 512 4 med med PROPN fnp-2993 512 5 . . PUNCT fnp-2993 513 1 2019;2(4):269 2019;2(4):269 X fnp-2993 513 2 - - PUNCT fnp-2993 513 3 281 281 NUM fnp-2993 513 4 . . PUNCT fnp-2993 514 1 doi:10.1002 doi:10.1002 NOUN fnp-2993 514 2 / / SYM fnp-2993 514 3 ame2.12088 ame2.12088 PROPN fnp-2993 514 4 104 104 NUM fnp-2993 514 5 . . PUNCT fnp-2993 515 1 politi politi PROPN fnp-2993 515 2 ls ls PROPN fnp-2993 515 3 , , PUNCT fnp-2993 515 4 salsano salsano NOUN fnp-2993 515 5 e e PROPN fnp-2993 515 6 , , PUNCT fnp-2993 515 7 grimaldi grimaldi PROPN fnp-2993 515 8 m. m. PROPN fnp-2993 515 9 magnetic magnetic PROPN fnp-2993 515 10 resonance resonance NOUN fnp-2993 515 11 imaging imaging NOUN fnp-2993 515 12 alteration alteration NOUN fnp-2993 515 13 of of ADP fnp-2993 515 14 the the DET fnp-2993 515 15 brain brain NOUN fnp-2993 515 16 in in ADP fnp-2993 515 17 a a DET fnp-2993 515 18 patient patient NOUN fnp-2993 515 19 with with ADP fnp-2993 515 20 coronavirus coronavirus NOUN fnp-2993 515 21 disease disease NOUN fnp-2993 515 22 2019 2019 NUM fnp-2993 515 23 ( ( PUNCT fnp-2993 515 24 covid-19 covid-19 PROPN fnp-2993 515 25 ) ) PUNCT fnp-2993 515 26 and and CCONJ fnp-2993 515 27 anosmia anosmia NOUN fnp-2993 515 28 . . PUNCT fnp-2993 516 1 jama jama PROPN fnp-2993 516 2 neurol neurol PROPN fnp-2993 516 3 . . PUNCT fnp-2993 517 1 2020;77(8):1028 2020;77(8):1028 NUM fnp-2993 517 2 - - SYM fnp-2993 517 3 1029 1029 NUM fnp-2993 517 4 . . PUNCT fnp-2993 518 1 doi:10.1001 doi:10.1001 PROPN fnp-2993 518 2 / / SYM fnp-2993 518 3 jamaneurol.2020.2125 jamaneurol.2020.2125 PROPN fnp-2993 518 4 105 105 NUM fnp-2993 518 5 . . PUNCT fnp-2993 519 1 fodoulian fodoulian PROPN fnp-2993 519 2 l l PROPN fnp-2993 519 3 , , PUNCT fnp-2993 519 4 tuberosa tuberosa PROPN fnp-2993 519 5 j j PROPN fnp-2993 519 6 , , PUNCT fnp-2993 519 7 rossier rossier PROPN fnp-2993 519 8 d d NOUN fnp-2993 519 9 , , PUNCT fnp-2993 519 10 et et PROPN fnp-2993 519 11 al al PROPN fnp-2993 519 12 . . PUNCT fnp-2993 520 1 sars sars PROPN fnp-2993 520 2 - - PUNCT fnp-2993 520 3 cov-2 cov-2 PART fnp-2993 520 4 receptors receptor NOUN fnp-2993 520 5 and and CCONJ fnp-2993 520 6 entry entry NOUN fnp-2993 520 7 genes gene NOUN fnp-2993 520 8 are be AUX fnp-2993 520 9 expressed express VERB fnp-2993 520 10 in in ADP fnp-2993 520 11 the the DET fnp-2993 520 12 human human ADJ fnp-2993 520 13 olfactory olfactory NOUN fnp-2993 520 14 neuroepithelium neuroepithelium NOUN fnp-2993 520 15 and and CCONJ fnp-2993 520 16 brain brain NOUN fnp-2993 520 17 . . PUNCT fnp-2993 521 1 iscience iscience NOUN fnp-2993 521 2 . . PUNCT fnp-2993 522 1 2020;23(12):101839 2020;23(12):101839 X fnp-2993 522 2 . . PUNCT fnp-2993 522 3 doi:10.1016 doi:10.1016 PROPN fnp-2993 522 4 / / SYM fnp-2993 522 5 j.isci.2020.101839 j.isci.2020.101839 PROPN fnp-2993 522 6 106 106 NUM fnp-2993 522 7 . . PUNCT fnp-2993 523 1 nampoothiri nampoothiri PROPN fnp-2993 523 2 s s PROPN fnp-2993 523 3 , , PUNCT fnp-2993 523 4 sauve sauve PROPN fnp-2993 523 5 f f X fnp-2993 523 6 , , PUNCT fnp-2993 523 7 ternier ternier NOUN fnp-2993 523 8 g g NOUN fnp-2993 523 9 , , PUNCT fnp-2993 523 10 et et PROPN fnp-2993 523 11 al al PROPN fnp-2993 523 12 . . PUNCT fnp-2993 524 1 the the DET fnp-2993 524 2 hypothalamus hypothalamus PROPN fnp-2993 524 3 as as ADP fnp-2993 524 4 a a DET fnp-2993 524 5 hub hub NOUN fnp-2993 524 6 for for ADP fnp-2993 524 7 putative putative ADJ fnp-2993 524 8 sars sar NOUN fnp-2993 524 9 - - PUNCT fnp-2993 524 10 cov-2 cov-2 NOUN fnp-2993 524 11 brain brain NOUN fnp-2993 524 12 infection infection NOUN fnp-2993 524 13 . . PUNCT fnp-2993 525 1 biorxiv biorxiv NOUN fnp-2993 525 2 . . PUNCT fnp-2993 526 1 published publish VERB fnp-2993 526 2 online online ADJ fnp-2993 526 3 january january PROPN fnp-2993 526 4 1 1 NUM fnp-2993 526 5 , , PUNCT fnp-2993 526 6 2020:2020.06.08.139329 2020:2020.06.08.139329 X fnp-2993 526 7 . . PUNCT fnp-2993 527 1 doi:10.1101/2020.06.08.139329 doi:10.1101/2020.06.08.139329 PROPN fnp-2993 527 2 107 107 PROPN fnp-2993 527 3 . . PUNCT fnp-2993 528 1 kim kim PROPN fnp-2993 528 2 wk wk PROPN fnp-2993 528 3 , , PUNCT fnp-2993 528 4 corey corey PROPN fnp-2993 528 5 s s PROPN fnp-2993 528 6 , , PUNCT fnp-2993 528 7 alvarez alvarez PROPN fnp-2993 528 8 x x PROPN fnp-2993 528 9 , , PUNCT fnp-2993 528 10 williams williams PROPN fnp-2993 528 11 k. k. PROPN fnp-2993 528 12 monocyte monocyte PROPN fnp-2993 528 13 / / SYM fnp-2993 528 14 macrophage macrophage ADJ fnp-2993 528 15 traffic traffic NOUN fnp-2993 528 16 in in ADP fnp-2993 528 17 hiv hiv PROPN fnp-2993 528 18 and and CCONJ fnp-2993 528 19 siv siv PROPN fnp-2993 528 20 encephalitis encephalitis NOUN fnp-2993 528 21 . . PUNCT fnp-2993 529 1 j j PROPN fnp-2993 529 2 leukoc leukoc VERB fnp-2993 529 3 biol biol PROPN fnp-2993 529 4 . . PUNCT fnp-2993 530 1 2003;74(5):650 2003;74(5):650 PROPN fnp-2993 530 2 - - PUNCT fnp-2993 530 3 656 656 NUM fnp-2993 530 4 . . PUNCT fnp-2993 531 1 doi:10.1189 doi:10.1189 NOUN fnp-2993 531 2 / / SYM fnp-2993 531 3 jlb.0503207 jlb.0503207 NOUN fnp-2993 531 4 108 108 NUM fnp-2993 531 5 . . PUNCT fnp-2993 532 1 trojanowicz trojanowicz PROPN fnp-2993 532 2 b b PROPN fnp-2993 532 3 , , PUNCT fnp-2993 532 4 ulrich ulrich PROPN fnp-2993 532 5 c c PROPN fnp-2993 532 6 , , PUNCT fnp-2993 532 7 kohler kohler PROPN fnp-2993 532 8 f f PROPN fnp-2993 532 9 , , PUNCT fnp-2993 532 10 et et PROPN fnp-2993 532 11 al al PROPN fnp-2993 532 12 . . PUNCT fnp-2993 533 1 monocytic monocytic ADJ fnp-2993 533 2 angiotensin angiotensin NOUN fnp-2993 533 3 - - PUNCT fnp-2993 533 4 converting convert VERB fnp-2993 533 5 enzyme enzyme NOUN fnp-2993 533 6 2 2 NUM fnp-2993 533 7 relates relate VERB fnp-2993 533 8 to to ADP fnp-2993 533 9 atherosclerosis atherosclerosis NOUN fnp-2993 533 10 in in ADP fnp-2993 533 11 patients patient NOUN fnp-2993 533 12 with with ADP fnp-2993 533 13 chronic chronic ADJ fnp-2993 533 14 kidney kidney NOUN fnp-2993 533 15 disease disease NOUN fnp-2993 533 16 . . PUNCT fnp-2993 534 1 nephrol nephrol PROPN fnp-2993 534 2 dial dial NOUN fnp-2993 534 3 transplant transplant NOUN fnp-2993 534 4 . . PUNCT fnp-2993 535 1 2017;32(2):287 2017;32(2):287 NUM fnp-2993 535 2 - - SYM fnp-2993 535 3 298 298 NUM fnp-2993 535 4 . . PUNCT fnp-2993 535 5 doi:10.1093 doi:10.1093 NOUN fnp-2993 535 6 / / SYM fnp-2993 535 7 ndt ndt PROPN fnp-2993 535 8 / / SYM fnp-2993 535 9 gfw206 gfw206 PROPN fnp-2993 535 10 109 109 NUM fnp-2993 535 11 . . PUNCT fnp-2993 536 1 salamanna salamanna PROPN fnp-2993 537 1 f f X fnp-2993 537 2 , , PUNCT fnp-2993 537 3 maglio maglio NOUN fnp-2993 537 4 m m PROPN fnp-2993 537 5 , , PUNCT fnp-2993 537 6 landini landini PROPN fnp-2993 537 7 mp mp PROPN fnp-2993 537 8 , , PUNCT fnp-2993 537 9 fini fini PROPN fnp-2993 537 10 m. m. NOUN fnp-2993 537 11 body body NOUN fnp-2993 537 12 localization localization NOUN fnp-2993 537 13 of of ADP fnp-2993 537 14 ace-2 ace-2 NUM fnp-2993 537 15 : : PUNCT fnp-2993 537 16 on on ADP fnp-2993 537 17 the the DET fnp-2993 537 18 trail trail NOUN fnp-2993 537 19 of of ADP fnp-2993 537 20 the the DET fnp-2993 537 21 keyhole keyhole NOUN fnp-2993 537 22 of of ADP fnp-2993 537 23 sars sar NOUN fnp-2993 537 24 - - PUNCT fnp-2993 537 25 cov-2 cov-2 NOUN fnp-2993 537 26 . . PUNCT fnp-2993 538 1 front front PROPN fnp-2993 538 2 med med PROPN fnp-2993 538 3 . . PUNCT fnp-2993 539 1 2020;7:935 2020;7:935 PROPN fnp-2993 539 2 . . PUNCT fnp-2993 540 1 https://www.frontiersin.org/article/10.3389/fmed.2020.594495 https://www.frontiersin.org/article/10.3389/fmed.2020.594495 PROPN fnp-2993 540 2 110 110 NUM fnp-2993 540 3 . . PUNCT fnp-2993 541 1 bergmann bergmann PROPN fnp-2993 541 2 cc cc PROPN fnp-2993 541 3 , , PUNCT fnp-2993 541 4 lane lane PROPN fnp-2993 541 5 te te PROPN fnp-2993 541 6 , , PUNCT fnp-2993 541 7 stohlman stohlman NOUN fnp-2993 541 8 sa sa PROPN fnp-2993 541 9 . . PUNCT fnp-2993 541 10 coronavirus coronavirus NOUN fnp-2993 541 11 infection infection NOUN fnp-2993 541 12 of of ADP fnp-2993 541 13 the the DET fnp-2993 541 14 central central ADJ fnp-2993 541 15 nervous nervous ADJ fnp-2993 541 16 system system NOUN fnp-2993 541 17 : : PUNCT fnp-2993 541 18 host host NOUN fnp-2993 541 19 - - PUNCT fnp-2993 541 20 virus virus NOUN fnp-2993 541 21 stand stand NOUN fnp-2993 541 22 - - PUNCT fnp-2993 541 23 off off NOUN fnp-2993 541 24 . . PUNCT fnp-2993 542 1 nat nat PROPN fnp-2993 542 2 rev rev PROPN fnp-2993 542 3 microbiol microbiol PROPN fnp-2993 542 4 . . PUNCT fnp-2993 543 1 2006;4(2):121 2006;4(2):121 NUM fnp-2993 543 2 - - SYM fnp-2993 543 3 132 132 NUM fnp-2993 543 4 . . PUNCT fnp-2993 543 5 doi:10.1038 doi:10.1038 NOUN fnp-2993 543 6 / / SYM fnp-2993 543 7 nrmicro1343 nrmicro1343 PROPN fnp-2993 543 8 111 111 NUM fnp-2993 543 9 . . PUNCT fnp-2993 544 1 neumann neumann PROPN fnp-2993 544 2 b b PROPN fnp-2993 544 3 , , PUNCT fnp-2993 544 4 schmidbauer schmidbauer NOUN fnp-2993 544 5 ml ml NOUN fnp-2993 544 6 , , PUNCT fnp-2993 544 7 dimitriadis dimitriadis VERB fnp-2993 544 8 k k NOUN fnp-2993 544 9 , , PUNCT fnp-2993 544 10 et et PROPN fnp-2993 544 11 al al PROPN fnp-2993 544 12 . . PUNCT fnp-2993 544 13 cerebrospinal cerebrospinal ADJ fnp-2993 544 14 fluid fluid ADJ fnp-2993 544 15 findings finding NOUN fnp-2993 544 16 in in ADP fnp-2993 544 17 covid-19 covid-19 PROPN fnp-2993 544 18 patients patient NOUN fnp-2993 544 19 with with ADP fnp-2993 544 20 neurological neurological ADJ fnp-2993 544 21 symptoms symptom NOUN fnp-2993 544 22 . . PUNCT fnp-2993 545 1 j j PROPN fnp-2993 545 2 neurol neurol PROPN fnp-2993 545 3 sci sci PROPN fnp-2993 545 4 . . PROPN fnp-2993 546 1 2020;418:117090 2020;418:117090 NUM fnp-2993 546 2 . . PUNCT fnp-2993 546 3 doi:10.1016 doi:10.1016 PROPN fnp-2993 546 4 / / SYM fnp-2993 546 5 j.jns.2020.117090 j.jns.2020.117090 PROPN fnp-2993 546 6 112 112 NUM fnp-2993 546 7 . . PUNCT fnp-2993 547 1 espíndola espíndola PROPN fnp-2993 547 2 o o PROPN fnp-2993 547 3 de de PROPN fnp-2993 547 4 m m PROPN fnp-2993 547 5 , , PUNCT fnp-2993 547 6 siqueira siqueira PROPN fnp-2993 547 7 m m PROPN fnp-2993 547 8 , , PUNCT fnp-2993 547 9 soares soares PROPN fnp-2993 547 10 cn cn PROPN fnp-2993 547 11 , , PUNCT fnp-2993 547 12 et et PROPN fnp-2993 547 13 al al PROPN fnp-2993 547 14 . . PUNCT fnp-2993 548 1 patients patient NOUN fnp-2993 548 2 with with ADP fnp-2993 548 3 covid-19 covid-19 PROPN fnp-2993 548 4 and and CCONJ fnp-2993 548 5 neurological neurological ADJ fnp-2993 548 6 manifestations manifestation NOUN fnp-2993 548 7 show show VERB fnp-2993 548 8 undetectable undetectable ADJ fnp-2993 548 9 sars sar NOUN fnp-2993 548 10 - - PUNCT fnp-2993 548 11 cov-2 cov-2 NOUN fnp-2993 548 12 rna rna NOUN fnp-2993 548 13 levels level NOUN fnp-2993 548 14 in in ADP fnp-2993 548 15 the the DET fnp-2993 548 16 cerebrospinal cerebrospinal ADJ fnp-2993 548 17 fluid fluid NOUN fnp-2993 548 18 . . PUNCT fnp-2993 549 1 int int NOUN fnp-2993 549 2 j j PROPN fnp-2993 549 3 infect infect VERB fnp-2993 549 4 dis dis PROPN fnp-2993 549 5 . . PUNCT fnp-2993 550 1 2020;96:567 2020;96:567 NUM fnp-2993 550 2 - - SYM fnp-2993 550 3 569 569 NUM fnp-2993 550 4 . . PUNCT fnp-2993 550 5 doi:10.1016 doi:10.1016 PROPN fnp-2993 550 6 / / SYM fnp-2993 550 7 j.ijid.2020.05.123 j.ijid.2020.05.123 PROPN fnp-2993 550 8 113 113 NUM fnp-2993 550 9 . . PUNCT fnp-2993 551 1 bellon bellon NOUN fnp-2993 551 2 m m PROPN fnp-2993 551 3 , , PUNCT fnp-2993 551 4 schweblin schweblin PROPN fnp-2993 551 5 c c PROPN fnp-2993 551 6 , , PUNCT fnp-2993 551 7 lambeng lambeng PROPN fnp-2993 551 8 n n CCONJ fnp-2993 551 9 , , PUNCT fnp-2993 551 10 et et PROPN fnp-2993 551 11 al al PROPN fnp-2993 551 12 . . PUNCT fnp-2993 551 13 cerebrospinal cerebrospinal ADJ fnp-2993 551 14 fluid fluid NOUN fnp-2993 551 15 features feature NOUN fnp-2993 551 16 in in ADP fnp-2993 551 17 sars sar NOUN fnp-2993 551 18 - - PUNCT fnp-2993 551 19 cov-2 cov-2 NOUN fnp-2993 551 20 rt rt ADJ fnp-2993 551 21 - - PUNCT fnp-2993 551 22 pcr pcr ADJ fnp-2993 551 23 positive positive ADJ fnp-2993 551 24 patients patient NOUN fnp-2993 551 25 . . PUNCT fnp-2993 552 1 clin clin PROPN fnp-2993 552 2 infect infect PROPN fnp-2993 552 3 dis dis PROPN fnp-2993 552 4 . . PUNCT fnp-2993 552 5 published publish VERB fnp-2993 552 6 online online ADJ fnp-2993 552 7 august august PROPN fnp-2993 552 8 8 8 NUM fnp-2993 552 9 , , PUNCT fnp-2993 552 10 2020 2020 NUM fnp-2993 552 11 : : PUNCT fnp-2993 552 12 ciaa1165 ciaa1165 PROPN fnp-2993 552 13 . . PUNCT fnp-2993 552 14 doi:10.1093 doi:10.1093 NOUN fnp-2993 552 15 / / SYM fnp-2993 552 16 cid cid PROPN fnp-2993 552 17 / / SYM fnp-2993 552 18 ciaa1165 ciaa1165 PROPN fnp-2993 552 19 114 114 NUM fnp-2993 552 20 . . PUNCT fnp-2993 553 1 hung hung PROPN fnp-2993 553 2 ecw ecw PROPN fnp-2993 553 3 , , PUNCT fnp-2993 553 4 chim chim PROPN fnp-2993 553 5 ssc ssc PROPN fnp-2993 553 6 , , PUNCT fnp-2993 553 7 chan chan PROPN fnp-2993 553 8 pks pks PROPN fnp-2993 553 9 , , PUNCT fnp-2993 553 10 et et PROPN fnp-2993 553 11 al al PROPN fnp-2993 553 12 . . PUNCT fnp-2993 553 13 detection detection NOUN fnp-2993 553 14 of of ADP fnp-2993 553 15 sars sars PROPN fnp-2993 553 16 coronavirus coronavirus PROPN fnp-2993 553 17 rna rna PROPN fnp-2993 553 18 in in ADP fnp-2993 553 19 the the DET fnp-2993 553 20 cerebrospinal cerebrospinal ADJ fnp-2993 553 21 fluid fluid NOUN fnp-2993 553 22 of of ADP fnp-2993 553 23 a a DET fnp-2993 553 24 patient patient NOUN fnp-2993 553 25 with with ADP fnp-2993 553 26 severe severe ADJ fnp-2993 553 27 acute acute ADJ fnp-2993 553 28 respiratory respiratory ADJ fnp-2993 553 29 syndrome syndrome NOUN fnp-2993 553 30 . . PUNCT fnp-2993 554 1 clin clin PROPN fnp-2993 554 2 chem chem PROPN fnp-2993 554 3 . . PUNCT fnp-2993 555 1 2003;49(12):2108 2003;49(12):2108 NUM fnp-2993 555 2 - - SYM fnp-2993 555 3 2109 2109 NUM fnp-2993 555 4 . . PUNCT fnp-2993 556 1 doi:10.1373 doi:10.1373 NOUN fnp-2993 556 2 / / SYM fnp-2993 556 3 clinchem.2003.025437 clinchem.2003.025437 PROPN fnp-2993 556 4 115 115 NUM fnp-2993 556 5 . . PUNCT fnp-2993 557 1 zhou zhou PROPN fnp-2993 557 2 l l PROPN fnp-2993 557 3 , , PUNCT fnp-2993 557 4 zhang zhang PROPN fnp-2993 557 5 m m PROPN fnp-2993 557 6 , , PUNCT fnp-2993 557 7 wang wang PROPN fnp-2993 557 8 j j PROPN fnp-2993 557 9 , , PUNCT fnp-2993 557 10 gao gao PROPN fnp-2993 557 11 j. j. PROPN fnp-2993 557 12 sars sars PROPN fnp-2993 557 13 - - PUNCT fnp-2993 557 14 cov-2 cov-2 PART fnp-2993 557 15 : : PUNCT fnp-2993 557 16 underestimated underestimated ADJ fnp-2993 557 17 damage damage NOUN fnp-2993 557 18 to to ADP fnp-2993 557 19 nervous nervous ADJ fnp-2993 557 20 system system NOUN fnp-2993 557 21 . . PUNCT fnp-2993 558 1 travel travel VERB fnp-2993 558 2 med me VERB fnp-2993 558 3 infect infect PROPN fnp-2993 558 4 dis dis PROPN fnp-2993 558 5 . . PUNCT fnp-2993 559 1 2020;36:101642 2020;36:101642 NUM fnp-2993 559 2 . . PUNCT fnp-2993 559 3 doi:10.1016 doi:10.1016 PROPN fnp-2993 559 4 / / SYM fnp-2993 559 5 j.tmaid.2020.101642 j.tmaid.2020.101642 PROPN fnp-2993 559 6 116 116 NUM fnp-2993 559 7 . . PUNCT fnp-2993 560 1 virhammar virhammar PROPN fnp-2993 560 2 j j PROPN fnp-2993 560 3 , , PUNCT fnp-2993 560 4 kumlien kumlien PROPN fnp-2993 560 5 e e PROPN fnp-2993 560 6 , , PUNCT fnp-2993 560 7 fällmar fällmar PROPN fnp-2993 560 8 d d PROPN fnp-2993 560 9 , , PUNCT fnp-2993 560 10 et et PROPN fnp-2993 560 11 al al PROPN fnp-2993 560 12 . . PROPN fnp-2993 560 13 acute acute PROPN fnp-2993 560 14 necrotizing necrotizing NOUN fnp-2993 560 15 encephalopathy encephalopathy NOUN fnp-2993 560 16 with with ADP fnp-2993 560 17 sars sar NOUN fnp-2993 560 18 - - PUNCT fnp-2993 560 19 cov-2 cov-2 NOUN fnp-2993 560 20 rna rna NOUN fnp-2993 560 21 confirmed confirm VERB fnp-2993 560 22 in in ADP fnp-2993 560 23 cerebrospinal cerebrospinal ADJ fnp-2993 560 24 fluid fluid NOUN fnp-2993 560 25 . . PUNCT fnp-2993 561 1 neurology neurology NOUN fnp-2993 561 2 . . PUNCT fnp-2993 562 1 2020;95(10):445 2020;95(10):445 PROPN fnp-2993 562 2 - - PUNCT fnp-2993 562 3 449 449 NUM fnp-2993 562 4 . . PUNCT fnp-2993 563 1 doi:10.1212 doi:10.1212 PROPN fnp-2993 563 2 / / SYM fnp-2993 564 1 wnl.0000000000010250 wnl.0000000000010250 NUM fnp-2993 564 2 117 117 NUM fnp-2993 564 3 . . PUNCT fnp-2993 565 1 chen chen PROPN fnp-2993 565 2 g g PROPN fnp-2993 565 3 , , PUNCT fnp-2993 565 4 wu wu PROPN fnp-2993 565 5 d d PROPN fnp-2993 565 6 , , PUNCT fnp-2993 565 7 guo guo PROPN fnp-2993 565 8 w w PROPN fnp-2993 565 9 , , PUNCT fnp-2993 565 10 et et PROPN fnp-2993 565 11 al al PROPN fnp-2993 565 12 . . PROPN fnp-2993 566 1 clinical clinical ADJ fnp-2993 566 2 and and CCONJ fnp-2993 566 3 immunological immunological ADJ fnp-2993 566 4 features feature NOUN fnp-2993 566 5 of of ADP fnp-2993 566 6 severe severe ADJ fnp-2993 566 7 and and CCONJ fnp-2993 566 8 moderate moderate ADJ fnp-2993 566 9 coronavirus coronavirus NOUN fnp-2993 566 10 disease disease NOUN fnp-2993 566 11 2019 2019 NUM fnp-2993 566 12 . . PUNCT fnp-2993 567 1 j j PROPN fnp-2993 567 2 clin clin PROPN fnp-2993 567 3 invest invest PROPN fnp-2993 567 4 . . PUNCT fnp-2993 568 1 2020;130(5):2620 2020;130(5):2620 NUM fnp-2993 568 2 - - SYM fnp-2993 568 3 2629 2629 NUM fnp-2993 568 4 . . PUNCT fnp-2993 569 1 doi:10.1172 doi:10.1172 PROPN fnp-2993 569 2 / / SYM fnp-2993 569 3 jci137244 jci137244 NOUN fnp-2993 569 4 118 118 NUM fnp-2993 569 5 . . PUNCT fnp-2993 570 1 huang huang PROPN fnp-2993 570 2 c c PROPN fnp-2993 570 3 , , PUNCT fnp-2993 570 4 wang wang PROPN fnp-2993 570 5 y y PROPN fnp-2993 570 6 , , PUNCT fnp-2993 570 7 li li PROPN fnp-2993 570 8 x x PROPN fnp-2993 570 9 , , PUNCT fnp-2993 570 10 et et PROPN fnp-2993 570 11 al al PROPN fnp-2993 570 12 . . PUNCT fnp-2993 571 1 clinical clinical ADJ fnp-2993 571 2 features feature NOUN fnp-2993 571 3 of of ADP fnp-2993 571 4 patients patient NOUN fnp-2993 571 5 infected infect VERB fnp-2993 571 6 with with ADP fnp-2993 571 7 2019 2019 NUM fnp-2993 571 8 novel novel ADJ fnp-2993 571 9 coronavirus coronavirus NOUN fnp-2993 571 10 in in ADP fnp-2993 571 11 wuhan wuhan PROPN fnp-2993 571 12 , , PUNCT fnp-2993 571 13 china china PROPN fnp-2993 571 14 . . PUNCT fnp-2993 572 1 lancet lancet PROPN fnp-2993 572 2 . . PUNCT fnp-2993 573 1 2020;395(10223):497 2020;395(10223):497 NUM fnp-2993 573 2 - - PUNCT fnp-2993 573 3 506 506 NUM fnp-2993 573 4 . . PUNCT fnp-2993 573 5 doi:10.1016 doi:10.1016 PROPN fnp-2993 573 6 / / SYM fnp-2993 573 7 s0140 s0140 PROPN fnp-2993 573 8 - - PUNCT fnp-2993 573 9 6736(20)30183 6736(20)30183 NUM fnp-2993 573 10 - - SYM fnp-2993 573 11 5 5 NUM fnp-2993 573 12 119 119 NUM fnp-2993 573 13 . . PUNCT fnp-2993 574 1 song song PROPN fnp-2993 574 2 p p PROPN fnp-2993 574 3 , , PUNCT fnp-2993 574 4 li li PROPN fnp-2993 574 5 w w PROPN fnp-2993 574 6 , , PUNCT fnp-2993 574 7 xie xie PROPN fnp-2993 574 8 j j PROPN fnp-2993 574 9 , , PUNCT fnp-2993 574 10 hou hou PROPN fnp-2993 574 11 y y PROPN fnp-2993 574 12 , , PUNCT fnp-2993 574 13 you you PRON fnp-2993 574 14 c. c. PROPN fnp-2993 574 15 cytokine cytokine NOUN fnp-2993 574 16 storm storm NOUN fnp-2993 574 17 induced induce VERB fnp-2993 574 18 by by ADP fnp-2993 574 19 sars sar NOUN fnp-2993 574 20 - - PUNCT fnp-2993 574 21 cov-2 cov-2 NOUN fnp-2993 574 22 . . PUNCT fnp-2993 575 1 clin clin PROPN fnp-2993 575 2 chim chim PROPN fnp-2993 575 3 acta acta PROPN fnp-2993 575 4 . . PUNCT fnp-2993 576 1 2020;509:280 2020;509:280 NUM fnp-2993 576 2 - - SYM fnp-2993 576 3 287 287 NUM fnp-2993 576 4 . . PUNCT fnp-2993 577 1 doi doi NOUN fnp-2993 577 2 : : PUNCT fnp-2993 577 3 https://doi.org/10.1016 https://doi.org/10.1016 NOUN fnp-2993 577 4 / / SYM fnp-2993 577 5 j.cca.2020.06.017 j.cca.2020.06.017 NOUN fnp-2993 577 6 120 120 NUM fnp-2993 577 7 . . PUNCT fnp-2993 578 1 goshua goshua PROPN fnp-2993 578 2 g g PROPN fnp-2993 578 3 , , PUNCT fnp-2993 578 4 pine pine PROPN fnp-2993 578 5 ab ab PROPN fnp-2993 578 6 , , PUNCT fnp-2993 578 7 meizlish meizlish PROPN fnp-2993 578 8 ml ml PROPN fnp-2993 578 9 , , PUNCT fnp-2993 578 10 et et PROPN fnp-2993 578 11 al al PROPN fnp-2993 578 12 . . PROPN fnp-2993 578 13 endotheliopathy endotheliopathy PROPN fnp-2993 578 14 in in ADP fnp-2993 578 15 covid-19 covid-19 PROPN fnp-2993 578 16 - - PUNCT fnp-2993 578 17 associated associate VERB fnp-2993 578 18 coagulopathy coagulopathy ADJ fnp-2993 578 19 : : PUNCT fnp-2993 578 20 evidence evidence NOUN fnp-2993 578 21 from from ADP fnp-2993 578 22 a a DET fnp-2993 578 23 single single ADJ fnp-2993 578 24 - - PUNCT fnp-2993 578 25 centre centre NOUN fnp-2993 578 26 , , PUNCT fnp-2993 578 27 cross cross ADJ fnp-2993 578 28 - - ADJ fnp-2993 578 29 sectional sectional ADJ fnp-2993 578 30 study study NOUN fnp-2993 578 31 . . PUNCT fnp-2993 579 1 lancet lancet PROPN fnp-2993 579 2 haematol haematol NOUN fnp-2993 579 3 . . PUNCT fnp-2993 580 1 2020;7(8):e575 2020;7(8):e575 NUM fnp-2993 580 2 - - PUNCT fnp-2993 580 3 e582 e582 PROPN fnp-2993 580 4 . . PUNCT fnp-2993 580 5 doi:10.1016 doi:10.1016 PROPN fnp-2993 580 6 / / SYM fnp-2993 580 7 s2352 s2352 PROPN fnp-2993 580 8 - - PUNCT fnp-2993 580 9 3026(20)30216 3026(20)30216 NUM fnp-2993 580 10 - - SYM fnp-2993 580 11 7 7 NUM fnp-2993 580 12 121 121 NUM fnp-2993 580 13 . . PUNCT fnp-2993 581 1 thachil thachil PROPN fnp-2993 581 2 j j PROPN fnp-2993 581 3 , , PUNCT fnp-2993 581 4 tang tang PROPN fnp-2993 581 5 n n CCONJ fnp-2993 581 6 , , PUNCT fnp-2993 581 7 gando gando PROPN fnp-2993 581 8 s s PROPN fnp-2993 581 9 , , PUNCT fnp-2993 581 10 et et PROPN fnp-2993 581 11 al al PROPN fnp-2993 581 12 . . PUNCT fnp-2993 582 1 isth isth NOUN fnp-2993 582 2 interim interim ADJ fnp-2993 582 3 guidance guidance NOUN fnp-2993 582 4 on on ADP fnp-2993 582 5 recognition recognition NOUN fnp-2993 582 6 and and CCONJ fnp-2993 582 7 management management NOUN fnp-2993 582 8 of of ADP fnp-2993 582 9 coagulopathy coagulopathy ADJ fnp-2993 582 10 in in ADP fnp-2993 582 11 covid-19 covid-19 PROPN fnp-2993 582 12 . . PUNCT fnp-2993 583 1 j j PROPN fnp-2993 583 2 thromb thromb PROPN fnp-2993 583 3 haemost haemost VERB fnp-2993 583 4 . . PUNCT fnp-2993 584 1 2020;18(5):1023 2020;18(5):1023 NUM fnp-2993 584 2 - - SYM fnp-2993 584 3 1026 1026 NUM fnp-2993 584 4 . . PUNCT fnp-2993 585 1 doi:10.1111 doi:10.1111 NOUN fnp-2993 585 2 / / SYM fnp-2993 585 3 jth.14810 jth.14810 NUM fnp-2993 585 4 122 122 NUM fnp-2993 585 5 . . PUNCT fnp-2993 586 1 yaqinuddin yaqinuddin VERB fnp-2993 586 2 a a PRON fnp-2993 586 3 , , PUNCT fnp-2993 586 4 kvietys kvietys NOUN fnp-2993 586 5 p p NOUN fnp-2993 586 6 , , PUNCT fnp-2993 586 7 kashir kashir PROPN fnp-2993 586 8 j. j. PROPN fnp-2993 586 9 covid-19 covid-19 PROPN fnp-2993 586 10 : : PUNCT fnp-2993 586 11 role role NOUN fnp-2993 586 12 of of ADP fnp-2993 586 13 neutrophil neutrophil ADJ fnp-2993 586 14 extracellular extracellular ADJ fnp-2993 586 15 traps trap NOUN fnp-2993 586 16 in in ADP fnp-2993 586 17 acute acute ADJ fnp-2993 586 18 lung lung NOUN fnp-2993 586 19 injury injury NOUN fnp-2993 586 20 . . PUNCT fnp-2993 587 1 respir respir VERB fnp-2993 587 2 investig investig NOUN fnp-2993 587 3 . . PUNCT fnp-2993 588 1 2020;58(5):419 2020;58(5):419 NOUN fnp-2993 588 2 - - PUNCT fnp-2993 588 3 420 420 NUM fnp-2993 588 4 . . PUNCT fnp-2993 589 1 doi:10.1016 doi:10.1016 PROPN fnp-2993 589 2 / / SYM fnp-2993 589 3 j.resinv.2020.06.001 j.resinv.2020.06.001 PROPN fnp-2993 589 4 123 123 NUM fnp-2993 589 5 . . PUNCT fnp-2993 590 1 agarwal agarwal PROPN fnp-2993 590 2 an an PROPN fnp-2993 590 3 , , PUNCT fnp-2993 590 4 mais mais X fnp-2993 590 5 dd dd PROPN fnp-2993 590 6 . . PROPN fnp-2993 590 7 sensitivity sensitivity NOUN fnp-2993 590 8 and and CCONJ fnp-2993 590 9 specificity specificity NOUN fnp-2993 590 10 of of ADP fnp-2993 590 11 alzheimer alzheimer PROPN fnp-2993 590 12 type type PROPN fnp-2993 590 13 ii ii PROPN fnp-2993 590 14 astrocytes astrocyte NOUN fnp-2993 590 15 in in ADP fnp-2993 590 16 hepatic hepatic ADJ fnp-2993 590 17 encephalopathy encephalopathy NOUN fnp-2993 590 18 . . PUNCT fnp-2993 591 1 arch arch ADJ fnp-2993 591 2 pathol pathol NOUN fnp-2993 591 3 lab lab NOUN fnp-2993 591 4 med me VERB fnp-2993 591 5 . . PUNCT fnp-2993 592 1 2019;143(10):1256 2019;143(10):1256 X fnp-2993 592 2 - - SYM fnp-2993 592 3 1258 1258 NUM fnp-2993 592 4 . . PUNCT fnp-2993 593 1 doi:10.5858 doi:10.5858 NOUN fnp-2993 593 2 / / SYM fnp-2993 594 1 arpa.2018 arpa.2018 NOUN fnp-2993 594 2 - - PUNCT fnp-2993 594 3 0455 0455 NUM fnp-2993 594 4 - - PUNCT fnp-2993 594 5 oa oa NOUN fnp-2993 594 6 copyright copyright NOUN fnp-2993 594 7 : : PUNCT fnp-2993 594 8 © © PROPN fnp-2993 594 9 2021 2021 NUM fnp-2993 594 10 the the DET fnp-2993 594 11 author(s author(s NOUN fnp-2993 594 12 ) ) PUNCT fnp-2993 594 13 . . PUNCT fnp-2993 595 1 this this PRON fnp-2993 595 2 is be AUX fnp-2993 595 3 an an DET fnp-2993 595 4 open open ADJ fnp-2993 595 5 access access NOUN fnp-2993 595 6 article article NOUN fnp-2993 595 7 distributed distribute VERB fnp-2993 595 8 under under ADP fnp-2993 595 9 the the DET fnp-2993 595 10 terms term NOUN fnp-2993 595 11 of of ADP fnp-2993 595 12 the the DET fnp-2993 595 13 creative creative ADJ fnp-2993 595 14 commons common NOUN fnp-2993 595 15 attribution attribution NOUN fnp-2993 595 16 4.0 4.0 NUM fnp-2993 595 17 international international ADJ fnp-2993 595 18 license license NOUN fnp-2993 595 19 ( ( PUNCT fnp-2993 595 20 https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/ PROPN fnp-2993 595 21 ) ) PUNCT fnp-2993 595 22 , , PUNCT fnp-2993 595 23 which which PRON fnp-2993 595 24 permits permit VERB fnp-2993 595 25 unrestricted unrestricted ADJ fnp-2993 595 26 use use NOUN fnp-2993 595 27 , , PUNCT fnp-2993 595 28 distribution distribution NOUN fnp-2993 595 29 , , PUNCT fnp-2993 595 30 and and CCONJ fnp-2993 595 31 reproduction reproduction NOUN fnp-2993 595 32 in in ADP fnp-2993 595 33 any any DET fnp-2993 595 34 medium medium NOUN fnp-2993 595 35 , , PUNCT fnp-2993 595 36 provided provide VERB fnp-2993 595 37 the the DET fnp-2993 595 38 original original ADJ fnp-2993 595 39 author author NOUN fnp-2993 595 40 and and CCONJ fnp-2993 595 41 source source NOUN fnp-2993 595 42 are be AUX fnp-2993 595 43 credited credit VERB fnp-2993 595 44 , , PUNCT fnp-2993 595 45 a a DET fnp-2993 595 46 link link NOUN fnp-2993 595 47 to to ADP fnp-2993 595 48 the the DET fnp-2993 595 49 creative creative ADJ fnp-2993 595 50 commons common NOUN fnp-2993 595 51 license license NOUN fnp-2993 595 52 is be AUX fnp-2993 595 53 provided provide VERB fnp-2993 595 54 , , PUNCT fnp-2993 595 55 and and CCONJ fnp-2993 595 56 any any DET fnp-2993 595 57 changes change NOUN fnp-2993 595 58 are be AUX fnp-2993 595 59 indicated indicate VERB fnp-2993 595 60 . . PUNCT fnp-2993 596 1 the the DET fnp-2993 596 2 creative creative ADJ fnp-2993 596 3 commons common NOUN fnp-2993 596 4 public public ADJ fnp-2993 596 5 domain domain NOUN fnp-2993 596 6 dedication dedication NOUN fnp-2993 596 7 waiver waiver NOUN fnp-2993 596 8 ( ( PUNCT fnp-2993 596 9 https://creativecommons.org/publicdomain/zero/1.0/ https://creativecommons.org/publicdomain/zero/1.0/ PROPN fnp-2993 596 10 ) ) PUNCT fnp-2993 596 11 applies apply VERB fnp-2993 596 12 to to ADP fnp-2993 596 13 the the DET fnp-2993 596 14 data datum NOUN fnp-2993 596 15 made make VERB fnp-2993 596 16 available available ADJ fnp-2993 596 17 in in ADP fnp-2993 596 18 this this DET fnp-2993 596 19 article article NOUN fnp-2993 596 20 , , PUNCT fnp-2993 596 21 unless unless SCONJ fnp-2993 596 22 otherwise otherwise ADV fnp-2993 596 23 stated state VERB fnp-2993 596 24 . . PUNCT